

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2018353112 B2**

(54) Title  
**Targeted gene integration of NK inhibitors genes for improved immune cells therapy**

(51) International Patent Classification(s)  
**C12N 5/078** (2010.01) **C12N 9/22** (2006.01)  
**A61K 35/17** (2015.01) **C12N 15/90** (2006.01)  
**C12N 5/0783** (2010.01)

(21) Application No: **2018353112** (22) Date of Filing: **2018.03.09**

(87) WIPO No: **WO19/076486**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>PCT/EP2017/076798</b>	<b>2017.10.19</b>	<b>EP</b>
<b>PCT/EP2018/053343</b>	<b>2018.02.09</b>	<b>EP</b>

(43) Publication Date: **2019.04.25**

(44) Accepted Journal Date: **2024.11.14**

(71) Applicant(s)  
**Cellectis**

(72) Inventor(s)  
**BUSSER, Brian;DUCHATEAU, Philippe;JULLERAT, Alexandre;POIROT, Laurent;VALTON, Julien**

(74) Agent / Attorney  
**Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU**

(56) Related Art  
**WO 2016/142532 A1**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

25 April 2019 (25.04.2019)



(10) International Publication Number

WO 2019/076486 A1

(51) International Patent Classification:

CI2N 5/078 (2010.01) CI2N 9/22 (2006.01)  
A61K 35/17 (2015.01) CI2N 5/0783 (2010.01)  
CI2N 15/90 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2018/055957

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

09 March 2018 (09.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2017/076798  
19 October 2017 (19.10.2017) EP  
PCT/EP2018/053343  
09 February 2018 (09.02.2018) EP

(71) Applicant: **CELLECTIS** [FR/FR]; 8 Rue de la Croix Jarry,  
75013 Paris (FR).

(72) Inventors: **BUSSER, Brian**; 295 Park Avenue South,  
NEW YORK, New York 10010 (US). **DUCHATEAU,**  
**Philippe**; Bateau Fawen, Quai des Dames, 91210  
DRAVEIL (FR). **JUILLERAT, Alexandre**; 444 East 82nd  
Street #5A, NEW YORK, NY 10028 (US). **POIROT, Lau-**  
**rent**; 10 rue de la Réunion, 75020 PARIS (FR). **VALTON,**  
**Julien**; 533 East 12th Street Apt No. 5D, NEW YORK, NY  
10009 (US).

(74) Agent: **ZACCO DENMARK A/S**; Arne Jacobsens Allé  
15, 2300 København S (DK).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: TARGETED GENE INTEGRATION OF NK INHIBITORS GENES FOR IMPROVED IMMUNE CELLS THERAPY

(57) Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

WO 2019/076486 A1

**TARGETED GENE INTEGRATION OF NK INHIBITORS GENES**  
**FOR IMPROVED IMMUNE CELLS THERAPY**

5

**Field of the invention**

The invention pertains to the field of adaptive cell immunotherapy. It aims to enhance the functionality of primary immune cells against pathologies that develop immune resistance, such as tumors, thereby improving the therapeutic potential of these immune cells. In particular, the method of the invention provides with the genetic insertion of exogenous coding sequence(s) encoding NK inhibitors to prevent allogeneic T-cells rejection from patient's NK cell attack and favor the engraftment of said T-cells, especially when they originate from donors. These exogenous coding sequences are more particularly inserted into the cell's genome under the transcriptional control of endogenous gene promoters that are upregulated upon immune cells activation, upon tumor microenvironment or life threatening inflammatory conditions or promoters that are insensitive to immune cells activation, more particularly at the  $\beta 2m$  locus. The invention further provides with sequence-specific endonuclease reagents and donor DNA vectors, such as AAV vectors, to perform such targeted insertions at said particular loci. The method of the invention contributes to improving the therapeutic potential and safety of engineered primary immune cells for their efficient use in cell therapy.

**Background of the invention**

Effective clinical application of primary immune cell populations including hematopoietic cell lineages has been established by a number of clinical trials over a decade against a range of pathologies, in particular HIV infection and Leukemia (Tristen S.J. et al. (2011) Treating cancer with genetically engineered T cells. *Trends in Biotechnology*. 29(11):550-557).

However, most of these clinical trials have used immune cells, mainly NK and T-cells, obtained from the patients themselves or from compatible donors, bringing some limitations with respect to the number of available immune cells, their fitness, and their efficiency to overcome diseases that have already developed strategies to get around or reduce patient's immune system.

As a primary advance into the procurement of allogeneic immune cells, universal immune cells, available as “off-the-shelf” therapeutic products, have been produced by gene editing (Poirot et al. (2015) Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies *Cancer Res.* 75: 3853-64). These universal immune cells are obtainable by expressing specific rare-cutting endonuclease into immune cells originating from donors, with the effect of disrupting, by double strand-break, their self-recognition genetic determinants.

Since the emergence of the first programmable sequence-specific reagents by the turn of the century, initially referred to as Meganucleases (Smith et al. (2006) A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. *Nucl. Acids Res.* 34 (22):e149.), different types of sequence-specific endonucleases reagents have been developed offering improved specificity, safety and reliability.

TALE-nucleases (WO2011072246), which are fusions of a TALE binding domain with a cleavage catalytic domain have been successfully applied to primary immune cells, in particular T-cells from peripheral blood mononuclear cell (PBMC). Such TALE-nucleases, marketed under the name TALEN<sup>®</sup>, are those currently used to simultaneously inactivate gene sequences in T-cells originating from donors, in particular to produce allogeneic therapeutic T-Cells in which the genes encoding TCR (T-cell receptor) and CD52 are disrupted. These cells can be endowed with chimeric antigen receptors (CAR) for treating cancer patients (US2013/0315884). TALE-nucleases are very specific reagents because they need to bind DNA by pairs under obligatory heterodimeric form to obtain dimerization of the cleavage domain Fok-1. Left and right heterodimer members each recognizes a different nucleic sequences of about 14 to 20 bp, together spanning target sequences of 30 to 50 bp overall specificity.

Other endonucleases reagents have been developed based on the components of the type II prokaryotic CRISPR (Clustered Regularly Interspaced Short palindromic Repeats) adaptive immune system of the bacteria *S. pyogenes*. This multi-component system referred to as RNA-guided nuclease system (Gasiunas, Barrangou et al. 2012; Jinek, Chylinski et al. 2012), involves members of Cas9 or Cpf1 endonuclease families coupled with a guide RNA molecules that have the ability to drive said nuclease to some specific genome sequences (Zetsche et al. (2015). Cpf1 is a single RNA-guided endonuclease that provides immunity in bacteria and can be adapted for genome editing in mammalian cells. *Cell* 163:759-771). Such programmable RNA-guided endonucleases are easy to produce because the cleavage specificity is determined by the sequence of

the RNA guide, which can be easily designed and cheaply produced. The specificity of CRISPR/Cas9 although stands on shorter sequences than TAL-nucleases of about 10 pb, which must be located near a particular motif (PAM) in the targeted genetic sequence. Similar systems have been described using a DNA single strand oligonucleotide (DNA guide) in combination with Argonaute proteins (Gao, F. et al. DNA-guided genome editing using the *Neisseria meningitidis* Argonaute (2016) doi:10.1038/nbt.3547).

Other endonuclease systems derived from homing endonucleases (ex: I-OnuI, or I-CreI), combined or not with TAL-nuclease (ex: MegaTAL) or zinc-finger nucleases have also proven specificity, but to a lesser extent so far.

In parallel, novel specificities can be conferred to immune cells through the genetic transfer of transgenic T-cell receptors or so-called chimeric antigen receptors (CARs) (Jena et al. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. *Blood*. 116:1035-1044). CARs are recombinant receptors comprising a targeting moiety that is associated with one or more signaling domains in a single fusion molecule. In general, the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and heavy variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully. The signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains. First generation CARs have been shown to successfully redirect T cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity in vivo. Signaling domains from co-stimulatory molecules including CD28, OX-40 (CD134), ICOS and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T cells. CARs have successfully allowed T cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors.

Recently engineered T-cells disrupted in their T-cell receptor (TCR) using TALE-nucleases, endowed with chimeric antigen receptor (CAR) targeting CD19 malignant antigen, referred to as "UCART19" product, have shown therapeutic potential in at least two infants who had refractory leukemia (Leukaemia success heralds wave of gene-editing therapies (2015) *Nature* 527:146–147). To obtain such UCART19 cells, the TALE-nuclease was transiently expressed into the cells upon electroporation of capped mRNA to operate TCR gene disruption, whereas a cassette encoding the chimeric antigen receptor (CAR CD19) was introduced randomly into the genome using a retroviral vector.

In this later approach, the steps of gene inactivation and of expressing the chimeric antigen receptor are independently performed after inducing activation of the T-Cell “ex-vivo”.

However, engineering primary immune cells is not without any consequences on the growth/physiology of such cells. In particular one major challenge is to avoid cells exhaustion/anergy that significantly reduces their immune reaction and life span. This is more likely to happen when the cells are artificially activated ahead of their infusion into the patient. It is also the case when a cell is endowed with a CAR that is too reactive.

To avoid these pitfalls, the inventors have thought about taking advantage of the transcriptional regulation of some key genes during T-cell activation to express exogenous genetic sequences increasing the therapeutic potential of the immune cells. The exogenous genetic sequences to be expressed or co-expressed upon immune cell activation are introduced by gene targeted insertion using sequence-specific endonuclease reagents, so that their coding sequences are transcribed under the control of the endogenous promoters present at said loci. Alternatively, loci that are not expressed during immune cell activation can be used as “safe-harbor loci” for the integration of expression cassettes without any adverse consequences on the genome.

These cell engineering strategies, as per the present invention, tend to reinforce the therapeutic potential of primary immune cells in general, in particular by increasing their life span, persistence and immune activity, as well as by limiting cell exhaustion. The invention may be carried out on primary cells originating from patients as part of autologous treatment strategies, as well as from donors, as part of allogeneic treatment strategies.

### **Summary of the invention**

In a first aspect, the present invention provides a method for preparing engineered primary T cells for cell immunotherapy, said method comprising:

- providing a population of cells comprising primary T cells;
  - introducing into a proportion of said primary T-cells:
    - i) at least one nucleic acid comprising an exogenous polynucleotide sequence to be integrated at a selected endogenous locus to encode at least one NK cell inhibitor;
    - ii) at least one sequence-specific reagent that specifically targets said selected endogenous locus,
- wherein said exogenous polynucleotide sequence is inserted by targeted gene integration into said endogenous locus; and
- wherein said exogenous polynucleotide sequence comprises a sequence encoding at least one non polymorphic class I molecule or comprises a sequence encoding at least one viral evasin.

In a second aspect, the present invention provides an engineered T-cell obtained by the method of the first aspect.

In a third aspect, the present invention provides an engineered T-cell, which comprises an exogenous sequence encoding HLA-E and/or HLA-G integrated at the  $\beta 2m$  locus, resulting in the expression of a fusion of a HLA-E and/or HLA-G with  $\beta 2m$  fragments.

In a fourth aspect, the present invention provides use of an engineered T-cell according to the second or third aspect, in the manufacture of a medicament for the treatment of cancer or an infection.

In a fifth aspect, the present invention provides a method for the treatment of cancer or an infection in a subject, comprising administering to said subject an engineered T-cell according to the second or third aspect.

Non-homologous end-joining (NHEJ) and homology-directed repair (HDR) are the two major pathways used to repair in vivo DNA breaks. The latter pathway repairs the break in a template-dependent manner (HDR naturally utilizes the sister chromatid as a DNA repair template). Homologous recombination has been used for decades to precisely edit genomes with targeted DNA modifications using exogenously supplied donor template. The artificial generation of a double strand break (DSB) at the target location using rare-cutting endonucleases considerably enhances the efficiency of homologous recombination (e.g. US 8,921,332). Also the co-delivery of a rare-cutting endonuclease along with a donor template containing DNA sequences homologous to the break site enables HDR-based gene editing such as gene correction or gene insertion. However,

such techniques have not been widely used in primary immune cells, especially CAR T-cells, due to several technical limitations: difficulty of transfecting DNA into such types of cells leading to apoptosis, immune cells have a limited life span and number of generations, homologous recombination occurs at a low frequency in general.

5 So far, sequence specific endonuclease reagents have been mainly used in primary immune cells for gene inactivation (e.g. WO2013176915) using the NHEJ pathway.

The adoptive transfer of CAR T-cells represents a highly promising strategy to fight against multiple cancers. The clinical outcome of such therapies is intimately linked to the ability of effector cells to engraft, proliferate and specifically kill tumor cells within patients.

10 When allogeneic CAR T-cell infusion is considered, host versus graft and graft versus host reactions must be avoided to prevent rejection of adoptively transferred cells, to minimize host tissue damages and to elicit significant antitumoral outcomes.

The present invention provides with a novel cell-engineering strategy to address the aforementioned considerations by successfully generating  $\beta 2m$  deficient CAR T-cells, in which an exogenous sequence encoding NK inhibitor has been inserted by site directed gene editing for its expression during T-cell activation.

15 One major advantage of the present invention is to place such exogenous sequences encoding NK inhibitor under control of endogenous promoters, which transcriptional activity is not reduced by the effects of the immune cells activation.

In a preferred aspect, the present invention relies on performing site directed gene editing at the  $\beta 2m$  locus, in particular gene insertion (or multi gene insertions) in a target cell in order to have said integrated gene transcription preferentially be under the control of an endogenous promoter of said  $\beta 2m$  locus, preferably to be expressed in lieu of  $\beta 2m$ . Alternatively, the invention can rely on performing gene editing in primary immune cells to have integrated genes transcription be under the control of an endogenous promoter while maintaining the expression of the native gene through the use of cis-regulatory elements (e.g. 2A cis-acting hydrolase elements) or of internal ribosome entry site (IRES) in the donor template.

20 In further aspects, the invention relies on expressing a chimeric antigen receptor (CAR) at the TCR locus or at selected gene loci that are upregulated upon immune cells activation. The exogenous sequence(s) encoding the CAR and the endogenous gene coding sequence (s) may be co-transcribed, for instance by being separated by cis-regulatory elements (e.g. 2A cis-acting hydrolase elements) or by an internal ribosome entry site (IRES), which are also introduced. For instance, the exogenous sequences encoding a CAR can be placed under transcriptional control of the promoter of

endogenous genes that are activated by the tumor microenvironment, such as HIF1a, transcription factor hypoxia-inducible factor, or the aryl hydrocarbon receptor (AhR), which are gene sensors respectively induced by hypoxia and xenobiotics in the close environment of tumors.

5 In preferred embodiments, the method of the invention comprises the step of generating a double-strand break at a locus highly transcribed under tumor microenvironment, by expressing sequence-specific nuclease reagents, such as TALEN, ZFN or RNA-guided endonucleases as non-limiting examples, in the presence of a DNA repair matrix preferably set into an AAV6 based vector. This DNA donor template  
10 generally includes two homology arms embedding unique or multiple Open Reading Frames and regulatory genetic elements (stop codon and polyA sequences).

The exogenous sequences encoding NK inhibitors preferably comprise sequences encoding non polymorphic class I molecules or viral evasins such as UL18 [Uniprot #F5HFB4] and UL16 [also called ULBP1 - Uniprot #Q9BZM6], fragments or fusions  
15 thereof.

According to a preferred embodiment said exogenous sequence encodes a polypeptide displaying at least 80% amino acid sequence identity with HLA-G or HLA-E or a functional variant thereof.

20 These exogenous sequences can be introduced into the genome by deleting or modifying the endogenous coding sequence(s) present at said locus (knock-out by knock-in), so that a gene inactivation can be combined with transgenesis.

Depending on the locus targeted and its involvement in immune cells activity, the targeted endogenous gene may be inactivated or maintained in its original function. Should the targeted gene be essential for immune cells activity, this insertion procedure  
25 can generate a single knock-in (KI) without gene inactivation. In the opposite, if the targeted gene is deemed involved in immune cells inhibition/exhaustion, the insertion procedure is designed to prevent expression of the endogenous gene, preferably by knocking-out the endogenous sequence, while enabling expression of the introduced exogenous coding sequence(s).

30 In more specific aspects, the invention relies on up-regulating, with various kinetics, the target gene expression upon activation of the CAR signalling pathway by targeted integration (with or without the native gene disruption) at the specific loci such as, as non-limiting example, PD1, PDL1, CTLA-4, TIM3, LAG3, TNFa or IFNg.

In an even more specific aspect, it is herein described engineered immune cells,  
35 and preferably primary immune cells for infusion into patients, comprising exogenous sequences encoding IL-15 or IL-12 polypeptide(s), which are integrated at the PD1,

CD25 or CD69 endogenous locus for their expression under the control of the endogenous promoters present at these loci.

The immune cells according to the present invention can be [CAR]<sup>positive</sup>, [CAR]<sup>negative</sup>, [TCR]<sup>positive</sup>, or [TCR]<sup>negative</sup>, depending on the therapeutic indications and recipient patients. In one preferred aspect, the immune cells are further made [TCR]<sup>negative</sup> for allogeneic transplantation. This can be achieved especially by genetic disruption of at least one endogenous sequence encoding at least one component of TCR, such as TRAC (locus encoding TCRalpha), preferably by integration of an exogenous sequence encoding a chimeric antigen receptor (CAR) or a recombinant TCR, or component(s) thereof.

According to a further aspect of the invention, the immune cells are transfected with further exogenous sequence, in addition to that coding for a NK inhibitor, encoding polypeptide which can associate and preferably interfere with a cytokine receptor of the IL-6 receptor family, such as a mutated GP130. In particular, the invention provides immune cells, preferably T-cells, which secrete soluble mutated GP130, aiming at reducing cytokine release syndrome (CRS) by interfering, and ideally block, interleukine-6 (IL-6) signal transduction. CRS is a well-known complication of cell immunotherapy leading to auto immunity that appears when the transduced immune cells start to be active in-vivo. Following binding of IL-6 to its receptor IL-6R, the complex associate with the GP130 subunit, initiating signal transduction and a cascade of inflammatory responses. According to a particular aspect, a dimeric protein comprising the extracellular domain of GP130 fused to the Fc portion of an IgG1 antibody (sgp130Fc) is expressed in the engineered immune cells to bind specifically soluble IL-R/IL-6 complex to achieve partial or complete blockade of IL-6 trans signaling.

According to a further aspect of the invention, cytokine release syndrome (CRS) can be mitigated by acting on other pathways, especially by inhibiting the macrophage activated syndrome (MAS) which is a amplifying component of CRS. To achieve this goal, the invention comprises integrating exogenous sequences encoding antagonists of the IL1 and IL18 activating pathways, such as IL1RA and/or IL18BP. Accordingly, the present invention provides methods for generating therapeutic cells, according to which exogenous sequences encoding IL1RA and/or IL18BP are integrated at selected loci, such as one selected loci presented herein.

The present invention thus refers to various methods for limiting CRS in immunotherapy, in combination or without NK inhibitors, wherein immune cells are genetically modified to express a soluble polypeptide which can associate and preferably interfere with IL1 or IL18, such as IL1RA, IL18BP, or cytokine receptor of the IL-6 receptor

family, such as sgp130Fc. According to a preferred aspect, this sequence encoding said soluble polypeptide which can associate and preferably interfere with IL1, IL18 or a cytokine receptor of the IL-6 receptor family, is integrated under control of an endogenous promoter, preferably at one locus responsive to T-cells activation, such as one selected from Tables 6, 8 or 9, more especially PD1, CD25 or CD69 loci. Polynucleotide sequences of the vectors, donor templates comprising the exogenous coding sequences and/or sequences homologous to the endogenous loci, the sequences pertaining to the resulting engineered cells, as well as those permitting the detection of said engineered cells are all part of the present disclosure.

The gene editing step of integrating an exogenous sequence encoding NK inhibitor as per the present invention can be combined with any other step contributing to enhance the potency or the safety of the engineered immune cells. As non-limiting examples, genetic sequences can be introduced for the expression of components of biological "logic gates" ("AND" or "OR" or "NOT" or any combination of these) by targeted integration. Similar to the electronic logic gates, such cellular components expressed at different loci can exchange negative and positive signals that rule, for instance, the conditions of activation of an immune cell. Such component encompasses as non-limiting examples positive and negative chimeric antigen receptors that may be used to control T-cell activation and the resulting cytotoxicity of the engineered T-cells in which they are expressed.

According to a preferred embodiment, the invention relies on introducing the sequence specific endonuclease reagent and/or the donor template containing the gene of interest and sequences homologous to the target gene by transfecting ssDNA (oligonucleotides as non-limiting example), dsDNA (plasmid DNA as non-limiting example), and more particularly adeno-associated virus (AAV) as non-limiting example.

The invention also relates to the vectors, donor templates, reagents, screening methods for identifying new NK inhibitors, and to the resulting engineered cells pertaining to the above methods, as well as their use thereof in therapy.

### **Brief description of the figures and Tables:**

**Figure 1:** Strategies for engineering hematopoietic stem cells (HSCs) by introducing exogenous sequences at specific loci under transcriptional control of endogenous promoters specifically activated in specific immune cell types. The figure lists examples of specific endogenous genes, at which loci the exogenous coding sequence(s) can be inserted for expression in the desired hematopoietic lineages as per the present

invention. The goal is to produce ex-vivo engineered HSCs to be engrafted into patients, in order for them to produce immune cells in-vivo, which will express selected transgenes while they get differentiated into a desired lineage.

**Figure 2:** Schematic representation of the donor sequences used in the experimental section to insert IL-15 exogenous coding sequence at the CD25 and PD1 loci and also the anti-CD22 CAR exogenous coding sequence at the TRAC locus. **A:** donor template (designated IL-15m-CD25) designed for site directed insertion of IL-15 at the CD25 locus for obtaining co-transcription of CD25 and IL-15 polypeptides by the immune cell. Sequences are detailed in the examples. **B:** donor template (designated IL-15m-PD1) designed for site directed insertion of IL-15 at the PD1 locus for obtaining transcription of IL-15 under the transcriptional activity of the promoter of PD1 endogenous gene. The PD1 right and Left border sequences can be selected so as to keep the PD1 endogenous coding sequence intact or disrupted. In this later case, PD1 is knocked-out while IL-15 is Knocked-in and transcribed. **C:** donor template designed for site directed insertion of a chimeric antigen receptor (ex: anti-CD22 CAR) into the TCR locus (ex: TRAC). In general, the left and right borders are chosen so as to disrupt the TCR in order to obtain  $[TCR]^{neg}[CAR]^{pos}$  engineered immune cells suitable for allogeneic transplant into patients.

**Figure 3:** Flow cytometry measures of the frequency of targeted integration of IL-15m at either the PD1 or CD25 locus by using respectively PD1 or CD25 TALEN<sup>®</sup>, in a context where an anti-CD22 CAR is also integrated at the TRAC locus using TRAC TALEN<sup>®</sup>. These results show efficient targeted integration of both the CAR anti-CD22 at the TRAC locus together and the IL-15 coding sequence at the PD1 or CD25 loci. **A:** mock transfected primary T-cells. **B:** primary T-cells transfected with the donor sequences described in figure 1 (B and C) and specific TALEN<sup>®</sup> for the double integration at the TCR and PD1 loci. **C:** primary T-cells transfected with the donor sequences described in figure 1 (A and C) and specific TALEN<sup>®</sup> for the double integration at the TCR and CD25 loci.

**Figure 4:** Schematic representation of the exogenous sequences used in the experimental section to transfect the primary immune cells to obtain the results shown in figures 5 and 6.

**Figure 5 and 6:** Flow cytometry measures for LNGFR expression among viable T-cells transfected with donor templates of figure 4 and specific TALEN<sup>®</sup> (TCR and CD25), upon antiCD3/CD28 non-specific activation (Dynabeads<sup>®</sup>) and upon CAR dependent

tumor cell activation (raji tumor cells). As shown in figure 6, LNGFR expression was specifically induced in [CAR anti-CD22]<sup>positive</sup> cells upon CAR/tumor engagement.

**Figure 7 and 8:** Flow cytometry measures for CD25 expression among viable T-cells transfected with donor templates of figure 4 and specific TALEN<sup>®</sup> (TCR and CD25) upon antiCD3/CD28 non-specific activation (Dynabeads<sup>®</sup>) and Tumor cell activation (raji tumor cells). As shown in figure 8, CD25 expression was specifically induced in [CAR anti-CD22]<sup>positive</sup> cells upon CAR/tumor engagement.

**Figure 9:** Schematic representation of the exogenous sequences used in the experimental section to transfect the primary immune cells to obtain the results shown in figures 11 and 12.

**Figure 10 and 11:** Flow cytometry measures for LNGFR expression among viable T-cells transfected with donor templates of figure 9 and specific TALEN<sup>®</sup> (TCR and PD1) upon antiCD3/CD28 non-specific activation (Dynabeads<sup>®</sup>) and Tumor cell activation (raji tumor cells). As shown in figure 11, LNGFR expression was specifically induced in [CAR anti-CD22]<sup>positive</sup> cells upon CAR/tumor engagement.

**Figure 12:** Flow cytometry measures for endogenous PD1 expression among viable T-cells transfected with donor templates of figure 9 upon antiCD3/CD28 non-specific activation (Dynabeads<sup>®</sup>) and Tumor cell activation (raji tumor cells) with and without using TALEN<sup>®</sup> (TCR and PD1). PD1 was efficiently Knocked-out by TALEN treatment (8% remaining expression of PD1 out of 54 %).

**Figure 13:** Diagram showing IL-15 production in [CAR]<sup>positive</sup> (CARm) and [CAR]<sup>negative</sup> engineered immune cells according to the invention transfected with the donor template described in Figure 2 (B) and TALEN<sup>®</sup> for insertion of IL-15 exogenous coding sequences into the PD1 locus. IL15, which transcription was under control of endogenous PD1 promoter, was efficiently induced upon antiCD3/CD28 non-specific activation (Dynabeads<sup>®</sup>) and Tumor cell activation (raji tumor cells) and secreted in the culture media.

**Figure 14:** Graph showing the amount of IL-15 secreted over time (days) post activation by the immune cells engineered according to the invention. **A:** Cells engineered by integration of the IL-15 coding sequence at the CD25 locus using the DNA donor templates described in Figures 2A (IL-15m\_CD25) and/or 2C (CARm). **B:** Cells engineered by integration of the IL-15 coding sequence at the PD1 locus using the DNA donor templates described in Figures 2B (IL-15m\_PD1) and/or 2C (CARm). Integrations

at both loci show similar IL-15 secretion profiles. Secretion of IL-15 is significantly increased by tumor specific activation of CAR.

**Figure 15:** Graph reporting number of Raji-Luc tumor cells expressing CD22 antigen (luciferase signal) over time in a survival assay (serial killing assay) as described in Example 2. The immune cells (PBMCs) have been engineered to integrate IL-15 coding sequences at the PD1 (**A**) or CD25 locus (**B**) and to express anti-CD22-CAR at the TCR locus (thereby disrupting TCR expression). In this assay, tumor cells are regularly added to the culture medium, while being partially or totally eliminated by the CAR positive cells. The re-expression of IL-15 at either PD1 or CD25 cells dramatically helps the elimination of the tumor cells by the CAR positive cells.

**Figure 16:** Schematic representation of the donor sequences used in the experimental section to insert at the PD1 locus the exogenous sequences encoding IL-12 and gp130Fc. **A:** donor template (designated IL-12m-PD1) designed for site directed insertion of IL-12a and IL-12b coding sequences (SEQ ID NO:47 and 48) at the PD1 locus for obtaining co-transcription of IL-12a and IL-12b, while disrupting PD1 endogenous coding sequence. The right and left border sequences homologous to the PD1 locus sequences are at least 100pb long, preferably at least 200 pb long, and more preferably at least 300 pb long and comprising SEQ ID NO:45 and 46. Sequences are detailed in Table 5. **B:** donor template (designated gp130Fcm-PD1) designed for site directed insertion of gp130Fc coding sequences (SEQ ID NO:51) for obtaining transcription at the PD1 locus under PD1 promoter, while disrupting PD1 endogenous coding sequence. The right and left border sequences homologous to the PD1 locus sequences are at least 100pb long, preferably at least 200 pb long, and more preferably at least 300 pb long and comprising SEQ ID NO:45 and 46. Sequences are detailed in Table 5.

**Figure 17:** MHC-I negative T cells can be targeted for NK cell attack.  $[\beta 2m]^{neg}$  T-cells were cultured in the presence or absence of CD2/NKp46 activated NK cells at the indicated E:T ratios. The data demonstrate greater than 50% depletion of MHC I negative T cells at all E:T ratios tested.

**Figure 18:** Diagrams showing the strategy deployed as per the method of the present invention to obtain engineered CAR T cells products resistant to both NK and allogeneic T cell cytolytic activity.

**Figure 19:** Schematic of targeted integration constructs for double targeted integration of CAR and NK inhibitors at the TRAC and  $\beta 2m$  loci respectively. (see example 3).

**Figure 20:** General structure of HLA-E trimer that can be encoded by the exogenous sequence integrated at the  $\beta 2m$  locus in the CAR positive T cells of the present invention.

**Figure 21:** Double targeted integration of CAR and NK inhibitor constructs in TRAC/B2M deficient T cells obtained as per the experiments presented in example 3. Flow cytometry analysis of engineered CAR T cells treated with TALENs and targeted integration constructions. NK inhibitor expression is documented within TRAC/B2M deficient CAR + T cells.

**Table 1:** ISU domain variants from diverse viruses.

**Table 2:** Aminoacid sequences of FP polypeptide from natural and artificial origins.

**Table 3:** List of genes involved into immune cells inhibitory pathways, which can be advantageously modified or inactivated by inserting exogenous coding sequence according to the invention.

**Table 4:** sequences referred to in example 1.

**Table 5:** sequences referred to in example 2 and 3.

**Table 6:** List of human genes that are up-regulated upon T-cell activation (CAR activation sensitive promoters), in which gene targeted insertion is sought according to the present invention to improve immune cells therapeutic potential.

**Table 7:** Selection of genes that are steadily transcribed during immune cell activation (dependent or independent from T-cell activation).

**Table 8:** Selection of genes that are transiently upregulated upon T-cell activation.

**Table 9:** Selection of genes that are upregulated over more than 24 hours upon T-cell activation.

**Table 10:** Selection of genes that are down-regulated upon immune cell activation.

**Table 11:** Selection of genes that are silent upon T-cell activation (safe harbor gene targeted integration loci).

**Table 12:** List of gene loci upregulated in tumor exhausted infiltrating lymphocytes (compiled from multiple tumors) useful for gene integration of exogenous coding sequences as per the present invention.

**Table 13:** List of gene loci upregulated in hypoxic tumor conditions useful for gene integration of exogenous coding sequences as per the present invention.

**Detailed description of the invention**

5 Unless specifically defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled artisan in the fields of gene therapy, biochemistry, genetics, and molecular biology.

All methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, with suitable methods and materials being described herein. All publications, patent applications, patents, and other  
10 references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will prevail. Further, the materials, methods, and examples are illustrative only and are not intended to be limiting, unless otherwise specified.

15 The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al,  
20 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I.  
25 Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press, Inc., New York), specifically, Vols.154 and 155 (Wu et al. eds.) and Vol. 185, "Gene Expression Technology" (D. Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In  
30 Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

35 The present invention is drawn to a general method of preparing primary immune cells for cell immunotherapy involving gene targeted integration of an exogenous coding

sequence into the chromosomal DNA of said immune cells. According to some aspects, this integration is performed in such a way that said coding sequence is placed under the transcriptional control of at least one promoter endogenous to said cells, said endogenous promoter being preferably not a constitutive promoter, such as the one transcribing T-cell receptor alpha constant (TRAC - NCBI Gene ID #28755) A constitutive promoter as per the present invention is for instance a promoter that is active independently from CAR activation – ex: when T-cells are not yet activated.

#### Improving the therapeutic potential of immune cells by gene targeted integration

Gene editing techniques using polynucleotide sequence-specific reagents, such as rare-cutting endonucleases, have become the state of the art for the introduction of genetic modifications into primary cells. However, they have not been used so far in immune cells to introduce exogenous coding sequences under the transcriptional control of endogenous promoters.

The present invention aims to improve the therapeutic potential of immune cells through gene editing techniques, especially by gene targeted integration.

By “gene targeting integration” is meant any known site-specific methods allowing to insert, replace or correct a genomic sequence into a living cell. According to a preferred aspect of the present invention, said gene targeted integration involves homologous gene recombination at the locus of the targeted gene to result the insertion or replacement of at least one exogenous nucleotide, preferably a sequence of several nucleotides (i.e. polynucleotide), and more preferably a coding sequence.

By “sequence-specific reagent” is meant any active molecule that has the ability to specifically recognize a selected polynucleotide sequence at a genomic locus, preferably of at least 9 bp, more preferably of at least 10 bp and even more preferably of at least 12 pb in length, in view of modifying said genomic locus. According to a preferred aspect of the invention, said sequence-specific reagent is preferably a sequence-specific nuclease reagent.

By “immune cell” is meant a cell of hematopoietic origin functionally involved in the initiation and/or execution of innate and/or adaptative immune response, such as typically CD3 or CD4 positive cells. The immune cell according to the present invention can be a dendritic cell, killer dendritic cell, a mast cell, a NK-cell, a B-cell or a T-cell selected from the group consisting of inflammatory T-lymphocytes, cytotoxic T-lymphocytes, regulatory T-lymphocytes or helper T-lymphocytes. Cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion,

spleen tissue, and from tumors, such as tumor infiltrating lymphocytes. In some embodiments, said immune cell can be derived from a healthy donor, from a patient diagnosed with cancer or from a patient diagnosed with an infection. In another embodiment, said cell is part of a mixed population of immune cells which present different phenotypic characteristics, such as comprising CD4, CD8 and CD56 positive cells.

By "primary cell" or "primary cells" are intended cells taken directly from living tissue (e.g. biopsy material) and established for growth in vitro for a limited amount of time, meaning that they can undergo a limited number of population doublings. Primary cells are opposed to continuous tumorigenic or artificially immortalized cell lines. Non-limiting examples of such cell lines are CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44 cells; K-562 cells, U-937 cells; MRC5 cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells; Molt 4 cells. Primary cells are generally used in cell therapy as they are deemed more functional and less tumorigenic.

In general, primary immune cells are provided from donors or patients through a variety of methods known in the art, as for instance by leukapheresis techniques as reviewed by Schwartz J. et al. (Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue (2013) *J Clin Apher.* 28(3):145-284).

The primary immune cells according to the present invention can also be differentiated from stem cells, such as cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells (HSC) and induced pluripotent stem cells (iPS).

By "nuclease reagent" is meant a nucleic acid molecule that contributes to a nuclease catalytic reaction in the target cell, preferably an endonuclease reaction, by itself or as a subunit of a complex such as a guide RNA/Cas9, preferably leading to the cleavage of a nucleic acid sequence target.

The nuclease reagents of the invention are generally "sequence-specific reagents", meaning that they can induce DNA cleavage in the cells at predetermined loci, referred to by extension as "targeted gene". The nucleic acid sequence which is recognized by the sequence specific reagents is referred to as "target sequence". Said target sequence is usually selected to be rare or unique in the cell's genome, and more extensively in the human genome, as can be determined using software and data available from human genome databases, such as <http://www.ensembl.org/index.html>.

“Rare-cutting endonucleases” are sequence-specific endonuclease reagents of choice, insofar as their recognition sequences generally range from 10 to 50 successive base pairs, preferably from 12 to 30 bp, and more preferably from 14 to 20 bp.

According to a preferred aspect of the invention, said endonuclease reagent is a nucleic acid encoding an “engineered” or “programmable” rare-cutting endonuclease, such as a homing endonuclease as described for instance by Arnould S., et al. (WO2004067736), a zing finger nuclease (ZFN) as described, for instance, by Urnov F., et al. (Highly efficient endogenous human gene correction using designed zinc-finger nucleases (2005) *Nature* 435:646-651), a TALE-Nuclease as described, for instance, by Mussolino et al. (A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity (2011) *Nucl. Acids Res.* 39(21):9283-9293), or a MegaTAL nuclease as described, for instance by Boissel et al. (MegaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering (2013) *Nucleic Acids Research* 42 (4):2591-2601).

According to another embodiment, the endonuclease reagent is a RNA-guide to be used in conjunction with a RNA guided endonuclease, such as Cas9 or Cpf1, as per, *inter alia*, the teaching by Doudna, J., and Chapentier, E., (The new frontier of genome engineering with CRISPR-Cas9 (2014) *Science* 346 (6213):1077), which is incorporated herein by reference.

According to a preferred aspect of the invention, the endonuclease reagent is transiently expressed into the cells, meaning that said reagent is not supposed to integrate into the genome or persist over a long period of time, such as be the case of RNA, more particularly mRNA, proteins or complexes mixing proteins and nucleic acids (eg: Ribonucleoproteins).

In general, 80% the endonuclease reagent is degraded by 30 hours, preferably by 24, more preferably by 20 hours after transfection.

An endonuclease under mRNA form is preferably synthesized with a cap to enhance its stability according to techniques well known in the art, as described, for instance, by Kore A.L., et al. (Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization (2009) *J Am Chem Soc.* 131(18):6364-5).

In general, electroporation steps that are used to transfect immune cells are typically performed in closed chambers comprising parallel plate electrodes producing a pulse electric field between said parallel plate electrodes greater than 100 volts/cm and less than 5,000 volts/cm, substantially uniform throughout the treatment volume such as described in WO/2004/083379, which is incorporated by reference, especially from page

23, line 25 to page 29, line 11. One such electroporation chamber preferably has a geometric factor ( $\text{cm}^{-1}$ ) defined by the quotient of the electrode gap squared ( $\text{cm}^2$ ) divided by the chamber volume ( $\text{cm}^3$ ), wherein the geometric factor is less than or equal to  $0.1 \text{ cm}^{-1}$ , wherein the suspension of the cells and the sequence-specific reagent is in a medium which is adjusted such that the medium has conductivity in a range spanning 0.01 to 1.0 milliSiemens. In general, the suspension of cells undergoes one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the cells in the chamber is substantially uniform.

Due to their higher specificity, TALE-nuclease have proven to be particularly appropriate sequence specific nuclease reagents for therapeutic applications, especially under heterodimeric forms – i.e. working by pairs with a “right” monomer (also referred to as “5” or “forward”) and “left” monomer (also referred to as “3” or “reverse”) as reported for instance by Mussolino et al. (TALEN<sup>®</sup> facilitate targeted genome editing in human cells with high specificity and low cytotoxicity (2014) *Nucl. Acids Res.* 42(10): 6762-6773).

As previously stated, the sequence specific reagent is preferably under the form of nucleic acids, such as under DNA or RNA form encoding a rare cutting endonuclease a subunit thereof, but they can also be part of conjugates involving polynucleotide(s) and polypeptide(s) such as so-called “ribonucleoproteins”. Such conjugates can be formed with reagents as Cas9 or Cpf1 (RNA-guided endonucleases) or Argonaute (DNA-guided endonucleases) as recently respectively described by Zetsche, B. et al. (Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System (2015) *Cell* 163(3): 759–771) and by Gao F. et al. (DNA-guided genome editing using the *Neisseria meningitidis* Argonaute (2016) *Nature Biotech.*), which involve RNA or DNA guides that can be complexed with their respective nucleases.

“Exogenous sequence” refers to any nucleotide or nucleic acid sequence that was not initially present at the selected locus. This sequence may be homologous to, or a copy of, a genomic sequence, or be a foreign sequence introduced into the cell. By opposition “endogenous sequence” means a cell genomic sequence initially present at a locus. The exogenous sequence preferably codes for a polypeptide which expression confers a therapeutic advantage over sister cells that have not integrated this exogenous sequence at the locus. A endogenous sequence that is gene edited by the insertion of a nucleotide or polynucleotide as per the method of the present invention, in order to express a different polypeptide is broadly referred to as an exogenous coding sequence

The method of the present invention can be associated with other methods involving physical of genetic transformations, such as a viral transduction or transfection

using nanoparticles, and also may be combined with other gene inactivation and/or transgene insertions.

According to one aspect, the method according to the invention comprises the steps of:

- 5       - providing a population of primary immune cells;
- introducing into a proportion of said primary immune cells:
  - i)       At least one nucleic acid comprising an exogenous nucleotide or polynucleotide sequence to be integrated at a selected endogenous locus to encode at least one molecule improving the therapeutic potential of said
  - 10       immune cells population;
  - ii)      At least one sequence-specific reagent that specifically targets said selected endogenous locus,

wherein said exogenous nucleotide or polynucleotide sequence is inserted by targeted gene integration into said endogenous locus, so that said exogenous nucleotide or

15       polynucleotide sequence forms an exogenous coding sequence under transcriptional control of an endogenous promoter present at said locus.

According to one aspect of the method, the sequence specific reagent is a nuclease and the targeted gene integration is operated by homologous recombination or NHEJ into said immune cells.

20       According to a further aspect of the invention, said endogenous promoter is selected to be active during immune cell activation and preferably up-regulated. More specifically, the invention is drawn to a method for preparing engineered primary immune cells for cell immunotherapy, said method comprising:

- providing a population of primary immune cells;
- 25       - introducing into a proportion of said primary immune cells:
  - i)       At least one exogenous nucleic acid comprising an exogenous coding sequence encoding at least one molecule improving the therapeutic potential of said immune cells population;
  - ii)      At least one sequence-specific nuclease reagent that specifically targets a
  - 30       gene which is under control of an endogenous promoter active during immune cell activation;

wherein said coding sequence is introduced into the primary immune cells genome by targeted homologous recombination, so that said coding sequence is placed under the transcriptional control of at least one endogenous promoter of said gene.

35       By "improving therapeutic potential" is meant that the engineered immune cells gain at least one advantageous property for their use in cell therapy by comparison to

their sister non-engineered immune cells. The therapeutic properties sought by the invention maybe any measurable one as referred to in the relevant scientific literature.

Improved therapeutic potential can be more particularly reflected by a resistance of the immune cells to a drug, an increase in their persistence *in-vitro* or *in-vivo*, or a  
5 safer/more convenient handling during manufacturing of therapeutic compositions and treatments.

In general said molecule improving the therapeutic potential is a polypeptide, but it can also be a nucleic acid able to direct or repress expression of other genes, such as interference RNAs or guide-RNAs. The polypeptides may act directly or indirectly, such as  
10 signal transducers or transcriptional regulators.

According to one embodiment of the present method, the exogenous sequence is introduced into the endogenous chromosomal DNA by targeted homologous recombination. Accordingly, the exogenous nucleic acid introduced into the immune cell comprises at least one coding sequence(s), along with sequences that can hybridize  
15 endogenous chromosomal sequences under physiological conditions. In general, such homologous sequences show at least 70 %, preferably 80% and more preferably 90% sequence identity with the endogenous gene sequences located at the insertion locus. These homologous sequences may flank the coding sequence to improve the precision of recombination as already taught for instance in US 6,528,313. Using available software  
20 and on-line genome databases, it is possible to design vectors that includes said coding sequence (s), in such a way that said sequence(s) is (are) introduced at a precise locus, under transcriptional control of at least one endogenous promoter, which is a promoter of an endogenous gene. The exogenous coding sequence(s) is (are) then preferably inserted "in frame" with said endogenous gene. The sequences resulting from the  
25 integration of the exogenous polynucleotide sequence(s) can encode many different types of proteins, including fusion proteins, tagged protein or mutated proteins. Fusion proteins allow adding new functional domains to the proteins expressed in the cell, such as a dimerization domain that can be used to switch-on or switch-off the activity of said protein, such as caspase-9 switch. Tagged proteins can be advantageous for the detection of the  
30 engineered immune cells and the follow-up of the patients treated with said cells. Introducing mutation into proteins can confer resistance to drugs or immune depletion agents as further described below.

*Conferring resistance to drugs or immune depletion agents*

According to one aspect of the present method, the exogenous sequence that is integrated into the immune cells genomic locus encodes a molecule that confers resistance of said immune cells to a drug.

Examples of preferred exogenous sequences are variants of dihydrofolate reductase (DHFR) conferring resistance to folate analogs such as methotrexate, variants of inosine monophosphate dehydrogenase 2 (IMPDH2) conferring resistance to IMPDH inhibitors such as mycophenolic acid (MPA) or its prodrug mycophenolate mofetil (MMF), variants of calcineurin or methylguanine transferase (MGMT) conferring resistance to calcineurin inhibitor such as FK506 and/or CsA, variants of mTOR such as mTORMut conferring resistance to rapamycin) and variants of Lck, such as Lckmut conferring resistance to Imatinib and Gleevec.

The term "drug" is used herein as referring to a compound or a derivative thereof, preferably a standard chemotherapy agent that is generally used for interacting with a cancer cell, thereby reducing the proliferative or living status of the cell. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents (e.g., cyclophosphamide, ifosamide), metabolic antagonists (e.g., purine nucleoside antimetabolite such as clofarabine, fludarabine or 2'-deoxyadenosine, methotrexate (MTX), 5-fluorouracil or derivatives thereof), antitumor antibiotics (e.g., mitomycin, adriamycin), plant-derived antitumor agents (e.g., vincristine, vindesine, Taxol), cisplatin, carboplatin, etoposide, and the like. Such agents may further include, but are not limited to, the anti-cancer agents TRIMETHOTRIZATE™ (TMTX), TEMOZOLOMIDE™, RALTITREXED™, S-(4-Nitrobenzyl)-6-thioinosine (NBMPR), 6-benzylguanidine (6-BG), bis-chloronitrosourea (BCNU) and CAMPTOTHECIN™, or a therapeutic derivative of any thereof.

As used herein, an immune cell is made "resistant or tolerant" to a drug when said cell, or population of cells is modified so that it can proliferate, at least in-vitro, in a culture medium containing half maximal inhibitory concentration (IC50) of said drug (said IC50 being determined with respect to an unmodified cell(s) or population of cells).

In a particular embodiment, said drug resistance can be conferred to the immune cells by the expression of at least one "drug resistance coding sequence". Said drug resistance coding sequence refers to a nucleic acid sequence that confers "resistance" to an agent, such as one of the chemotherapeutic agents referred to above. A drug resistance coding sequence of the invention can encode resistance to anti-metabolite, methotrexate, vinblastine, cisplatin, alkylating agents, anthracyclines, cytotoxic antibiotics, anti-immunophilins, their analogs or derivatives, and the like (Takebe, N., S. C. Zhao, et al. (2001) "Generation of dual resistance to 4-hydroperoxycyclophosphamide and

methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene". *Mol. Ther.* 3(1): 88-96), (Zielske, S. P., J. S. Reese, et al. (2003) "In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning." *J. Clin. Invest.* 112(10): 1561-70) (Nivens, M. C., T. Felder, et al. (2004) "Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase" *Cancer Chemother Pharmacol* 53(2): 107-15), (Bardenheuer, W., K. Lehmborg, et al. (2005). "Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells". *Leukemia* 19(12): 2281-8), (Kushman, M. E., S. L. Kabler, et al. (2007) "Expression of human glutathione S-transferase P1 confers resistance to benzo[a]pyrene or benzo[a]pyrene-7,8-dihydrodiol mutagenesis, macromolecular alkylation and formation of stable N2-Gua-BPDE adducts in stably transfected V79MZ cells co-expressing hCYP1A1" *Carcinogenesis* 28(1): 207-14).

The expression of such drug resistance exogenous sequences in the immune cells as per the present invention more particularly allows the use of said immune cells in cell therapy treatment schemes where cell therapy is combined with chemotherapy or into patients previously treated with these drugs.

Several drug resistance coding sequences have been identified that can potentially be used to confer drug resistance according to the invention. One example of drug resistance coding sequence can be for instance a mutant or modified form of Dihydrofolate reductase (DHFR). DHFR is an enzyme involved in regulating the amount of tetrahydrofolate in the cell and is essential to DNA synthesis. Folate analogs such as methotrexate (MTX) inhibit DHFR and are thus used as anti-neoplastic agents in clinic. Different mutant forms of DHFR which have increased resistance to inhibition by antifolates used in therapy have been described. In a particular embodiment, the drug resistance coding sequence according to the present invention can be a nucleic acid sequence encoding a mutant form of human wild type DHFR (GenBank: AAH71996.1), which comprises at least one mutation conferring resistance to an anti-folate treatment, such as methotrexate. In particular embodiment, mutant form of DHFR comprises at least one mutated amino acid at position G15, L22, F31 or F34, preferably at positions L22 or F31 (Schweitzer et al. (1990) "Dihydrofolate reductase as a therapeutic target" *Faseb J* 4(8): 2441-52; International application WO94/24277; and US patent US 6,642,043). In a particular embodiment, said DHFR mutant form comprises two mutated amino acids at position L22 and F31. Correspondence of amino acid positions described herein is frequently expressed in terms of the positions of the amino acids of the form of wild-type

DHFR polypeptide. In a particular embodiment, the serine residue at position 15 is preferably replaced with a tryptophan residue. In another particular embodiment, the leucine residue at position 22 is preferably replaced with an amino acid which will disrupt binding of the mutant DHFR to antifolates, preferably with uncharged amino acid residues such as phenylalanine or tyrosine. In another particular embodiment, the phenylalanine residue at positions 31 or 34 is preferably replaced with a small hydrophilic amino acid such as alanine, serine or glycine.

Another example of drug resistance coding sequence can also be a mutant or modified form of ionisine-5'- monophosphate dehydrogenase II (IMPDH2), a rate-limiting enzyme in the de novo synthesis of guanosine nucleotides. The mutant or modified form of IMPDH2 is a IMPDH inhibitor resistance gene. IMPDH inhibitors can be mycophenolic acid (MPA) or its prodrug mycophenolate mofetil (MMF). The mutant IMPDH2 can comprises at least one, preferably two mutations in the MAP binding site of the wild type human IMPDH2 (Genebank: NP\_000875.2) leading to a significantly increased resistance to IMPDH inhibitor. Mutations in these variants are preferably at positions T333 and/or S351 (Yam, P., M. Jensen, et al. (2006) "Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells" *Mol. Ther.* 14(2): 236-44)(Jonnalagadda, M., et al. (2013) "Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy." *PLoS One* 8(6): e65519).

Another drug resistance coding sequence is the mutant form of calcineurin. Calcineurin (PP2B - NCBI: ACX34092.1) is an ubiquitously expressed serine/threonine protein phosphatase that is involved in many biological processes and which is central to T-cell activation. Calcineurin is a heterodimer composed of a catalytic subunit (CnA; three isoforms) and a regulatory subunit (CnB; two isoforms). After engagement of the T-cell receptor, calcineurin dephosphorylates the transcription factor NFAT, allowing it to translocate to the nucleus and active key target gene such as IL2. FK506 in complex with FKBP12, or cyclosporine A (CsA) in complex with CyPA block NFAT access to calcineurin's active site, preventing its dephosphorylation and thereby inhibiting T-cell activation (Brewin et al. (2009) "Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease" *Blood* 114(23): 4792-803). In a particular embodiment, said mutant form can comprise at least one mutated amino acid of the wild type calcineurin heterodimer a at positions: V314, Y341, M347, T351, W352, L354, K360, preferably double mutations at positions T351 and L354 or V314 and Y341. In a particular

embodiment, the valine residue at position 341 can be replaced with a lysine or an arginine residue, the tyrosine residue at position 341 can be replaced with a phenylalanine residue; the methionine at position 347 can be replaced with the glutamic acid, arginine or tryptophane residue; the threonine at position 351 can be replaced with the glutamic acid residue; the tryptophane residue at position 352 can be replaced with a cysteine, glutamic acid or alanine residue, the serine at position 353 can be replaced with the histidine or asparagines residue, the leucine at position 354 can be replaced with an alanine residue; the lysine at position 360 can be replaced with an alanine or phenylalanine residue. In another particular embodiment, said mutant form can comprise at least one mutated amino acid of the wild type calcineurin heterodimer b at positions: V120, N123, L124 or K125, preferably double mutations at positions L124 and K125. In a particular embodiment, the valine at position 120 can be replaced with a serine, an aspartic acid, phenylalanine or leucine residue; the asparagines at position 123 can be replaced with a tryptophan, lysine, phenylalanine, arginine, histidine or serine; the leucine at position 124 can be replaced with a threonine residue; the lysine at position 125 can be replaced with an alanine, a glutamic acid, tryptophan, or two residues such as leucine-arginine or isoleucine-glutamic acid can be added after the lysine at position 125 in the amino acid sequence. Correspondence of amino acid positions described herein is frequently expressed in terms of the positions of the amino acids of the form of wild-type human calcineurin heterodimer b polypeptide (NCBI: ACX34095.1).

Another drug resistance coding sequence is O(6)-methylguanine methyltransferase (MGMT - UniProtKB: P16455) encoding human alkyl guanine transferase (hAGT). AGT is a DNA repair protein that confers resistance to the cytotoxic effects of alkylating agents, such as nitrosoureas and temozolomide (TMZ). 6-benzylguanine (6-BG) is an inhibitor of AGT that potentiates nitrosourea toxicity and is co-administered with TMZ to potentiate the cytotoxic effects of this agent. Several mutant forms of MGMT that encode variants of AGT are highly resistant to inactivation by 6-BG, but retain their ability to repair DNA damage (Maze, R. et al. (1999) "Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment" *J. Pharmacol. Exp. Ther.* 290(3): 1467-74). In a particular embodiment, AGT mutant form can comprise a mutated amino acid of the wild type AGT position P140. In a preferred embodiment, said proline at position 140 is replaced with a lysine residue.

Another drug resistance coding sequence can be multidrug resistance protein (MDR1) gene. This gene encodes a membrane glycoprotein, known as P-glycoprotein (P-GP) involved in the transport of metabolic byproducts across the cell membrane. The P-

Gp protein displays broad specificity towards several structurally unrelated chemotherapy agents. Thus, drug resistance can be conferred to cells by the expression of nucleic acid sequence that encodes MDR-1 (Genebank NP\_000918).

Another drug resistance coding sequence can contribute to the production of cytotoxic antibiotics, such as those from *ble* or *mcrA* genes. Ectopic expression of *ble* gene or *mcrA* in an immune cell gives a selective advantage when exposed to the respective chemotherapeutic agents bleomycine and mitomycin C (Belcourt, M.F. (1999) "Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA". *PNAS*. 96(18):10489-94).

Another drug resistance coding sequence can come from genes encoded mutated version of drug targets, such as mutated variants of mTOR (mTOR mut) conferring resistance to rapamycin such as described by Lorenz M.C. et al. (1995) "TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin" *The Journal of Biological Chemistry* 270, 27531-27537, or certain mutated variants of Lck (Lckmut) conferring resistance to Gleevec as described by Lee K.C. et al. (2010) "Lck is a key target of imatinib and dasatinib in T-cell activation", *Leukemia*, 24: 896–900.

As described above, the genetic modification step of the method can comprise a step of introduction into cells of an exogenous nucleic acid comprising at least a sequence encoding the drug resistance coding sequence and a portion of an endogenous gene such that homologous recombination occurs between the endogenous gene and the exogenous nucleic acid. In a particular embodiment, said endogenous gene can be the wild type "drug resistance" gene, such that after homologous recombination, the wild type gene is replaced by the mutant form of the gene which confers resistance to the drug.

#### *Enhancing persistence of the immune cells in-vivo*

According to one aspect of the present method, the exogenous sequence that is integrated into the immune cells genomic locus encodes a molecule that enhances persistence of the immune cells, especially *in-vivo* persistence in a tumor environment.

By "enhancing persistence" is meant extending the survival of the immune cells in terms of life span, especially once the engineered immune cells are injected into the patient. For instance, persistence is enhanced, if the mean survival of the modified cells is significantly longer than that of non-modified cells, by at least 10%, preferably 20%, more preferably 30%, even more preferably 50%.

This especially relevant when the immune cells are allogeneic. This may be done by creating a local immune protection by introducing coding sequences that ectopically express and/or secrete immunosuppressive polypeptides at, or through, the cell

membrane. A various panel of such polypeptides in particular antagonists of immune checkpoints, immunosuppressive peptides derived from viral envelope or NKG2D ligand can enhance persistence and/or an engraftment of allogeneic immune cells into patients.

According to one embodiment, the immunosuppressive polypeptide to be encoded by said exogenous coding sequence is a ligand of Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4 also known as CD152, GenBank accession number AF414120.1). Said ligand polypeptide is preferably an anti-CTLA-4 immunoglobulin, such as CTLA-4a Ig and CTLA-4b Ig or a functional variant thereof.

According to one embodiment, the immunosuppressive polypeptide to be encoded by said exogenous coding sequence is an antagonist of PD1, such as PD-L1 (other names: CD274, Programmed cell death 1 ligand; ref. UniProt for the human polypeptide sequence Q9NZQ7), which encodes a type I transmembrane protein of 290 amino acids consisting of a Ig V-like domain, a Ig C-like domain, a hydrophobic transmembrane domain and a cytoplasmic tail of 30 amino acids. Such membrane-bound form of PD-L1 ligand is meant in the present invention under a native form (wild-type) or under a truncated form such as, for instance, by removing the intracellular domain, or with one or more mutation(s) (Wang S et al., 2003, *J Exp Med.* 2003; 197(9): 1083–1091). Of note, PD1 is not considered as being a membrane-bound form of PD-L1 ligand according to the present invention. According to another embodiment, said immunosuppressive polypeptide is under a secreted form. Such recombinant secreted PD-L1 (or soluble PD-L1) may be generated by fusing the extracellular domain of PD-L1 to the Fc portion of an immunoglobulin (Haile ST et al., 2014, *Cancer Immunol. Res.* 2(7): 610–615; Song MY et al., 2015, *Gut.* 64(2):260-71). This recombinant PD-L1 can neutralize PD-1 and abrogate PD-1-mediated T-cell inhibition. PD-L1 ligand may be co-expressed with CTLA4 Ig for an even enhanced persistence of both.

According to another embodiment, the exogenous sequence encodes a polypeptide comprising a viral env immusuppressive domain (ISU), which is derived for instance from HIV-1, HIV-2, SIV, MoMuLV, HTLV-I, -II, MPMV, SRV-1, Syncitin 1 or 2, HERV-K or FELV.

The following Table 1 shows variants of ISU domain from diverse virus which can be expressed within the present invention.

**Table 1:** ISU domain variants from diverse viruses

ISU Amino acids sequences														
Amino acid positions														Virus origin
1	2	3	4	5	6	7	8	9	10	11	12	13	14	Origin

L	Q	A	R	I/V	L	A	V	E	R	Y	L	K/R/Q	D	HIV-1
L	Q	A	R	V	T	A	I	E	K	Y	L	K/A/Q	D/H	HIV-2
L	Q	A	R	L	L	A	V	E	R	Y	L	K	D	SIV
L	Q	N	R	R	G	L	D	L	L	F	L	K	E	MoMuLV
A	Q	N	R	R	G	L	D	L	L	F	W	E	Q	HTLV-I, -II
L	Q	N	R	R	G	L	D	L	L	T	A	E	Q	MPMV, SRV-1
L	Q	N	R	R	A	L	D	L	L	T	A	E	R	Syncitin 1
L	Q	N	R	R	G	L	D	M	L	T	A	A	Q	Syncitin 2
L	A	N	Q	I	N	D	L	R	Q	T	V	I	W	HERV-K
L	Q	N	R	R	G	L	D	I	L	F	L	Q	E	FELV

According to another embodiment, the exogenous sequence encodes a FP polypeptide such as gp41. The following Table 2 represents several FP polypeptide from natural and artificial origins.

**Table 2:** Amino acid sequences of FP polypeptide from natural and artificial origins

FP Amino acids sequences									
Amino acid positions									Origin
1	2	3	4	5	6	7	8	9	
G	A	L	F	L	G	F	L	G	HIV-1 gp41
A	G	F	G	L	L	L	G	F	Synthetic
A	G	L	F	L	G	F	L	G	Synthetic

According to another embodiment, the exogenous sequence encodes a non-human MHC homolog, especially a viral MHC homolog, or a chimeric  $\beta 2m$  polypeptide such as described by Margalit A. et al. (2003) "Chimeric  $\beta 2$  microglobulin/CD3 $\zeta$  polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8<sup>+</sup> T cells" *Int. Immunol.* 15 (11): 1379-1387.

According to one embodiment, the exogenous sequence encodes NKG2D ligand. Some viruses such as cytomegaloviruses have acquired mechanisms to avoid NK cell mediate immune surveillance and interfere with the NKG2D pathway by secreting a protein able to bind NKG2D ligands and prevent their surface expression (Welte, S.A et al. (2003) "Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein". *Eur. J. Immunol.*, 33, 194–203). In tumors cells, some mechanisms have evolved to evade NKG2D response by secreting NKG2D ligands such as ULBP2, MICB or MICA (Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, et al.

(2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. *Blood* 102: 1389–1396)

According to one embodiment, the exogenous sequence encodes a cytokine receptor, such as an IL-12 receptor. IL-12 is a well known activator of immune cells activation (Curtis J.H. (2008) "IL-12 Produced by Dendritic Cells Augments CD8+ T Cell Activation through the Production of the Chemokines CCL1 and CCL171". *The Journal of Immunology*. 181 (12): 8576-8584.

According to one embodiment the exogenous sequence encodes an antibody that is directed against inhibitory peptides or proteins. Said antibody is preferably be secreted under soluble form by the immune cells. Nanobodies from shark and camels are advantageous in this respect, as they are structured as single chain antibodies (Muyldermans S. (2013) "Nanobodies: Natural Single-Domain Antibodies" *Annual Review of Biochemistry* 82: 775-797). Same are also deemed more easily to fuse with secretion signal polypeptides and with soluble hydrophilic domains.

The different aspects developed above to enhance persistence of the cells are particularly preferred, when the exogenous coding sequence is introduced by disrupting an endogenous gene encoding  $\beta 2m$  or another MHC component.

More specific embodiments concern the integration of NK cells inhibitors to enhance the persistence of the engineered T cells of the present invention, which are based on the methods detailed in this specification and more specifically illustrated in figures 17 to 21 and Example 3.

In particular, the present invention further provides with methods for preparing engineered primary immune cells for cell immunotherapy, said method comprising:

- providing a population of cells comprising T-cells, preferably primary T-cells,
- introducing into a proportion of said T-cells:

- i) At least one nucleic acid comprising an exogenous polynucleotide sequence to be integrated at a selected endogenous locus to encode at least one NK cell inhibitor;

- ii) At least one sequence-specific reagent that specifically targets said selected endogenous locus,

wherein said exogenous polynucleotide sequence is inserted by targeted gene integration into said endogenous locus.

By NK cell inhibitor is meant a polypeptide which confers a protective effect to allogeneic T-cells against depletion by NK cells, in-vivo or in co-culture of immune cells. Such depletion, without NK cell inhibitor is observed for instance on the graph of figure 17.

5 Example of NK cell inhibitors are provided herein in example 3.

The exogenous polynucleotide sequence encoding the NK cell inhibitor, which preferably comprises one the sequences referred to in example 3, is preferably integrated under transcriptional control of an endogenous promoter present at said locus to obtain a  
10 more constant expression of said NK cell inhibitor.

According to a preferred aspect of the invention, said endogenous promoter is selected to be active during immune cell activation, such as the loci listed in Table 6, which are deemed actively transcribed during T-cell activation, at least deemed responsive to the activation of T-cells endowed with chimeric antigen receptor (CAR).  
15

According to preferred embodiments, the exogenous sequence encoding the NK inhibitor is integrated at an endogenous locus, which is up-regulated over more than 24 hours upon T-cell activation such as one selected from *Gzmb*, *Tbx21*, *Plek*, *Chek1*, *Slamf7*, *Zbtb32*, *Tigit*, *Lag3*, *Gzma*, *Wee1*, *IL12rb2*, *Eea1* and *Dtl*.

20 According to preferred embodiments, the exogenous sequence encoding the NK inhibitor is integrated at an endogenous locus, which is constitutively expressed, such as at the TCR locus.

According to the invention it can be advantageous to integrate the exogenous sequence encoding the NK inhibitor at a locus of insertion expressing a MHC I component, in particular at the  $\beta 2m$  locus, which is also a locus constitutively transcribed.  
25

According to the invention, it can be advantageous to inactivate the endogenous  $\beta 2m$  endogenous coding sequence, while having the integrated exogenous sequence encoding the NK inhibitor being transcribed at this locus.

According to a preferred aspect of the invention, the engineered T-cells comprising said exogenous sequence encoding NK inhibitor are endowed with a chimeric antigen receptor (CAR) as described in different parts of the present specification. Said chimeric antigen receptor (CAR) can be advantageously integrated at the TCR locus, while the exogenous sequence encoding NK inhibitor is preferably integrated at the  $\beta 2m$  locus, thereby preventing or reducing both TCR and/or  $\beta 2m$  expression.  
30

35 The sequence specific reagent used in this method is preferably a rare-cutting endonuclease as described before in the present specification or known by one skilled in

the art. Targeted gene integration is generally operated by homologous recombination or NHEJ into said immune cells. Said specific endonuclease reagent is preferably selected from a RNA or DNA-guided endonuclease, such as Cas9 or Cpf1, a RNA or DNA guide, a TAL-endonuclease, a zing finger nuclease, a homing endonuclease or any combination thereof.

In one preferred embodiment of the present invention illustrated in example 3, TALE-nucleases have been optimized and successfully used to perform gene integration at the  $\beta 2m$  locus by limiting off site cleavage in human T-cells. Better specificity and efficiency were unexpectedly obtained using TALE-nuclease heterodimers of polypeptide sequences SEQ ID NO. 80 and/or SEQ ID NO.81 or SEQ ID NO.82 and/or SEQ ID NO.83 – right and left dimers respectively. The present patent application thus specifically pertains to the above polypeptide sequences encoding those specific  $\beta 2m$  TALEN, alone or by pairs, or any endonuclease sequence involving TAL repeats comprising one of the following RVD sequences:

- HD-HD-NN-NG-NN-NN-HD-HD-NG-NG-NI-NN-HD-NG-NN
- HD-HD-NI-NN-NN-HD-HD-NI-NN-NI-NI-NI-NN-NI-NN
- NG-NI-NN-HD-NG-NN-NG-NN-HD-NG-HD-NN-HD-NN-HD
- NN-NN-NI-NG-NI-NN-HD-HD-NG-HD-HD-NI-NN-NN-HD

as well as to any polynucleotides and vectors encoding these polypeptides.

Furthermore, it is an object of the present invention to carry out integration of an exogenous sequence into the genome of a T-cell by using an endonuclease that specifically recognizes or binds a  $\beta 2m$  genomic sequence comprising one of the following target sequences SEQ ID NO.78 and SEQ ID NO.79.

It is also an object of the present invention to inactivate a  $\beta 2m$  genomic sequence in a T-cell by using an endonuclease that specifically recognizes a sequence comprising the target sequences SEQ ID NO.78 and SEQ ID NO.79.

According to the present invention, said exogenous sequence encoding NK inhibitors preferably comprise sequences encoding non polymorphic class I molecules, such as HLA-G or HLA-E or at least fragment(s) comprising a heavy chain from these molecules.

According to a preferred aspect, said exogenous sequence, when integrated at  $\beta 2m$  endogenous locus, results into the expression of a fusion of a HLA-E or HLA-G of fragment thereof with  $\beta 2m$  fragments, which generally results into the expression of dimer or trimers of HLA-E or HLA-G, such as illustrated in figure 20 and exemplified in Example 3.

According to a preferred embodiment said exogenous sequence encodes a polypeptide displaying at least 80% amino acid sequence identity with one selected from SEQ ID NO.84 to 90.

Exogenous sequence encoding NK inhibitors can also comprise sequences encoding viral evasins or fragments comprising an epitope thereof, such as from UL16 (also called ULBP1 - Uniprot ref.:#Q9BZM6) or UL18.

The integration of the exogenous sequence encoding NK inhibitor(s) into the T-cell genome, preferably operated at the  $\beta 2m$  can be combined with the other exogenous sequence insertion described in the present specification in view of improving the potency and the suitability of the T-cells for adoptive cell immunotherapy.

Alternatively, the exogenous sequence encoding NK inhibitor(s) can be also advantageously integrated at loci encoding immune checkpoints, such as PD1 or CTLA4 (see complete list in the present specification), preferably with the effect of inactivating these genes.

Many examples of other successful loci are described elsewhere in the present application which could be appropriate to confer additional therapeutic advantage to the engineered T cells, such as for instance to confer resistance to drugs commonly used in cancer therapy, such as the DCK, HPRT or Glucocorticoids receptors (GR) loci.

As a result the present specification discloses engineered primary immune cells obtainable by the method described above.

Such immune cells can have the following features:

- 1) An engineered T-cell, which comprises an exogenous sequence encoding a NK inhibitor, which has been integrated under transcriptional control of an endogenous gene promoter.
- 2) An engineered T-cell according to any of item 1, wherein said endogenous gene promoter is selected at one locus listed in Table 6.
- 3) An engineered T-cell according to any one of items 1 or 2, wherein said exogenous sequence encoding a NK inhibitor has been integrated at a  $\beta 2m$  locus.
- 4) An engineered T-cell according to any one of items 1 to 3, wherein said T- cell is endowed with a chimeric antigen receptor.
- 5) An engineered T-cell according to item 4, which has a genotype  $[TCR]^{neg}[\beta 2m]^{neg}[CAR]^{pos}$
- 6) An engineered T-cell according to item 4 or 5, wherein the exogenous sequence(s) encoding said CAR has been integrated at a TCR locus.

- 7) An engineered T-cell according to any one of items 1 to 6, wherein said T-cell is a primary cell.
- 8) An engineered T-cell according to any one of items 1 to 7 for its use for the treatment of cancer or an infection.
- 5 9) A therapeutically effective population of immune cells, comprising at least 30 %, preferably 50 %, more preferably 80 % of engineered T-cells according to any one of items 1 to 8.

Preferred engineered T-cells according to the present invention comprise a  
 10 polynucleotide sequence, which shares at least 80%, more preferably 90%, even more preferably 95% identity with one of the polynucleotide sequences SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74 or SEQ ID NO. 76 (integration of trimer matrix at the  $\beta 2m$  locus as disclosed in example 3).

15 Examples of preferred genotypes of the engineered T-cells of the present invention, in connection with the other gene editing steps disclosed in the present application, are as follows:

- [CAR]<sup>pos</sup>[TCR]<sup>neg</sup>[ $\beta 2m$ ]<sup>neg</sup>[PD1]<sup>neg</sup>
- [CAR]<sup>pos</sup>[TCR]<sup>neg</sup>[ $\beta 2m$ ]<sup>neg</sup>[DCK]<sup>neg</sup>
- 20 - [CAR]<sup>pos</sup>[TCR]<sup>neg</sup>[ $\beta 2m$ ]<sup>neg</sup>[CTLA4]<sup>neg</sup>

The present specification also provides with therapeutic compositions comprising the engineered cells according to the present invention, in particular the following ones:

- 1) A therapeutically effective population of immune cells as per the present invention,  
 25 wherein at least 30 %, preferably 50 %, more preferably 80 % of cells originate from a donor, preferably one single donor.
- 2) A population of primary immune cells according to the above, wherein more than 50% of said immune cells are TCR negative T-cells.
- 30 3) A population of primary immune cells as described above, wherein more than 50% of said immune cells are CAR positive cells.

4) A pharmaceutical composition comprising an engineered immune cell population as described above.

5) A method for treating a patient in need thereof, wherein said method comprises:

- 5
- preparing a population of engineered primary immune cells as previously described;
  - optionally, purifying or sorting said engineered primary immune cells;
  - activating said population of engineered primary immune cells upon or after infusion of said cells into said patient.

10

6) A method as described above, wherein said patient is treated for cancer.

7) A method as described above, wherein said patient is treated for an infection.

15 The invention further provides with a method for screening candidate NK inhibitors by integration of exogenous sequences into T-cells, such as summarized below:

1) A method for identifying an appropriate sequence encoding a NK inhibitor expressible in a T-cell, wherein said method comprises at least the steps of:

- 20
- providing a T-cell in which both TCR and  $\beta 2m$  expressions are repressed and/or inactivated;
  - integrating a candidate sequence coding a putative NK inhibitor at an endogenous locus under control of an endogenous promoter in said T-cell ;
  - cultivating the resulting engineered T-cell in the presence of NK cells

25

2) A method for identifying an appropriate sequence encoding a NK inhibitor expressible in a T-cell, wherein said method comprises at least the steps of:

- 30
- providing a T-cell in which TCR expression is repressed or inactivated;
  - Inactivating  $\beta 2m$  expression in said T-cell by integrating a candidate sequence coding a putative NK inhibitor at the  $\beta 2m$  locus, the expression of said putative NK inhibitor being placed under transcriptional control of a endogenous promoter of said  $\beta 2m$  locus
  - cultivating the resulting engineered T-cell in the presence of NK cells

- 3) A method as described above, wherein said method further comprises the step of:
- endowing said T-cell with a chimeric antigen receptor.

- 5 4) A method as described above, wherein said method further comprises the step of :
- comparing the survival of said resulting engineered T-cell with same not expressing said candidate sequence.
  - Optionally, selecting the engineered cells that are more resistant to NK cells.

*Enhancing the therapeutic activity of immune cells*

According to one aspect of the present method, the exogenous sequence that is integrated into the immune cells genomic locus encodes a molecule that enhances the therapeutic activity of the immune cells.

5 By “enhancing the therapeutic activity” is meant that the immune cells, or population of cells, engineered according to the present invention, become more aggressive than non-engineered cells or population of cells with respect to a selected type of target cells. Said target cells generally belong to a defined type of cells, or population of cells, preferably characterized by common surface marker(s). In the present specification,  
10 “therapeutic potential” reflects the therapeutic activity, as measured through *in-vitro* experiments. In general sensitive cancer cell lines, such as Daudi cells, are used to assess whether the immune cells are more or less active towards said cells by performing cell lysis or growth reduction measurements. This can also be assessed by measuring levels of degranulation of immune cells or chemokines and cytokines production.  
15 Experiments can also be performed in mice with injection of tumor cells, and by monitoring the resulting tumor expansion. Enhancement of activity is deemed significant when the number of developing cells in these experiments is reduced by the immune cells by more than 10%, preferably more than 20%, more preferably more than 30 %, even more preferably by more than 50 %.

20 According to one aspect of the invention, said exogenous sequence encodes a chemokine or a cytokine, such as IL-12. It is particularly advantageous to express IL-12 as this cytokine is extensively referred to in the literature as promoting immune cell activation (Colombo M.P. et al. (2002) “Interleukin-12 in anti-tumor immunity and immunotherapy” *Cytokine Growth Factor Rev.* 13(2):155-68).

25 According to a preferred aspect of the invention the exogenous coding sequence encodes or promote secreted factors that act on other populations of immune cells, such as T-regulatory cells, to alleviate their inhibitory effect on said immune cells.

According to one aspect of the invention, said exogenous sequence encodes an inhibitor of regulatory T-cell activity is a polypeptide inhibitor of forkhead/winged helix  
30 transcription factor 3 (FoxP3), and more preferably is a cell-penetrating peptide inhibitor of FoxP3, such as that referred as P60 (Casares N. et al. (2010) “A peptide inhibitor of FoxP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.” *J Immunol* 185(9):5150-9).

By “inhibitor of regulatory T-cells activity” is meant a molecule or precursor of said  
35 molecule secreted by the T-cells and which allow T-cells to escape the down regulation

activity exercised by the regulatory T-cells thereon. In general, such inhibitor of regulatory T-cell activity has the effect of reducing FoxP3 transcriptional activity in said cells.

According to one aspect of the invention, said exogenous sequence encodes a secreted inhibitor of Tumor Associated Macrophages (TAM), such as a CCR2/CCL2 neutralization agent. Tumor-associated macrophages (TAMs) are critical modulators of the tumor microenvironment. Clinicopathological studies have suggested that TAM accumulation in tumors correlates with a poor clinical outcome. Consistent with that evidence, experimental and animal studies have supported the notion that TAMs can provide a favorable microenvironment to promote tumor development and progression. (Theerawut C. et al. (2014) "Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment" *Cancers (Basel)* 6(3): 1670–1690). Chemokine ligand 2 (CCL2), also called monocyte chemoattractant protein 1 (MCP1 - NCBI NP\_002973.1), is a small cytokine that belongs to the CC chemokine family, secreted by macrophages, that produces chemoattraction on monocytes, lymphocytes and basophils. CCR2 (C-C chemokine receptor type 2 - NCBI NP\_001116513.2), is the receptor of CCL2.

#### *Enhancing specificity and safety of immune cells*

Expressing chimeric antigen receptors (CAR) have become the state of the art to direct or improve the specificity of primary immune cells, such as T-Cells and NK-cells for treating tumors or infected cells. CARs expressed by these immune cells specifically target antigen markers at the surface of the pathological cells, which further help said immune cells to destroy these cells *in-vivo* (Sadelain M. et al. "The basic principles of chimeric antigen receptor design" (2013) *Cancer Discov.* 3(4):388-98). CARs are usually designed to comprise activation domains that stimulate immune cells in response to binding to a specific antigen (so-called positive CAR), but they may also comprise an inhibitory domain with the opposite effect (so-called negative CAR)(Fedorov, V. D. (2014) "Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells" *Cancer Journal* 20 (2):160–165. Positive and negative CARs may be combined or co-expressed to finely tune the cells immune specificity depending of the various antigens present at the surface of the target cells.

The genetic sequences encoding CARs are generally introduced into the cells genome using retroviral vectors that have elevated transduction efficiency but integrate at random locations. Here, according to the present invention, components of chimeric antigen receptor (CAR) can be introduced at selected loci, more particularly under control of endogenous promoters by targeted gene recombination.

According to one aspect, while a positive CAR is introduced into the immune cell by a viral vector, a negative CAR can be introduced by targeted gene insertion and vice-versa, and be active preferably only during immune cells activation. Accordingly, the inhibitory (i.e. negative) CAR contributes to an improved specificity by preventing the immune cells to attack a given cell type that needs to be preserved. Still according to this aspect, said negative CAR can be an apoptosis CAR, meaning that said CAR comprise an apoptosis domain, such as FasL (CD95 - NCBI: NP\_000034.1) or a functional variant thereof, that transduces a signal inducing cell death (Eberstadt M; et al. "NMR structure and mutagenesis of the FADD (Mort1) death-effector domain" (1998) *Nature*. 392 (6679): 941–5).

Accordingly, the exogenous coding sequence inserted according to the invention can encode a factor that has the capability to induce cell death, directly, in combination with, or by activating other compound(s).

As another way to enhance the safety of use of the primary immune cells, the exogenous coding sequence can encode molecules that confer sensitivity of the immune cells to drugs or other exogenous substrates. Such molecules can be cytochrome(s), such as from the P450 family (Preissner S et al. (2010) "SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions". *Nucleic Acids Res* 38 (Database issue): D237-43), such as CYP2D6-1 (NCBI - NP\_000097.3), CYP2D6-2 (NCBI - NP\_001020332.2), CYP2C9 (), CYP3A4 (NCBI - NP\_000762.2), CYP2C19 (NCBI - NP\_000760.1) or CYP1A2 (NCBI - NP\_000752.2.), conferring hypersensitivity of the immune cells to a drug, such as cyclophosphamide and/or isophosphamide.

According to a further aspect of the invention, an exogenous sequence is introduced into the engineered immune cells for its expression, especially in vivo, to reduce IL-6 or IL-8 trans signalling in view of controlling potential Cytokine Release Syndrome (CRS).

Such an exogenous sequence can encode for instance antibodies directed against IL-6 or IL-8 or against their receptors IL-6R or IL-8R [Shannon, L. et al. (2014) Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. *Cancer J*. 20(2): 119–122].

More specifically, cytokine release syndrome (CRS) can be mitigated by interfering with the macrophage activated syndrome which is one component of CRS [Lee, D.W. et al. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 124:188-195]. To achieve this goal, the invention comprises integrating exogenous sequences encoding antagonists of the IL1 or IL18 activating pathways, such

as IL1RA (Uniprot #P18510) or IL18BP (Uniprot #O95998) or active fragments or variants thereof.

By "antagonists of the IL1 and IL18 activating pathway" is meant any polypeptide able to interfere with higher expression of IL1 or IL18. Accordingly, the present invention provides methods for generating therapeutic cells, wherein exogenous sequences encoding IL1RA or IL18BP are integrated at selected loci, especially PD1, CD25 or CD69, and more preferably in combination with the expression of a CAR, optionally integrated at the TCR and/or PD1 loci.

Preferred exogenous sequences encode antagonists or antibodies that have been approved by drug agencies, such as those marketed under the following names and references:

- Anakinra (CAS registry no: 143090-92-0) (brand name Kineret) is a recombinant version of the interleukin 1 receptor antagonist (IL1-RA). Anakinra is a variant form of IL1RA as it differs from native human IL-1Ra by the addition of a single methionine residue at its amino terminus. Anakinra blocks the biologic activity of naturally occurring IL-1 [Kalliolias, GD. et al. (2008) The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. *Expert Opin Investig Drugs*. 17(3):349–59].

- Rilonacept, (CAS registry no: 501081-76-1) also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the brand name Arcalyst), is also an interleukin 1 inhibitor. It is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1 [McDermott, M.F., (2009) Rilonacept in the treatment of chronic inflammatory disorders. *Drugs of Today*. 45(6):423-430].

- Canakinumab (brand name Ilaris - CAS registry no: 914613-48-2) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha [Rondeau J.M. et al. (2015) The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1 $\beta$ . *MAbs*. 7(6):1151–60].

- Tocilizumab (brand name Actemra - CAS registry no: 375823-41-9) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) [Venkiteshwaran, A. (2009) Tocilizumab. *MAbs*. 1(5): 432–438].

- Siltuximab (brand name Sylvant - CAS registry no: 541502-14-1) is anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse

proteins) monoclonal antibody that binds to interleukin-6 [Rhee, F. et al. (2010) Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody for Castleman's Disease. *Journal of Clinical Oncology* 28 (23):3701–3708].

According to a preferred aspect said exogenous sequence can encode soluble extracellular domain of GP130, such as one showing at least 80% identity with SEQ ID NO. 61

Such soluble extracellular domain of GP130 is described for instance by Rose-John S. [The Soluble Interleukine Receptor: Advanced Therapeutic Options in Inflammation (2017) *Clinical Pharmacology & Therapeutics*, 102(4):591-598] can be fused with fragments of immunoglobulins, such as sgp130Fc (SEQ ID NO.62). As stated before, said exogenous sequence can be stably integrated into the genome by site directed mutagenesis (i.e. using sequence specific nuclease reagents) and be placed under the transcriptional activity of an endogenous promoter at a locus which is active during immune cell activation, such as one listed in Tables 6, 8 or 9, and preferably up-regulated upon CAR activation or being CAR dependent.

According to a more preferred embodiment, the exogenous sequence is introduced into a CAR positive immune cell, such as one expressing an anti-CD22 CAR T-cell polynucleotide sequence such as SEQ ID NO:31. According to some more specific embodiments, said exogenous sequence coding for a polypeptide which can associate, and preferably interfere, with a cytokine receptor of the IL-6 receptor family, such as said soluble extracellular domain of GP130, is integrated at a PD1, CD25 or CD69 locus. As per the present invention, the endogenous sequence encoding PD1 locus is preferably disrupted by said exogenous sequence.

The invention thus provides with a method for treating or reducing CRS in cell immunotherapy, wherein cells or a therapeutic composition thereof are administered to patients, said cells being genetically modified to secrete polypeptide(s) comprising a soluble extracellular domain of GP130, sGP130Fc, an anti-IL-6 or anti-IL6R antibody, an anti-IL-8 or anti-IL8R antibody, or any fusion thereof.

Examples of preferred genotypes of the engineered immune cells are:

- [CAR]<sup>positive</sup>[GP130]<sup>positive</sup>
- [CAR]<sup>positive</sup>[GP130]<sup>positive</sup>[TCR]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [GP130]<sup>positive</sup> [PD1]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [GP130]<sup>positive</sup> [β2m]<sup>negative</sup>
- [CAR]<sup>positive</sup>[GP130]<sup>positive</sup> [CD25]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [GP130]<sup>positive</sup> [CD25]<sup>negative</sup>
- [CAR]<sup>positive</sup>[sGP130]<sup>positive</sup>

- [CAR]<sup>positive</sup>[sGP130]<sup>positive</sup>[TCR]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [sGP130]<sup>positive</sup> [PD1]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [sGP130]<sup>positive</sup> [β2m]<sup>negative</sup>
- [CAR]<sup>positive</sup>[sGP130]<sup>positive</sup> [CD25]<sup>negative</sup>
- 5 - [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL1RA]<sup>positive</sup> [CD25]<sup>negative</sup>
- [CAR]<sup>positive</sup>[IL1RA]<sup>positive</sup>
- [CAR]<sup>positive</sup>[IL1RA]<sup>positive</sup>[TCR]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL1RA]<sup>positive</sup> [PD1]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL1RA]<sup>positive</sup> [β2m]<sup>negative</sup>
- 10 - [CAR]<sup>positive</sup>[IL1RA]<sup>positive</sup> [CD25]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL18BP]<sup>positive</sup> [CD25]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL18BP]<sup>positive</sup> [PD1]<sup>negative</sup>
- [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL18BP]<sup>positive</sup> [β2m]<sup>negative</sup>
- [CAR]<sup>positive</sup>[IL18BP]<sup>positive</sup> [CD25]<sup>negative</sup>
- 15 - [CAR]<sup>positive</sup>[TCR]<sup>negative</sup> [IL18BP]<sup>positive</sup> [CD25]<sup>negative</sup>

#### Improving the efficiency of gene targeted insertion in primary immune cells using AAV vectors

The present specification provides with donor templates and sequence specific reagents as illustrated in the figures that are useful to perform efficient insertion of a coding sequence in frame with endogenous promoters, in particular PD1 and CD25, as well as means and sequences for detecting proper insertion of said exogenous sequences at said loci.

The donor templates according to the present invention are generally polynucleotide sequences which can be included into a variety of vectors described in the art prompt to deliver the donor templates into the nucleus at the time the endonuclease reagents get active to obtain their site directed insertion into the genome generally by NHEJ or homologous recombination,

Specifically, the present invention provides specific donor polynucleotides for expression of IL-15 (SEQ ID NO.59) at the PD1 locus comprising one or several of the following sequences:

- Sequence encoding IL-15, such as one presenting identity with SEQ ID NO:50;
- Upstream and downstream (also referred to left and right) sequences homologous to the PD1 locus, comprising preferably polynucleotide sequences SEQ ID NO:45 and SEQ ID NO:46;

- optionally, a sequence encoding soluble form of an IL-15 receptor (sIL-15R), such as one presenting identity with SEQ ID NO:50;
- optionally, at least one  $\alpha$ 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

5

Specifically, the present invention provides specific donor polynucleotides for expression of IL-12 (SEQ ID NO:58) at the PD1 locus comprising one or several of the following sequences:

- Sequence encoding IL-12a, such as one presenting identity with SEQ ID NO:47;
- Upstream and downstream (also referred to left and right) sequences homologous to the PD1 locus, comprising preferably polynucleotide sequences SEQ ID NO:45 and SEQ ID NO:46;
- optionally, a sequence encoding IL-12b, such as one presenting identity with SEQ ID NO:48;
- optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of soluble GP130 (comprising SEQ ID NO.61) at the PD1 locus comprising one or several of the following sequences:

- Sequence encoding soluble GP130, preferably a soluble gp130 fused to a Fc, such as one presenting identity with SEQ ID NO:62;
- Upstream and downstream (also referred to left and right) sequences homologous to the PD1 locus, comprising preferably polynucleotide sequences SEQ ID NO:45 and SEQ ID NO:46;
- optionally, at least one  $\alpha$ 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of IL-15 (SEQ ID NO.59) at the CD25 locus comprising one or several of the following sequences:

- Sequence encoding IL-15, such as one presenting identity with SEQ ID NO:50;

- Upstream and downstream (also referred to left and right) sequences homologous to the CD25 locus, comprising preferably polynucleotide sequences SEQ ID NO:43 and SEQ ID NO:44;
- optionally, a sequence encoding soluble form of an IL-15 receptor (sIL-15R), such as one presenting identity with SEQ ID NO:50;
- optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of IL-12 (SEQ ID NO:58) at the CD25 locus comprising one or several of the following sequences:

- Sequence encoding IL-12a, such as one presenting identity with SEQ ID NO:47;
- Upstream and downstream (also referred to left and right) sequences homologous to the CD25 locus, comprising preferably polynucleotide sequences SEQ ID NO:43 and SEQ ID NO:44;
- optionally, a sequence encoding IL-12b, such as one presenting identity with SEQ ID NO:48;
- optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

Specifically, the present invention provides specific donor polynucleotides for expression of soluble GP130 (comprising SEQ ID NO.61) at the CD25 locus comprising one or several of the following sequences:

- Sequence encoding soluble GP130, preferably a soluble gp130 fused to a Fc, such as one presenting identity with SEQ ID NO:62;
- Upstream and downstream (also referred to left and right) sequences homologous to the CD25 locus, comprising preferably polynucleotide sequences SEQ ID NO:43 and SEQ ID NO:44;
- optionally, at least one 2A peptide cleavage site such as one of SEQ ID NO:53 (F2A), SEQ ID NO:54 (P2A) and/or SEQ ID NO:55 (T2A),

As illustrated in the examples herein, the inventors have significantly improved the rate of gene targeted insertion into human cells by using AAV vectors, especially vectors from the AAV6 family.

One broad aspect of the present invention is thus the transduction of AAV vectors in human primary immune cells, in conjunction with the expression of sequence specific endonuclease reagents, such as TALE endonucleases, more preferably introduced under mRNA form, to increase homologous recombination events in these cells.

5        According to one aspect of this invention, sequence specific endonuclease reagents can be introduced into the cells by transfection, more preferably by electroporation of mRNA encoding said sequence specific endonuclease reagents, such as TALE nucleases.

10       Still according to this broad aspect, the invention more particularly provides a method of insertion of an exogenous nucleic acid sequence into an endogenous polynucleotide sequence in a cell, comprising at least the steps of:

- transducing into said cell an AAV vector comprising said exogenous nucleic acid sequence and sequences homologous to the targeted endogenous DNA sequence, and
- 15       - Inducing the expression of a sequence specific endonuclease reagent to cleave said endogenous sequence at the locus of insertion.

The obtained insertion of the exogenous nucleic acid sequence may result into the introduction of genetic material, correction or replacement of the endogenous sequence, more preferably "in frame" with respect to the endogenous gene sequences at that locus.

20       According to another aspect of the invention, from  $10^5$  to  $10^7$  preferably from  $10^6$  to  $10^7$ , more preferably about  $5 \cdot 10^6$  viral genomes are transduced per cell.

According to another aspect of the invention, the cells can be treated with proteasome inhibitors, such as Bortezomib to further help homologous recombination.

25       As one object of the present invention, the AAV vector used in the method can comprise a promoterless exogenous coding sequence as any of those referred to in this specification in order to be placed under control of an endogenous promoter at one loci selected among those listed in the present specification.

30       As one object of the present invention, the AAV vector used in the method can comprise a 2A peptide cleavage site followed by the cDNA (minus the start codon) forming the exogenous coding sequence.

As one object of the present invention, said AAV vector comprises an exogenous sequence coding for a chimeric antigen receptor, especially an anti-CD19 CAR, an anti-CD22 CAR, an anti-CD123 CAR, an anti-CS1 CAR, an anti-CCL1 CAR, an anti-HSP70 CAR, an anti-GD3 CAR or an anti-ROR1 CAR.

The invention thus encompasses any AAV vectors designed to perform the method herein described, especially vectors comprising a sequence homologous to a locus of insertion located in any of the endogenous gene responsive to T-cell activation referred to in Table 4.

Many other vectors known in the art, such as plasmids, episomal vectors, linear DNA matrices, etc... can also be used following the teachings to the present invention.

As stated before, the DNA vector used according to the invention preferably comprises: (1) said exogenous nucleic acid comprising the exogenous coding sequence to be inserted by homologous recombination, and (2) a sequence encoding the sequence specific endonuclease reagent that promotes said insertion. According to a more preferred aspect, said exogenous nucleic acid under (1) does not comprise any promoter sequence, whereas the sequence under (2) has its own promoter. According to an even more preferred aspect, the nucleic acid under (1) comprises an Internal Ribosome Entry Site (IRES) or "self-cleaving" 2A peptides, such as T2A, P2A, E2A or F2A, so that the endogenous gene where the exogenous coding sequence is inserted becomes multicistronic. The IRES of 2A Peptide can precede or follow said exogenous coding sequence.

Preferred vectors of the present invention are vectors derived from AAV6, comprising donor polynucleotides as previously described herein or illustrated in the experimental section and figures. Examples of vectors according to the invention comprise or consist of polynucleotides having identity with sequences SEQ ID NO:37 (matrix for integration of sequence coding for IL-15 into the CD25 locus), SEQ ID NO:38 (matrix for integration of sequence coding for IL-15 into the PD1 locus), SEQ ID NO:39 (matrix for integration of sequence coding for IL-12 into the CD25 locus), SEQ ID NO:40 (matrix for integration of sequence coding for IL-12 into the PD1 locus), SEQ ID NO:69 (matrix for integration of HLA-E VMAPRTLFL peptide), SEQ ID NO:71 (matrix for integration of HLA-E VMAPRTLIL peptide), SEQ ID NO:73 (matrix for integration of UL18 actine peptide into the B2m locus), SEQ ID NO:75 (matrix for integration of UL18 HLA-Cw peptide inserted at the B2m locus), and SEQ ID NO:77 (matrix for integration of UL18- $\beta$ HLA-G peptide into the  $\beta$ 2m locus).

#### Gene targeted integration in immune cells under transcriptional control of endogenous promoters

The present invention, in one of its main aspects, is taking advantage of the endogenous transcriptional activity of the immune cells to express exogenous sequences that improve their therapeutic potential.

The invention provides with several embodiments based on the profile of transcriptional activity of the endogenous promoters and on a selection of promoter loci useful to carry out the invention. Preferred loci are those, which transcription activity is generally high upon immune cell activation, especially in response to CAR activation (CAR-sensitive promoters) when the cells are endowed with CARs.

Accordingly, the invention provides with a method for producing allogeneic therapeutic immune cells by expressing a first exogenous sequence encoding a CAR at the TCR locus, thereby disrupting TCR expression, and expressing a second exogenous coding sequence under transcriptional activity of an endogenous locus, preferably dependent from either:

- CD3/CD28 activation, such as dynabeads, which is useful for instance for promoting cells expansion;
- CAR activation, such as through the CD3zeta pathway, which is useful for instance to activate immune cells functions on-target;
- Transcriptional activity linked to the appearance of disease symptom or molecular marker. which is useful for instance for activating the cells *in-situ* in ill organs.
- Cell differentiation, which is useful for conferring therapeutic properties to cells at a given level of differentiation or to express protein into a particular lineage (see figure 1), for instance at the time hematopoietic cells gain their immune functions; or/and
- TME (Tumor microenvironment), which is useful for redirect cells activity and their amplification to specific tumor conditions (hypoxia, low glucose...), or for preventing exhaustion and/or sustaining activation;
- CRS (cytokine release syndrome), which is useful to mitigate adverse events related to CAR T-cell activity

The inventors have established a first list of endogenous genes (Table 6) which have been found to be particularly appropriate for applying the targeted gene recombination as per the present invention. To draw this list, they have come across several transcriptome murine databases, in particular that from the Immunological Genome Project Consortium referred to in Best J.A. et al. (2013) "Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation" *Nat. Immunol.* 14(4):404-12., which allows comparing transcription levels of various genes upon T-cell activation, in response to ovalbumin antigens. Also, because very few data is available with respect to human T-cell activation, they had to make some extrapolations and analysis from these data and compare with the human situation by studying available

literature related to the human genes. The selected loci are particularly relevant for the insertion of sequences encoding CARs. Based on the first selection of Table 6, they made subsequent selections of genes based on their expected expression profiles (Tables 7 to 10).

On another hand, the inventors have identified a selection of transcriptional loci that are mostly inactive, which would be most appropriate to insert expression cassette(s) to express exogenous coding sequence under the transcriptional control of exogenous promoters. These loci are referred to as "safe harbor loci" as those being mostly transcriptionally inactive, especially during T-Cell activation. They are useful to integrate a coding sequence by reducing at the maximum the risk of interfering with genome expression of the immune cells.

*Gene targeted insertion under control of endogenous promoters that are steadily active during immune cell activation*

A selection of endogenous gene loci related to this embodiment is listed in Table 7.

Accordingly the method of the present invention provides with the step of performing gene targeted insertion under control of an endogenous promoter that is constantly active during immune cell activation, preferably from of an endogenous gene selected from *CD3G*, *Rn28s1*, *Rn18s*, *Rn7sk*, *Actg1*,  $\beta 2m$ , *Rpl18a*, *Pabpc1*, *Gapdh*, *Rpl17*, *Rpl19*, *Rplp0*, *Cfl1* and *Pfn1*.

By "steadily active" means that the transcriptional activity observed for these promoters in the primary immune cell is not affected by a negative regulation upon the activation of the immune cell.

As reported elsewhere (Acuto, O. (2008) "Tailoring T-cell receptor signals by proximal negative feedback mechanisms". *Nature Reviews Immunology* 8:699-712), the promoters present at the TCR locus are subjected to different negative feedback mechanisms upon TCR engagement and thus may not be steadily active or up regulated during for the method of the present invention. The present invention has been designed to some extent to avoid using the TCR locus as a possible insertion site for exogenous coding sequences to be expressed during T-cell activation. Therefore, according to one aspect of the invention, the targeted insertion of the exogenous coding sequence is not performed at a TCRalpha or TCRbeta gene locus.

Examples of exogenous coding sequence that can be advantageously introduced at such loci under the control of steadily active endogenous promoters, are those encoding or positively regulating the production of a cytokine, a chemokine receptor, a molecule

conferring resistance to a drug, a co-stimulation ligand, such as 4-1BRL and OX40L, or of a secreted antibody.

*Gene integration under endogenous promoters that are dependent from immune cell activation or dependent from CAR activation*

As stated before, the method of the present invention provides with the step of performing gene targeted insertion under control of an endogenous promoter, which transcriptional activity is preferably up-regulated upon immune cell activation, either transiently or over more than 10 days.

By "immune cell activation" is meant production of an immune response as per the mechanisms generally described and commonly established in the literature for a given type of immune cells. With respect to T-cell, for instance, T- cell activation is generally characterized by one of the changes consisting of cell surface expression by production of a variety of proteins, including CD69, CD71 and CD25 (also a marker for Treg cells), and HLA-DR (a marker of human T cell activation), release of perforin, granzymes and granulysin (degranulation), or production of cytokine effectors IFN- $\gamma$ , TNF and LT-alpha.

According to a preferred embodiment of the invention, the transcriptional activity of the endogenous gene is up-regulated in the immune cell, especially in response to an activation by a CAR. The CAR can be independently expressed in the immune cell. By "independently expressed" is meant that the CAR can be transcribed in the immune cell from an exogenous expression cassette introduced, for instance, using a retroviral vector, such as a lentiviral vector, or by transfecting capped messenger RNAs by electroporation encoding such CAR. Many methods are known in the art to express a CAR into an immune cell as described for instance by (REF.)

Said endogenous gene whose transcriptional activity is up regulated are particularly appropriate for the integration of exogenous sequences to encode cytokine(s), such as IL-12 and IL-15, immunogenic peptide(s), or a secreted antibody, such as an anti-IDO1, anti-IL10, anti-PD1, anti-PDL1, anti-IL6 or anti-PGE2 antibody.

According to a preferred embodiment of the invention, the endogenous promoter is selected for its transcriptional activity being responsive to, and more preferably being dependent from CAR activation.

As shown herein, CD69, CD25 and PD1 are such loci, which are particularly appropriate for the insertion of expression of an exogenous coding sequences to be expressed when the immune cells get activated, especially into CAR positive immune cells.

The present invention thus combines any methods of expressing a CAR into an immune cell with the step of performing a site directed insertion of an exogenous coding sequence at a locus, the transcriptional activity of which is responsive to or dependent from the engagement of said CAR with a tumor antigen. Especially, the method comprises the step of introducing into a CAR positive or Recombinant TCR positive immune cell an exogenous sequence encoding IL-12 or IL-15 under transcriptional control of one promoter selected from PD1, CD25 and CD69 promoters.

In particular, CAR positive cells can be obtained by following the steps of co-expressing into an immune cell, preferably a primary cell, and more preferably into a primary T- cell, at least one exogenous sequence encoding a CAR and another exogenous sequence placed under an endogenous promoter dependent, which transcriptional activity is dependent from said CAR, such as PD1, CD25 or CD71.

The expression "dependent from said CAR" means that the transcriptional activity of said endogenous promoter is necessarily increased by more than 10%, preferably by more than 20 %, more preferably by more than 50% and even more preferably more than 80 %, as a result of the engagement of the CAR with its cognate antigen, in a situation where, in general, the antigens are exceeding the number of CARs present at the cell surface and the number of CARs expressed at the cell surface is more than 10 per cell, preferably more than 100, and more preferably more than 1000 molecules per cells.

The present invention thus teaches the expression of a CAR sequence, preferably inserted at the TCR locus and constitutively expressed, whereas another exogenous sequence integrated at another locus is co-expressed, in response to, or dependent from, the engagement of said CAR with its cognate antigen. Said another locus is for instance CD25, PD1 or CD71 or any loci being specifically transcribed upon CAR activation.

In other words, the invention provides the co-expression of a CAR and at least one exogenous coding sequence, the expression of said exogenous sequence being under control of an endogenous promoter the transcriptional activity of which is influenced by the CAR activity, this being done in view of obtaining engineered immune cells offering a better immune response.

As previously described, this can be performed by transfecting the cells with sequence-specific nuclease reagents targeting the coding regions of such loci being specifically CAR dependent, along with donor templates comprising sequences homologous to said genomic regions. The sequence specific nuclease reagents help the donor templates to be integrated by homologous recombination or NHEJ.

According to a preferred embodiment, the exogenous coding sequence is integrated in frame with the endogenous gene, so that the expression of said endogenous gene is

preserved. This is the case for instance with respect to CD25 and CD69 in at least one example of the experimental section herein.

According to a preferred embodiment, the exogenous sequence disrupts the endogenous coding sequence of the gene to prevent its expression of one endogenous coding sequence, especially when this expression has a negative effect on the immune cell functions, as it the case for instance with PD1 in the experimental section herein.

According to an even more preferred embodiments, the exogenous coding sequence, which disrupts the endogenous gene sequence is placed in frame with the endogenous promoter, so that its expression is made dependent from the endogenous promoter as also shown in the experimental section.

The present invention is also drawn to the polynucleotide and polypeptide sequences encoding the different TAL-nucleases exemplified in the present patent application, especially those permitting the site directed insertion at the CD25 locus (SEQ ID NO:18 and 19), as well as their respective target and RVD sequences.

The present invention also encompasses kits for immune cells transfection comprising polynucleotides encoding the sequence-specific endonuclease reagents and the donor sequences designed to integrate the exogenous sequence at the locus targeted by said reagents. Examples of such kits are a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding IL-12, a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding IL-15, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding IL-12, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding IL-15, a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding soluble gp130, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding soluble gp130, and any kits involving endonuclease reagents targeting a gene listed in table 6, and a donor matrix for introducing a coding sequence referred to in the present specification.

Further examples of such kits are a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding IL-12, a kit comprising mRNA encoding rare-cutting endonuclease targeting PD1 locus (ex: PD1 TALEN<sup>®</sup>) and an AAV vector comprising an

exogenous sequence encoding IL-15, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding IL-12, a kit comprising mRNA encoding rare-cutting endonuclease targeting CD25 locus (ex: CD25 TALEN<sup>®</sup>) and an AAV vector comprising  
 5 an exogenous sequence encoding IL-15, a kit comprising mRNA encoding rare-cutting endonuclease targeting  $\beta$ 2m locus (ex:  $\beta$ 2m TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence encoding NK inhibitor, such as comprising a heavy chain from HLA-E or HLA-G, a kit comprising mRNA encoding rare-cutting endonuclease targeting  $\beta$ 2m locus (ex:  $\beta$ 2m TALEN<sup>®</sup>) and an AAV vector comprising an exogenous sequence  
 10 encoding soluble gp130, and any kits involving endonuclease reagents targeting a gene listed in table 6, and a donor matrix for introducing a coding sequence referred to in the present specification

The present invention also provides kits for immune cells transfection comprising polynucleotides encoding sequence-specific endonuclease reagents and an exogenous  
 15 polynucleotide sequence, preferably comprised into a AAV vector, said exogenous sequence comprising a sequence encoding antagonists of the IL1 and IL18 activating pathways, such as IL1RA (Uniprot #P18510) or IL18BP (Uniprot #O95998) or active fragments or variants thereof.

According to one aspect of the invention, the endogenous gene is selected for a  
 20 weak up-regulation. The exogenous coding sequence introduced into said endogenous gene whose transcriptional activity is weakly up regulated, can be advantageously a constituent of an inhibitory CAR, or of an apoptotic CAR, which expression level has generally to remain lower than that of a positive CAR. Such combination of CAR expression, for instance one transduced with a viral vector and the other introduced  
 25 according to the invention, can greatly improve the specificity or safety of CAR immune cells

Some endogenous promoters are transiently up-regulated, sometimes over less than 12 hours upon immune cell activation, such as those selected from the endogenous gene loci *Spata6*, *Itga6*, *Rcbtb2*, *Cd1d1*, *St8sia4*, *Itgae* and *Fam214a* (Table 8). Other  
 30 endogenous promoters are up-regulated over less than 24 hours upon immune cell activation, such as those selected from the endogenous gene loci *IL3*, *IL2*, *Ccl4*, *IL21*, *Gp49a*, *Nr4a3*, *Lilrb4*, *Cd200*, *Cdkn1a*, *Gzmc*, *Nr4a2*, *Cish*, *Ccr8*, *Lad1* and *Crabp2* (Table 9) and others over more than 24 hours, more generally over more than 10 days, upon immune cell activation. Such as those selected from *Gzmb*, *Tbx21*, *Plek*, *Chek1*, *Slamf7*,  
 35 *Zbtb32*, *Tigit*, *Lag3*, *Gzma*, *Wee1*, *IL12rb2*, *Eea1* and *Dtl* (Table 9).

Alternatively, the inventors have found that endogenous gene under transcriptional control of promoters that are down-regulated upon immune cell activation, could also be of interest for the method according to the present invention. Indeed they have conceived that exogenous coding sequences encoding anti-apoptotic factors, such as of Bcl2 family, BclXL, NF-kB, Survivin, or anti-FAP (fibroblast activation protein), such as a constituent of a CAR anti-FAP, could be introduced at said loci. Said endogenous gene under transcriptional control of promoters that are down-regulated upon immune cell activation can be more particularly selected from *Slc6a19*, *Cd55*, *Xkrx*, *Mturn*, *H2-Ob*, *Cnr2*, *Itgae*, *Raver2*, *Zbtb20*, *Arrb1*, *Abca1*, *Tet1*, *Slc16a5* and *Ampd3* (Table 10)

Gene integration under endogenous promoters activated under tumor microenvironment (TME) conditions

One aspect of the present invention more particularly concerns methods to prevent immune cells exhaustion in tumor microenvironment (TME) conditions. Immune cells often get exhausted in response to nutrient depletion or molecular signals found in the microenvironment of tumors, which helps tumor resistance. The method comprises the steps of engineering immune cells by integrating exogenous coding sequences under control of endogenous promoters which are up-regulated under arginine, cysteine, tryptophan and oxygen deprivation as well as extracellular acidosis (lactate build up).

Such exogenous sequences may encode chimeric antigen receptors, interleukins, or any polypeptide given elsewhere in this specification to bolster immune cells function or activation and/or confer a therapeutic advantage.

The inventors have listed a number of loci which have been found to be upregulated in a large number of exhausted tumor infiltrating lymphocytes (TIL), which are listed in tables 12 and 13. The invention provides with the step of integrating exogenous coding sequences at these preferred loci to prevent exhaustion of the immune cells, in particular T-cells, in tumor microenvironment.

For instance, the exogenous sequences encoding a CAR can be placed under transcriptional control of the promoter of endogenous genes that are activated by the tumor microenvironment, such as HIF1a, transcription factor hypoxia-inducible factor, or the aryl hydrocarbon receptor (AhR). These genes are sensors respectively induced by hypoxia and xenobiotics in the close environment of tumors.

The present invention is thus useful to improve the therapeutic outcome of CAR T-cell therapies by integrating exogenous coding sequences, and more generally genetic

attributes/circuits, under the control of endogenous T-cell promoters influenced by tumor microenvironment (TME).

Pursuant to the invention, upregulation of endogenous genes can be “hijacked” to re-express relevant exogenous coding sequences to improve the antitumor activity of CAR T-cells in certain tumor microenvironment.

#### Gene targeted insertion and expression in Hematopoietic Stem Cells (HSCs)

One aspect of the present invention more particularly concerns the insertion of transgenes into hematopoietic stem cells (HSCs).

Hematopoietic stem cells (HSCs) are multipotent, self-renewing progenitor cells from which all differentiated blood cell types arise during the process of hematopoiesis. These cells include lymphocytes, granulocytes, and macrophages of the immune system as well as circulating erythrocytes and platelets. Classically, HSCs are thought to differentiate into two lineage-restricted, lymphoid and myelo-erythroid, oligopotent progenitor cells. The mechanisms controlling HSC self-renewal and differentiation are thought to be influenced by a diverse set of cytokines, chemokines, receptors, and intracellular signaling molecules. Differentiation of HSCs is regulated, in part, by growth factors and cytokines including colony-stimulating factors (CSFs) and interleukins (ILs) that activate intracellular signaling pathways. The factors depicted below are known to influence HSC multipotency, proliferation, and lineage commitment. HSCs and their differentiated progeny can be identified by the expression of specific cell surface lineage markers such as cluster of differentiation (CD) proteins and cytokine receptors into hematopoietic stem cells.

Gene therapy using HSCs has enormous potential to treat diseases of the hematopoietic system including immune diseases. In this approach, HSCs are collected from a patient, gene-modified ex-vivo using integrating retroviral vectors, and then infused into a patient. To date retroviral vectors have been the only effective gene delivery system for HSC gene therapy. Gene delivery to HSCs using integrating vectors thereby allowing for efficient delivery to HSC-derived mature hematopoietic cells. However, the gene-modified cells that are infused into a patient are a polyclonal population, where the different cells have vector proviruses integrated at different chromosomal locations, which can result into many adverse mutations, which may be amplified due to some proliferative/survival advantage of these mutations (Powers and

Trobridge (2013) "Identification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies" *J Stem Cell Res Ther* S3:004. doi:10.4172/2157-7633.S3-00).

HSCs are commonly harvested from the peripheral blood after mobilization (patients receive recombinant human granulocyte-colony stimulating factor (G-CSF)).

5 The patient's peripheral blood is collected and enriched for HSCs using the CD34+ marker. HSCs are then cultured ex vivo and exposed to viral vectors. The ex vivo culture period varies from 1 to 4 days. Prior to the infusion of gene-modified HSCs, patients may be treated with chemotherapy agents or irradiation to help enhance the engraftment efficiency. Gene-modified HSCs are re-infused into the patient intravenously.

10 The cells migrate into the bone marrow before finally residing in the sinusoids and perivascular tissue. Both homing and hematopoiesis are integral aspects of engraftment. Cells that have reached the stem cell niche through homing will begin producing mature myeloid and lymphoid cells from each blood lineage. Hematopoiesis continues through the action of long-term HSCs, which are capable of self-renewal for life-long generation  
15 of the patient's mature blood cells, in particular the production of common lymphoid progenitor cells, such as T cells and NK cells, which are key immune cells for eliminating infected and malignant cells.

The present invention provides with performing gene targeted insertion in HSCs to introduce exogenous coding sequences under the control of endogenous promoters,  
20 especially endogenous promoters of genes that are specifically activated into cells of a particular hematopoietic lineage or at particular differentiation stage, preferably at a late stage of differentiation. The HSCs can be transduced with a polynucleotide vector (donor template), such as an AAV vector, during an ex-vivo treatment as referred to in the previous paragraph, whereas a sequence specific nuclease reagent is expressed as to  
25 promote the insertion of the coding sequences at the selected locus. The resulting engineered HSCs can be then engrafted into a patient in need thereof for a long term *in-vivo* production of engineered immune cells that will comprise said exogenous coding sequences. Depending on the activity of the selected endogenous promoter, the coding sequences will be selectively expressed in certain lineages or in response to the local  
30 environment of the immune cells in-vivo, thereby providing adoptive immunotherapy.

According to one preferred aspect of the invention, the exogenous coding sequences are placed under the control of promoters of a gene, which transcriptional activity is specifically induced in common lymphoid progenitor cells, such as CD34, CD43, Flt-3/Flk-2, IL-7 R alpha/CD127 and Neprilysin/CD10.

35 More preferably, the exogenous coding sequences are placed under the control of promoters of a gene, which transcriptional activity is specifically induced in NK cells, such

as CD161, CD229/SLAMF3, CD96, DNAM-1/CD226, Fc gamma RII/CD32, Fc gamma RII/RIII (CD32/CD16), Fc gamma RIII (CD16), IL-2 R beta, Integrin alpha 2/CD49b, KIR/CD158, NCAM-1/CD56, NKG2A/CD159a, NKG2C/CD159c, NKG2D/CD314, NKp30/NCR3, NKp44/NCR2, NKp46/NCR1, NKp80/KLRF1, Siglec-7/CD328 and TIGIT, or induced in T-cells, such as CCR7, CD2, CD3, CD4, CD8, CD28, CD45, CD96, CD229/SLAMF3, DNAM-1/CD226, CD25/IL-2 R alpha, L-Selectin/CD62L and TIGIT.

The invention comprises as a preferred aspect the introduction of an exogenous sequence encoding a CAR, or a component thereof, into HSCs, preferably under the transcriptional control of a promoter of a gene that is not expressed in HSC, more preferably a gene that is only expressed in the hematopoietic cells produced by said HSC, and even more preferably of a gene that is only expressed in T-cells or NK cells.

*Conditional CAR expression in HSCs to overpass the thymus barrier*

A particular aspect of the present invention concerns the *in-vivo* production by the above engineered HSCs of hematopoietic immune cells, such as T-cells or NK-cells, expressing exogenous coding sequences, in particular a CAR or a component thereof.

One major bar of the production of hematopoietic CAR positive cells by engineered HSCs, for instance, is the rejection of the CAR positive cells by the immune system itself, especially by the thymus.

The blood-thymus barrier regulates exchange of substances between the circulatory system and thymus, providing a sequestered environment for immature T cells to develop. The barrier also prevents the immature T cells from contacting foreign antigens (since contact with antigens at this stage will cause the T cells to die by apoptosis).

One solution provided by the present invention is to place the sequences encoding the CAR components in the HSCs under the transcriptional control of promoters which are not significantly transcribed into the hematopoietic cells when they pass through the thymus barrier. One example of a gene that offers a conditional expression of the CAR into the hematopoietic cells with reduced or no significant transcriptional activity in the thymus is LCK (Uniprot: P06239).

According to a preferred aspect of the invention the exogenous sequence encoding a CAR, or a component thereof, is introduced into the HSC under the transcriptional control of a gene that is described as being specifically expressed in T-cells or NK cells, preferably in these types of cells only.

The invention thereby provides with a method of producing HSCs comprising an exogenous coding sequences to be expressed exclusively in selected hematopoietic

lineage(s), said coding sequences encoding preferably at least one component of a CAR or of an antigen in order to stimulate the immune system.

More broadly, the invention provides with a method of engineering HSCs by gene targeted insertion of an exogenous coding sequences to be selectively expressed in the hematopoietic cells produced by said HSCs. As a preferred embodiment, said hematopoietic cells produced by said engineered HSCs express said exogenous coding sequences in response to selected environmental factors or in-vivo stimuli to improve their therapeutic potential.

10 Combining targeted sequence insertion(s) in immune cells with the inactivation of endogenous genomic sequences

One particular focus of the present invention is to perform gene inactivation in primary immune cells at a locus, by integrating exogenous coding sequence at said locus, the expression of which improves the therapeutic potential of said engineered cells. Examples of relevant exogenous coding sequences that can be inserted according to the invention have been presented above in connection with their positive effects on the therapeutic potential of the cells. Here below are presented the endogenous gene that are preferably targeted by gene targeted insertion and the advantages associated with their inactivation.

20 According to a preferred aspect of the invention, the insertion of the coding sequence has the effect of reducing or preventing the expression of genes involved into self and non-self recognition to reduce host versus graft disease (GVHD) reaction or immune rejection upon introduction of the allogeneic cells into a recipient patient. For instance, one of the sequence-specific reagents used in the method can reduce or prevent the expression of TCR in primary T-cells, such as the genes encoding TCR-alpha or TCR-beta.

30 As another preferred aspect, one gene editing step is to reduce or prevent the expression of the  $\beta 2m$  protein and/or another protein involved in its regulation such as C2TA (Uniprot P33076) or in MHC recognition, such as HLA proteins. This permits the engineered immune cells to be less alloreactive when infused into patients.

By "allogeneic therapeutic use" is meant that the cells originate from a donor in view of being infused into patients having a different haplotype. Indeed, the present invention provides with an efficient method for obtaining primary cells, which can be gene edited in various gene loci involved into host-graft interaction and recognition.

35 Other loci may also be edited in view of improving the activity, the persistence of the therapeutic activity of the engineered primary cells as detailed here after:

*Inactivation of checkpoint receptors and immune cells inhibitory pathways:*

According to a preferred aspect of the invention, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of a protein involved in immune cells inhibitory pathways, in particular those referred to in the literature as “immune checkpoint” (Pardoll, D.M. (2012) The blockade of immune checkpoints in cancer immunotherapy, *Nature Reviews Cancer*, 12:252-264). In the sense of the present invention, “immune cells inhibitory pathways” means any gene expression in immune cells that leads to a reduction of the cytotoxic activity of the lymphocytes towards malignant or infected cells. This can be for instance a gene involved into the expression of FOXP3, which is known to drive the activity of Tregs upon T cells (moderating T-cell activity).

“Immune checkpoints” are molecules in the immune system that either turn up a signal (co-stimulatory molecules) or turn down a signal of activation of an immune cell. As per the present invention, immune checkpoints more particularly designate surface proteins involved in the ligand–receptor interactions between T cells and antigen-presenting cells (APCs) that regulate the T cell response to antigen (which is mediated by peptide–major histocompatibility complex (MHC) molecule complexes that are recognized by the T cell receptor (TCR)). These interactions can occur at the initiation of T cell responses in lymph nodes (where the major APCs are dendritic cells) or in peripheral tissues or tumours (where effector responses are regulated). One important family of membrane-bound ligands that bind both co-stimulatory and inhibitory receptors is the B7 family. All of the B7 family members and their known ligands belong to the immunoglobulin superfamily. Many of the receptors for more recently identified B7 family members have not yet been identified. Tumour necrosis factor (TNF) family members that bind to cognate TNF receptor family molecules represent a second family of regulatory ligand–receptor pairs. These receptors predominantly deliver co-stimulatory signals when engaged by their cognate ligands. Another major category of signals that regulate the activation of T cells comes from soluble cytokines in the microenvironment. In other cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on APCs. A2aR, adenosine A2a receptor; B7RP1, B7-related protein 1; BTLA, B and T lymphocyte attenuator; GAL9, galectin 9; HVEM, herpesvirus entry mediator; ICOS, inducible T cell co-stimulator; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; LAG3, lymphocyte activation gene 3; PD1, programmed cell death protein 1; PDL, PD1 ligand; TGF $\beta$ , transforming growth factor- $\beta$ ; TIM3, T cell membrane protein 3.

Examples of further endogenous genes, which expression could be reduced or suppressed to turn-up activation in the engineered immune cells according the present invention are listed in Table 3.

For instance, the inserted exogenous coding sequence(s) can have the effect of reducing or preventing the expression, by the engineered immune cell of at least one protein selected from PD1 (Uniprot Q15116), CTLA4 (Uniprot P16410), PPP2CA (Uniprot P67775), PPP2CB (Uniprot P62714), PTPN6 (Uniprot P29350), PTPN22 (Uniprot Q9Y2R2), LAG3 (Uniprot P18627), HAVCR2 (Uniprot Q8TDQ0), BTLA (Uniprot Q7Z6A9), CD160 (Uniprot O95971), TIGIT (Uniprot Q495A1), CD96 (Uniprot P40200), CRTAM (Uniprot O95727), LAIR1 (Uniprot Q6GTX8), SIGLEC7 (Uniprot Q9Y286), SIGLEC9 (Uniprot Q9Y336), CD244 (Uniprot Q9BZW8), TNFRSF10B (Uniprot O14763), TNFRSF10A (Uniprot O00220), CASP8 (Uniprot Q14790), CASP10 (Uniprot Q92851), CASP3 (Uniprot P42574), CASP6 (Uniprot P55212), CASP7 (Uniprot P55210), FADD (Uniprot Q13158), FAS (Uniprot P25445), TGFBRII (Uniprot P37173), TGFRBRI (Uniprot Q15582), SMAD2 (Uniprot Q15796), SMAD3 (Uniprot P84022), SMAD4 (Uniprot Q13485), SMAD10 (Uniprot B7ZSB5), SKI (Uniprot P12755), SKIL (Uniprot P12757), TGIF1 (Uniprot Q15583), IL10RA (Uniprot Q13651), IL10RB (Uniprot Q08334), HMOX2 (Uniprot P30519), IL6R (Uniprot P08887), IL6ST (Uniprot P40189), EIF2AK4 (Uniprot Q9P2K8), CSK (Uniprot P41240), PAG1 (Uniprot Q9NWQ8), SIT1 (Uniprot Q9Y3P8), FOXP3 (Uniprot Q9BZS1), PRDM1 (Uniprot Q60636), BATF (Uniprot Q16520), GUCY1A2 (Uniprot P33402), GUCY1A3 (Uniprot Q02108), GUCY1B2 (Uniprot Q8BXH3) and GUCY1B3 (Uniprot Q02153). The gene editing introduced in the genes encoding the above proteins is preferably combined with an inactivation of TCR in CAR T cells.

Preference is given to inactivation of PD1 and/or CTLA4, in combination with the expression of non-endogenous immunosuppressive polypeptide, such as a PD-L1 ligand and/or CTLA-4 Ig (see also peptides of Table 1 and 2).

**Table 3:** List of genes involved into immune cells inhibitory pathways

Pathway		Genes that can be inactivated In the pathway
Co-inhibitory receptors	CTLA4 (CD152)	CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22
	PDCD1 (PD-1, CD279)	PDCD1
	CD223 (lag3)	LAG3
	HAVCR2 (tim3)	HAVCR2
	BTLA(cd272)	BTLA
	CD160(by55)	CD160
	IgSF family	TIGIT

		CD96
		CRTAM
	LAIR1(cd305)	LAIR1
	SIGLECs	SIGLEC7
		SIGLEC9
	CD244(2b4)	CD244
Death receptors	TRAIL	TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7
	FAS	FADD, FAS
Cytokine signalling	TGF-beta signaling	TGFBRII, TGFBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1
	IL10 signalling	IL10RA, IL10RB, HMOX2
	IL6 signalling	IL6R, IL6ST
Prevention of TCR signalling		CSK, PAG1
		SIT1
Induced Treg	induced Treg	FOXP3
Transcription factors controlling exhaustion	transcription factors controlling exhaustion	PRDM1
		BATF
Hypoxia mediated tolerance	iNOS induced guanylated cyclase	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3

#### *Inhibiting suppressive cytokines/metabolites*

- 5 According to another aspect of the invention, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of genes encoding or positively regulating suppressive cytokines or metabolites or receptors thereof, in particular TGFbeta (Uniprot:P01137), TGFbR (Uniprot:P37173), IL10 (Uniprot:P22301), IL10R (Uniprot: Q13651 and/or Q08334), A2aR (Uniprot: P29274), GCN2 (Uniprot: P15442) and PRDM1 (Uniprot: O75626).

Preference is given to engineered immune cells in which a sequence encoding IL-2, IL-12 or IL-15 replaces the sequence of at least one of the above endogenous genes.

#### *Inducing resistance to chemotherapy drugs*

- 15 According to another aspect of the present method, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of a gene responsible for the sensitivity of the immune cells to compounds used in standard of care treatments for cancer or infection, such as drugs purine nucleotide analogs (PNA) or 6-Mercaptopurine (6MP) and 6 thio-guanine (6TG) commonly used in chemotherapy.
- 20 Reducing or inactivating the genes involved into the mode of action of such compounds

(referred to as “drug sensitizing genes”) improves the resistance of the immune cells to same.

Examples of drug sensitizing gene are those encoding DCK (Uniprot P27707) with respect to the activity of PNA, such a clorofarabine et fludarabine, HPRT (Uniprot P00492) with respect to the activity of purine antimetabolites such as 6MP and 6TG, and GGH (Uniprot Q92820) with respect to the activity of antifolate drugs, in particular methotrexate.

This enables the cells to be used after or in combination with conventional anti-cancer chemotherapies.

#### *Resistance to immune-suppressive treatments*

According to another aspect of the present invention, the inserted exogenous coding sequence has the effect of reducing or preventing the expression of receptors or proteins, which are drug targets, making said cells resistant to immune-depletion drug treatments. Such target can be glucocorticoids receptors or antigens, to make the engineered immune cells resistant to glucocorticoids or immune depletion treatments using antibodies such as Alemtuzumab, which is used to deplete CD52 positive immune cells in many cancer treatments.

Also the method of the invention can comprise gene targeted insertion in endogenous gene(s) encoding or regulating the expression of CD52 (Uniprot P31358) and/or GR (Glucocorticoids receptor also referred to as NR3C1 - Uniprot P04150).

#### *Improving CAR positive immune cells activity and survival*

According to another aspect of the present invention, the inserted exogenous coding sequence can have the effect of reducing or preventing the expression of a surface antigen, such as BCMA, CS1 and CD38, wherein such antigen is one targeted by a CAR expressed by said immune cells.

This embodiment can solve the problem of CAR targeting antigens that are present at the surface of infected or malignant cells, but also to some extent expressed by the immune cell itself.

According to a preferred embodiment the exogenous sequence encoding the CAR or one of its constituents is integrated into the gene encoding the antigen targeted by said CAR to avoid self-destruction of the immune cells.

#### Engineered immune cells and populations of immune cells

The present invention is also drawn to the variety of engineered immune cells obtainable according to one of the method described previously under isolated form or as part of populations of cells.

According to a preferred aspect of the invention the engineered cells are primary  
5 immune cells, such as NK cells or T-cells, which are generally part of populations of cells that may involve different types of cells. In general, population deriving from patients or donors isolated by leukapheresis from PBMC (peripheral blood mononuclear cells).

According to a preferred aspect of the invention, more than 50% of the immune cells comprised in said population are TCR negative T-cells. According to a more preferred  
10 aspect of the invention, more than 50% of the immune cells comprised in said population are CAR positive T-cells.

The present invention encompasses immune cells comprising any combinations of the different exogenous coding sequences and gene inactivation, which have been respectively and independently described above. Among these combinations are  
15 particularly preferred those combining the expression of a CAR under the transcriptional control of an endogenous promoter that is steadily active during immune cell activation and preferably independently from said activation, and the expression of an exogenous sequence encoding a cytokine, such as IL-2, IL-12 or IL-15, under the transcriptional control of a promoter that is up- regulated during the immune cell activation.

Another preferred combination is the insertion of an exogenous sequence encoding  
20 a CAR or one of its constituents under the transcription control of the hypoxia-inducible factor 1 gene promoter (Uniprot: Q16665).

The invention is also drawn to a pharmaceutical composition comprising an engineered primary immune cell or immune cell population as previously described for the  
25 treatment of infection or cancer, and to a method for treating a patient in need thereof, wherein said method comprises:

- preparing a population of engineered primary immune cells according to the method of the invention as previously described;
- optionally, purifying or sorting said engineered primary immune cells;
- 30 - activating said population of engineered primary immune cells upon or after infusion of said cells into said patient.

#### Activation and expansion of T cells

Whether prior to or after genetic modification, the immune cells according to the  
35 present invention can be activated or expanded, even if they can activate or proliferate independently of antigen binding mechanisms. T-cells, in particular, can be activated and

expanded using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. T cells can be expanded *in vitro* or *in vivo*. T cells are generally expanded by contact with an agent that stimulates a CD3 TCR complex and a co-stimulatory molecule on the surface of the T cells to create an activation signal for the T-cell. For example, chemicals such as calcium ionophore A23187, phorbol 12-myristate 13-acetate (PMA), or mitogenic lectins like phytohemagglutinin (PHA) can be used to create an activation signal for the T-cell.

As non-limiting examples, T cell populations may be stimulated *in vitro* such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- $\gamma$ , IL-4, IL-7, GM-CSF, -10, -2, IL-15, TGF $\beta$ , and TNF- or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, A1M-V, DMEM, MEM,  $\alpha$ -MEM, F-12, X-Vivo 1, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C) and atmosphere (e.g., air plus 5% CO<sub>2</sub>). T cells that have been exposed to varied stimulation times may exhibit different characteristics

In another particular embodiment, said cells can be expanded by co-culturing with tissue or cells. Said cells can also be expanded *in vivo*, for example in the subject's blood after administering said cell into the subject.

#### Therapeutic compositions and applications

The method of the present invention described above allows producing engineered primary immune cells within a limited time frame of about 15 to 30 days, preferably between 15 and 20 days, and most preferably between 18 and 20 days so that they keep their full immune therapeutic potential, especially with respect to their cytotoxic activity.

5        These cells form a population of cells, which preferably originate from a single donor or patient. These populations of cells can be expanded under closed culture recipients to comply with highest manufacturing practices requirements and can be frozen prior to infusion into a patient, thereby providing “off the shelf” or “ready to use” therapeutic compositions.

10        As per the present invention, a significant number of cells originating from the same Leukapheresis can be obtained, which is critical to obtain sufficient doses for treating a patient. Although variations between populations of cells originating from various donors may be observed, the number of immune cells procured by a leukapheresis is generally about from  $10^8$  to  $10^{10}$  cells of PBMC. PBMC comprises several  
15 types of cells: granulocytes, monocytes and lymphocytes, among which from 30 to 60 % of T-cells, which generally represents between  $10^8$  to  $10^9$  of primary T-cells from one donor. The method of the present invention generally ends up with a population of engineered cells that reaches generally more than about  $10^8$  T-cells, more generally more than about  $10^9$  T-cells, even more generally more than about  $10^{10}$  T-cells, and usually  
20 more than  $10^{11}$  T-cells.

The invention is thus more particularly drawn to a therapeutically effective population of primary immune cells, wherein at least 30 %, preferably 50 %, more preferably 80 % of the cells in said population have been modified according to any one the methods described herein. Said therapeutically effective population of primary immune  
25 cells, as per the present invention, comprises immune cells that have integrated at least one exogenous genetic sequence under the transcriptional control of an endogenous promoter from at least one of the genes listed in Table 6.

Such compositions or populations of cells can therefore be used as medicaments; especially for treating cancer, particularly for the treatment of lymphoma, but also for solid  
30 tumors such as melanomas, neuroblastomas, gliomas or carcinomas such as lung, breast, colon, prostate or ovary tumors in a patient in need thereof.

The invention is more particularly drawn to populations of primary TCR negative T-cells originating from a single donor, wherein at least 20 %, preferably 30 %, more preferably 50 % of the cells in said population have been modified using sequence-  
35 specific reagents in at least two, preferably three different loci.

In another aspect, the present invention relies on methods for treating patients in need thereof, said method comprising at least one of the following steps:

(a) Determining specific antigen markers present at the surface of patients tumors biopsies;

5 (b) providing a population of engineered primary immune cells engineered by one of the methods of the present invention previously described expressing a CAR directed against said specific antigen markers;

(c) Administrating said engineered population of engineered primary immune cells to said patient,

10 Generally, said populations of cells mainly comprises CD4 and CD8 positive immune cells, such as T-cells, which can undergo robust *in vivo* T cell expansion and can persist for an extended amount of time *in-vitro* and *in-vivo*.

The treatments involving the engineered primary immune cells according to the present invention can be ameliorating, curative or prophylactic. It may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment. By  
15 autologous, it is meant that cells, cell line or population of cells used for treating patients are originating from said patient or from a Human Leucocyte Antigen (HLA) compatible donor. By allogeneic is meant that the cells or population of cells used for treating patients are not originating from said patient but from a donor.

20 In another embodiment, said isolated cell according to the invention or cell line derived from said isolated cell can be used for the treatment of liquid tumors, and preferably of T-cell acute lymphoblastic leukemia.

Adult tumors/cancers and pediatric tumors/cancers are also included.

The treatment with the engineered immune cells according to the invention may be  
25 in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.

According to a preferred embodiment of the invention, said treatment can be administrated into patients undergoing an immunosuppressive treatment. Indeed, the  
30 present invention preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent. In this aspect, the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the patient.

The administration of the cells or population of cells according to the present invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, 5 intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.

The administration of the cells or population of cells can consist of the administration of  $10^4$ - $10^9$  cells per kg body weight, preferably  $10^5$  to  $10^6$  cells/kg body 10 weight including all integer values of cell numbers within those ranges. The present invention thus can provide more than 10, generally more than 50, more generally more than 100 and usually more than 1000 doses comprising between  $10^6$  to  $10^8$  gene edited cells originating from a single donor's or patient's sampling.

The cells or population of cells can be administered in one or more doses. In 15 another embodiment, said effective amount of cells are administered as a single dose. In another embodiment, said effective amount of cells are administered as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual 20 needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions within the skill of the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administered will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.

25 In another embodiment, said effective amount of cells or composition comprising those cells are administered parenterally. Said administration can be an intravenous administration. Said administration can be directly done by injection within a tumor.

In certain embodiments of the present invention, cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant 30 treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizimab treatment for MS patients or efalizimab treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as 35 cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody

therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycoplienolic acid, steroids, FR901228, cytokines, and irradiation. These drugs inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin). In a further embodiment, the cell compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery.

When CARs are expressed in the immune cells or populations of immune cells according to the present invention, the preferred CARs are those targeting at least one antigen selected from CD22, CD38, CD123, CS1, HSP70, ROR1, GD3, and CLL1.

The engineered immune cells according to the present invention endowed with a CAR or a modified TCR targeting CD22 are preferably used for treating leukemia, such as acute lymphoblastic leukemia (ALL), those with a CAR or a modified TCR targeting CD38 are preferably used for treating leukemia such as T-cell acute lymphoblastic leukemia (T-ALL) or multiple myeloma (MM), those with a CAR or a modified TCR targeting CD123 are preferably used for treating leukemia, such as acute myeloid leukemia (AML), and blastic plasmacytoid dendritic cells neoplasm (BPDCN), those with a CAR or a modified TCR targeting CS1 are preferably used for treating multiple myeloma (MM).

The present invention also encompasses means for detecting the engineered cells of the present invention comprising the desired genetic insertions, especially by carrying out steps of using PCR methods for detecting insertions of exogenous coding sequences at the endogenous loci referred to in the present specification, especially at the PD1, CD25, CD69, TCR and  $\beta 2m$  loci, by using probes or primers hybridizing any sequences represented by SEQ ID NO:36 to 40.

Immunological assays may also be performed for detecting the expression by the engineered cells of CARs, GP130, and to check absence or reduction of the expression of

TCR, PD1, IL-6 or IL-8 in the cells where such genes have been knocked-out or their expression reduced.

### Other definitions

5           - Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue.

          - Amino acid substitution means the replacement of one amino acid residue with another, for instance the replacement of an Arginine residue with a Glutamine residue in a  
10       peptide sequence is an amino acid substitution.

          - Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine. For the degenerated nucleotides, r represents g or a (purine nucleotides), k represents g or t, s represents g or c, w represents a or t, m represents a or c, y represents t or c (pyrimidine  
15       nucleotides), d represents g, a or t, v represents g, a or c, b represents g, t or c, h represents a, t or c, and n represents g, a, t or c.

          - “As used herein, “nucleic acid” or “polynucleotides” refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and  
20       fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base  
25       moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and  
30       pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Nucleic acids can be either single stranded or double stranded.

          - The term “endonuclease” refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA

molecule, preferably a DNA molecule. Endonucleases do not cleave the DNA or RNA molecule irrespective of its sequence, but recognize and cleave the DNA or RNA molecule at specific polynucleotide sequences, further referred to as "target sequences" or "target sites". Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 10 base pairs (bp) in length, more preferably of 14-55 bp. Rare-cutting endonucleases significantly increase homologous recombination by inducing DNA double-strand breaks (DSBs) at a defined locus thereby allowing gene repair or gene insertion therapies (Pingoud, A. and G. H. Silva (2007). Precision genome surgery. *Nat. Biotechnol.* 25(7): 743-4.).

- By "DNA target", "DNA target sequence", "target DNA sequence", "nucleic acid target sequence", "target sequence", or "processing site" is intended a polynucleotide sequence that can be targeted and processed by a rare-cutting endonuclease according to the present invention. These terms refer to a specific DNA location, preferably a genomic location in a cell, but also a portion of genetic material that can exist independently to the main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting example. As non-limiting examples of RNA guided target sequences, are those genome sequences that can hybridize the guide RNA which directs the RNA guided endonuclease to a desired locus.

- By "mutation" is intended the substitution, deletion, insertion of up to one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty, twenty five, thirty, forty, fifty, or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide sequence. The mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA.

- By "vector" is meant a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. A "vector" in the present invention includes, but is not limited to, a viral vector, a plasmid, a RNA vector or a linear or circular DNA or RNA molecule which may consists of a chromosomal, non chromosomal, semi-synthetic or synthetic nucleic acids. Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available. Viral vectors include retrovirus, adenovirus, parvovirus (e. g. adenoassociated viruses (AAV), coronavirus, negative strand RNA viruses such as orthomyxovirus (e. g., influenza virus), rhabdovirus (e. g., rabies and vesicular stomatitis virus),

paramyxovirus (e. g. measles and Sendai), positive strand RNA viruses such as picornavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e. g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e. g., vaccinia, fowlpox and canarypox). Other viruses include

5 Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., *Retroviridae: The viruses and their replication*, In *Fundamental Virology*, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).

10 - As used herein, the term "locus" is the specific physical location of a DNA sequence (e.g. of a gene) into a genome. The term "locus" can refer to the specific physical location of a rare-cutting endonuclease target sequence on a chromosome or on an infection agent's genome sequence. Such a locus can comprise a target sequence that is recognized and/or cleaved by a sequence-specific endonuclease according to the

15 invention. It is understood that the locus of interest of the present invention can not only qualify a nucleic acid sequence that exists in the main body of genetic material (i.e. in a chromosome) of a cell but also a portion of genetic material that can exist independently to said main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting examples.

20 - The term "cleavage" refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA,

25 RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.

- "identity" refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence

30 is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a

35 part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting. For example, polypeptides having at least

70%, 85%, 90%, 95%, 98% or 99% identity to specific polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated.

5       - The term "subject" or "patient" as used herein includes all members of the animal kingdom including non-human primates and humans.

      - The above written description of the invention provides a manner and process of making and using it such that any person skilled in this art is enabled to make and use the same, this enablement being provided in particular for the subject matter of the appended claims, which make up a part of the original description.

10       Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.

      Having generally described this invention, a further understanding can be obtained by reference to certain specific examples, which are provided herein for purposes of  
15       illustration only, and are not intended to limit the scope of the claimed invention.

## EXAMPLES

**Example 1: AAV driven homologous recombination in human primary T-cells at various loci under control of endogenous promoters with knock-out of the endogenous gene.**

### Introduction

Sequence specific endonuclease reagents, such as TALEN® (Cellestis, 8 rue de la Croix Jarry, 75013 PARIS) enable the site-specific induction of double-stranded breaks (DSBs) in the genome at desired loci. Repair of DSBs by cellular enzymes occurs mainly through two pathways: non-homologous end joining (NHEJ) and homology directed repair (HDR). HDR uses a homologous piece of DNA (template DNA) to repair the DSB by recombination and can be used to introduce any genetic sequence comprised in the template DNA. As shown therein, said template DNA can be delivered by recombinant adeno-associated virus (rAAV) along with an engineered nuclease such as TALEN® to introduce a site-specific DSB.

### Design of the integration matrices

#### **1.1. Insertion of an apoptosis CAR in an upregulated locus with knock-out of the endogenous PD1 gene coding sequence**

The location of the TALEN target site has been designed to be located in the targeted endogenous PDCD1 gene (Programmed cell death protein 1 referred to as PD1 – Uniprot # Q15116). The sequence encompassing 1000bp upstream and downstream the TALEN targets is given in SEQ ID NO.1 and SEQ ID NO.2. Target sequences of the TALEN (SEQ ID: SEQ ID NO.3 and NO.4) is given in SEQ ID NO.5. The integration matrix is designed to be composed of a sequence (300 bp) homologous to the endogenous gene upstream of the TALEN site (SEQ ID NO.1), followed by a 2A regulatory element (SEQ ID NO.6), followed by a sequence encoding an apoptosis inducing CAR without the start codon (SEQ ID NO.7), followed by a STOP codon (TAG), followed by a polyadenylation sequence (SEQ ID NO.8), followed by a sequence (1000bp) homologous to the endogenous gene downstream of the TALEN site (SEQ ID NO.2)). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

## **1.2 Insertion of an interleukin in an upregulated locus with knock-out of the endogenous gene**

The location of the TALEN target site is designed to be located in the targeted endogenous PDCD1 gene (Programmed cell death protein 1, PD1). The sequence encompassing 1000bp upstream and downstream the TALEN targets is given in SEQ ID NO.1 and SEQ ID NO.2. Target sequences of the TALEN (SEQ ID: SEQ ID NO.3 and NO.4) is given in SEQ ID NO.5. The integration matrix is designed to be composed of a sequence (300 bp) homologous to the endogenous gene upstream of the TALEN site (SEQ ID NO.1), followed by a 2A regulatory element (SEQ ID NO.6), followed by a sequence encoding an engineered single-chained human IL-12 p35 (SEQ ID NO.9) and p40 (SEQ ID NO.10) subunit fusion protein, followed by a STOP codon (TAG), followed by a polyadenylation sequence (SEQ ID NO.8), followed by a sequence (1000bp) homologous to the endogenous gene downstream of the TALEN site (SEQ ID NO.2). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

## **1.3 Insertion of an apoptosis CAR in a weakly expressed locus without knocking out the endogenous gene – N-terminal insertion**

The location of the TALEN target site is designed to be located as close as possible to the start codon of the targeted endogenous LCK gene (LCK, LCK proto-oncogene, Src family tyrosine kinase [Homo sapiens (human)]). The sequence encompassing 1000bp upstream and downstream the start codon is given in SEQ ID NO.11 and NO.12. The integration matrix is designed to be composed of a sequence (1000bp) homologous to the endogenous gene upstream of the start codon, followed by a sequence encoding an apoptosis inducing CAR containing a start codon (SEQ ID NO.13), followed by a 2A regulatory element (SEQ ID NO.8), followed by a sequence (1000bp) homologous to the endogenous gene downstream of the start codon (SEQ ID NO.12). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

## **1.4 Insertion of an apoptosis CAR in a weakly expressed locus without knocking out the endogenous gene – C-terminal insertion**

The location of the TALEN target site is designed to be located as close as possible to the stop codon of the targeted endogenous LCK gene (LCK, LCK proto-oncogene, Src family tyrosine kinase [Homo sapiens (human)]). The sequence encompassing 1000bp upstream and downstream the stop codon is given in SEQ ID NO.14 and NO.15. The integration matrix is designed to be composed of a sequence (1000bp) homologous to the endogenous gene upstream of the stop codon, followed by a 2A regulatory element (SEQ ID NO.8), followed by a sequence encoding an apoptosis inducing CAR without the start codon (SEQ ID NO.7), followed by a STOP codon (TAG), followed by a sequence (1000bp) homologous to the endogenous gene downstream of the stop codon (SEQ ID NO.15). The insertion matrix is subsequently cloned into a promoterless rAAV vector and used to produce AAV6.

### **Expression of the sequence-specific nuclease reagents in the transduced cells**

TALEN® mRNA is synthesized using the mMessage mMachine T7 Ultra kit (Thermo Fisher Scientific, Grand Island, NY) as each TALEN is cloned downstream of a T7 promoter, purified using RNeasy columns (Qiagen, Valencia, CA) and eluted in "cytoporation medium T" (Harvard Apparatus, Holliston, MA). Human T-cells are collected and activated from whole peripheral blood provided by ALLCELLS (Alameda, CA) in X-Vivo-15 medium (Lonza, Basel, Switzerland) supplemented with 20 ng/ml human IL-2 (Miltenyi Biotech, San Diego, CA), 5% human AB serum (Gemini Bio-Products, West San Francisco, CA) and Dynabeads Human T-activator CD3/CD28 at a 1:1 bead:cell ratio (Thermo Fisher Scientific, Grand Island, NY). Beads are removed after 3 days and  $5 \times 10^6$  cells are electroporated with 10 µg mRNA of each of the two adequate TALEN® using Cytopulse (BTX Harvard Apparatus, Holliston, MA) by applying two 0.1 mS pulses at 3,000 V/cm followed by four 0.2 mS pulses at 325 V/cm in 0.4 cm gap cuvettes in a final volume of 200 µl of "cytoporation medium T" (BTX Harvard Apparatus, Holliston, Massachusetts). Cells are immediately diluted in X-Vivo-15 media with 20 ng/mL IL-2 and incubated at 37°C with 5% CO<sub>2</sub>. After two hours, cells are incubated with AAV6 particles at  $3 \times 10^5$  viral genomes (vg) per cell (37°C, 16 hours). Cells are passaged and maintained in X-Vivo-15 medium supplemented with 5% human AB serum and 20 ng/mL IL-2 until examined by flow cytometry for expression of the respective inserted gene sequences.

**Table 4:** Sequences referred to in example 1

Sequence name	Ref. sequences	Polynucleotide or polypeptide sequences
PD1 left homology	SEQ ID NO.1	CCAAGCCCTGACCCTGGCAGGCATATGTTTCAGGAGGTCCTTGCTTGGGA GCCCAGGGTCGGGGGCCCCGTGTCTGTCCACATCCGAGTCAATGGCCCAT CTCGTCTCTGAAGCATCTTTGCTGTGAGCTCTAGTCCCCACTGTCTTGCTGG AAAATGTGGAGGCCCACTGCCCACTGCCAGGGCAGCAATGCCCATACC ACGTGGTCCCAGCTCCGAGCTTGTCTGAAAAGGGGGCAAAGACTGGACC CTGAGCCTGCCAAGGGGGCCACACTCTCCAGGGCTGGGGTCTCCATGGG CAGCCCCCACCACCCAGACCAGTTACACTCCCCTGTGCCAGAGCAGTGC AGACAGGACCAGGCCAGGATGCCAAGGGTCAGGGGCTGGGGATGGGT AGCCCCAAACAGCCCTTTCTGGGGAACTGGCCTCAACGGGGAAGGGG GTGAAGGCTCTTAGTAGGAAATCAGGGAGACCCAAGTCAGAGCCAGGTG CTGTGCAGAAGCTGCAGCCTCACGTAGAAGGAAGAGGCTCTGCAGTGGA GGCCAGTGCCCATCCCCGGGTGGCAGAGGCCCCAGCAGAGACTTCTCAAT GACATTCCAGCTGGGGTGGCCCTTCCAGAGCCCTTGCTGCCCGAGGGATG TGAGCAGGTGGCCGGGGAGGCTTTGTGGGGCCACCCAGCCCTTCTCTCAC CTCTCTCATCTCTCAGACTCCCCAGACAGGCCCTGGAACCCCCCACCTTC TCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGC AGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGC CCCAGCAACCAGACGGACAAGCTGGCCGCTTCCCCGAGGACCGCAGCCA GCCCGGCCAGGACTGCCGCTTCCGTGTACACAAGTCCCAACGGGCGTG ACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACC
PD1 right homology	SEQ ID NO.2	GCCTGCGGGCAGAGCTCAGGGTGACAGGTGCGGCCTCGGAGGCCCGGG GCAGGGGTGAGCTGAGCCGGTCTGGGGTGGGTGTCCCTCCTGCACAG GATCAGGAGCTCCAGGGTCGTAGGGCAGGGACCCCCAGCTCCAGTCCAG GGCTCTGTCCTGCACCTGGGGAATGGTGACCGGCATCTCTGTCCTTAGCT CTGGAAGCACCCCAGCCCTCTAGTCTGCCCTCACCCCTGACCTTGACCTC CACCCTGACCCCGTCTAACCCTGACCTTTGTGCCCTTCCAGAGAGAAGG GCAGAAGTGCCACAGCCCACCCAGCCCTCACCCAGGCCAGCCGGCCA GTTCCAAACCCTGGTGGTTGGTGTGCGTGGGCGGCCTGCTGGGCAGCCTGG TGCTGCTAGTCTGGGTCTGGCCGTATCTGCTCCCGGGCCGCACGAGGTA ACGTCATCCCAGCCCCCTGGCCTGCCCTGCCCTAACCTGCTGGCGGCCCT CACTCCCGCCTCCCCTTCTCCACCCTTCCCTCACCCACCCACCTCCCCC ATCTCCCGCCAGGCTAAGTCCCTGATGAAGGCCCTGGACTAAGACCCC CACCTAGGAGCACGGCTCAGGGTCGGCCTGGTGACCCCAAGTGTGTTTCT CTGCAGGGACAATAGGAGCCAGGCGCACCGGCCAGCCCTGGTGAGTCTC ACTCTTTTCTGCATGATCACTGTGCCTTCTTCTGGGTGGGCAGAGGT GGAAGGACAGGCTGGGACCACACGGCCTGCAGGACTCACATTCTATTATA GCCAGGACCCACCTCCCCAGCCCCAGGCAGCAACCTCAATCCCTAAAGC CATGATCTGGGGCCCCAGCCACCTGCGGTCTCCGGGGGTGCCGGCCCCA TGTGTGTGCCTGCCTGCGGTCTCCAGGGGTGCCTGGCCACGCGTGTGCC CGCCTGCGGTCTCTGGGGGTGCCCGGCCACATATGTGCC
PD1_T3C-L2	SEQ ID NO.3	ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATATCGCCGATCTACG CACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTT GTTCGACAGTGGCGCAGCACACGAGGCACTGGTCGGCCACGGGTTTACA CACGCGCACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGT CGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCGACACACG AAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGA GGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGG

		<p>ACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTG GAGGCAGTGTCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTT GACCCCCGAGCAAGTGGTGGCTATCGCTTCCAAGCTGGGGGGAAAGCAG GCCCTGGAGACCGTCCAGGCCCTTCTCCAGTGCTTTGCCAGGCTCACGGA CTGACCCCTGAACAGGTGGTGGCAATTGCCTCACACGACGGGGGCAAGCA GGCACTGGAGACTGTCCAGCGGCTGCTGCCTGTCTTGCCAGGCCACG GACTCACTCCTGAGCAGGTCGTGGCCATTGCCAGCCACGATGGGGGCAAA CAGGCTCTGGAGACCGTGCAGCGCCTCCTCCAGTGCTGTGCCAGGCTCAT GGGCTGACCCACAGCAGGTGCTCGCCATTGCCAGTAACGGCGGGGGGA AGCAGGCCCTCGAAACAGTGACAGAGGCTGCTGCCGTCTTGTGCCAAGCA CACGGCCTGACACCCGAGCAGGTGGTGGCCATCGCCTCTCATGACGGCGG CAAGCAGGCCCTTGAGACAGTGACAGAGACTGTTGCCCGTGTGTGTCAGG CCCACGGGTTGACACCCAGCAGGTGGTCGCCATCGCCAGCAATGGCGGG GGAAAGCAGGCCCTTGAGACCGTGCAGCGGTTGCTTCCAGTGTTGTGCCA GGCACACGGACTGACCCCTCAACAGGTGGTCGCAATCGCCAGCTACAAGG GCGGAAAGCAGGCTCTGGAGACAGTGACAGCGCCTCCTGCCGTGCTGTGT CAGGCTCACGGACTGACACCACAGCAGGTGGTCGCCATCGCCAGTAACGG GGGCGGCAAGCAGGCTTTGGAGACCGTCCAGAGACTCCTCCCCGTCTTT GCCAGGCCACGGGTTGACACCTCAGCAGGTGCTCGCCATTGCCTCCAAC AACGGGGGCAAGCAGGCCCTCGAACTGTGCAGAGGCTGCTGCCTGTGCT GTGCCAGGCTCATGGGCTGACACCCAGCAGGTGGTGGCCATTGCCTCTA ACAACGGCGGCAACAGGCACTGGAGACCGTGCAAAGGCTGCTGCCGT CCTCTGCCAAGCCACGGGCTCACTCCACAGCAGGTGCTGGCCATCGCCTC AAACAATGGCGGGAAGCAGGCCCTGGAGACTGTGCAAAGGCTGCTCCCT GTGCTCTGCCAGGCACACGGACTGACCCCTCAGCAGGTGGTGGCAATCGC TTCCAACAACGGGGGAAAGCAGGCCCTCGAAACCGTGACAGCGCCTCTCC CAGTGCTGTGCCAGGCACATGGCCTCACACCCGAGCAAGTGGTGGCTATC GCCAGCCACGACGGAGGGAAGCAGGCTCTGGAGACCGTGACAGGCTGC TGCTGTCTGTGCCAGGCCACGGGCTTACTCCAGAGCAGGTGCTCGCCA TCGCCAGTCATGATGGGGGGAAGCAGGCCCTTGAGACAGTCCAGCGGCT GCTGCCAGTCCTTTGCCAGGCTCACGGCTTGACTCCCGAGCAGGTGCTGGC CATTGCCTCAAACATTGGGGGCAACAGGCCCTGGAGACAGTGACAGGCC TGCTGCCCGTGTGTGTGTCAGGCCACGGCTTGACACCCAGCAGGTGGTC GCCATTGCCTCTAATGGCGGCGGGAGACCCGCCTTGAGAGAGCATTGTTGC CCAGTTATCTCGCCTGATCCGGCGTTGGCCGCTTGACCAACGACCACCT CGTCGCCTTGGCCTGCCTCGGCGGGCGTCTGCGCTGGATGCAGTGAAAA AGGGATTGGGGATCCTATCAGCCGTCCCAGCTGGTGAAGTCCGAGCTG GAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACG AGTACATCGAGCTGATCGAGATCGCCCGGAACAGCACCCAGGACCGTATC CTGGAGATGAAGGTGATGGAGTTCTCATGAAGGTGTACGGCTACAGGG GCAAGCACCTGGGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTG GGCTCCCCCATCGACTACGGCGTGATCGTGACACCAAGGCCTACTCCGG CGGCTACAACCTGCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGG AGGAGAACCAGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGGAA GGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCTGTTCGTGTCCGGCCA CTTCAAGGGCAACTACAAGGCCAGCTGACCAGGCTGAACCACATACCA ACTGCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCTGATCGGCGGCGA GATGATCAAGGCCGGCACCTGACCCTGGAGGAGGTGAGGAGGAAGTTC</p>
--	--	---

		AACAACGGCGAGATCAACTTCGCGGCCGACTGATAA
PD1T3R	SEQ ID NO.4	ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATATCGCCGATCTACG CACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAAGGTTT GTTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACA CACGCGCACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGT CGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCGACACACG AAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGA GGCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGG ACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTG GAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTT GACCCCCGAGCAAGTCGTCGCAATCGCCAGCCATGATGGAGGGAAGCAA GCCCTCGAAACCGTGACGCGGTTGCTTCTGTGCTCTGCCAGGCCACGGC CTTACCCCTCAGCAGGTGGTGGCCATCGCAAGTAACGGAGGAGGAAAGCA AGCCTTGGAGACAGTGCAGCGCCTGTTGCCCGTGCTGTGCCAGGCACACG GCCTCACACCAGAGCAGGTCTGGCCATTGCCTCCATGACGGGGGGGAAA CAGGCTCTGGAGACCGTCCAGAGGCTGCTGCCCGTCTCTGTCAAGCTCAC GGCCTGACTCCCCAACAAGTGGTCGCCATCGCCTCTAATGGCGGCGGGAA GCAGGCACTGGAAACAGTGCAGAGACTGCTCCCTGTGCTTTGCCAAGCTC ATGGGTTGACCCCCCAACAGGTCGTCGCTATTGCCTCAAACGGGGGGGGC AAGCAGGCCCTTGAGACTGTGCAGAGGCTGTTGCCAGTGCTGTGTACGGC TCACGGGCTCACTCCACAACAGGTGGTCGCAATTGCCAGCAACGGCGGCG GAAAGCAAGCTCTTGAAACCGTGCAACGCCTCCTGCCGTGCTCTGTACAG CTCATGGCCTGACACCACAACAAGTCGTGGCCATCGCCAGTAATAATGGC GGGAAACAGGCTCTTGAGACCGTCCAGAGGCTGCTCCAGTGCTCTGCCA GGCACACGGGCTGACCCCCGAGCAGGTGGTGGCTATCGCCAGCAATATTG GGGGCAAGCAGGCCCTGGAAACAGTCCAGGCCCTGCTGCCAGTGCTTTGC CAGGCTCACGGGCTCACTCCCCAGCAGGTGCTGGCAATCGCCTCCAACGG CGGAGGGAAGCAGGCTCTGGAGACCGTGACAGAGACTGCTGCCGTCTTGT GCCAGGCCACGGACTCACACCTGAACAGGTGCTCGCCATTGCCTCTCACG ATGGGGGCAAACAAGCCCTGGAGACAGTGCAGCGGCTGTTGCCTGTGTTG TGCCAAGCCACGGCTTGACTCCTCAACAAGTGGTCGCCATCGCCTCAAAT GGCGGCGGAAAACAAGCTCTGGAGACAGTGCAGAGGTTGCTGCCGTCC TCTGCCAAGCCACGGCCTGACTCCCCAACAGGTGCTCGCCATTGCCAGCA ACAACGGAGGAAAGCAGGCTCTCGAAACTGTGCAGCGGCTGCTTCCTGTG CTGTGTACGGCTCATGGGCTGACCCCCGAGCAAGTGGTGGCTATTGCCTCT AATGGAGGCAAGCAAGCCCTTGAGACAGTCCAGAGGCTGTTGCCAGTGCT GTGCCAGGCCACGGGCTCACACCCAGCAGGTGGTCGCCATCGCCAGTA ACAACGGGGGCAAACAGGCATTGGAAACCGTCCAGCGCCTGCTTCCAGTG CTTGCCAGGCACACGGACTGACACCCGAACAGGTGGTGGCCATTGCATC CCATGATGGGGGCAAGCAGGCCCTGGAGACCGTGACAGAGACTCCTGCCA GTGTTGTGCCAAGCTCACGGCCTACCCCTCAGCAAGTCGTGGCCATCGCC TCAAACGGGGGGGGCGGCCCTGCACTGGAGAGCATTGTTGCCAGTTATC TCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTCGCCTT GGCCTGCCTCGGCGGGCGTCTGCGCTGGATGCAGTGAAAAAGGGATTG GGGGATCCTATCAGCCGTTCCAGCTGGTGAAGTCCGAGCTGGAGGAGAA GAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCG AGCTGATCGAGATCGCCGGAACAGCACCCAGGACCGTATCCTGGAGATG AAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGCAAGCACCT

		GGGCGGCTCCAGGAAGCCCCGACGGCGCCATCTACACCGTGGGCTCCCCCA TCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCGGCTACAAC CTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACC AGACCAGGAACAAGCACATCAACCCCAACGAGTGGTGAAGGTGTACCCC TCCAGCGTGACCGAGTTCAAGTTCCTGTTCTGTCCGGCCACTTCAAGGGC AACTACAAGGCCAGCTGACCAGGCTGAACCACATCACCAACTGCAACGG CGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAG GCCGGCACCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCG AGATCAACTTCGCGGCCGACTGATAA
PD1-T3	SEQ ID NO.5	TACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGA
2A-element	SEQ ID NO.6	TCCGGTGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGA ATCCGGGGCCCC
apoptosis CAR (without start codon)	SEQ ID NO.7	GCTTTCCTGTCACTGCCTTGCTGCTTCCACTTGCTCTGTTGTTGCACGCCG CAAGACCCGAGGTCAAGCTCCAGGAAAGCGGACCAGGGCTGGTGGCCCC TAGTCAGTCATTGAGCGTCACTTGACCGTCAGCGGCGTGTCTCTGCCGA TTACGGCGTGAGCTGGATCAGACAGCCCCCAAGGAAGGGACTGGAGTGG CTGGGCGTCATCTGGGGGAGCGAGACTACCTACTACAACAGCGCCCTGAA GAGCAGGCTGACCATCATTAAAGGACAACTCCAAGTCCCAGGTCTTTCTGAA AATGAACAGCCTGCAGACTGATGACACTGCCATCTACTACTGCGCCAAGCA TTACTACTACGGGGGACGCTACGCTATGGACTACTGGGGGACGGGGACCT CTGTACAGTGTCAAGTGGCGGAGGAGGAGTGGCGGAGGGGGAAGTG GGGGCGGCGGAGCGACATCCAGATGACCCAGACAACATCCAGCCTCTCC GCCTCTCTGGGCGACAGAGTGACAATCAGCTGCCGGGCCAGTCAGGACAT CAGCAAGTATCTCAATTGGTACCAGCAGAAACCAGACGGGACAGTGAAT TGCTGATCTACCACACATCCAGGCTGCACTCAGGAGTCCCCAGCAGGTTTT CCGGCTCCGGCTCCGGGACAGATTACAGTCTGACCATTTCACCTGGAGC AGGAGGATATTGCCACATACTTTTCCAGCAAGGCAACACTCTGCCCTATA CCTTCGGCGGAGGCAAAAACCTGGAGATTACTCGGTGCGATCCCAGGCC AAATCTCTGACAAAACCTCACACATGCCACCGTGCCAGCACCTCCCGTG GCCGGCCCGTCAGTGTTCTCTCCCCCAAAACCAAGGACACCTCATG ATCGCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGA GGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCAT AATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG TGGTCAGCGTCCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAGGAG TACAAGTGCAAGGTGTCCAACAAAGCCCTCCAGCCCCATCGAGAAAAC CATCTCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCTGC CCCCATCCCGGGATGAGCTGACCAAGAACCAGGTGAGCCTGACCTGCCTG GTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG GCAACCGGAGAACAACTACAAGACCACGCCTCCCGTGTGGACTCCGACG GCTCCTTCTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGC AGGGGAACGTGTTCTCATGCTCCGTGATGCATGAGGCCCTGCACAATCACT ATACCCAGAAATCTCTGAGTCTGAGCCCAGGCAAGAAGGATATTTGGGG TGGCTTTCCTTCTTCTTTGCCAATCCACTAATTGTTGGGTGAAGAGAA AGGAAGTACAGAAAACATGCAGAAAGCACAGAAAGGAAAACCAAGGTTT TCATGAATCTCAACCTTAAATCCTGAAACAGTGGCAATAAATTTATCTGAT GTTGACTTGAGTAAATATATCACCCTATTGCTGGAGTCATGACACTAAGT

		CAAGTTAAAGGCTTTGTTTCGAAAGAATGGTGTCAATGAAGCCAAAATAGA TGAGATCAAGAATGACAATGTCCAAGACACAGCAGAACAGAAAGTTCAAC TGCTTCGTAATTGGCATCAACTTCATGGAAAAGAAAGCGTATGACACAT TGATTGCAGATCTCAAAAAAGCCAATCTTTGTACTCTTGACAGAGAAAATTC AGACTATCATCCTCAAGGACATTACTAGTGACTCAGAAAATTCAAACCTCA GAAATGAAATCCAGAGCTTGGTCGAA
BGH polyA	SEQ ID NO.8	TCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGT TGCCAGCCATCTGTTGTTTGCCCTCCCCGTGCCTTCCTTGACCCTGGAAG GTGCCACTCCCCTGTCCTTTCTAATAAAATGAGGAAATTGCATCGCATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAG CAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGT GGGCTCTATGACTAGTGCGAATTC
Interleukin-12 subunit alpha	SEQ ID NO.9	MCPARSLLLVATLVLLDHLNLPVATPDPMFCLHHSQNLRAVSNNML QKARQTLEFYPTSEEIDHEDITKDKTSTVEACPLELTKNESCLNSRETSFITNG SCLSRKTSFMMALCLSIYEDLKMVQVEFKTMNAKLLMDPKRQIFLDQNNML AVIDELMQALNFNSETVPQKSSLEEDFYKTIKILCILLHAFRIRAVTIDRVMSYL NAS
Interleukin-12 subunit beta	SEQ ID NO.10	MCHQQLVISWFLVFLASPLVAIWELKKDVVVELDWYPDAPGEMVVLTCDT PEEDGITWTLDDQSEVLGSGKTLTIQVKEFGDAGQYTKHKGGEVLSHLLLLHK KEDGIWSTDLKDQKEPKNKTLRCEAKNYSGRFTCWWLTISTDLTSVKSSR GSSDPQGVTCGAATLSAERVGRDNKEYEYSEVCQEDSACPAEESLPIEVMV DAVHKLKYENYTSFFIRDIIPDPKPNLQLKPLKNSRQVEVSWEYPTWSTPH SYFSLTFCVQVQGKSKREKDRVFTDKTSATVICRKNASISVRAQDRYSSWS EWASVPCS
Lck left homology	SEQ ID NO.11	GGGATAGGGGGTGCCTCTGTGTGTGTGTGTGAGAGTGTGTGTGTAGG GTGTGTATATGTATAGGGTGTGTGTGAGTGTGTGTGTGAGAGAGTGTG TGTGTGCGAGAATAGACTGCGGAGGTGGATTTTCATCTTGATATGAAAGGT CTGGAATGCATGGTACATTAACTTTGAGGACAGCGCTTTCCAAGCACTCT GAGGAGCAGCCCTAGAGAAGGAGGAGCTGCAGGGACTCCGGGGGCTTCA AAGTGAGGGCCCCACTCTGCTTCAGGCAAAACAGGCACACATTATCACTT TATCTATGGAGTTCTGCTTGATTTCATCAGACAAAAAATTCCTGCTAAA ACAGGCAAATAAACAAAAAAGTTATGGCCAACAGAGTCACTGGAGG GTTTTCTGCTGGGGAGAAGCAAGCCCGTGTGTAAGGAACCTGTGAGAT GACTGTGGGCTGTGTGAGGGGAACAGCGGGGCTTGATGGTGGACTTCG GGAGCAGAAGCCTCTTCTCAGCCTCCTCAGCTAGACAGGGGAATTATAAT AGGAGGTGTGGCGTGACACCTCTCCAGTAGGGGAGGGTCTGATAAGTC AGGTCTCTCCAGGCTTGGGAAAGTGTGTGTATCTCTAGGAGGTGGTCCT CCCAACACAGGGTACTGGCAGAGGGAGAGGGAGGGGGCAGAGGCAGGA AGTGGGTAAGTACTAGACTAACAAAGGTGCCTGTGGCGGTTTGGCCATCCAG GTGGGAGGGTGGGGCTAGGGCTCAGGGGCCGTGTGTGAATTTACTTGTA GCCTGAGGGCTCAGAGGGAGCACCGGTTTGGAGCTGGGACCCCTATTTT AGCTTTTCTGTGGCTGGTGAATGGGGATCCAGGATCTCACAATCTCAGGT ACTTTTGAAGTTTCCAGGGCAAGGCCCATATATCTGATGTTGGGGGAG CAGATCTTGGGGGAGCCCTTCAGCCCCCTCTCCATTCCTCAGGGACC
Lck right homology	SEQ ID NO.12	GGCTGTGGCTGCAGCTCACACCCGGAAGATGACTGGATGGAAAACATCGA TGTGTGTGAGAACTGCCATTATCCCATAGTCCCACTGGATGGCAAGGGCA CGGTAAGAGGCGAGACAGGGGCTTGGTGAGGGAGTTGGGTAGAGAAT GCAACCCAGGAGAAAGAAATGACCAGCACTACAGGCCCTTGAAAGAATA GAGTGGCCCTCTCCCCTGAAATACAGAAAGGAAAAGAGGCCAGAGAGG GGAAGGGAATCTCCTAAGATCACACAGAAAGTAGTTGGTAACTCAGGGA

		<p>TAACATCTAACCAGGCTGGAGAGGCTGAGAGCAGAGCAGGGGGGAAGG  GGGCCAGGGTCTGACCCAATCTTCTGCTTCTGACCCACCCCTCATCCCCA  CTCCACAGCTGCTCATCCGAAATGGCTCTGAGGTGCGGGACCCACTGGTTA  CCTACGAAGGCTCCAATCCGCCGGCTTCCCCACTGCAAGGTGACCCACGGC  AGCAGGGCCTGAAAGACAAGGCCTGCGGATCCCTGGCTGTTGGCTCCAC  CTCTCCCCACCTACTTTCTCCCCGGTCTTGCCTTCTTGTCCCCACCCGT  AACTCCAGGCTTCTGCCGATCCCAGCTCGGTTCTCCCTGATGCCCCTTGTC  TTTACAGACAACCTGGTTATCGCTCTGCACAGCTATGAGCCCTCTCACGAC  GGAGATCTGGGCTTTGAGAAGGGGAACAGCTCCGCATCCTGGAGCAGT  GAGTCCCTCTCCACCTTGCTCTGGCGGAGTCCGTGAGGGAGCGGCGATCT  CCGCGACCCGACGCCCTCTGCGGCCCTTGACCAGCTCGGGGTGGCCGCC  CTTGGGACAAAATTCAGGGCTCAGTATTGCTGAGCCAGGGTTGGGGGAG  GCTGGCTTAAGGGGTGGAGGGGTCTTTGAGGGAGGGTCTCAGGTCGACG  GCTGAGCGAGCCACACTGACCCACCTCCGTGGCGCAGGAGCGGCGAGTG</p>
apoptosis CAR (with start codon)	SEQ ID NO.13	<p>ATGGCTTTGCCTGTCACTGCCTTGCTGCTTCCACTTGCTCTGTTGTTGCACG  CCGCAAGACCCGAGGTCAAGCTCCAGGAAAGCGGACCAGGGGTGGTGGC  CCCTAGTCAGTCATTGAGCGTCACTTGACCCGTGACGGCGTGTCTCTGCC  CGATTACGGCGTGAGCTGGATCAGACAGCCCCAAGGAAGGGACTGGAG  TGGCTGGGCGTCATCTGGGGGAGCGAGACTACCTACTACAACAGCGCCCT  GAAGAGCAGGCTGACCATCATTAAGGACAACCTCCAAGTCCCAGGTCTTTCT  GAAAATGAACAGCCTGCAGACTGATGACACTGCCATCTACTACTGCGCCAA  GCATTACTACTACGGGGGACGCTACGCTATGGACTACTGGGGGACAGGGG  ACCTCTGTCACAGTGTCAAGTGGCGGAGGAGGAGTGGCGGAGGGGGAA  GTGGGGGCGGCGGACGACATCCAGATGACCCAGACAACATCCAGCCTC  TCCGCCTCTCTGGGCGACAGAGTGACAATCAGTGCCGGGCCAGTCAGGA  CATCAGCAAGTATCTCAATTGGTACCAGCAGAAACCAGACGGGACAGTGA  AATTGCTGATCTACCACACATCCAGGCTGCACTCAGGAGTCCCCAGCAGGT  TTTCCGGCTCCGGCTCCGGGACAGATTACAGTCTGACCATTTCACACCTGG  AGCAGGAGGATATTGCCACATACTTTTCCAGCAAGGCAACACTCTGCCCT  ATACCTTCGGCGGAGGCACAAAACCTGGAGATTACTCGGTGGATCCCGAG  CCCAAATCTCTGACAAAACCTCACACATGCCACCGTGCCAGCACCTCCC  GTGGCCGGCCCGTCAGTGTTCTTCTTCCCCCAAAACCAAGGACACCCTC  ATGATCGCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCA  CGAGGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG  CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACC  GTGTGGTCAGCGTCCTCACCCTGCTGACCAGGACTGGCTGAATGGCAAG  GAGTACAAGTGCAAGGTGTCCAACAAAGCCCTCCAGCCCCATCGAGAA  AACCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCC  TGCCCCCATCCCGGATGAGCTGACCAAGAACCAGGTGACCTGACCTGC  CTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAA  TGGGCAACCGGAGAACAACCTACAAGACCACGCTCCCGTGGTGGACTCCG  ACGGCTCCTTCTTCTCTACAGCAAGCTACCGTGGACAAGAGCAGGTGGC  AGCAGGGGAACGTGTTCTCATGCTCCGTGATGCATGAGGCCCTGCACAA  CACTATACCCAGAAATCTCTGAGTCTGAGCCAGGCAAGAAGGATATTTG  GGGTGGCTTTGCCCTTCTTTTGGCAATTCCAATAATTGTTGGGTGAAGA  GAAAGGAAGTACAGAAAACATGCAGAAAGCACAGAAAGGAAAACCAAGG  TTCTCATGAATCTCAACCTTAAATCCTGAAACAGTGGCAATAAATTTATCT  GATGTTGACTTGAGTAAATATATCACCCTATTGCTGGAGTCATGACACTA</p>

		AGTCAAGTTAAAGGCTTTGTTGCGAAAGAATGGTGTCAATGAAGCCAAAAT AGATGAGATCAAGAATGACAATGTCCAAGACACAGCAGAACAGAAAGTTC AACTGCTTCGTAATTGGCATCAACTTCATGGAAAGAAAGAAGCGTATGAC ACATTGATTGCAGATCTCAAAAAAGCCAATCTTTGTAATCTTGCAGAGAAA ATTCAGACTATCATCCTCAAGGACATTACTAGTGACTCAGAAAATTCAAAC TTCAGAAATGAAATCCAGAGCTTGGTCGAA
Lck left homology	SEQ ID NO.14	CTCATAACAATTCTATGAGGTAGGAACAGTTATTTACTCTATTTTCCAAATA AGGAAACTGGGCTCGCCCAAGGTTCCACAATAACATGTGTGTATTATTGA GCATTTAATTTACACCAGGGAAGCAGGTTGTGGTGGTGTGCACCTGTTGTC CAGCTATTTAGGAGGCTGAGGTGAAAGGATCACTTGAACGGAGGAGTTCA AATTTGCAATGTGCTATGATTGTGCCTGTGAACAGCTGCTGCACTCCAGCC TGGGCAACATAGTGAGATCCCTTATCTAAAACATTTTTTTAAGTAAATAAT CAGGTGGGCACGGTGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCTGA GGCGGGCGGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGACCAACAT GGAGAAACCCGTCTCTACTAAAAATACAAAATTAGCTTGGCGTGGTGGTG CATGCCTGTAATCCCAGCTACTCGAGAAGCTGAGGCAGGAGAATTGTTTG AACCTGGGAGGTGGAGGTTGCGGTGAGCCGAGATCGCACCATTGCACTCC AGCCTGGGCAACAAGAGTGAAATTGCATCTCAAAAAAAGAAAAGGAA ATAATCTATACCAGGCACTCCAAGTGGTGTGACTGATATTCAACAAGTACC TCTAGTGTGACCTTACCATTGATGAAGACCAAGATTCTTTTGGATTGGTGC TCACACTGTGCCAGTTAAATATTCCGAACATTACCCTTGCTGTGGGCTTCC AGTGCCTGACCTTGATGTCCTTTCACCCATCAACCCGTAGGGATGACCAAC CCGGAGGTGATTCAGAACCTGGAGCGAGGCTACCGCATGGTGCGCCCTGA CAACTGTCCAGAGGAGCTGTACCAACTCATGAGGCTGTGCTGGAAGGAGC GCCCAGAGGACCGGCCACCTTTGACTACCTGCGCAGTGTGCTGGAGGAC TTCTTCACGGCCACAGAGGGCCAGTACCAGCCTCAGCCT
Lck right homology	SEQ ID NO.15	GAGGCCTTGAGAGGCCCTGGGGTTCTCCCCCTTCTCTCCAGCCTGACTTG GGGAGATGGAGTTCTTGCCATAGTCACATGGCCTATGCACATATGGAC TCTGCACATGAATCCACCCACATGTGACACATATGCACCTTGTGTCTGTAC ACGTGTCCTGTAGTTGCGTGGACTCTGCACATGTCTTGACATGTGTAGCC TGTGCATGTATGTCTTGACACTGTACAAGTACCCCTTCTGGCTCTCCCA TTTCTGAGACCACAGAGAGAGGGGAGAAGCCTGGGATTGACAGAAGCT TCTGCCCACCTACTTTTCTTCTCAGATCATCCAGAAGTTCCTCAAGGGCC AGGACTTTATCTAATACTCTGTGTGCTCCTCCTTGGTGCCTGGCCTGGCAC ACATCAGGAGTTCAATAAATGTCTGTTGATGACTGTTGTACATCTCTTTGCT GTCCACTCTTTGTGGGTGGGCAGTGGGGGTTAAGAAAATGGTAATTAGGT CACCTGAGTTGGGTGAAAGATGGGATGAGTGGATGTCTGGAGGCTCT GCAGACCCCTTCAAATGGGACAGTGCTCCTCACCCCTCCCAAAGGATTCA GGGTGACTCCTACCTGGAATCCCTTAGGGAATGGGTGCGTCAAAGGACCT TCCTCCCCATTATAAAAGGGCAACAGCATTTTTTACTGATTCAAGGGCTATA TTTGACCTCAGATTTTGTTTTTTAAGGCTAGTCAAATGAAGCGGCGGGAA TGGAGGAGGAACAAATAAATCTGTAATATCCTCAGATTTTTTTTTTTTTT GAGACTGGGTCTCACTTTTTCATCCAGGCTGGAGTGCACTGCATGATCAC GGCTCACTGTAGCCTCAACCTCTCCAGCTCAAATGCTCCTCCTGTCTCAGCC TCCCGAGTACCTGGGACTACTTTCTTGAGGCCAGGAATTCAAGAACAGAG TAAGATCCTGGTCTCCAAAAAAGTTTTAAA

## Example 2: TALEN<sup>®</sup>-mediated double targeted integration of IL-15 and CAR encoding matrices in T-cells

### Materials

5 X-vivo-15 was obtained for Lonza (cat#BE04-418Q), IL-2 from Miltenyi Biotech (cat#130-097-748), human serum AB from Seralab (cat#GEM-100-318), human T activator CD3/CD28 from Life Technology (cat#11132D), QBEND10-APC from R&D Systems (cat#FAB7227A), vioblue-labeled anti-CD3, PE-labeled anti-LNGFR, APC-labeled anti-CD25 and PE-labeled anti-PD1 from Miltenyi (cat# 130-094-363, 130-112-790, 130-109-10  
10 021 and 130-104-892 respectively) 48 wells treated plates (CytoOne, cat#CC7682-7548), human IL-15 Quantikine ELISA kit from R&D systems (cat#S1500), ONE-Glo from Promega (cat#E6110). AAV6 batches containing the different matrices were obtained from Virovek, PBMC cells were obtained from Allcells, (cat#PB004F) and Raji-Luciferase cells were obtained after Firefly Luciferase-encoding lentiviral particles transduction of Raji cells  
15 from ATCC (cat#CCL-86).

### Methods

#### 2.1-Transfection-transduction

The double targeted integration at TRAC and PD1 or CD25 loci were performed as  
20 follows. PBMC cells were first thawed, washed, resuspended and cultivated in X-vivo-15 complete media (X-vivo-15, 5% AB serum, 20 ng/mL IL-2). One day later, cells were activated by Dynabeads human T activator CD3/CD28 (25  $\mu$ L of beads/ $1\text{E}^6$  CD3 positive cells) and cultivated at a density of  $1\text{E}^6$  cells/mL for 3 days in X-vivo complete media at 37°C in the presence of 5% CO<sub>2</sub>. Cells were then split in fresh complete media and  
25 transduced/transfected the next day according to the following procedure. On the day of transduction-transfection, cells were first de-beaded by magnetic separation (EasySep), washed twice in Cytoporation buffer T (BTX Harvard Apparatus, Holliston, Massachusetts) and resuspended at a final concentration of  $28\text{E}^6$  cells/mL in the same solution. Cellular suspension was mixed with 5  $\mu$ g mRNA encoding TRAC TALEN<sup>®</sup> arms (SEQ ID NO:16  
30 and 17) in the presence or in the absence of 15  $\mu$ g of mRNA encoding arms of either CD25 or PD1 TALEN<sup>®</sup> (SEQ ID NO:18 and 19 and SEQ ID NO:20 and 21 respectively) in a final volume of 200  $\mu$ L. TALEN<sup>®</sup> is a standard format of TALE-nucleases resulting from a fusion of TALE with Fok-1 Transfection was performed using Pulse Agile technology, by applying two 0.1 mS pulses at 3,000 V/cm followed by four 0.2 mS pulses at 325 V/cm in  
35 0.4 cm gap cuvettes and in a final volume of 200  $\mu$ L of Cytoporation buffer T (BTX Harvard

Apparatus, Holliston, Massachusetts). Electroporated cells were then immediately transferred to a 12-well plate containing 1 mL of prewarm X-vivo-15 serum-free media and incubated for 37°C for 15 min. Cells were then concentrated to  $8 \times 10^6$  cells/mL in 250  $\mu$ L of the same media in the presence of AAV6 particles ( $\text{MOI} = 3 \times 10^5$  vg/cells) comprising the donor matrices in 48 wells regular treated plates. After 2 hours of culture at 30°C, 250  $\mu$ L of Xvivo-15 media supplemented by 10% AB serum and 40 ng/ml IL-2 was added to the cell suspension and the mix was incubated 24 hours in the same culture conditions. One day later, cells were seeded at  $1 \times 10^6$  cells/mL in complete X-vivo-15 media and cultivated at 37°C in the presence of 5%  $\text{CO}_2$ .

## 2.2-Activation-dependent expression of $\Delta$ LNFR and secretion of IL15

Engineered T-cells were recovered from the transfection-transduction process described earlier and seeded at  $1 \times 10^6$  cells/mL alone or in the presence of Raji cells (E:T=1:1) or Dynabeads (12.5  $\mu$ L/ $1 \times 10^6$  cells) in 100  $\mu$ L final volume of complete X-vivo-15 media. Cells were cultivated for 48 hours before being recovered, labeled and analyzed by flow cytometry. Cells were labeled with two independent sets of antibodies. The first sets of antibodies, aiming at detecting the presence of  $\Delta$ LNFR, CAR and CD3 cells, consisted in QBEND10-APC (diluted 1/10), vioblu-labeled anti CD3 (diluted 1/25) and PE-labeled anti- $\Delta$ LNFR (diluted 1/25). The second sets of antibodies, aiming at detecting expression of endogenous CD25 and PD1, consisted in APC-labeled anti-CD25 (diluted 1/25) and vioblu-labeled anti PD1 (diluted 1/25).

The same experimental set up was used to study IL-15 secretion in the media. Cells mixture were kept in co-culture for 2, 4, 7 and 10 days before collecting and analyzing supernatant using an IL-15 specific ELISA kit.

## 2.3-Serial killing assay

To assess the antitumor activity of engineered CAR T-cells, a serial killing assay was performed. The principle of this assay is to challenge CAR T-cell antitumor activity everyday by a daily addition of a constant amount of tumor cells. Tumor cell proliferation, control and relapse could be monitored via luminescence read out thanks to a Luciferase marker stably integrated in Tumor cell lines.

Typically, CAR T-cells are mixed to a suspension of  $2.5 \times 10^5$  Raji-luc tumor cells at variable E:T ratio (E:T=5:1 or 1:1) in a total volume of 1 mL of Xvivo 5% AB, 20 ng/uL IL-2. The mixture is incubated 24 hours before determining the luminescence of 25  $\mu$ L of cell suspension using ONE-Glo reagent. Cells mixture are then spun down, the old media is discarded and substituted with 1 mL of fresh complete X-vivo-15 media containing  $2.5 \times 10^5$

Raji-Luc cells and the resulting cell mixture is incubated for 24 hours. This protocol is repeated 4 days.

## Experiments and results

5 This example describes methods to improve the therapeutic outcome of CAR T-cell therapies by integrating an IL-15/soluble IL-15 receptor alpha heterodimer (IL15/sIL15 $\alpha$ ) expression cassette under the control of the endogenous T-cell promoters regulating PD1 and CD25 genes. Because both genes are known to be upregulated upon tumor engagement by CAR T-cells, they could be hijacked to re-express IL- IL15/sIL15 $\alpha$   
10 only in vicinity of a tumor. This method aims to reduce the potential side effects of IL15/sIL15 $\alpha$  systemic secretion while maintaining its capacity to reduced activation induced T-cell death (AICD), promote T-cell survival, enhance T-cell antitumor activity and to reverse T-cell anergy.

The method developed to integrate IL15/sIL15 $\alpha$  at PD1 and CD25 loci consisted  
15 in generating a double-strand break at both loci using TALEN in the presence of a DNA repair matrix vectorized by AAV6. This matrix consists of two homology arms embedding IL15/sIL15 $\alpha$  coding regions separated by a 2A cis acting elements and regulatory elements (stop codon and polyA sequences). Depending on the locus targeted and its involvement in T-cell activity, the targeted endogenous gene could be inactivated or not  
20 via specific matrix design. When CD25 gene was considered as targeted locus, the insertion matrix was designed to knock-in (KI) IL15/sIL15 $\alpha$  without inactivating CD25 because the protein product of this gene is regarded as essential for T-cell function. By contrast, because PD1 is involved in T-cell inhibition/exhaustion of T-cells, the insertion matrix was designed to prevent its expression while enabling the expression and secretion  
25 of IL15/sIL15 $\alpha$ .

To illustrate this approach and demonstrate the feasibility of double targeted insertion in primary T-cells, three different matrices were designed (figure 2A, 2B and 2C). The first one named CARm represented by SEQ ID NO:36 was designed to insert an anti-CD22 CAR cDNA at the TRAC locus in the presence of TRAC TALEN<sup>®</sup> (SEQ ID NO:16  
30 and 17). The second one, IL-15\_CD25m (SEQ ID NO:37) was designed to integrate IL15, sIL15 $\alpha$  and the surface marker named  $\Delta$ LNGFR cDNAs separated by 2A cis-acting elements just before the stop codon of CD25 endogenous coding sequence using CD25 TALEN<sup>®</sup> (SEQ ID NO:18 and 19). The third one, IL-15\_PD1m (SEQ ID NO:38), contained the same expression cassette and was designed to integrate in the middle of the PD1

open reading frame using PD1 TALEN<sup>®</sup> (SEQ ID NO:20 and 21). The three matrices contained an additional 2A cis-acting element located upstream expression cassettes to enable co-expression of IL15/sIL15 $\alpha$  and CAR with the endogenous gene targeted.

We first assessed the efficiency of double targeted insertion in T-cells by transducing them with one of the AAV6 encoding IL15/sIL15 $\alpha$  matrices (SEQ ID NO:41; pCLS30519) along with the one encoding the CAR and subsequently transfected the corresponding TALEN<sup>®</sup>. AAV6-assisted vectorization of matrices in the presence of mRNA encoding TRAC TALEN<sup>®</sup> (SEQ ID NO:22 and 23) and PD1 TALEN<sup>®</sup> (SEQ ID NO:24 and 25) or CD25 TALEN<sup>®</sup> (SEQ ID NO:26 and 27) enabled expression of the anti CD22 CAR in up to 46% of engineered T-cells (figure 3).

To determine the extent of IL15m integration at CD25 and PD1 locus, engineered T-cells were activated with either antiCD3/CD28 coated beads or with CD22 expressing Raji tumor cells. 2 days post activation, cells were recovered and analyzed by FACS using LNGFR expression as IL15/sIL15 $\alpha$  secretion surrogate (figure 4 and 5). Our results showed that antiCD3/CD28 coated beads induced expression of  $\Delta$ LNGFR by T-cells containing IL-15m\_CD25 or IL-15m\_PD1, independently of the presence of the anti CD22 CAR (figure 4A-B). Tumor cells however, only induced expression of  $\Delta$ LNGFR by T-cell treated by both CARm and IL-15m. This indicated that expression of  $\Delta$ LNGFR could be specifically induced through tumor cell engagement by the CAR (figures 5 and 6).

As expected the endogenous CD25 gene was still expressed in activated treated T-cells (figures 7 and 8) while PD1 expression was strongly impaired (figure 12).

To verify that expression of  $\Delta$ LNGFR correlated with secretion of IL15 in the media, T-cells expressing the anti-CD22 CAR and  $\Delta$ LNGFR were incubated in the presence of CD22 expressing Raji tumor cells (E:T ratio = 1:1) for a total of 10 days. Supernatant were recovered at day 2, 4, 7 and 10 and the presence of IL15 was quantified by ELISA assay. Our results showed that IL15 was secreted in the media only by T-cells that were co-treated by both CARm and IL15m matrices along with their corresponding TALEN<sup>®</sup> (figure 13). T-cell treated with either one of these matrices were unable to secrete any significant level of IL15 with respect to resting T-cells. Interestingly, IL-15 secretion level was found transitory, with a maximum peak centered at day 4 (Figure 14).

To assess whether the level of secreted IL-15 (SEQ ID NO:59) could impact CAR T-cell activity, CAR T-cell were co-cultured in the presence of tumor cells at E:T ratio of 5:1 for 4 days. Their antitumor activity was challenged everyday by pelleting and

resuspended them in a culture media lacking IL-2 and containing fresh tumor cells. Antitumor activity of CAR T-cell was monitored everyday by measuring the luminescence of the remaining Raji tumor cells expressing luciferase. Our results showed that CAR T-cells co-expressing IL-15 had a higher antitumor activity than those lacking IL15 at all time points considered (figure 15).

Thus, together our results showed that we have developed a method allowing simultaneous targeted insertions of CAR and IL15 cDNA at TRAC and CD25 or PD1 loci. This double targeted insertion led to robust expression of an antiCD22 CAR and to the secretion of IL15 in the media. Levels of secreted IL15 were sufficient to enhance the activity of CAR T-cells.

**Table 5:** Sequences referred to in example 2 and 3.

[illegible]

[illegible]

21	TALEN Left PD1	MGDPKKRKVIDKETAAAKFERQHMSIDIADLRTLGYSSQQQKEIKPK VRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTAVVKYQDMIAALPEA THEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIARGGV TAVEAVHAWRNALTGAPLNLTPQVVAIASHDGGKQALETVQRLLPVL CQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCAHGLTPEQVVAI ASHDGGKQALETVQRLLPVLCAHGLTPQQVVAIASNNGGKQALETVQ RLLPVLCAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCAHGLTP QQVVAIASNNGGKQALETVQRLLPVLCAHGLTPQQVVAIASNNGGKQ ALETVQRLLPVLCAHGLTPEQVVAIASNNGGKQALETVQALLPVLCA HGLTPQQVVAIASNNGGKQALETVQRLLPVLCAHGLTPEQVVAIASH DGGKQALETVQRLLPVLCAHGLTPQQVVAIASNNGGKQALETVQRLL PVLCAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCAHGLTPEQV VAIASNNGGKQALETVQRLLPVLCAHGLTPQQVVAIASNNGGKQALETV QRLLPVLCAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCAHGLT PQQVVAIASNNGGKQALETVQRLLPVLCAHGLTNDHLVALACLGGRP ALDAVKKGLGDPISRSQVLKSELEKKSELRHKLKYVPHEYIELIEIARNS TQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVVD TKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWVKVPSSVTE FKFLFVSGHFHKGNYKAQLTRLNHNITNCNGAVLSVEELLIGGEMIKAGTLT LEEVRKFNNGEINFAAD	HD-NG-HD-NG- NG-NG-NN-NI-NG- HD-NG-NN-N-NN- HD-NG#
----	-------------------	--	---

Table 5 (continued): Sequences referred to in example 2 and 3.

5

SEQ ID NO#	Sequence Name	Polynucleotide sequence
22	TALEN TRAC pCLS11370	ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTAT CGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAGATCAAACCGAA GGTTTCGTTGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGC ACATCGTTGCGTTAAGCCAAACCCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACA TGATCGCAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCC GGCGCACGCGCTCTGGAGGCTTGTACCGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACA GTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGT GCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTGACCCCCCAGCAGGTGGTGG CCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTG CTGTGCCAGGCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGG CAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGA CCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGT CCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCGAGCAGGTGGTGGCCA TCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTG TGCCAGGCCACGGCTTGACCCCCGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCA GCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCC CGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCA GCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCGAGCAGGTGGTGGCCATCG CCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAAGGCGCTGTTGCCGGTGCTGTGC CAGGCCACGGCTTGACCCCCGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCA GGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCG GAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAAGG GCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCA GCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAG GCCCACGGCTTGACCCCCGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGC GCTGGAGACGGTGCAAGGCGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCCAGC AGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCT GTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCGAGCAGGTGGTGGCCATCGCCAGCA ATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAAGGCGCTGTTGCCGGTGCTGTGCCAGGCC CACGGCTTGACCCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCT GGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCGAGCAG GTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTT GCCGGTGCTGTGCCAGGCCACGGCTTGACCCCTCAGCAGGTGGTGGCCATCGCCAGCAATG GCGGCGGCGAGGCCGCGCTGGAGAGCATTGTTGCCAGTTATCTCGCCCTGATCCGGCGTTG GCCGCGTTGACCAACGACCACCTCGTCGCTTGCCCTGCCTCGGCGGGCGCTCTGCGCTGGA TGCAAGTAAAAAGGGATTGGGGGATCCTATCAGCCGTTCCAGCTGGAGTCCAGTCCGAGCTGGA GGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGAT

		CGAGATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCAT GAAGGTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCGACGGCGCCATCT ACACCGTGGGCTCCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCGGC TACAACCTGCCCATCGGCCAGGCCGACGAATGCAGAGGTACGTGGAGGAGAACCAGACCA GAACAAGCACATCAACCCCAACGAGTGGTGGAAAGGTGTACCCCTCCAGCGTGACCGAGTTCAA GTTCTGTTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCAGCTGACCAGGCTGAACCA CATCACCAGTGAACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGA TCAAGGCCGACCCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAAC TTCGCGGCCGACTGATAA
23	TALEN TRAC pCLS11369	ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTTCGAG AGACAGCACATGGACAGCATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAA CAGGAGAAGATCAAACCGAAGGTTCTGTCGACAGTGGCGCAGCACCACGAGGCACTGGTTCGG CCACGGGTTTACACACGCGCACATCGTTGCGTTAAGCCAAACCCGGCAGCGTTAGGGACCGT CGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCGACAGCAGCGCTGAGCGTTGG CGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCGTTGCTCACGGTGGCGGGAGAGT TGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCG TGACCGCAGTGGAGGCACTGCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTG ACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCGCGTGGAGACGG TCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCC ATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCT GTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGC AAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGAC CCCGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGC AGGCGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCCATC GCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTG CCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGCAAGCAGGC CAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCC CCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAG CGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCCATCGC CAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCC AGGCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATGGCGGTGGCAAGCAG GCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCCA GCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGG CTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAG CAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGGAGGCGCTGTTGCCGGTGCTGTGCCAGG CCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGCAAGCAGGC GCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGC AGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTG TTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCA CGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCC CACGGCTTGACCCCCAGCAGGTGGTGGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCT GGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCTCAGCAGG TGGTGGCCATCGCCAGCAATGGCGGCGGCGAGGCCGCTGGAGACGATTGTTGCCAGTTA TCTCGCCCTGATCCGGGCTTGCGCGCTTGACCAACGACCACTCGTCGCTGGCCTGGCCTC GGCGGGCGTCTGCGCTGGATGCAGTGAAAAAGGGATTGGGGATCCTATCAGCCGTTCCCA GCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCC CCACGAGTACATCGAGCTGATCGAGATCGCCCGAACAGCACCCAGGACCGTATCCTGGAGAT GAAGGTGATGGAGTTCTTCTATGAAGGTGTACGGCTACAGGGGCAAGCACTGGGCTGCCATCA GGAAGCCCGACGGCGCCATCTACACCGTGGGCTCCCCATCGACTACGGCGTGATCGTGGAC ACCAAGGCCCTACTCCGGCGGCTACAACCTGCCATCGGCCAGGCCAGCAAATGCAGAGGTA CGTGGAGGAGAACCAGACAGGAACAAGCACATCAACCCCAACGAGTGGTGGAAAGGTGTAAC CCTCCAGCGTGACCGAGTTCAAGTTCTGTTCTGTCGTCGGGCACTCAAGGGCAACTCAAGG CCCAGCTGACCAGGCTGAACCACATCAACCACTGCAACGGCGCCGTGCTGTCCGTGGAGGAG CTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACCTGACCCTGGAGGAGGTGAGGAGGAA GTTCAACAACGGCGAGATCAACTTCGCGGCCGACTGATAA
24	TALEN CD25 pCLS30480	ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTAT CGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAA GGTTCTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCGGCCACGGGTTTACACACGCGC ACATCGTTGCGTTAAGCCAAACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACA TGATCGCAGCGTTGCCAGAGGCGACACAGGCGATCGTTGGCGTGGCAACAGTGGTCC GGCGCACGCGCTCTGGAGGCGCTTGTACAGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACA GTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCACT GCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTTGACCCCCAGCAGGTGGTGG CCATCGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTG CTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGG CAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTG CCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGT CCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGGCCA TCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTG TGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAA GCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCC CCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCA

		<p>GCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCG  CCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGC  CAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATGGCGGTGGCAAGCA  GGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCC  AGCAGGTGGTGCCATCGCCAGCAATAATGGTGCAAGCAGGCGCTGGAGACGGTCCAGCGG  CTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAG  CAATAATGGTGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGG  CCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCG  CTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCA  GGTGGTGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTG  TTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAA  TGGCGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCC  CACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCT  GGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCGAGCAG  GTGGTGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTT  GCCGGTGCTGTGCCAGGCCACGGCTTGACCCCTCAGCAGGTGGTGCCATCGCCAGCAATG  GCGGCGGCAGGCCGCGCTGGAGAGCATTGTTGCCAGTTATCTCGCCCTGATCCGAGTGGC  AGCGGAAGTGGCGGGATCCTATCAGCCGTTCCAGCTGGTGAAGTCCGAGCTGAGGAGAA  GAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGT  CGCCCCGAACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGT  GTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCCAGGCGCCATCTACACCG  TGGGCTCCCCATCGACTACGGCGTGATCGTGACACCAAGGCCGAGTGGCGGCTACCAACC  TGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAACAAG  CACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCCTG  TTCGTGTCCGGCCACTTCAAGGGCAACTACAAGGCCAGCTGACCAGGCTGAACCATCACC  AACTGCAACGGCGCCGTGCTGTCCGTGGAGAGCTCCTGATCGGCGGAGATCAAGGCG  CGCACCCCTGACCCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGG  CCGACTGATAA</p>
25	TALEN CD25 pCLS30479	<p>ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTAT  CGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAA  GGTTCGTTTCGACAGTGGCGCAGCACACAGGCACTGGTCCGCCACGGGTTTACACACGCGC  ACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACA  TGATCGCAGCGTTGCCAGAGGCGACACAGCAAGCGATCGTTGGCGTCGGCAACAGTGGTCC  GGCGCACGCGCTCTGGAGGCCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACA  GTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCTGACCCGAGTGGAGGCACT  GCATGCATGGCGCAATGCACTGACGGGTGCCCCGCTCAACTGACCCCGGAGCAGGTGGTGG  CCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTG  CTGTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGCCATCGCCAGCCACGATGGCGG  CAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGACCCGAGTCCAGGCCAGCTGA  CCCCGAGCAGGTGGTGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTG  CAGGCGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCAT  CGCCAGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGT  GCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATAATGGTGGCAAG  CAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCC  GGAGCAGGTGGTGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGG  CGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCC  AGCAATAATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCA  GGCCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATAATGGTGGCAAGCAGG  CGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAG  CAGGTGGTGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCT  GTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGGTGCCATCGCCAGCA  ATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGCTGTGCCAGGCC  CACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATAATGGTGGCAAGCAGGCGCT  GGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGCAG  GTGGTGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTT  GCCGGTGCTGTGCCAGGCCACGGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATA  ATGGTGGCAAGCAGGCGCTGGAGACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCAC  GGCTTGACCCCCAGCAGGTGGTGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGA  GACGGTCCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCACGGCTTGACCCCGGAGCAGGTGG  TGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCG  GTGCTGTGCCAGGCCACGGCTTGACCCCTCAGCAGGTGGTGCCATCGCCAGCAATGGCGG  CGGCAGGCCGCGCTGGAGAGCATTGTTGCCAGTTATCTCGCCCTGATCCGAGTGGCAGCG  GAAGTGGCGGGATCCTATCAGCCGTTCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAAT  CCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCC  GGAACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACG  GCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCCAGGCGCCATCTACACCGTGGGC  TCCCCATCGACTACGGCGTGATCGTGGACACCAAGGCCTACTCCGGCGGCTACAACCTGCC  ATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAACAACACAT  CAACCCCAACGAGTGGTGGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAGTTCCTGTTCTG  GTCCGGCCACTTCAAGGGCAACTACAAGGCCAGCTGACCAGGCTGAACCATCACCAACTG  CAACGGCGCCGTGCTGTCCGTGGAGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCA  CCCTGACCCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGAC  TGATAA</p>

26	TALEN PD1 pCLS28959	<p>ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATTACCCATACGATGTTCCAGATTACGCTAT CGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAAGATCAAACCGAA GGTTTCGTTTCGACAGTGGCGCAGCACCACGAGGCACTGGTTCGGCCACGGGTTTACACACGCGC ACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCAAGTATCAGGACA TGATCGCAGCGTTGCCAGAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAAACAGTGGTCC GGCGCAGCGCTCTGGAGGCCCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACA GTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCCGAGTGGAGGCAGT GCATGCATGGCGCAATGCACTGACGGGTGCCCGCTCAACTTGACCCCGAGCAAGTGGTGG CTATCGCTTCCAAGCTGGGGGGAAAGCAGGCCCTGGAGACCGTCCAGGCCCTTCTCCAGTG CTTTGCCAGGCTCACGGAAGTACCCCTGAACAGGTGGTGGCAATTGCCTCACACGACGGGGG CAAGCAGGCACTGGAGACTGTCCAGCGGCTGCTGCCTGTCTCTGCCAGGCCACGGAAGTCA CTCCTGAGCAGGTGCTGGCCATTGCCAGCCACGATGGGGGCAAAACAGGCTCTGGAGACCGTG CAGCGCCTCCTCCAGTGCTGTGCCAGGCTCATGGGCTGACCCCTGACCCAGCAGTGTGCGCATT GCCAGTAACGGCGGGGGGAAGCAGGCCCTCGAAACAGTGCAGAGGCTGCTGCCCGTCTTGTG CCAAGCACACGGCCTGACACCCGAGCAGGTGGTGGCCATCGCCTCTCATGACGGCGGCAAGC AGGCCCTTGAGACAGTGCAGAGACTGTTGCCCGTGTGTGTGTCAGGCCACCGGTTGACACCCC AGCAGGTGGTCCCATCGCCAGCAATGGCGGGGAAAGCAGGCCCTTGAGACCGTGCAGCGG TTGCTTCCAGTGTGTGCCAGGCACACGGAAGTACCCCTCAACAGGTGGTGCATCGCAATCGTGG TACAAGGGCGGAAAGCAGGCTCTGGAGACAGTGCAGCGCCTCTGCCCGTGTGTGTGTCAGGC TCACGGAAGTGCACACACAGCAGGTGGTGCCTATCGCCAGTAACGGGGGCGGCAAGCAGGCTT TGGAGACCGTCCAGAGACTCCTCCCGTCTTTGCCAGGCCACGGGTTGACACCTCAGCAGG TCGTGCCATTGCTTCCAACACGGGGGCAAGCAGGCCCTCGAAACAGTGTGTCAGGCTGCTG CCTGTGCTGTGCCAGGCTCATGGGCTGACACCCAGCAGGTGGTGGCCATTGCCTCTAACAAC GGCGGCAAAACAGGCACTGGAGACCGTGCAAAGGCTGCTGCCCGTCTCTGCCAAGCCACCG GCTCACTCCACAGCAGGTGCTGGCCATCGCCTCAAAACATGGCGGGAAGCAGGCCCTGGAGA CTGTGCAAAAGGCTGCTCCCTGTGCTCTGCCAGGCACACGGAAGTACCCCTCAGCAGGTGGT GCAATCGCTTCCAACAACGGGGGAAAGCAGGCCCTCGAAACCGTGCAGCGCCTCTCCAGT GCTGTGCCAGGCACATGGCCTCACACCCGAGCAAGTGGTGGCTATCGCCAGCCACGACGAG GGAAGCAGGCTCTGGAGACCGTGCAGAGGCTGCTGCCTGTCTGTGCCAGGCCACGGGCTT ACTCCAGAGCAGGTGCTCGCCATCGCCAGTCAATGATGGGGGGAAGCAGGCCCTTGAGACAGT CCAGCGGCTGCTGCCAGTCTTTGCCAGGCTCACGGCTTGAACCCGAGCAGGTGCTGGCCAT TGCCTCAAAACATTGGGGGCAAAACAGGCCCTGGAGACAGTGCAGGCCCTGCTGCCCGTGTGTG TCAGGCCACCGGTTGACACCCAGCAGGTGGTGCCTATGCTCTAATGGCGGCGGGAGAC CCGCTTGGAGAGCATTGTTGCCAGTATCTCGCCCTGATCCGCGGCTGGCCGCGTTGACCA ACGACCACCTCGTCCGCTTGGCCTCGCTCGCGGGCGTCTGCGCTGGATGCAATCGTGAAGG GGATTGGGGATCCTATCAGCCGTTCCAGCTGGTGAAGTCCGAGCTGGAGGAGAAGAAATCC GAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCG AACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTATGAAGGTGACGGC TACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCCGACGGCGCCATCTACACCGTGGGCTC CCCCATCGACTACGGCGTGTGCTGGACACCAAGGCCCTACTCGGCGGCTACAACCTGCCAT CGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACAGGAACAAGCACATCA ACCCCAACGAGTGGTGAAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTCTGTTCTGT CCGGCCACTTCAAGGGCAACTACAAGGCCAGCTGACAGGCTGAACCATACCAAGTGCAC ACGGCGCCGTGCTGTCCGTGGAGGAGCTCCTGATCGGCGGCGAGATGATCAAGGCCGGCACC CTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGACTG ATAA</p>
27	TALEN PD1 pCLS18792	<p>ATGGGCGATCCTAAAAAGAAACGTAAGGTCATCGATAAGGAGACCGCCGCTGCCAAGTTCGAG AGACAGCACATGGACAGCATCGATATCGCCGATCTACGCACGCTCGGCTACAGCCAGCAGCAA CAGGAGAAGATCAAACCGAAGGTTCTGTTTCGACAGTGGCGCAGCACCACGAGGCACTGGTCCG CCACGGGTTTACACACGCGCACATCGTTGCGTTAAGCCAACACCCGGCAGCGTTAGGGACCGT CGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCAGAGGCGACACAGCAAGCGATCGTTGG CGTCGGCAAAACAGTGGTCCGGCGCAGCGCTCTGGAGGCCCTTGAACAGGTGGCGGGAGAGT TGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCG TGACCCGAGTGGAGGCACTGCATGCATGGCGCAATGCACTGACGGGTGCCCGCTCAACTTG ACCCCGAGCAAGTCTGCGCAATCGCCAGCCATGATGGAGGGAAGCAAGCCCTCGAAACCGT GCAGCGGTTGCTTCTGTGCTCTGCCAGGCCACGGCCTTACCCTCAGCAGGTGGTGGCCAT CGCAAGTAACGGAGGAGGAAAGCAAGCCTTGGAGACAGTGCAGCGCCTGTTGCCCGTGTGT GCCAGGCACACGGCCTCACACCAGAGCAGGTGCTGGCCATTGCCTCCCATGACGGGGGGA CAGGCTCTGGAGACCGTCCAGAGGCTGCTGCCCGTCTCTGTCAAGCTCACGGCGCTGACTCCC CAACAAGTGGTGCCTATCGCCTAATGGCGGGGAAAGCAGGCACTGGAACAGTGCAGAG ACTGCTCCCTGTGCTTTGCCAAGCTCATGGGTTGACCCCAACAGGCTCGTCTGCTGCTCA AACGGGGGGGGAAGCAGGCCCTTGAAGTGTGCAGAGGCTGTTGCCAGTGTGTGTGTCAGGC TCACGGGCTCACTCCACAACAGGTGGTGCATTTGCCAGCAACGGCGGCGGAAAGCAAGCTCT TGAAACCGTGCAACGCCTCCTGCCCGTGTCTGTGAGGCTCATGGCTGACACCAACAAGT CGTGGCCATCGCCAGTAAATAATGGCGGGAAACAGGCTCTTGAGACCGTCCAGAGGCTGCTCC AGTGTCTGTGCCAGGCACACGGGCTGACCCCGAGCAGGTGGTGGCTATGCCAGCAATATTG GGGGCAAGCAGGCCCTGGAACAGTCCAGGCCCTGCTGCCAGTGTCTTGCCAGGCTCACGGG CTCACTCCCCAGCAGGTGCTGGCAATCGCCTCAACGGCGGAGGGAAGCAGGCTCTGGAGAC CGTGCAGAGACTGCTGCCCGTCTTGTGCCAGGCCACGGACTCACACAGTGCAGAGTGTGCGC CATTGCCTCTCAGATGGGGGCAAAACAGCCCTGGAGACAGTGCAGCGGCTGTTGCCTGTGTT GTGCCAAGGCCACGGCTTGACTCCTCAACAAGTGGTGCCTATCGCCTCAAATGGCGGCGGAAA ACAAGCTCTGGAGACAGTGCAGAGGTTGCTGCCCGTCTCTGCCAAGCCACGGCCTGACTCC</p>

		CCAACAGGTCGTCGCCATTGCCAGCAACAACGGAGGAAAGCAGGCTCTCGAAACTGTGCAGCG GCTGCTTCCTGTGCTGTGTCAGGCTCATGGGCTGACCCCCGAGCAAGTGGTGGCTATTGCCTC TAATGGAGGCAAGCAAGCCCTTGAGACAGTCCAGAGGCTGTTGCCAGTGCTGTGCCAGGCCCA CGGGCTCACACCCAGCAGGTGGTCGCCATCGCCAGTAACAACGGGGGCAACAGGCATTGG AAACCGTCCAGCGCCTGCTTCCAGTGCTCTGCCAGGCACACGGACTGACACCCGAACAGGTGG TGGCCATTGCATCCCATGATGGGGGCAAGCAGGCCCTGGAGACCGTGACAGACTCCTGCCA GTGTTGTGCCAAGCTCACGGCCTCACCCCTCAGCAAGTCGTGGCCATCGCCTCAAACGGGGG GGGCCGGCCTGCACTGGAGAGCATTGTTGCCCAGTTATCTCGCCCTGATCCGGCGTTGGCCG CGTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGGCGTCTCGCTGGATGCA GTGAAAAAGGGATTGGGGGATCCTATCAGCCGTTCCAGCTGGTGAAGTCGAGCTGGAGGAG AAGAAATCCGAGTTGAGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAG ATCGCCCGGAACAGCACCCAGGACCGTATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAG GTGTACGGCTACAGGGGCAAGCACCTGGGCGGCTCCAGGAAGCCGACGGCGCCATCTACAC CGTGGGCTCCCCATCGACTACGGCGTGATCGTGACACCAAGGCCACTCCGGCGGCTACA ACCTGCCCATCGGCCAGGCCGACGAAATGCAGAGGTACGTGGAGGAGAACCAGACCAGGAAC AAGCACATCAACCCCAACGAGTGGTGGAGGTGTACCCCTCCAGCGTGACCGAGTTCAAGTTC CTGTTCTGTCCGGCCACTTCAAGGGCAACTACAAGGCCAGCTGACCAGGCTGAACCACATC ACCAACTGCAACGGCGCCGTGCTGTCCGTGGAGGAGCTCTGATCGGCGGCGAGATGATCAA GGCCGGCACCCCTGACCCTGGAGGAGGTGAGGAGGAAGTTCAACAACGGCGAGATCAACTCG CGGCCGACTGATAA
28	TALEN target TRAC	TTGTCCACAGATATCCAGAACCCTGACCCTGCCGTGTACCAGCTGAGA
29	TALEN target CD25	TACAGGAGGAAGAGTAGAAGAACAATCTAGAAAACCAAAAGAACA
30	TALEN target PD1	TACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGA
31	Matrice TRAC locus_CubiCA R CD22 pCLS30056	TTGCTGGGCCTTTTTCCCATGCCTGCCTTTACTCTGCCAGAGTTATTGCTGGGGTTTTGAAGA AGATCCTATTAATAAAAAGATAAGCAGTATTATTAAGTAGCCCTGCATTTAGGTTTCCTTGAGT GGCAGGCCAGGCTGGCCGTGAACGTTCTACTGAAATCATGGCCTTTGGCCAAGATTGATAGC TTGTGCCTGTCCCTGAGTCCCACTCATCAGAGCAGCTGGTTTCTAAGATGCTATTTCCCGTA TAAAGCATGAGACCGTGACTTGCCAGCCCCACAGAGCCCCGCCCTGTCCATCACTGGCATCT GGACTCCAGCCTGGGTTGGGGCAAGAGGGGAAATGAGATCATGTCTAACCCTGATCCTCTTG TCCCACAGATATCCAGTACCCTACGACGTGCCGACTACGCTCCGGTGAGGGCAGAGGAAG TCTCTAACATGCGGTGACGTGGAGGAGAATCCGGGCCCGGATCCGCTCTGCCGTCACCGC TCTGCTGCTGCCACTGGCACTGCTGCTGCACGCTGCTAGGCCCGGAGGGGGAGGCAGCTGCC CCTACAGCAACCCAGCCTGTGCAGCGGAGGCGGCGGACGCGGCGGAGGGGTAGCCAGGT GCAGCTGCAGCAGAGCGGCCCTGGCCTGGTGAAGCCAAGCCAGACACTGTCCCTGACCTGCG CCATCAGCGCGATTCCGTGAGCTCCAACCTCCGCCGCTGGAATTGATCAGGCAGTCCCCTT CTCGGGGCCTGGAGTGGCTGGGAAGGACATACTATCGGTCTAAGTGGTACAACGATTATGCCG TGTCTGTGAAGAGCAGAATACAATCAACCCTGACACCTCCAAGAATCAGTTCTCTCTGCAGCT GAATAGCGTGACACCAGAGGACACCGCCGTGTACTATTGCGCCAGGGAGGTGACCGGCGACC TGGAGGATGCCCTTGACATCTGGGGCCAGGGCACAATGGTGACCGTGAGCTCCGGAGGCGGC GGATCTGGCGGAGGAGGAAGTGGGGCGGCGGGAGTGATATCCAGATGACACAGTCCCCATC CTCTCTGAGCGCCTCCGTGGGCGACAGAGTGACAATCACCTGTAGGGCCTCCAGACCATCTG GTCTTACCTGAACTGGTATCAGCAGAGGCCCGGCAAGGCCCTAATCTGCTGATCTACCGAGC AAGCTCCCTGCAGAGCGGAGTGCCATCCAGATTCTCTGGCAGGGCTCCGGCACAGACTTCAC CCTGACCATCTCTAGCCTGCAGGCCGAGGACTTCGCCACCTACTATTGCCAGCAGTCTTATAGC ATCCCCCAGACATTTGGCCAGGGCACCAAGCTGGAGATCAAGTCGGATCCCGGAAGCGGAGG GGGAGGCAGCTGCCCCACAGCAACCCAGCCTGTGCAGCGGAGGCGGCGGACGAGCTG CCCACCCAGGGCACCTTCTCAACGTGTCCACCAACGTGAGCCAGCCAGCCACCCACCCACC GCCTGTCTTATTCCAATCCTTCCCTGTGTGCTCCCAACCAACCCCGCTCCAAGGCCCTTA CCCCCGACCAACTATTGCCTCCCAGCCACTCTCACTGCGGCCTGAGGCCTGTGCGGCCGCTG CTGGAGGCGCAGTGATACAAGGGGCTCGATTTCGCCTGCGATATTACATCTGGGCACCCC TCGCCGGCACCTGCGGGGTGCTTCTCCTCTCCCTGGTGATTACCCTGTATTGCAGACGGGGCC GGAAGAAGCTCCTCTACATTTTAAAGCAGCCTTTATGCGGGCAGTGACAGACAACCCAAAGAGGA GGATGGGTGTTCTCTGCAGATTCCCTGAGGAAGAGGAAGGCGGGTGCGAGCTGAGAGTGAAGT TCTCCAGGAGCGCAGATGCCCCGCGCTATCAACAGGGCCAGAACCAGCTCTACAACGAGCTTA ACCTCGGGAGGCGCAAGAATACGACGTGTTGGATAAGAGAAGGGGGCGGGACCCCGAGATG GGAGGAAAGCCCGGAGGAAGAACCTCAGGAGGGCTGTACAACGAGTGACAGAAGGATAA GATGGCCGAGGCCTACTCAGAGATCGGGATGAAGGGGGAGCGGCGCGGGAAGGGGCAC GATGGGCTCTACCAGGGGCTGAGCACAGCCACAAAGGACACATACGACGCTTGACATGCAG GCCCTTCCACCCCGGAATAGTCTAGAGGGCCCGTTAAACCCGCTGATCAGCCTCGACTGTG CCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCCGTGCCTTCTTGACCCTGGAAGGTG CCACTCCCACTGTCTTTCTAATAAAATGAGGAAATTGCATCGCATGTCTGATGTGTCAT TCTATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAG GCATGCTGGGGATGCGGTGGGCTCTATGACTAGTGGCGAATTCCCGTGTACCAGCTGAGAGAC TCTAAATCCAGTGACAAGTCTGTCTGCCTATTCAACGATTTTGATTCTCAACAAATGTGTACA AAGTAAGGATTCTGATGTATATCACAGACAAACTGTGCTAGAGTCTAGGCTGATGGTCTCA AGAGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAACGCCCTTCAACAA

		CAGCATTATTCCAGAAGACACCTTCTTCCCCAGCCCAGGTAAGGGCAGCTTTGGTGCCTTCGCA GGCTGTTTCCTTGCTTCAGGAATGGCCAGGTTCTGCCCAGAGCTCTGGTCAATGATGTCTAAAA CTCCTCTGATTGGTGGTCTCGGCCTTATCCATTGCCACCAAAACCCTCTTTTTACTAA
32	Matrice CD25 locus_IL15_2 A_sIL15Ra pCLS30519	GTTTATTATTCTGTTCCACAGCTATTGTCTGCCATATAAAAACTTAGGCCAGGCACAGTGGCTC ACACCTGTAATCCCAGCACTTTGGAAGGCCGAGGCAGGCAGATCACAAGGTCAGGAGTTCGAG ACCAGCCTGGCCAAATAGCAAAACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGG TGGCGTGTGCACTGGTTTAGAGTGAGGACCACATTTTTTTGGTGCCGTGTTACACATATGACCG TGACTTTGTTACACCACTACAGGAGGAAGAGTAGAAGAACAATCGGTTCTGGCGTGAAACAGAC TTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCGGTACCGG GTCCGCCACCATGGACTGGACCTGGATTCTGTTCTCTGGCTGCTGCTACAAGAGTGACACAG CGGCATTATGTCTTTCATTTTGGGCTGTTTCAGTGCAGGGCTTCTAAAACAGAAGCCAACTGG GTGAATGTAATAAGTGATTTGAAAAAATTGAAGATCTTATTCAATCTATGCATATTGATGCTACT TTATATACGGAAAGTGATGTTCAACCCAGTTGCAAAGTAACAGCAATGAAGTGCTTTCTCTTGG GTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGTATTCAATGATGAGAAATCTGATCA TCCTAGCAAACAACAGTTTGTCTTCTAATGGGAATGTACAGAATCTGGATGCAAAGAATGTGAG GAACTGGAGGAAAAAATATTAAAGAATTTTTGCAGAGTTTTGTACATATTGTCCAAATGTTTCATC AACACTTCTGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAG AACCTGGACCTGGGACCGGCTCTGCAACCATGGATTGGACGTGGATCCCTGTTCTCGTGGCA GCTGCCACAAGAGTTCACAGTATCACGTGCCCTCCCCCATGTCCGTGGAACACGCAGACATC TGGGTCAAGAGCTACAGCTTGTACTCCAGGGAGCGGTACATTGTAACTCTGTTTCAAGCGTA AAGCCGGCACGTCCAGCCTGACGGAGTGCCTGTTGAACAAGGCCACGAATGTCGCCCACTGG ACAACCCCACTCTCAAATGCATTAGAGACCCCTGCCCTGGTTCAACCAAGGCCACCC TCCACAGTAACGACGGCAGGGGTGACCCACAGCCAGAGAGCCTCTCCCCCTCTGGAAGAGAG CCCGCAGCTTCATCTCCAGCTCAAACAACACAGCGGCCACAACAGCAGCTATTGTCCCGGGC TCCCAGCTGATGCCTTCAAATCACCTTCCACAGGAACCAAGAGATAAGCAGTCATGATCCT CCCACGGCACCCCTCTCAGACAACAGCCAAGAACTGGGAATCACAGCATCCGCTCCACC AGCCGCCAGGTGTGTATCCACAGGGCCACAGCGACACCACTGAGGGCAGAGGCAGCCTGCTG ACCTGCGGCGACGTGAGGAGAACCCCGGGCCCATGGGGGCAGGTGCCACCGGCCGCGCCA TGGACGGGCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCTTGGAGGTGCCAAGGAG GCATGCCCCACAGGCCTGTACACACACAGCGGTGAGTGTGCAAAGCCTGCAACCTGGGCGA GGGTGTGGCCAGCCTTGTGGAGCCAACAGACCGTGTGTGAGCCTGACCGTGCAGCGTGA CGTTCTCCGACGTGGTGAGCGCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCCTGGGGCTC CAGAGCATGTGCGCGCCGTGCGTGAGGCGCGATGACGCCGTGTGCCGTGCGCTACGGCTA CTACCAGGATGAGACGACTGGGCGCTGCGAGGCGTGCCGCTGTGCGAGGCGGGCTCGGGC CTCGTGTCTCTGCGGAGGACAAGCAGAACCCGTGTGCGAGGAGTGCCCGCAGCGCACGTAT TCCGACGAGGCCAACACAGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCG CCAGCTCCGCGAGTGACACACGCTGGGCGGACGCGGAGTGCGAGGAGATCCCTGGCCGTTGGA TTACACGGTCCACACCCCAAGAGGGCTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAG GCACCTCCAGAACAAAGACCTCATAGCCAGCACGCTGGCAGGTGTTGACCCACAGTGATGGG CAGCTCCAGCCCGTGGTGACCCGAGGACACCGACAACCTCATCCCTGTCTATTGCTCCAT CCTGGCTGCTGTGTTGTGGGTCTTGTGGCTACATAGCCTTCAAGAGGTGAAAAACCAAAAGA ACAAGAATTTCTTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCA AAGGTGCTAAATGGTCGCCAGGAGACATCCGTTGTGCTTGCCTGCGTTTTGGAAGCTCTGAA GTCACATCACAGGACAGGGGACAGTGGCAACCTTGTCTCTATGCCAGCTCAGTCCCATCAGAG AGCGAGCGCTACCCACTTCTAAATAGCAATTTGCGCGTTGAAGAGGAAGGGCAAAACCACTAGA ACTCTCCATCTTATTTTCATGTATATGTGTTTCAT
33	Matrice PD1 locus_IL15_2 A_sIL15Ra pCLS30513	GACTCCCCAGACAGGCCCTGGAACCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAA GGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGG TACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCA GCCCCGCCAGGACTGCCGCTTCCGTGTACACAACCTGCCAACGGGCGTGACTTCCACATGAG CGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTGTGTGGGGCGGTTCTGGCGTGA AACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCG GTACCGGGTCCGCCACCATGGACTGGACCTGGATTCTGTTCTCTGCTGCTGCTACAAGAG TGCACAGCGGCAATTCATGTCTTCAATTTTGGGCTGTTTCAGTGCAGGGCTTCTAAAACAGAAGC CAACTGGGTGAATGTAATAAGTGATTTGAAAAAATTGAAGATCTTATTCAATCTATGCATATTGA TGCTACTTTATATACGGAAGTGATGTTCAACCCAGTTGCAAAGTAACAGCAATGAAGTGCTTTC TCTTGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGTATTGATGACAGTAGAAAA CTGATCATCTAGCAAACAACAGTTTGTCTTCTAATGGGAATGTAAACAGAATCTGGATGCAAAGA ATGTGAGGAACTGGAGGAAAAAATATTAAAGAATTTTTGCAGAGTTTTGTACATATTGTCCAAAT GTTTCATCAACACTTCTGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGT GGAGGAGAACCCTGGACCTGGGACCGGCTCTGCAACCATGGATTGGAGCTGGATCCCTGTTCT CGTGGCAGCTGCCACAAGAGTTCACAGTATCACGTGCCCTCCCCCATGTCCGTGGAACACGC AGACATCTGGGTCAAGAGCTACAGCTTGTACTCCAGGGAGCGGTACATTTGTAACCTCTGGTTTC AAGCGTAAAGCCGGCACGTCCAGCCTGACGGAGTGCCTGTTGAACAAGGCCACGAATGTGCG CCACTGGACAACCCCACTCTCAAATGCATTAGAGACCCCTGCCCTGGTTGTTTCAACCAAGGCCAGC GCCACCTCCACAGTAACGACGGCAGGGGTGACCCACAGCCAGAGAGCCTCTCCCCCTCTG GAAAAGAGCCCGCAGCTTCATCTCCAGCTCAAACAACACAGCGGCCACAACAGCAGCTATTG TCCCGGGCTCCAGCTGATGCCTTCAAATCACCTTCCACAGGAACCAAGAGATAAGCAGTCA TGAGTCTCCACAGCACCCCTCTCAGACAACAGCCAAGAAGTGGAACTGACAGTACCGCTCCG CTCCACAGCCGCCAGGTGTGTATCCACAGGGCCACAGCGACACCACTGAGGGCAGAGGCA GCCTGCTGACCTGCGGCGACGTGAGGAGAACCCCGGGCCCATGGGGGCAGGTGCCACCGG CCGCGCATGGACGGGCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCTTGGAGGTG

		<p>CCAAGGAGGCATGCCCCACAGGCCTGTACACACACAGCGGTGAGTGCTGCAAAGCCTGCAAC  CTGGGCGAGGGTGTGGCCCAGCCTTGTGGAGCCAACCAGACCGTGTGTGAGCCCTGCCTGGA  CAGCGTGACGTTCTCCGACGTGGTGAGCGCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCG  TGGGGCTCCAGAGCATGTGCGCGCCGTGCGTGAGGGCCGATGACGCCGTGTGCCGTGCGC  CTACGGCTACTACCAGGATGAGACGACTGGCGCGTGGCAGGCGTGGCGCGTGTGCGAGGCGG  GCTCGGGCCTCGTGTCTCCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGAC  GGCAGTATTCCGACGAGGCCAACCACGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGA  CACCGAGCGCCAGCTCCGCGAGTGACACGCTGGGCCGACGCCGAGTGCGAGGAGATCCCT  GGCCGTTGGATTACACGGTCCACACCCCCAGAGGGCTCGGACAGCACAGCCCCCAGCACCCA  GGAGCCTGAGGCACCTCCAGAACAAGACCTCATAGCCAGCACGGTGGCAGGTGTGGTGACCA  CAGTGATGGGCAGTCCCAGCCCGTGGTGACCCGAGGCACACCGACAACCTCATCCCTGTCT  ATTGCTCCATCCTGGCTGCTGTGGTTGTGGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGATC  TAGAGGGCCCGTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTT  GTTTGCCCTCCCCCGTGCCTTCTTACCCTGGAAGGTGCCACTCCCAGTGTCTTCTCTAAT  AAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCTATTCTATTTCTGGGGGTGGGGTGGG  GCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCT  CTATGACTAGTGCGAATTCGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACA  GGTGCGGCTCGGAGGCCCGGGGAGGGGTGAGCTGAGCGGCTGTGGGGTGGGTGTCCC  CTCCTGCACAGGATCAGGAGCTCCAGGGTCTGAGGGCAGGGACCCCCAGCTCCAGTCCAGG  GCTCTGTCTGCACCTGGGGAATGGTGACCGGCATCTGTCTCTAGCTCTGGAAGCACCCC  AGCCCTCTAGTCTGCCCTCACCCCTGACCCTGACCCTCCACCCTGACCCCGTCTAACCCCT  GACCTTG</p>
34	Matrice CD25 locus_IL12a_ 2A_IL12b pCLS30520	<p>GTTTATTATTCCTGTTCCACAGCTATTGTCTGCCATATAAAACTTAGGCCAGGCACAGTGGCTC  ACACCTGTAATCCCAGCACTTTGGAAGGCCGAGGCAGGCAGATCACAAGGTCAGGAGTTCGAG  ACCAGCCTGGCCAACATAGCAAAACCCCATCTCTACTAAAAATACAAAATTAGCCAGGCATGG  TGGCGTGTGCACTGTTTAGAGTGAGGACCACATTTTTTTGGTGCCGTGTACACATATGACCG  TGACTTTGTTACACCACTACAGGAGGAAGAGTAGAAGAACAATCGTTCTGGCGTGAAACAGAC  TTTGAATTTTACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCATGTGGCC  CCCTGGGTACAGCCTCCCAGCCACCGCCCTCACCTGCCCGCGCCACAGGTCTGCATCCAGCGG  CTCGCCCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGCGCAGCCTCCTCTGTGG  CTACCCTGGTCTCTCGGACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACTCCAGCC  CAGGAATGTTCCCATGCCTTACCCTCCCAAACTGCTGAGGGCCGTGAGCAACATGCTCCA  GAAGGCCAGACAACTCTAGAATTTTACCCTTGCACTTCTGAAGAGATTGATCATGAAGATATCA  CAAAAGATAAAACCAGCACAGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAATGAGAGTTG  CCTAAATTCCAGAGAGACCTCTTTCATAACTAATGGGAGTTGCCCTGCCCTCCAGAAAGACCTCT  TTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGTGGAGTTCAA  GACCATGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTCTAGATCAAAACATGCTG  GCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAATCCT  CCCTTGAAAGAACCGGATTTTATAAACTAAATCAAGCTCTGCATACCTTCTCATGCTTTTCAGAA  TTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCGGAAGCGGAGCTACTAA  CTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCTATGTGTACCAGCA  GTTGGTCATCTCTTGGTTTTCCCTGGTTTTCTGGCATCTCCCTCGTGGCCATATGGGAACCTGA  AGAAAGATGTTTATGTCGTAGAATTGGATTGGTATCCGGATGCCCTGGAGAAATGGTGTCT  CACCTGTGACACCCCTGAAGAAGATGGTATCACCTGGACCTTGGACCAACATGAGGTCTT  AGGCTCTGGCAAAACCCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGT  CACAAAGGAGGCGAGGTTCTAAGCCATTGCTCTGCTGCTTCAAAAAGGAAGATGGAATTT  GGTCCACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGC  CAAGAATTATTCTGGACGTTTACCTGCTGGTGGCTGACGACATCTCATGACTTATTGACATTCA  GTGTCAAAAGCAGCAGAGGCTCTTCTGACCCCAAGGGGTGACGTGCGGAGCTGCTACACTCT  CTGCAGAGAGAGTCAGAGGGGACAACAAGGAGTATGAGTACTCAGTGGAGTGCCAGGAGGAC  AGTGCCCTGCCAGCTGCTGAGGAGAGTCTGCCATTGAGGTCTAGTGGATGCCGTTCACAAG  CTCAAGTATGAAAACCTACACGACGCTTCTTCTCATCAGGAGATCTCAAACTGACCCACCA  AGAACTTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTGAGTGGGAGTACCCCTG  ACACCTGGAGTACTCCACATTCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAGAG  CAAGAGAGAAAAGAAAGATAGAGTCTTACGGACAAGACCTCAGCCACGGTCATCTGCCGCAA  AAATGCCAGCATTAGCGTGCGGGCCAGGACCGCTACTATAGCTATCTGGAGCTGAGTGGGC  ATCTGTGCCCTGCAGTGAGGGCAGAGGCAGCCTGCTGACCTGCGGCGACGTGAGGAGAACC  CCGGGCCCATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGCGCGCCTGCTGCTGTT  GCTGCTTCTGGGGGTGTCCCTTGGAGGTGCCAAGGAGGCATGCCCCACAGGCCTGTACACAC  ACAGCGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCAGCCTGTGGAGCC  AACCAGACCGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCGAC  CGAGCCGTGCAAGCCGTGACCCGAGTGCGTGGGGCTCCAGAGCATGTCGGCGCCGTGCGTG  GAGGCCGATGACGCCGTGTGCCGCTGCGCCTACGGCTACTACCAGGATGAGACGACTGGGCG  CTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTCTCCTGCCAGGACAAGC  AGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACAGGCCAACCGTGGAC  CCGTGCTGCTGCTGACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTGACACGCTG  GGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGATTACACGGTCCACACCCCCAGAGG  GCTCGGACAGCACAGCCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCATA  GCCAGCACGGTGGCAGGTGTGGTGACCAAGTATGGGCAAGTCCCAAGCCGTGGTGACCCG  AGGCACACCGACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGTGGGTCTT  GTGGCCTACATAGCCTTCAAGAGGTGAAAAACCAAAAGAACAAAGATTTCTTGGTAAGAAGCCG  GGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAAAGGTGCTAAATGGTCGCCACAGGA  GACATCCGTTGTGCTTGCCTGCGTTTTGGAAGCTCTGAAGTCACATCACAGGACAGGGGACG  TGGCAACCTTGTCTCTATGCCAGCTCAGTCCCATCAGAGAGCGAGCGCTACCCACTTCTAAATA</p>

		GCAATTTGCGCGTTGAAGAGGAAGGGCAAACCCTAGAACTCTCCATCTTATTTTCATGTATATGTGTTTCA
35	Matrice PD1 locus_IL12a_2A_IL12b pCLS30511	<p>             GACTCCCCAGACAGGCCCTGGAACCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAA              GGGGACAACGCCACCTTCACTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAACTGG              TACCGCATGAGCCCCAGCAACCAGACGACAAAGCTGGCCGCTTCCCCGAGGACCGCAGCCA              GCCCGGCCAGGACTGCCGCTTCCGTGTACACAACCTGCCAACGGGCGTGACTTCCACATGAG              CGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCGTTCTGGCGTGA              AACAGACTTTGAATTTTACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCAT              GTGGCCCCCTGGGTACGCTCCAGCCACCGCCCTCACCTGCCGCGGCCACAGGTCTGCATC              CAGCGGCTCGCCCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGCGCAGCCTCCTC              CTTGTGGTACCCTGGTCCTCCTGGACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACT              CCAGACCCAGGAATGTTCCCATGCCTTCACTACTCCCAAAACCTGCTGAGGGCCGTCAGCAAC              ATGCTCCAGAAGGCCAGACAACTCTAGAATTTTACCCTTGCACTTCTGAAGAGATTGATCATGA              AGATATCACAAGAGATAAAACACGACAGTGAGGCGCTGTTTACCATTGGAACTAACCAAGAT              GAGAGTTGCCTAAATTCAGAGAGACCTCTTTCATACTAATGGGAGTTGCCTGGCCTCCAGAA              AGACCTCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGTG              GAGTTCAAGACCATGAATGCAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTCTAGATCAAAA              CATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGCTGTGCCAA              AAATCCTCCCTTGAAGAACCGGATTTTATAAACTAAAATCAAGCTCTGCATCTTCTTCATGCT              TTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCGGAAGCGGAG              CTAATACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCTATGTGTC              ACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTCTGGCATCTCCCCCTGTCGCCATATGG              GAACTGAAGAAAGATGTTTATGTCTGATGAATTGGATTGGTATCCGGATGCCCTGGAGAAATGG              TGGTCCTCACCTGTGACACCCCTGAAGAAGATGGTATCACCTGGACCTTGGACCAGAGCAGTG              AGGTCTTAGGCTCTGGCAAACCCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTA              CACCTGTCAAAAGGAGGCGAGTTCTAAGCCATTGCTCCTGCTTCCACAAAAGGAAGAT              GGAATTTGGTCCACTGATATTTTAAAGGACGAGAAAGAACCCAAATAAGACCTTCTAAGATG              CGAGGCCAAGAATTATTCTGGACGTTTCACTGCTGGTGGCTGACGACAATCAGTACTGATTTG              ACATTGAGTGTCAAAAGCAGCAGAGGCTCTTCTGACCCCCAAGGGGTGACGTGCGGAGCTGCT              AACTCTCTGCAGAGAGATCAGAGGGGACAAACAGGAGTATGAGTACTCAGTGGAGTGCCAG              GAGGACAGTGCCCTGCCAGCTGCTGAGGAGAGTCTGCCATTGAGGCTGATGGATGCCGTT              CACAAGCTCAAGTATGAAACTACACCAGCAGCTTCTTCATCAGGGACATCATCAACCTGACC              CACCAAGAACTTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGT              ACCCTGACACCTGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCCAGTCCAGGG              CAAGAGCAAGAGAGAAAAAGAAAGATAGAGTCTTACGGACCAAGACCTCAGCCACGCTCATCTG              CCGCAAAATGCCAGCATTAGCGTGCAGGGCCAGGACCGCTACTATAGCTCATCTTGGAGCGA              ATGGGCATCTGTGCCCTGCAGTGAGGGCAGAGGCAGCCTGCTGACCTGCGGCGACGTGCGAGG              AGAACCCCGGGCCCATGGGGGCAGGTGCCACCGGCCCGCCATGGACGGGCGCGCCTGCT              GCTGTTGCTGCTTCTGGGGGTGTCCTTGGAGGTGCCAAGGAGGACCTCAGCCACAGGCTCATGTA              CACACACAGCGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCAGCCTTGTG              GAGCCAACCAGACCGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGC              GCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTCCAGAGCATGTGCGCGCCGT              GCGTGGAGGCCGATGACGCCGTGTGCCGCTGCGCCTACGGCTACTACGAGATGAGACGACT              GGGCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCGTGCTTCTCCTGCCAGG              ACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCGACGAGGCCAACCCAC              GTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTGACAC              ACGCTGGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTACACGGTCCACACCCC              CAGAGGGCTCGGACAGCACAGCCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGAC              CTCATAGCCAGCACGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCTCCAGCCCGTGGT              GACCCGAGGCACCCACCAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGT              GGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGATCTAGAGGGCCCCGTTAAACCCGCTGATCA              GCCTCGACTGTGCCCTTAGTGTGCCAGCCTGTTGTTTCCCCCTCCCTGCTCCTTCTCTGTA              CCCTGGAAGGTGCCACTCCACTGTCTTTTCTAATAAAATGAGGAAATTCATCGCATTGTCT              GAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGG              AAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGACTAGTGCGGAATTCGGCGCAG              ATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGGTGACGCTCGGAGGCCCGGGCGG              AGGGGTGAGCTGAGCCGCTCCTGGGGTGGGTGTCCCCTCCTGCACAGGATCAGGAGCTCCAG              GGTGCTAGGGCAGGGACCCCCAGCTCCAGTCCAGGGCTGTGCTGACCTGGGGAATGGT              GACCGGCATCTGTGCTCTAGCTCTGGAAGCACCCAGCCCCCTAGTCTGCCCTCACCCCT              GACCCTGACCCTCCACCCTGACCCCGTCTAACCCTGACCTTG           </p>
36	Inserted matrice TRAC locus_CubiCA R CD22 (60 nucleotides upstream and downstream)	<p>             ATGAGATCATGTCCTAACCCCTGATCCTCTTGTCCACAGATATCCAGAACCCTGACCCTGTTGCT              GGGCCTTTTTCCCATGCCTGCCTTTACTCTGCCAGAGTTATATTGCTGGGGTTTTGAAGAAGATC              CTATTAAATAAAAGAATAAGCAGTATTATTAAGTAGCCCTGCATTTAGGTTTCCCTTGAGTGGCA              GGCCAGGCCTGGCCGTGAACGTTCACTGAAATCATGGCCTCTTGGCCAAGATTGATAGCTTGT              GCCTGTCCCTGAGTCCAGTCCATCAGAGCAGCTGGTTTCTAAGATGCTGCTATTTCCTGATATAA              GCATGAGACCGTGACTTGCCAGCCCCACAGAGCCCCGCCCTTGTCCATCACTGGCATCTGGAC              TCCAGCCTGGGTTGGGGCAAAGAGGGAAATGAGATCATGTCTTAACCTGATCCTCTTGTCCCA              CAGATATCCAGTACCCCTACGACGTGCCCGACTACGCTCCGGTGAGGGCAGAGGAAGTCTTC              TAACATGCGGTGACGTGGAGGAGAAATCCGGCCCCGATCCCGTCTGCTGCTGCTGCTGCTGCTG              CTGCTGCCACTGGCACTGCTGCTGCACGCTGCTAGGCCCGGAGGGGGAGGCAGCTGCCCTTA              CAGCAACCCAGCCTGTGCAGCGGAGGCGGCGGACGCGGCGAGGGGGTAGCCAGGTGCAG              CTGCAGCAGAGCGGCCCTGGCCTGGTGAAGCCAAGCCAGACACTGTCCCTGACCTGCGCCAT           </p>

		<p> CAGCGGCGATTCCGTGAGCTCCAACCTCCGCCGCTGGAATTGGATCAGGCAGTCCCCTTCTCG  GGGCTGGAGTGGCTGGGAAGGACATACTATCGGTCTAAGTGGTACAACGATTATGCCGTGTC  TGTGAAGAGCAGAATCACAATCAACCTGACACCTCCAAGAATCAGTTCTCTGACAGTGAAT  AGCGTGACACCAGAGGACACCGCCGTGTACTATTGCGCCAGGGAGGTGACCGGCGACCTGGGA  GGATGCCCTTTGACATCTGGGGCCAGGGCACAATGGTGACCGTGAGCTGCGGAGGCGCGGAT  CTGGCGGAGGAGGAAGTGGGGGCGGCGGGAGTGATATCCAGATGACACAGTCCCCATCTCT  CTGAGCGCCTCCGTGGGCGACAGAGTGACAATCACCTGTAGGGCCTCCCAGACCATCTGGTCT  TACCTGAACTGGTATCAGCAGAGGCCCCGCAAGGCCCTAATCTGCTGATCTACGCAGCAAGC  TCCCTGCAGAGCGGAGTGCCATCCAGATTCTCTGGCAGGGCTCCGGCACAGACTTCAACCCTG  ACCATCTCTAGCCTGCAGGCCGAGGACTTCGCCACCTACTATTGCCAGCAGTCTTATAGCATCC  CCCAGACATTTGGCCAGGGCACCAGCTGGAGATCAAGTCGGATCCCGGAAGCGGAGGGGGA  GGCAGCTGCCCCCTACAGCAACCCCAGCCTGTGCAGCGGAGGCGGCGGCGAGCTGCCCA  CCCAGGGCACCTTCTCCAACGTGTCCACCAACGTGAGCCAGCCAGCTAACCCACCAACCCCT  GTCCTTATTCCAATCCTTCCCTGTGTGCTCCCAACCAACCCCGCTCCAAGGCCCTTACCCC  CGCACCAACTATTGCCTCCCAGCCACTCTCACTGCGGCCTGAGGCCTGTGCGCCCGCTGCTGG  AGGCGCAGTGATACAAGGGGCTCGATTTGCGCTGCGATATTTACATCTGGGCACCCCTCGC  CGGCACCTGCGGGGTGCTTCTCTCTCCCTGGTGATTACCCTGTATTGCAGACGGGGCCGGAA  GAAGCTCCTCTACATTTTAAAGCAGCCTTTCATGCGGCCAGTGACAGCAACGAAGGAGGAT  GGGTGTTCTGCAGATTCCCTGAGGAAGAGGAAGGCGGGTGCGAGCTGAGAGTGAAGTTCTC  CAGGAGCGCAGATGCCCCCGCTATCAACAGGGCCAGAACCAAGCTCTACAACGAGCTTAACCT  CGGGAGGCGCGAAGAATACGACGTGTTGGATAAGAGAAGGGGGCGGGACCCCGAGATGGGA  GGAAAGCCCCGGAGGAAGAACCCTCAGGAGGGCCTGTACAAAGGCTGACCAAGGATGAAGAT  GGCCGAGGCCTACTCAGAGATCGGGATGAAGGGGGAGCGGCGCCGCGGGAAGGGGCACGAT  GGGCTCTACCAGGGGCTGAGCACAGCCACAAAGGACACATACGACGCCTTGACATGCAGGC  CCTTCCACCCCGGAATAGTCTAGAGGGCCCCGTTAAACCCGCTGATCAGCCTCGACTGTGCC  TTCTAGTTGCCAGCATCTGTTGTTTGGCCCTCCCCCGTGCTTCTGACCTGGAAGGTGCC  ACTCCCACTGTCTTTCTAATAAAATGAGGAAATTCATCGCATTGTCTGAGTAGGTGTCTTC  TATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGC  ATGCTGGGGATGCGGTGGGCTCTATGACTAGTGCGCAATTCCCGTGTACCAGCTGAGAGACTC  TAAATCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAATGTGTACAAA  GTAAGGATTCTGATGTGTATATCACAGACAAAACCTGTGCTAGACATGAGGTCTATGGACTCAAG  AGCAACAGTGCTGTGGCCTGGAGCAACAAATCTGACTTTGCATGTGCAACGCCTTCAACAACA  GCATTATTCCAGAAGACACCTTCTTCCCCAGCCAGGTAAGGGCAGCTTTGGTGCCCTCGCAG  GCTGTTTCTTGTCTCAGGAATGGCCAGGTTCTGCCAGAGCTCTGGTCAATGATGTCTAAAC  TCCTCTGATTGGTGGTCTCGGCCTTATCCATTGCCACCAAAACCTCTTTTACTAAGAAACAGT  GAGCCTTGTCTGGCAGTCCAGAGAATGACACGGGAAAAAAGCAGATGAAGA </p>
37	<p> Inserted  matrice CD25  locus IL15_2  A_sIL15Ra  (60  nucleotides  upstream and  downstream) </p>	<p> AGTGCTGGCTAGAAACCAAGTGCTTTACTGCATGCACATCATTTAGCACAGTTAGTTGCTGTTTA  TTATTCCTGTTCCACAGCTATTGTCTGCCATATAAAAACTTAGGCCAGGCACAGTGGCTCACACC  TGTAATCCCAGCACTTTGGAAGGCCGAGGCAGGCAGATCACAAGGTACGAGTTTCGAGACCAG  CCTGGCCAAACATAGCAAAACCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCG  TGTGCACTGGTTAGAGTGAGGACCACATTTTTTTGGTGCCGTGTTACACATATGACCGTGACTT  TGTTACACCACTACAGGAGGAAGAGTAGAAGAACAAATCGGTTCTGGCGTGAAACAGACTTTGAA  TTTTGACCTTCTCAAGTTGGCGGGAGAGCTGGAGTCCAACCCAGGCCCCGGTACCGGGTCCGC  CACCATGGACTGGACCTGGATTCTGTTCTCGTGGCTGCTGCTACAAGATGACAGCGGCAT  TCATGTCTTCATTTTGGGCTGTTTCACTGCAGGGCTTCTAAAAACAGAAGCCAACCTGGGTGAAT  GTAATAAGTGATTTGAAAAAAATGAAGATCTTATTCAATCTATGCATATTGATGCTACTTTATATA  CGGAAAGTGATGTTACCCCAAGTTGCAAGTAACAGCAATGAAGTGCTTTCTTTGGAGTTACA  AGTTATTTCACTTGAGTCCGGAGATGCAAGTATTCATGATACAGTAGAAGATCTGCTGGCCTAG  CAACAACAGTTTGTCTTCTAATGGGAATGAACAGAATCTGGATGCAAAGAATGTGAGGAACT  GGAGGAAAAAATATTAAAGAATTTTGCAGAGTTTTGTACATATTGTCCAAATGTTTCATCAACAC  TTCTGGAAGCGGAGCTACTAAGTTCAGCCTGCTGAAGCAGGCTGGAGAGCTGGAGGAGAACCC  TGGACCTGGGACCGGCTCTGCAACCATGGATTGGACGTGGATCTGTTTCTGCTGGCAGCTGC  CACAAGAGTTCACAGTATCACGTGCCCTCCCCCATGTCCGTGGAACACGCAGACATCTGGGT  CAAGAGCTACAGCTTGTACTCCAGGGAGCGGTACATTTGTAACCTCTGGTTTCAAGCGTAAAGCC  GGCAGCTCCAGCCTGACGGAGTGCGTGTGAACAAGGCCACGAATGTCGCCCTGCGGACCTGGAAC  CCCCAGTCTCAAATGCATTAGAGACCTGCCCCTGGTTACCAAAAGGCCACCTCACCCTCCAC  AGTAACGACGGCAGGGGTGACCCACAGCCAGAGAGCCTCTCCCCCTTCTGGAAGAGAGCCG  CAGCTTCATCTCCAGCTCAAACAACACAGCGGCCACAACAGCAGCTATTGTCCCGGGCTCCC  AGCTGATGCCCTTCAAATCACCTTCCACAGGAACACAGAGATAAGCAGTCATGATCCTCCCA  CGGCACCCCTCTCAGACAACAGCCAAGAACTGGGAACCTACAGCATCCGCTCCCACAGCC  GCCAGGTGTGATCCACAGGGCCACAGCGACACCACTGAGGGCAGAGGCAGCCTGCTGACCT  GCGGCGACGTCGAGGAGAACCCCGGGCCCATGGGGGCGAGGTGCCACCGGCCGCGCCATGGA  CGGGCCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCTTGGAGGTGCCAAGGAGGCAT  GCCCCACAGGCCTGTACACACACAGCGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGT  GTGGCCAGCCTTGTGGAGCCAACACAGACCTGTGTGAGCCCTGCTGACCGCTGACAGCTGCTT  CTCCGACGTGGTGAGCGCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTCCAGA  GCATGTGCGGCGCCGTGCGTGGAGGCCGATGACGCCGTGTGCCGCTGCGCCTACGGCTACTAC  CAGGATGAGACGACTGGGCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCG  TGTTCTCCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCGGACGGCAGCTATTCCG  ACGAGGCCAACCAGTGAGCCCGTGCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAG  CTCCGCGAGTGACACGCTGGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTAC  ACGGTCCACACCCCCAGAGGGCTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAGGCAC  CTCCAGAACAAAGACCTCATAGCCAGCACGGTGCCAGGTGTGGTGACCACAGTGATGGGACGT  CCCAGCCCGTGGTGACCCGAGGCACCAACCGACAACCTCATCCCTGTCTATTGCCATCCTCG </p>

		CTGCTGTGGTTGTGGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGAAAAACCAAAAGAACAAG AATTTCTTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAAAGGT GCTAAATGGTTCGCCCAGGAGACATCCGTTGTGCTTGCCTGCGTTTTGGAAGCTCTGAAGTCACA TCACAGGACACGGGGCAGTGGCAACCTTGTCTCTATGCCAGCTCAGTCCCATCAGAGAGCGAG CGCTACCCACTTCTAAATAGCAATTTCCGCCGTGGAAGAGGAAGGGCAAAACCACTAGAACCTC CATCTTATTTTCATGTATATGTGTTTCATTAAGCATGAATGGTATGGAACCTCTCCACCCTATAT GTAGTATAAAGAAAAGTAGGTT
38	Inserted matrice PD1 locus_IL15_2 A_sIL15Ra (60 nucleotides upstream and downstream)	GGTGGCCGGGGAGGCTTTGTGGGGCCACCCAGCCCCCTTCTCACCTCTCTCCATCTCTCAGAC TCCCCAGACAGGCCCTGGAACCCCCCACCCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGG GGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTAC CGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCC CGGCCAGGACTGCCGCTTCCGTGTACACAACCTGCCAACGGGCGTGACTTCCACATGAGCGT GGTCAGGGCCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCGGTTCTGGCGTGAAC AGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCAAGGGCCCGTGA CCGGGTCCGCCACCATGGACTGGACCTGGATTCTGTTCTCTGCTGGCTGCTGCTACAAGAGTGC ACAGCGGCATTTCATGTCTTTCATTTTGGGCTGTTTCAGTGCAGGGCTTCTTAAACAGAAAGCCAA CTGGGTGAATGTAATAAGTGATTTGAAAAAATTGAAGATCTTATTCATCTATGCATATTGATGC TACTTTATATACGGAAGTGATTTACCCCAAGTTGCAAAAGTGAAGCATGAAGTCCGCTCTCT TGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGTATTCATGATACAGTAGAAAAATCTG ATCATCCTAGCAACAACAGTTTGTCTTCTAATGGGAATGTAAACAGAATCTGGATGCAAAAGAATG TGAGGAACTGGAGGAAAAAATATTAAGAATTTTGCAGAGTTTGTACATATTGTCAAATGTT CATCAACACTTCTGGAAGCGGAGCTACTAAGCTTCAAGCTGCTGCAAGGCTGGAGTCCGCTGGA GGAGAACCCTGGACCTGGGACCGGCTCTGCAACCATGGATTGGACGTGGATCCTGTTTCTCGT GGCAGCTGCCACAAGAGTTTCACAGTATCACGTGCCCTCCCCCATGTCCGTGGAACACGCAGA CATCTGGGTCAAGAGCTACAGCTTGTACTCCAGGGAGCGGTACATTTGTAACCTCTGGTTTCAAG CGTAAAGCCGGCACGTCCAGCCTGACGGAGTGCCTGTTGAACAAGGCCAAGTGTGCGCCA CTGGACAACCCCCAGTCTCAAATGCATTAGAGACCCTGCCCTGGTTACCAAGGCTGCAACCTGG ACCCTCCACAGTAACGACGGCAGGGGTGACCCACAGCCAGAGAGCCTCTCCCCCTCTGGAAA AGAGCCCCGACGTTTCATCTCCAGCTCAAACAACACAGCGGCCACAACAGCAGCTATTGTCCC GGGCTCCCAGCTGATGCCTTCAAATCACCTTCCACAGGAACCAAGAGATAAGCAGTCATGAG TCCTCCCACGGCACCCCTCTCAGACAACAGCCAAGAACTGGGAACCTACAGCATCCGCTCC CACCAGCCGCCAGGTGTGTATCCACAGGGCCACAGCGACACCACTGAGGGCAGAGGCAGCCT GCTGACCTGCGGCGACGTGAGGAGAACCCCGGGCCCATGGGGGCAGGTGCCACCGGCCCGC GCCATGGACGGGCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCCTTGGAGGTGCCAA GGAGGCATGCCCCACAGGCCTGTACACACACAGCGGTGAGTGCTGCAAAAGCTGCAACCTGG GCGAGGGTGTGGCCAGCCTTGTGGAGCCAACCAGACCGTGTGTGAGCCCTGCCTGGACAGC GTGACGTTCTCCGACGTGGTGAGCGCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCCTGGG GCTCCAGAGCATGTCCGCGCCGTGCGTGGAGGCCGATGACGCCGTGTGCCGCTGCGCCTACG GCTACTACAGGATGAGACGACTGGCGCTGCGAGGCGTGCCGCTGTGCGAGGCGGGCTC GGGCCTCGTGTCTCTGCGCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCGACGGCA CGTATTCGACGAGGCCAACCACGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACC GAGCGCCAGCTCCGCGAGTGCACACGCTGGGCCGACGCCGAGTGCAGGAGATCCCTGGCC GTTGGATTACACGGTCCACACCCCAAGGGCTCGGACAGCACAGCCCCCAGCACCCAGGAG CCTGAGGCACCTCCAGAACAAGACCTCATAGCCAGCACGCTGGCAGGTGGTGGTACACAGTG ATGGGCAGCTCCAGCCCGTGGTGACCCGAGGCACCCAGACAACCTCATCCCTGTCTATTGC TCCATCCTGGCTGCTGTGTTGTGGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGATCTAGAG GGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCTCTGTTGTTTG CCCCCCCCCTGCCTTCTTGAACCTTGGAAAGGTGCCACTCCCATGTCCTTCTAATAAAAT GAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGGCAG GACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTAT GACTAGTGGCGAATTCGGCGCAGATCAAAGAGAGCCTGCGGGGCAGGCTCAGGGTGACAGGT GCGGCCTCGGAGGCCCGGGGCGAGGGTGAGCTGAGCGGCTGCTGGGTGGGTGCTCCCTC CTGCACAGGATCAGGAGCTCCAGGGTCTAGGGCAGGGACCCCCCAGCTCCAGTCCAGGGCT CTGTCTGCACCTGGGGAATGGTGACCGGCATCTCTGTCTCTAGCTCTGGAAGCACCCACAGC CCCTCTAGTCTGCCCTCACCCCTGACCCCTGACCCCTCCACCCTGACCCCGTCTAACCCCTGAC CTTGTGCCCTTCCAGAGAGAAGGGCAGAAGTGCCACAGCCCACCCAGCCCCCTACCCAGG CC
39	Inserted matrice CD25 locus_IL12a_2A_IL12b (60 nucleotides upstream and downstream)	AGTGCTGGCTAGAAACCAAGTGCTTTACTGCATGCACATCATTTAGCACAGTTAGTTGCTGTTTA TTATTCCTGTTCCACAGCTATTGTCTGCCATATAAAAACTTAGGCCAGGCACAGTGCTCACACC TGTAATCCCAGCACTTTGGAAGGCCGAGGCAGGCAGATCACAAGGTCAGGAGTTCGAGACCAG CCTGGCCAACATAGCAAAACCCCTCTCTACTAAAAATAACAAAATAGCCAGGCATGGTGGCG TGTGCACTGGTTAGAGTGAGGACCACATTTTTTTGGTGCCGTGTTACACATATGACCGTGACTT TGTTACACCACTACAGGAGGAAGAGTAGAAGAACAATCGGTTCTGGCGTGAAACAGACTTTGAA TTTTGACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCATGTGGCCCCCTGG GTCAGCCTCCCAGCCACCGCCCTCACCTGCGCGGCCACAGGTCTGCATCCAGCGGCTCGCC CTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGCGCAGCCTCCTCCTTGTGGCTACCC TGGTCCTCCTGGACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACTCCAGACCCAGGAA TGTTCCCATGCCTTCACCACTCCCAAAACCTGCTGAGGGCCGTGACCAACATGCTCCAGAAAGG CCAGACAACCTCTAGAATTTTACCCTTGCACTTCTGAAGAGATTGATCATGAAGATATCACAAA GATAAAACCAGCACAGTGAGGCGCTGTTTACCATTGGAATTAACCAAGAATGAGAGTTGCCTAA ATTCCAGAGAGACCTCTTTCATACTAATGGGAGTTGCCTGGCCTCCAGAAAGACCTCTTTTATG ATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGTGGAGTTCAAGACCA

		<p>TGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTCTAGATCAAAACATGCTGGCAGTT  ATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCTCCCTTG  AAGAACC GGATTTTTATAAACTAAATCAAGCTCTGCATACTTCTTCATGCTTTCAGAATTCGGG  CAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCGGAAGCGGAGCTACTAACTTCAG  CCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCTATGTGTACCAACCTGTCCAG  CATCTCTTGGTTTTCCCTGGTTTTCTGGCATCTCCCCTCGTGGCCATATGGGAAGTGAAGAAA  GATGTTTATGTCTAGAAATTGGATTGGTATCCGGATGCCCCTGGAGAAAATGGTGGTCCTCACCT  GTGACACCCCTGAAGAAGATGGTATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCT  CTGGCAAAACCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGTCCACAA  AGGAGGCGAGGTTCTAAGCCATTGCTCCTGCTGCTTCAAAAAAGGAAGATGGAATTTGGTCC  ACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGGCCAAGAA  TTATTCTGGACGTTTCACTGCTGGTGGCTGACGACAATCAGTACTGATTTGACATTCACTGTCA  AAAGCAGCAGAGGCTCTTCTGACCCCAAGGGTGACGTGCGGAGTCTGCTACACTCTCTGCAG  AGAGAGTCAGAGGGGACAACAAGGAGTATGAGTACTCAGTGAGTGCCAGGAGGACAGTGCC  TGCCAGCTGCTGAGGAGAGTCTGCCATTGAGGTGATGGTGGATGCCGTTCAAGCTCAAG  TATGAAAACCTACACCAGCAGCTTCTTCATCAGGGACATCATCAAACCTGACCCACCAAGAACTT  GCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGACACCTG  GAGTACTCCACATTCTTCTCTCCCTGACATTCTGCGTTTCAAGCTGACCCAGGAGGAGAGA  GAAAAGAAAGATAGAGTCTTACGGACAAGACCTCAGCCACGGTCATCTGCCGCAAAAAATGCCA  GCATTAGCGTGCGGGCCCCAGGACCGCTACTATAGCTCATCTTGGAGCGAATGGGCATCTGTGC  CCTGCAGTGAGGGCAGAGGCAGCCTGCTGACCTGCGGCGACGTCGAGGAGAAACCCGGGCC  CATGGGGGCAGGTGCCACCGCGCGCCGCTGGACGGGCGCGCTGCTGCTGCTGCTGCTGCTTCT  TGGGGGTGTCCCTTGGAGGTGCCAAGGAGGCATGCCCCACAGGCCGTGTACACACACAGCGGT  GAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCACAGCCTGTGGAGCCAACCAGAC  CGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCGACCCGAGCCGT  GCAAGCCGTGCACCGAGTGCGTGGGGCTCAGAGCATGTCCGCGCCGCTGCTGGAGCCGGA  TGACGCCGTGTGCCCTGCGCTACGGCTACTACCAGGATGAGACGACTGGGCGCTGCGAGG  CGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTCTCCTGCCAGGACAAGCAGAACACC  GTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACGAGGCCAACACGTGGACCCGTGCCT  GCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTGACACGCTGGGCCGAC  GCCGAGTGCGAGGAGATCCCTGGCCGTGGATTACACGGTCAGTCCACCCCAAGCGGGAAGCA  CAGCACAGCCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCATAGCCAGCA  CGGTGGCAGGTGTGGTGACACAGTGATGGGCAGCTCCCAGCCCGTGGTGACCCGAGGCACC  ACCGACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGTGGGTCTTGTGGCCT  ACATAGCCTTCAAGAGGTGAAAAACCAAAAGAACAAAGAAATTTCTGGAAGAACCGGGAACAG  ACAACAGAAGTCATGAAGCCCAAGTGAATCAAAGGTGCTAAATGGTCGCCCAGGAGACATCC  GTTGTGCTTGCCCTGCGTTTTGGAAGCTCTGAAGTCACATCACAGGACACGGGGCAGTGGAAC  CTTGCTCTATGCCAGCTCAGTCCCATCAGAGAGCGAGCGCTACCCACTTCTAAATAGCAATTT  CGCCGTTGAAGAGGAAGGGCAAAACCACTAGAACTCTCCATCTTATTTTCATGTATATGTGTTCA  TGAATGGTATGGAACCTCTCCACCCTATATGTAGTATAAGAAAAGTAGGTT</p>
40	Inserted matrice PD1 locus_IL12a_2A_IL12b (60 nucleotides upstream and downstream)	<p>GGTGGCCGGGGAGGCTTTGTGGGGCCACCCAGCCCTTCTCACCTCTCTCCATCTCTCAGAC  TCCCCAGACAGGCCCTGGAACCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGG  GGACAACGCCACCTTCACTGCGAGTCTCTCAACACATCGGAGAGCTTCGTGCTAACTGGTATC  CGCATGAGCCCCAGCAACCCAGAGCGGACAAGCTGGCCGCTTCCCCGATTGACCCGAGCCGAGCC  CGGCCAGGACTGCCGCTTCCGTGTACACAACCTGCCAACGGGCGTGACTTCCACATGAGCGT  GGTCAGGGCCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCGGTCTGGCGTGAAAC  AGACTTTGAATTTTGAACCTTCTCAAGTTGGCGGGAGACGTGGAGTCAACCCAGGGCCCCATG  GGCCCCCTGGGTGAGCCTCCAGCCACCGCCCTCACCTGCCGCGGCCACAGGTCTGCATCCA  GCGGCTCGCCCTGTGTCCCTGCACTGCCGGCTCAGCATGTGTCCAGCGCGCAGCCTCCTCCTT  GTGGCTACCCCTGGTCTCCTGGACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACTCCA  GACCCAGGAATGTTCCCATGCCTTCACTACTCCAAACCTGCTGAGGGCCGCTCAGCAACATG  CTCCAGAAGGCCAGACAAACTCTAGAATTTTACCCTTGCACTTCTGGAAGAGATGATCATGAAGA  TATCACAAGAGATAAAACCAGCACAGTGGAGGCCTGTTTACCATTGGAATTAACCAAGAAATGAG  AGTTGCCCTAAATTCAGAGAGACCTCTTTTCATAACTAATGGGAGTTGCCCTGGCCTCCAGAAAGA  CCTCTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTGAAGATGTACAGGTTGGAG  TTCAAGACCATGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTCTAGATCAAAACAT  GCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAA  TCCTCCCTTGAAGAACCGGATTTTTATAAACTAAATCAAGCTCTGCATACTTCTTCATGCTTTC  AGAATTCGGGCGAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCGGAAGCGGAGCTA  TAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCTATGTGTCCACC  AGCAGTTGGTCATCTTGGTTTTCCCTGGTTTTCTGGCATCTCCCCTCGTGGCCATATGGGAA  CTGAAGAAAGATGTTTATGTCTAGAAATTGGATTGGTATCCGGATGCCCCTGGAGAAATGGTGG  TCCTCACCTGTGACACCCCTGAAGAAGATGGTATCACCTGGACCTTGGACCAGAGCAGTGAGG  TCTTAGGCTCTGGCAAAACCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACAC  CTGTCAAAAGGAGGCGAGGTTCTAAGCCATTGCTCCTGCTGCTTCACAAAAAGGAAGATGGA  ATTTGGTCCACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCCA  GGCCAAGAATTATTCTGGACGTTTCACTGCTGGTGGGTGACGACAATCAGTACTGATTTGACA  TTCAGTGTCAAAAGCAGCAGAGGCTCTTCTGACCCCAAGGGGTGACGTGCGGAGCTGCTACA  CTCTCTGCAGAGAGAGTGCAGAGGGGACAACAAGGAGTATGAGTACTCAGTGAGTGCCAGGAG  GACAGTGCCCTGCCAGCTGCTGAGGAGAGTCTGCCATTGAGGTGATGGTGGATGCCGTTTAC  AAGCTCAAGTATGAAAACCTACACCAGCAGCTTCTTCATCAGGGACATCATCAAACCTGACCCAC  CCAAGAACTTGACAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTGAGCTGGGAGTACC  CTGACACCTGGAGTACTCCACATTCTACTTCTCCCTGACATTCTGCGTTCCAGTCCAGGGCAA  GAGCAAGAGAGAAAAGAAAGATAGAGTCTTACGGACAAGACCTCAGCCACGGTCATCTGCCG</p>

		CAAAAATGCCAGCATTAGCGTGCGGGGCCAGGACCGCTACTATAGCTCATCTTGGAGCGAATG GGCATCTGTGCCCTGCAGTGAGGGCAGAGGCAGCCTGCTGACCTGCGGCGACGTGAGGAGA ACCCGGGGCCCATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGCGCGCCTGCTGCT GTTGCTGCTTCTGGGGGTGTCCCTTGAGGTGCCAAGGAGGCATGCCCCACAGGCCGTGACAC ACACAGCGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTTGCCAGCCTTGTGGAG CCAACCAGACCGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCG ACCGAGCCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTCCAGAGCATGTCGGCGCCGTGCGT GGAGGCCGATGACGCCGTGTGCCGTGCGCCTACGGCTACTACCAGGATGAGACGACTGGGC GCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTTCTCCTGCCAGGACAAG CAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACGAGGCCAACACGTGGA CCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTGACACGCT GGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTACACGGTCCACACCCCCAGAG GGCTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCAT AGCCAGCACGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCTCCAGCCCGTGGTGACCC GAGGCACACCGACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGTGGGTCT TGTGGCCTACATAGCCTTCAAGAGGTGATCTAGAGGGCCCGTTAAACCCGCTGATCAGCCTC GACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTCCCCCTCCCCGTGCCCTTCTTGACCCTG GAAGGTGCCACTCCCAGTGTCTTTTCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTA GGTGTCATTCTATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGAC AATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGACTAGTGGCGAATTCGGCGCAGATCAA AGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGGTGCGGCCTCGGAGGCCCGGGGCAGGGG TGAGCTGAGCCGTCCTGGGGTGGGTGTCCCCTCCTGCACAGGATCAGGAGCTCCAGGGTCTG TAGGGCAGGGACCCCCAGCTCCAGTCCAGGGCTCTGTCTGCACCTGGGGAATGGTGACCG GCATCTCTGTCTCTAGCTCTGGAAGCACCCAGCCCCCTAGTCTGCCCTCACCCCTGACCC GACCCCTCCACCTGACCCCGTCTAACCCCTGACCTTTGTGCCCTTCCAGAGAGAAGGGCAGA AGTGCCACAGGCCACCCAGCCCCCTACCCAGGCC
41	upstream TRAC locus polynucleotide sequence	ATGAGATCATGTCCTAACCTGATCCTCTTGTCCACAGATATCCAGAACCCTGACC CTG
42	downstream TRAC locus polynucleotide sequence	GAAACAGTGAGCCTTGTCTGGCAGTCCAGAGAATGACACGGGAAAAAGCAGATG AAGA
43	upstream CD25 locus polynucleotide sequence	AGTGCTGGCTAGAAACCAAGTGCTTTACTGCATGCACATCATTTAGCACAGTTAGTT GCT
44	downstream CD25 locus polynucleotide sequence	GAATGGTATGGAACCTCTCTCCACCCTATATGTAGTATAAAGAAAAGTAGGTT
45	upstream PD1 locus polynucleotide sequence	GGTGGCCGGGAGGCTTTGTGGGGCCACCCAGCCCCCTCCTCACCTCTCTCCATCT CTCA
46	downstream PD1 locus polynucleotide sequence	TGCCCTTCCAGAGAGAAGGGCAGAAGTGCCACAGCCCACCCAGCCCCCTACCC AGGCC
47	IL-12a polynucleotide	ATGTGGCCCCCTGGGTCAGCCTCCCAGCCACCGCCCTCACCTGCCGCGGCCACAG GTCTGCATCCAGCGGCTCGCCCTGTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCA GCGCGCAGCCTCCTCCTTGTGGCTACCCTGGTCCTCCTGGACCACCTCAGTTTGGC CAGAAACCTCCCCGTGGCCACTCCAGACCCAGGAATGTTCCCATGCCTTACCCT CCAAAACCTGCTGAGGGCCGTGAGCAACATGCTCCAGAAGGCCAGACAACTCTA GAATTTTACCCTTGCATTCTGAAGAGATTGATCATGAAGATATCAGAAAGATAAAA CCAGCACAGTGGAGGCCGTGTTTACCATTGGAATTAACCAAGAATGAGAGTTGCCTAA ATTCCAGAGAGACCTCTTTCATAACTAATGGGAGTTGCCTGGCCTCCAGAAAGACCT CTTTTATGATGGCCCTGTGCCTTAGTAGTATTTATGAAGACTTGAAGATGTACCAGGT GGAGTTCAAGACCATGAATGCAAAGCTTCTGATGGATCCTAAGAGGCAGATCTTTCT AGATCAAAACATGCTGGCAGTTATTGATGAGCTGATGCAGGCCCTGAATTTCAACAG

		TGAGACTGTGCCACAAAAATCCTCCCTTGAAGAACCGGATTTTTATAAACTAAAATC AAGCTCTGCATACTTCTTCATGCTTTCAGAATTCGGGCAGTGACTATTGATAGAGTGA TGAGCTATCTGAATGCTTCC
48	IL12b polynucleotide	ATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTCTGGCATCTCCCC TCGTGGCCATATGGGAAGTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGTATC CGGATGCCCCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAAGAAGATGGT ATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCCTGAC CATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGTACAAAAGGAGCG AGGTTCTAAGCCATTGCTCCTGCTGCTTCAAAAAAGGAAGATGGAATTTGGTCCA CTGATATTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGAGG CCAAGAATTATTCTGGACGTTTCACCTGCTGGTGGCTGACGACAATCAGTACTGATT TGACATTCAGTGTCAAAGCAGCAGAGGCTCTTCTGACCCCCAAGGGGTGACGTGC GGAGCTGCTACACTCTCTGCAGAGAGAGTCAGAGGGGACAACAAGGAGTATGAGTA CTCAGTGGAGTGCCAGGAGGACAGTGCCTGCCAGCTGCTGAGGAGAGTCTGCCC ATTGAGGTCATGGTGGATGCCGTTTCAAGCTCAAGTATGAAAATACACCAGCAGC TTCTTCATCAGGGACATCATCAACCTGACCCACCAAGAATTGACAGCTGAAGCCA TTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCTGACACCTGGAGTAC TCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAGAGCAAGAG AGAAAAGAAAGATAGAGTCTTACGGACAAGACCTCAGCCACGGTCATCTGCCGCA AAAATGCCAGCATTAGCGTGCGGGCCCAGGACCGCTACTATAGCTCATCTTGAGC GAATGGGCATCTGTGCCCTGCAGT
49	IL15 polynucleotide	GGCATTTCATGTCTTCATTTTGGGCTGTTTCAGTGCAGGGCTTCTTAAACAGAAGCC AACTGGGTGAATGTAATAAGTGATTTGAAAAAATTGAAGATCTTATTCAATCTATGC ATATTGATGCTACTTTATATACGAAAGTGATGTTACCCCCAGTTGCAAAAGTAACAGC AATGAAGTGCTTTCTCTTGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGT ATTCATGATACAGTAGAAAATCTGATCATCCTAGCAAACAACAGTTTGTCTTCTAATG GGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAACTGGAGGAAAAAATATTA AGAATTTTTGCAGAGTTTTGTACATATTGTCCAAATGTTTCATCAACACTTCT
50	sIL15ra polynucleotide	ATCACGTGCCCTCCCCCATGTCCGTGGAACACGCAGACATCTGGGTCAAGAGCTA CAGCTTGTACTCCAGGGAGCGGTACATTTGTAACCTCTGGTTTCAAGCGTAAAGCCGG CACGTCCAGCCTGACGGAGTGCGTGTTGAACAAGGCCACGAATGTGCCCCACTGGA CAACCCCCAGTCTCAAATGCATTAGAGACCCTGCCCTGGTTACCAAAGGCCAGCG CCACCCCTCCACAGTAACGACGGCAGGGGTGACCCACAGCCAGAGAGCCTCTCCC CTTCTGGAAGAGAGCCCGCAGCTTCATCTCCCAGCTCAAACAACACAGCGGCCACA ACAGCAGCTATTGTCCCGGGCTCCAGCTGATGCCTTCAAAATCACCTTCCACAGGA ACCACAGAGATAAGCAGTCATGAGTCCTCCACGGCACCCCTCTCAGACAACAGC CAAGAACTGGGAACTCACAGCATCCGCCTCCACAGCCGCCAGGTGTGTATCCAC AGGGCCACAGCGACACCACT
51	soluble GP130 polynucleotide	ATGCTGACACTGCAGACTTGGCTGGTGCAGGCACTGTTTATTTTTCTGACTACTGAA TCAACTGGCGAACTGCTGGACCCTTGTGGCTACATCAGCCCTGAGTCCCCAGTGGT GCAGCTGCACAGCAACTTCACCGCCGTGTGCGTGCTGAAGGAGAAGTGTATGGACT ACTTTACAGTGAACGCCAATTATATCGTGTGGAAGAACCAACCACTTCACAATCCCCAA GGAGCAGTACACCATCATCAATAGGACAGCCAGCTCCGTGACCTTTACAGACATCG CCTCCCTGAACATCCAGCTGACCTGCAATATCCTGACATTCGGCCAGCTGGAGCAG AACGTGTATGGCATCACCATCATCTGGCCTGCCCTGAGAAGCCTAAGAACCTG AGCTGCATCGTGAATGAGGGCAAGAAGATGCGGTGTGAGTGGGACGGCGGCAGAG AGACACACCTGGAGACAACTTCACCCTGAAGTCCGAGTGGGCCACACACAAGTTT GCCGACTGCAAGGCCAAGCGCGATACCCCAACATCCTGTACCGTGGATTACTCTAC AGTGTATTTTGTGAACATCGAAGTGTGGGTGGAGGCCGAGAATGCCCTGGGCAAGG TGACCTCCGACCACATCAACTTCGATCCCGTGTACAAGGTGAAGCCTAACCCACCCC ACAATCTGAGCGTGATCAATTCGAGGAGCTGTCTAGCATCCTGAAGCTGACCTGGA CAAAACCATCTATCAAGAGCGTGATCATCCTGAAAGTACAATATCCAGTATCGGACCA AGGACGCCTCCACATGGAGCCAGATCCCTCCAGAGGATACCGCCAGCACAAAGATCC TCTTTCACCGTGCAGGACCTGAAGCCCTTCACAGAGTACGTGTTTCGGATCAGATGT ATGAAGGAGGACGGCAAGGGCTACTGGAGCGATTGGTCCGAGGAGGCCAGCGGCA TCACCTATGAGGACAGGCCTTCTAAGGCCCCAGCTTCTGGTACAAGATCGATCCAT CCCACACCCAGGGCTATCGCACAGTGCAGCTGGTGTGGAAGAACCTGCCCCCTTTC GAGGCCAACGGCAAGATCCTGGACTACGAGGTGACCCTGACACGGTGGAAAGTCCC ACCTGCAGAACTATACCGTGAATGCCACCAAGCTGACAGTGAACCTGACAAATGATC GGTACCTGGCCACCCTGACAGTGAGAAACCTGGTGGGCAAGCTGACGCCCGCGT GCTGACCATCCCTGCCTGCGATTTCCAGGCCACACACCCAGTGATGGACCTGAAGG CCTTTCCAAGGATAATATGCTGTGGGTGGAGTGGACCACACCTAGAGAGTCCGTG

		AAGAAGTACATCCTGGAGTGGTGCCTGCTGTCTGACAAGGCCCATGTATCACCGA CTGGCAGCAGGAGGATGGCACCCTGCACAGGACATATCTGCGCGGCAACCTGGCC GAGTCTAAGTGTTACCTGATCACCGTGACACCCGTGTATGCAGACGGACCAGGCTC TCCTGAGAGCATCAAGGCCTACCTGAAGCAGGCACCACCAAGCAAGGGACCAACCG TGCGGACAAAGAAGGTGCGCAAGAATGAGGCCGTGCTGGAGTGGGACCAGCTGCC TGTGGATGTGCAGAACGGCTTCATCAGGAATTACACCATCTTTTATCGCACAAATCATC GGCAACGAGACAGCCGTGAATGTGGACAGCTCCACACCGAGTATACACTGTCTAG CCTGACCTCCGATACACTGTACATGTTGAGGATGGCCGCCTATACAGACGAGGGCG GCAAGGATGGCCCCGAGTTT
52	IgE signal sequence	GGTACCGGGTCCGCCACCATGGACTGGACCTGGATTCTGTTCCCTCGTGGCTGCTGC TACAAGAGTGCACAGC
53	F2A	GGTTCTGGCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGACGTG GAGTCCAACCCAGGGCCC
54	P2A	GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGA ACCCTGGACCT
55	T2A	GAGGGCAGAGGCAGCCTGCTGACCTGCGGCGACGTCGAGGAGAACCCCGGGCCC
56	LNGFR	ATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGGCCGCGCCTGCTGCTGTTG CTGCTTCTGGGGGTGTCCCTTGAGGTGCCAAGGAGGCATGCCCCACAGGCCTGT ACACACACAGCGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCCA GCCTTGTGGAGCCAACCAGACCGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCT CCGACGTGGTGAGCGCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCGTGCGGC TCCAGAGCATGTCGGCGCCGTGCGTGGAGGCCGATGACGCCGTGTGCCGCTGCGC CTACGGCTACTACCAGGATGAGACGACTGGGCGCTGCGAGGCGTGCCGCGTGTGC GAGGCGGGCTCGGGCCTCGTGTTCTCCTGCCAGGACAAGCAGAACACCGTGTGCG AGGAGTGCCCCGACGGCACGTATTCCGACGAGGCCAACACGTGGACCCGTGCCT GCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTGACACGCTGG GCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTACACGGTCCACACCCC CAGAGGGCTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGA ACAAGACCTCATAGCCAGCACGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCT CCCAGCCCGTGGTGACCCGAGGCACCAACCTCATCCCTGTCTATTGCTCC ATCCTGGCTGCTGTGGTTGTGGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGA
<b>SEQ ID NO#</b>	<b>Sequence Name</b>	<b>Polypeptide sequence</b>
57	IL-12a polypeptide	MWPPGSASQPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNL PVATPDPMFPCLLHHSQNLLRAVSNMLQKARQTLEFYPTSEEIDHEDITDKTSTVEA CLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSIYEDLKMYQVEFKTMNAK LLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEDFYKTIKLCILLHAFRIRA VTIDRVMSYLNAS
58	IL12b polypeptide	MCHQQLVISWFLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMV/VLTCDTPEEDGIT WTLDSSEVLGSGKTLTIQVKEFGDAGQYCHKGGEVLSHSLLLHKKEDGIWSTDILKD QKEPKNKTFLRCEAKNYSGRFTCWLLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAE RVRGDNKEYEYSVEQEDSACPAAEESLPIEVMDAVHKLKYENYSSFFIRDIIKPDPP KNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSA TVICRKNASISVRAQDRYSSSWSEWASVPCS
59	IL15 polypeptide	GIHVFI LGCF SAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKC FLELQVISLESGDASHIDTVENLIILANNLSNNGNVTESGCKECEELEEKNIKEFLQSFV HIVQMFINTS
60	sIL15ra polypeptide	ITCPPPMSVEHADIWVKSYSLSYRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTSP LKCIRDPALVHQRPAAPPSTVTAGVTPQPESLSPSGKEPAASSPSSNNTAATTAIVPGS QLMPSPSTGTTEISSHESHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTT
61	soluble gp130	MLTLQTWLVQALFIFLTTESTGELLDPGYSIPESPVVQLHSNFTAVCVLKEKCMDYFHV NANYIVWKTNHFTIPKEQYTIINRTASSVTFDIALSLNIQLTCNILTFGQLEQNVYGITIISGL

		PPEKPKNLSCIVNEGKKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDTPTSC TVDYSTVYFVNIEVWVEAENALGKVTS DHINFDPVYKVKPNPPHNLSVINSEELSSILKLT WTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIRCMKE DGKGYWSDWSEEASGITYEDRPSKAPSFYWKIDPSHTQGYRTVQLVWKTLPPEANGK ILDYEVTLTRWKSHLQNYTVNATKLTVNLTNDRYLATLTVRNLVVGKSDAAVLTPACDFQA THPVMDLKAFPKDNMLWVWETTPRESVKYILEWCVLSDKAPCITDWQQEDGTVHRTY LRGNLAESKCYLITVTPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVLEWD QLPVDVQNGFIRNYTIFYRTIIGNETA VNVDSSTHEYTLSSLTSDTLYMVRMAAYTDEGG KDGPEF
62	soluble gp130 fused to a Fc	MLTLQTWLVQALFIFLTTESTGELLDPGYSIPESPVVQLHSNFTAVCVLKEKCMDYFHV NANYIVWKTNHFTIPKEQYTIINRTASSVTFTDIASLNIQLTCNILTFGQLEQNVYGITIISGL PPEKPKNLSCIVNEGKKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDTPTSC TVDYSTVYFVNIEVWVEAENALGKVTS DHINFDPVYKVKPNPPHNLSVINSEELSSILKLT WTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIRCMKE DGKGYWSDWSEEASGITYEDRPSKAPSFYWKIDPSHTQGYRTVQLVWKTLPPEANGK ILDYEVTLTRWKSHLQNYTVNATKLTVNLTNDRYLATLTVRNLVVGKSDAAVLTPACDFQA THPVMDLKAFPKDNMLWVWETTPRESVKYILEWCVLSDKAPCITDWQQEDGTVHRTY LRGNLAESKCYLITVTPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVLEWD QLPVDVQNGFIRNYTIFYRTIIGNETA VNVDSSTHEYTLSSLTSDTLYMVRMAAYTDEGG KDGPEFRSCDKTHTCPPCPAPEAEGGPSVFLFPPKPKD TLMISRTPEVTCV/VVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMH EALHNHYTQKSLSLSP GK
<b>SEQ ID NO#</b>	<b>Sequence Name</b>	<b>Polypeptide sequence</b>
63	Matrice TRAC locus_CubiCA R CD22 pCLS30056 full sequence	GTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACA TTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAA AAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCTTTTTTGCGGC ATTTTGCCTTCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAA GATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTG CTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCG CATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTT ACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAAC ACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCCTTT TTTGACAACATGGGGGATCATGTAACCTCGCTTGTATCGTTGGGAACCGGAGCTGA ATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACA ACGTTGCGCAAATATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTA TAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCGG GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGTTCTCGCGGTAT CATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGA CGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCC TCACTGATTAAGCATTGGTAACGTGCAGACCAAGTTTACTCATATATACTTTAGATTGA TTTAAACTTCATTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCAT GACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAA GATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGTGCTTGCAAACA AAAAAACCACCGCTACCAGCGGTGGTTTGTGCGCGGATCAAGAGCTACCAACTCTT TTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTG TAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC GCCTACATACCTCGCT CTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGG GTTGGA CTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGG GGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCT ACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGCGGACAGG TATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGG GAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTC GATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGAAAAACGCCAGCAACCGG GCCTTTTTACGGTTCTGCGCTTTTGTGCTGCGCTTTTGTGCTACATGCTTCTTCTGCT TATCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTC GCCGACGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAGAGCG CCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGC ACGACAGGTTTCCCGACTGGAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGT

	<p>TAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGT GTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACG CCAAGCGCGTCAATTAACCCTCACTAAAGGGAACAAAAGCTGTTAATTAATTGCTGG GCCTTTTTCCCATGCCTGCCTTTACTCTGCCAGAGTTATATTGCTGGGGTTTTGAAGA AGATCCTATTAAATAAAAAGAATAAGCAGTATTATTAAGTAGCCCTGCATTTACAGTTTT CCTTGAGTGGCAGGCCAGGCCTGGCCGTGAACGTTCACTGAAATCATGGCCTCTTG GCCAAGATTGATAGCTTGTGCCTGTCCCTGAGTCCCAGTCCATCACGAGCAGCTGG TTTCTAAGATGCTATTTCCCGTATAAAGCATGAGACCGTGACTTGCCAGCCCCACAG AGCCCCGCCCTTGTCCATCACTGGCATCTGGACTCCAGCCTGGGTTGGGGCAAAGA GGGAAATGAGATCATGTCCTAACCCCTGATCCTCTTGTCACAGATATCCAGTACCC CTACGACGTGCCCCACTACGCCTCCGGTGAGGGCAGAGGAAGTCTTCTAACATGCG GTGACGTGGAGGAGAATCCGGGGCCCCGGATCCGCTCTGCCCGTCACCGCTCTGCT GCTGCCACTGGCACTGCTGCTGCACGCTGCTAGGCCCCGAGGGGGAGGCAGCTGC CCCTACAGCAACCCCAGCCTGTGCAGCGGAGGCGGCGGCGAGCGGCGAGGGGGT AGCCAGGTGCAGCTGCAGCAGAGCGCCCTGGCCTGTGAAGCCAGCCCCACAG TGTCCTGACCTGCGCCATCAGCGGCGATTCCGTGAGCTCCAACCTCCGCCGCTGG AATTGGATCAGGCAGTCCCCTTCTCGGGGCTGGAGTGGCTGGGAAGGACATACTA TCGGTCTAAGTGGTACAACGATTATGCCGTGTCTGTGAAGAGCAGAATCACAATCAA CCCTGACACCTCCAAGAATCAGTTCTCTCTGCAGCTGAATAGCGTGACACCAGAGGA CACCGCCGTGTACTATTGCGCCAGGGAGGTGACCGGCGACCTGGAGGATGCCTTT GACATCTGGGGCCAGGGCACAAATGGTGACCGTGAGCTCCGAGGCGGCGGATCTG GCGGAGGAGGAAGTGGGGGCGGCGGAGTGATATCCAGATGACACAGTCCCCATC CTCTCTGAGCGCCTCCGTGGGCGACAGAGTGACAATCACCTGTAGGGCCTCCCAGA CCATCTGGTCTTACCTGAACCTGGTATCAGCAGAGGCCCGGCAAGGCCCTAATCTG CTGATCTACGCAGCAAGCTCCCTGCAGAGCGGAGTGCCATCCAGATTCTCTGGCAG GGGCTCCGGCACAGACTTCACCCTGACCATCTCTAGCCTGCAGGCCGAGGACTTCG CCACCTACTATTGCCAGCAGTCTTATAGCATCCCCCAGACATTTGGCCAGGGCACCA AGCTGGAGATCAAGTCGGATCCCGGAAGCGGAGGGGGAGGCAGCTGCCCTACAG CAACCCCAGCCTGTGCAGCGGAGGCGGCGGCGAGCTGCCACCCAGGGCAG CTTCTCCAACGTGTCCACCAACGTGAGCCCAGCCAAGCCACCACCACCGCTGTC CTTATTCCAATCCTTCCCTGTGTGCTCCACCACAACCCCCGCTCCAAGGCCCTTA CCCCCGCACCAACTATTGCCTCCCAGCCACTCTCACTGCGGCCTGAGGCCTGTGCG CCCGCTGCTGGAGGCGCAGTGCATACAAGGGGCTCGATTTGCGCTGCGATATTTA CATCTGGGCACCCCTCGCCGGCACCTGCGGGGTGCTTCTCCTCTCCCTGGTGATTA CCCTGTATTGCAGACGGGGCCGGAAGAAGCTCCTCTACATTTTTAAGCAGCCTTTCA TGCGGCCAGTGACAGACAACCCAAGAGGAGGATGGGTGTTCTGAGATTCCCTGAG GAAGAGGAAGGCGGGTGCGAGCTGAGAGTGAAGTTCTCCAGGAGCGCAGATGCC CCGCTATCAACAGGGCCAGAACCAGCTCTACAACGAGCTTAACCTCGGGAGGCGC GAAGAATACGACGTGTTGGATAAGAGAAGGGGGCGGGACCCCGAGATGGGAGGAA AGCCCCGGAGGAAGAACCCTCAGGAGGGCCTGTACAACGAGCTGCAGAAGGATAA GATGGCCGAGGCCTACTCAGAGATCGGGATGAAGGGGGAGCGGCGCCGCGGGAA GGGGCACGATGGGCTCTACCAGGGGCTGAGCACAGCCACAAAGGACACATACGAC GCCTTGACATGCAGGCCCTTCCACCCCGGAATAGTCTAGAGGGCCCGTTAAAC CCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATGTGTTGTTGCCCTC CCCCGTGCCTTCCCTGACCCTGGAAGGTGCCACTCCCCTGTCTTCTCCTAATAAAA TGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCACTTCTATTCTGGGGGTGGGGT GGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGAT GCGGTGGGCTCTATGACTAGTGCGCAATTCCTGTACCAGCTGAGAGACTCTAAA TCCAGTGACAAGTCTGTCTGCCTATTCACCGATTTTGATTCTCAAACAAATGTGTCAC AAAGTAAGGATTCTGATGTGTATATCACAGACAAAAGTGTAGTACATGAGGTCTAT GGACTTCAAGAGCAACAGTGCTGTGGCCTGGAGCAACAACTGACTTTGAGTGTG CAAACGCCTTCAACAACAGCATTATTCAGAAGACACCTTCTTCCCCAGCCAGGTA AGGGCAGCTTTGGTGCCTTCGCAGGCTGTTTCCTTGCTTCAGGAATGGCCAGGTTT TGCCCAGAGCTCTGGTCAATGATGTCTAAAACTCCTCTGATTGGTGGTCTCGGCCTT ATCCATTGCCACCAAAACCCTCTTTTTACTAAGCGATCGCTCCGGTGCCCGTCAGTG GGCAGAGCGCACATCGCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTGCGCAAT TGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAACTGGGAAAGTGATGCTCGTGT ACTGGCTCCGCCTTTTCCCCAGGGTGGGGGAGAACCCTGATTAAGTGCAGTAGTC GCCGTGAACGTTCTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCG AGGGGCTCGCATCTCTCCTTACGCGCCCCGCCGCCCTACCTGAGGCCGCCATCCA CGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTC CGCCGTCTAGGTAAGTTTAAAGCTCAGGTGAGACCGGGCCTTTGTCCGGCGCTCC CTTGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCT CAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGAC CGCGCCTACCTGAGATCACCGGCCACCATGGCTTCTTACCCTGGACACCAGCA TGCTTCTGCCTTTGACCAGGCTGCCAGATCCAGGGGCCACTCCAACAGGAACTG CCCTAAGACCCAGAAGACAGCAGGAAGCCACTGAGGTGAGGCCTGAGCAGAAGAT</p>
--	--

		<p>GCCAACCCTGCTGAGGGTGTACATTGATGGACCTCATGGCATGGGCAAGACCACCA          CCACTCAACTGCTGGTGGCACTGGGCTCCAGGGATGACATTGTGTATGTGCCTGAG          CCAATGACCTACTGGAGAGTGTAGGAGCCTCTGAGACCATTGCCAACATCTACACC          ACCCAGCACAGGCTGGACCAGGGAGAAATCTCTGCTGGAGATGCTGCTGTGGTGAT          GACCTCTGCCCAGATCACAATGGGAATGCCCTATGCTGTGACTGATGCTGTTCTGGC          TCCTCACATTGGAGGAGAGGCTGGCTCTTCTCATGCCCCTCCACCTGCCCTGACCC          TGATCTTTGACAGACACCCCATTTGCAGCCCTGCTGTGCTACCCAGCAGCAAGGTAC          CTCATGGGCTCCATGACCCACAGGCTGTGCTGGCTTTTGTGGCCCTGATCCCTCC          AACCTCCCTGGCACCAACATTGTTCTGGGAGCACTGCCTGAAGACAGACACATTGA          CAGGCTGGCAAAGAGGCAGAGACCTGGAGAGAGACTGGACCTGGCCATGCTGGCT          GCAATCAGAAGGGTGTATGGACTGCTGGCAAACACTGTGAGATACCTCCAGTGTGG          AGGCTCTTGGAGAGAGGACTGGGGACAGCTCTCTGGAACAGCAGTGCCCCCTCAA          GGAGCTGAGCCCCAGTCCAATGCTGGTCCAAGACCCACATTGGGGACACCCTGTT          CACCCTGTTAGAGCCCCCTGAGCTGCTGGCTCCCAATGGAGACCTGTACAATGTGT          TTGCCTGGGCTCTGGATGTTCTAGCCAAGAGGCTGAGGTGACATGTGTTTCATCC          TGGACTATGACCAGTCCCCTGCTGGATGCAGAGATGCTCTGCTGCAACTAACCTCTG          GCATGGTGCAGACCCATGTGACCACCCCTGGCAGCATCCCCACCATCTGTGACCTA          GCCAGAACCTTTGCCAGGGAGATGGGAGAGGCCAACTAAGGCGCGCCACTCGAGC          GCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAGA          ATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC          CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTATTTATGTTTCAGG          TTCAGGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAAATGTGGTA          TGGAAGGCGCGCCCAATTCGCCCTATAGTGAGTCGTATTACGTCGCGCTCACTGGC          CGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACCCAACCTAATCGCCT          TGCAGCACATCCCCCTTTCCGAGCTGGCGTAATAGCGAAGAGGCCCGCACCGAAA          CGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGAGCGCCCTGTAGCGG          CGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCC          AGCGCCCTAGCGCCCGCTCCTTTCCGCTTTCTCCCTTCTTTCTCGCCACGTTTCGCC          GGCTTTCCCCGTCAAGCTCTAAATCGGGGCTCCCTTAGGGTCCGATTAGTGTCT          TTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGATGGTTGGCTGTAGTGGG          CCATAGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATA          GTGGACTCTTGTTCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGA          TTTATAAGGGATTTTGGCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAA          AAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAG</p>
64	Matrice CD25 locus_IL15_2 A_sIL15Ra pCLS30519 full sequence	<p>GTTTATTATTCCTGTTCCACAGCTATTGTCTGCCATATAAAAACTTAGGCCAGGCACA          GTGGCTCACACCTGTAATCCAGCACTTTGGAAGGCCGAGGCAGGCAGATCACAAG          GTCAGGAGTTTCGAGACCAGCCTGGCCAACATAGCAAAACCCCATCTCTACTAAAAAT          ACAAAAATTAGCCAGGCATGGTGGCGTGTGCACTGGTTTAGAGTGAGGACCACATTT          TTTTGGTGCCGTGTTACACATATGACCGTGACTTTGTTACACCACTACAGGAGGAAG          AGTAGAAGAACAATCGGTTCTGGCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGT          TGGCGGGAGACGTGGAGTCCAACCCAGGGCCCGGTACCGGGTCCGCCACCATGGA          CTGGACCTGGATTCTGTTCTCGTGGCTGCTGCTACAAGAGTGCACAGCGGCATTC          ATGTCTTCATTTTGGGCTGTTTCAGTGCAGGGCTTCTTAAACAGAAGCCAACCTGGG          TGAATGTAATAAGTGATTTGAAAAAATTGAAGATCTTATCAATGATGCTATTGAT          GCTACTTTATATACGGAAAGTGATGTTACCCCAAGTTGCAAAAGTAACAGCAATGAAG          TGCTTTCTCTTGGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAGTATTCATG          ATACAGTAGAAAATCTGATCATCCTAGCAAACAACAGTTTGTCTTCTAATGGGAATGT          AACAGAATCTGGATGCAAAGAATGTGAGGAACTGGAGGAAAAAATATTAAGAATTT          TTTGCAGAGTTTTGTACATATTGTCCAAATGTTTCATCAACACTTCTGGAAGCGGAGCT          ACTAATTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCTGG          GACCGGCTCTGCAACCATGGATTGGACGTGGATCCTGTTTCTCGTGGCAGCTGCCA          CAAGAGTTCACAGTATCACGTGCCCTCCCCCATGTCCGTGGAACACGCAGACATC          TGGGTCAAGAGCTACAGCTTGACTCCAGGGAGCGGTACATTTGTAACCTCTGGTTTC          AAGCGTAAAGCCGGCACGTCCAGCCTGACGGAGTGCGTGTGAAACAAGGCCACGA          ATGTGCGCCCACTGGACAACCCCCAGTCTCAAATGCATTAGAGACCCTGCCCTGGTTC          ACCAAAGGCCAGCGCCACCCTCCACAGTAACGACGGCAGGGGTGACCCACAGCC          AGAGAGCCTCTCCCCTTCTGGAAAAGAGCCCGCAGCTTCATCTCCAGCTCAAACAA          CACAGCGGCCACAACAGCAGCTATTGTCCCGGGCTCCAGCTGATGCCTTCAAAT          CACCTTCCACAGGAACCAAGAGATAAGCAGTCATGAGTCTCCCAAGGCCACCCCC          TCTCAGACAACAGCCAAGAAGTGGGAACCTCACAGCATCCGCCTCCACACAGCCGCC          AGGTGTGTATCCACAGGGCCACAGCGACACCACTGAGGGCAGAGGCAGCCTGCTG          ACCTGCGGCGACGTGAGGAGAACCCCGGGCCCATGGGGGCAGGTGCCACCGGC          CGCGCCATGGACGGGCCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCCTTG          GAGGTGCCAAGGAGGCATGCCCCACAGGCCTGTACACACACAGCGGTGAGTGCTG          CAAAGCCTGCAACCTGGGCGAGGGTGTGGCCAGCCTTGTGGAGCCAACCAGACC</p>

	<p>GTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCGACCG AGCCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTCCAGAGCATGTCGGCGCCGTG CGTGGAGGCCGATGACGCCGTGTGCCGTGCGCCTACGGCTACTACCAGGATGAG ACGACTGGGCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTG TTCTCCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGT ATTCCGACGAGGCCAACACGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGA CACCGAGCGCCAGCTCCGCGAGTGACACGCTGGGCCGACGCCGAGTGCGAGGA GATCCCTGGCCGTTGGATTACACGGTCCACACCCCCAGAGGGCTCGGACAGCACA GCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCATAGCCAGCA CGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCTCCAGCCCCGTGGTGACCCG AGGCACCACCGACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGT GGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGAAAAACCAAAAGAACAAGATTTT TTGGTAAGAAGCCGGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAAAG GTGCTAAATGGTCGCCCAGGAGACATCCGTTGTGCTTGCTGCTGTTTTGGAAGCTCT GAAGTCACATCACAGGACACGGGGCATGGCAACCTTGCTCTGTTCCGACCGCAT CCCATCAGAGAGCGAGCGCTACCCACTTCTAAATAGCAATTTGCGCGTTGAAGAGGA AGGGCAAAACCACTAGAACTCTCCATCTTATTTTCATGTATATGTGTTTCATGCGATCG CTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCACAGTCCCCGAGAAGTTG GGGGGAGGGGTGCGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACT GGGAAAGTGATGTCGTGACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCG TATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGA ACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCTTAC CTGAGGCCGCCATCCACGCCGTTGAGTCGCGTTCTGCCGCTCCCGCCTGTGGT GCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGG CCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT GCCTGACCCTGCTTGCTCAACTCTACGCTTTTGTTTCGTTTTCTGTTCTGCGCCGTTA CAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACCGGCGCCACCATGGCTTCT TACCCTGGACACCAGCATGCTTCTGCCTTTGACCAGGCTGCCAGATCCAGGGGCCA CTCCAACAGGAGAACTGCCCTAAGACCCAGAAGACAGCAGGAAGCCACTGAGGTGA GGCCTGAGCAGAAGATGCCAACCCCTGCTGAGGGTGTACATTGATGGACCTCATGGC ATGGGCAAGACCACCACCACTCAACTGCTGGTGGCACTGGGCTCCAGGGATGACAT TGTGTATGTGCTGAGCCAATGACCTACTGGAGAGTGCTAGGAGCCTCTGAGACCA TTGCCAACATCTACACCACCCAGCACAGGCTGGACCAGGGAGAAATCTCTGCTGGA GATGCTGCTGTGGTGATGACCTCTGCCCAGATCACAATGGGAATGCCCTATGCTGT GACTGATGCTGTTCTGGCTCCTCACATTGGAGGAGAGGCTGGCTCTTCTCATGCCC CTCCACCTGCCCTGACCCTGATCTTTGACAGACACCCATTGACGCCCTGCTGTGCT ACCCAGCAGCAAGGTACCTCATGGGCTCCATGACCCACAGGCTGTGCTGCTGCT GTGGCCCTGATCCCTCCAACCTCCCTGGCACCAACATTGTTCTGGGAGCACTGCC TGAAGACAGACACATTGACAGGCTGGCAAAGAGGCAGAGACCTGGAGAGAGACTG GACCTGGCCATGCTGGCTGCAATCAGAAGGGTGTATGGACTGCTGGCAAACACTGT GAGATACCTCCAGTGTGGAGGCTCTTGAGAGAGAGGACTGGGGACAGCTCTCTGGAA CAGCAGTGCCCCCTCAAGGAGCTGAGCCCCAGTCCAATGCTGGTCCAAGACCCAC ATTGGGGACACCCTGTTACCCCTGTTGAGAGCCCCTGAGCTGCTGGCTCCCAATGG AGACCTGTACAATGTGTTGCTGGGCTCTGGATGTTCTAGCCAAAGAGGTTTAAAGCAAGTAA CCATGCATGTGTTTCATCCTGGACTATGACCAGTCCCCTGCTGGATGCAGAGATGCTC TGCTGCAACTAACCTCTGGCATGGTGACAGCCCATGTGACCACCCCTGGCAGCATC CCCACCATCTGTGACCTAGCCAGAACCTTTGCCAGGGAGATGGGAGAGGCCAACTA AGGCGCGCCACTCGAGCGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTT GGACAAACCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATG CTATTGCTTTATTTGTAACCAATTATAAGCTGCAATAAACAAGTTAAACAACAATTGC ATTCATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAA ACCTCTACAAATGTGGTATGGAAGGCGCGCCCAATTCGCCCTATAGTGAGTCGTATT ACGTCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCCTGGCGT TACCCAACTTAATCGCCTTGACGACATCCCCCTTCGCCAGCTGGCGTAATAGCGA AGAGGCCCGCACCGAAACGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATG GGAGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCG TGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTTCTCCCTTCT TTCTCGCCACGTTTCGCCGGCTTTCCCGTCAAGCTCTAAATCGGGGAGCTCCCTTTAG GGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGGTGATG GTTGGCCTGTAGTGGGCCATAGCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGGA GTCCACGTTCTTTAATAGTGGAATCTTGTTCCAAACCTGGAACAACACTCAACCCTATC TCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTGCGCCTATTGGTTAAAAAA TGAGCTGATTTAAACAAAAATTTAACGCGAATTTTAAACAAATATTAACGCTTACAATTT AGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTCTAAATA CATTCAAATATGTATCCGCTCATGAGACAATAACCCCTGATAAATGCTTCAATAATATT GAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCTTTTGC GGCATTTTGCTTCCTGTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAGATGC</p>
--	--

		<p>TGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTA  AGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGT  TCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTC  GCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGC  ATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTG  ATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACC  GCTTTTTTGCACAACATGGGGGATCATGTAACCTGCCTTGATCGTTGGGAACCGGAG  CTGAATGAAGCCATACCAAACGACGAGCGTGACACCAGTGAAGCCTGTAGCAATGGC  AACAACGTTGCGCAAATACTAATACTGGCGAACTACTTACTCTAGCTTCCCGGCAACA  ATTAATAGACTGGATGGAGGCGGATAAAAGTTGCAGGACCACTTCTGCGCTCGGCC  TTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGTTCTCGC  GGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTAC  ACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGG  TGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG  ATTGATTTAAAACCTTCATTTTTAATTTAAAGGATCTAGGTGAGTCTTTTTGTAAT  CTCATGACCAAAATCCCTTAACGTGAGTTTTCTGTTCCACTGAGCGTCAGACCCCGTA  GAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCTTGC  AAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTGGCCGATCAAGAGCTACCAA  CTCTTTTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCT  AGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCT  CGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTAC  CGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACG  GGGGTTCTGTGCACACAGCCCAGCTTGAGCGAACGACCTACACCGAACTGAGATA  CCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGCGGAC  AGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAG  GGGAAACGCCTGGTATCTTTATAGTCCTGTGCGGTTTCGCCACCTCTGACTTGAGC  GTGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGGAAAAACGCCAGCAAC  GCGGCCTTTTTACGGTTCCTGGCCTTTTGTGCTGCTTTTGTCTACATGGTCTTTCT  GCGTTATCCCTGATTCTGTGGATAACCGTATTACCGCTTTGAGTGAGCTGATACC  GCTCGCCGACGCCGAACGACCGAGCGCAGCGAGTCACTGAGCGAGGAGCGGAG  AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCTTAATGCAGC  TGGCAGCAGAGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGT  GAGTTAGCTCACTCATTAGGCACCCACAGGCTTTACACTTTATGCTTCCGGCTCGTAT  GTTGTGTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGA  TTACGCCAAGCGCGTCAATTAACCTCACTAAAGGGAACAAAAGCTGTTAATTA</p>
65	Matrice PD1 locus_IL15_2 A_sIL15Ra pCLS30513 full sequence	<p>GACTCCCCAGACAGGCCCTGGAACCCCCCACCTTCTCCCCAGCCCTGCTCGTGGT  GACCGAAGGGGACAACGCCACCTTACCTGCAGCTTCTCCAACACATCGGAGAGCT  TCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCC  TTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTCCGTGTACACAAC  TGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCCGGCGCAATGACAG  CGGCACCTACCTCTGTGGGGCCGGTTCTGGCGTGAAACAGACTTTGAATTTTGACCT  TCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCCGTACCGGGTCCGCC  ACCATGGACTGGACCTGGATTCTGTTCTCTGCTGGCTGCTGCTACAAGATGTCACAG  CGGCATTCACTGCTTCAATTTGGGCTGTTTCACTGACGAGGCTTCTTAAACAGAACG  CAACTGGGTGAATGTAATAAGTGATTTGAAAAAATTGAAGATCTTATTCAATCTATG  CATATTGATGCTACTTTATATACGGAAGTGATGTTACCCCACTTGCAAAGTAACAG  CAATGAAGTGCTTTCTCTTGAGTTACAAGTTATTTCACTTGAGTCCGGAGATGCAAG  TATTCATGATACAGTAGAAAACTGATCATCCTAGCAAACAACAGTTTGTCTTCTAAT  GGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAACTGGAGGAAAAAATATT  AAAGAATTTTTGCAGAGTTTTGTACATATTGTCCAAATGTTTCATCAACACTTCTGGAA  GCGGAGCTACTAATTCAGCCTGCTGAAGCAGGCTGGAGCTGGAGGAGAAACCCCT  GGACCTGGGACCGGCTCTGCAACCATGGATTGGACGTGGATCCTGTTTCTCGTGGC  AGCTGCCACAAGAGTTCACAGTATCACGTGCCCTCCCCCATGTCCGTGGAACACG  CAGACATCTGGGTCAAGAGCTACAGCTTGACTCCAGGGAGCGGTACATTTGTAAC  CTGGTTTCAAGCGTAAAGCCGGCACGTCCAGCCTGACGGAGTGCGTGTTGAACAAG  GCCACGAATGTCGCCCACTGGACAACCCCCAGTCTCAATGCATTAGAGACCCCTGC  CCTGGTTCACCAAAGGCCAGCGCCACCCTCCACAGTAACGACGGCAGGGGTGACC  CCACAGCCAGAGAGCCTCTCCCCTTCTGAAAAAGAGCCCCCGAGCTTCATCTCCAG  CTCAAACAACACAGCGGGCCACAACAGCAGCTATTGTCCCCGGCTCCAGCTGATGC  CTTCAAAATCACCTTCCACAGGAACACAGAGATAAGCAGTCATGAGTCTTCCACG  GCACCCCTCTCAGACAACAGCCAAGAACTGGGAACTCACAGCATCCGCTCCAC  CAGCCGCCAGGTGTGTATCCACAGGGCCACAGCGACCACTGAGGGCAGAGGCA  GCCTGCTGACCTGCGGCGACGTGAGGAGAAACCCCGGGCCCATGGGGGCAGGTG  CCACCGGCCGCGCCATGGACGGGCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGT  GTCCCTTGAGGTGCCAAGGAGGCATGCCCCACAGGCCTGTACACACACAGCGGT</p>

	<p>GAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCCAGCCTTGTGGAGCCA ACCAGACCGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAG CGCGACCGAGCCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTCCAGAGCATGTCCG GCGCCGTGCGTGAGGGCCGATGACGCCGTGTGCCGCTGCCGCTACGGCTACTACC AGGATGAGACGACTGGGCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGG GCCTCGTGTTCCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGA CGGCACGTATTCCGACGAGGCCAACCACGTGGACCCGTGCCTGCCCTGCACCGTG TGCGAGGACACCGAGCGCCAGCTCCGCGAGTGCAACAGCTGGGCCGACGCCGAGT GCGAGGAGATCCCTGGCCGTTGGATTACACGGTCCACACCCCCAGAGGGCTCGGA CAGCACAGCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCATAG CCAGCACGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCTCCAGCCCGTGGT GACCCGAGGCACCAACGACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTG TGGTTGTGGGTCTTGTGGCCTACATAGCCTTCAAGAGGTGATCTAGAGGGCCCCGTTT AAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTTGGC CCTCCCCCGTGCCCTTCTTGACCCCTGGAAGGTGCCACTGCCCTCTGTTTCTAAT AAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCACTTCTATTCTGGGGGTG GGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGG GGATGCGGTGGGCTCTATGACTAGTGGCGAATTCGGCGCAGATCAAAGAGAGCCTG CGGGCAGAGCTCAGGGTGACAGGTGCGGCCCTCGGAGGCCCGGGGCAGGGGTGA GCTGAGCCGGTCTTGGGGTGGGTGTCCCTCCTGCACAGGATCAGGAGCTCCAGG GTCGTAGGGCAGGGACCCCCAGCTCCAGTCCAGGGCTCTGTCTGCACCTGGGG AATGGTGACCGGCATCTCTGTCTCTAGCTCTGGAAGCACCCCGCCCTCTAGTCT GCCCTCACCCCTGACCCTGACCCTCCACCCTGACCCCGTCTTAACCCCTGACCTTT GGCGATCGCTCCGGTGCCCGTCACTGGGCAGAGCGCACATCGCCCACAGTCCCCG AGAAGTTGGGGGGAGGGGTGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG GGTAAACTGGGAAAGTGATGTCTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGG GAGAACCCTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTG CCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCTTACGCGCCCCG CGCCCTACCTGAGGCCGCCATCCACGCCGTTGAGTCGCGTCTGCCGCTCCCG CCTGTGGTGCCCTCTGAACCTGCGTCCGCGCTCTAGGTAAGTTTAAAGTCAAGGTCG AGACCGGGCCTTTGTCCGGCGCTCCCTTGAGCCTACCTAGACTCAGCCGGCTCTC CACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGCTTTGTTTCGTTTTCTGTTCTG CGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACCGGCGCCACCA TGGCTTCTTACCCTGGACACCAGCATGCTTCTGCCTTTGACCAGGCTGCCAGATCCA GGGGCCACTCCAACAGGAGAACTGCCCTAAGACCCAGAAGACAGCAGGAAGCCAC TGAGGTGAGGCCTGAGCAGAAGATGCCAACCCCTGTGAGGGTGATATTGATGGAC CTCATGGCATGGGCAAGACCACCACTCAACTGCTGTTGGCACTGGGCTCCAGG GATGACATTGTGTATGTGCCTGAGCCAATGACCTACTGGAGAGTGCTAGGAGCCTCT GAGACCATTGCCAACATCTACACCACCCAGCACAGGCTGGACCAGGGAGAAATCTC TGCTGGAGATGCTGCTGTGGTGATGACCTCTGCCCAGATCACAATGGGAATGCCCT ATGCTGTGACTGATGCTGTTCTGGCTCCTCACATTGGAGGAGAGGCTGGCTCTTCTC ATGCCCCCTCCACCTGCCCTGACCCTGATCTTTGACAGACACCCCATTCAGCCCTG CTGTGCTACCCAGCAGCAAGGTACCTCATGGGCTCCATGACCCACAGGCTGTGCT GGCTTTTGTGGCCCTGATCCCTCAACCTCCCTGGCACCACCACTGTTCTGGGAG CACTGCCTGAAGACAGACACATTGACAGGCTGGCAAAGAGGCAGAGACCTGGAGAG AGACTGGACCTGGCCATGCTGGCTGCAATCAGAAGGGTGTATGGACTGCTGGCAAA CACTGTGAGATACCTCCAGTGTGGAGGCTCTTGAGAGAGGACTGGGGACAGCTCT CTGGAACAGCAGTGCCCCCTCAAGGAGCTGAGCCCCAGTCCAATGCTGTTCCAAGA CCCCACATTGGGGACACCCTGTTACCCCTGTTACAGAGCCCCCTGAGCTGCTGGCTCC CAATGGAGACCTGTACAATGTGTTTGCTGGGCTCTGGATGTTCTAGCCAAGAGAGCT GAGGTCCATGCATGTGTTTCATCTGGACTATGACCAGTCCCCTGCGGATGCAGAG ATGCTCTGCTGCAACTAACCTCTGGCATGGTGACAGCCCATGTGACCACCCCTGGC AGCATCCCCACCATCTGTGACCTAGCCAGAACCTTTGCCAGGGAGATGGGAGAGGC CAACTAAGGCGCGCCACTCGAGCGCTAGCTGGCCAGACATGATAAGATACATTGAT GAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTT GTGATGCTATTGCTTTATTTGTAACCATATAAGCTGCAATAAACAAGTTAACAACAAC AATTGCATTCATTTTATGTTTCAGGTTTCAGGGGGAGGTGGGAGGTTTTTTAAAGCA AGTAAACCTCTACAAATGTGGTATGGAAGGCGCGCCCAATTCGCCCTATAGTGAGT CGTATTACGTGCGGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCT GGCGTTACCCAACCTAATCGCCTTGACGACATCCCCCTTTGCCAGCTGGCGTAAT AGCGAAGAGGCCCGCACCGAAACGCCCTTCCCAACAGTTGCGCAGCCTGAATGGC GAATGGGAGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGGTTACGCG CAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCC CTTCCTTTCTCGCCACGTTCCGCCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCC CTTAGGGTTCCGATTAGTGCTTTACGGCACCTCGACCCCAAAAACTGGATTAGG GTGATGGTTGGCCTGTAGTGGGCCATAGCCCTGATAGCGGTTTTTCGCCCTTTGAC GTTGGAGTCCACGTTCTTTAATAGTGACTCTTGTTCAAACTGGAACAACACTCAAC</p>
--	--

		<p> CCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTGCGCCTATTGGT  TAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAAACAAATATTAACGCTT  ACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTGTGTTATTTTT  CTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCCTGATAAATGCTTCAA  TAATATTGAAAAAGGAAGAGTATGAGTATCAACATTTCCGTGTGCGCCCTTATTCCCT  TTTTGCGGCATTTTGCCTTCTGTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAA  AGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACA  GCGGTAAGATCCTTGAGAGTTTTTCGCCCGAAGAACGTTTTCCAATGATGAGCACTT  TTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAAC  TCGGTCGCCGCATACACTATTCTCAGAATGACTTGTTGAGTACTCACCAGTCACAG  AAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCA  TGAGTGATAACACTGCGGCCAATTACTTCTGACAACGATCGGAGGACCGAAGGAG  CTAACCGCTTTTTTGACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAA  CCGGAGCTGAATGAAGCCATACCAACGACGAGCGTGACACCAGCATGCCTGTAGC  AATGGCAACAACGTTGCGCAAACTATTAACCTGGCGAACTACTGATCTTCCCG  GCAACAATTAAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCT  CGGCCCTTCCGGCTGGCTGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGT  TCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGT  TATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTG  AGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATAT  ACTTTAGATTGATTTAAACTTTCATTTTTAATTTAAAGGATCTAGGTGAAGATCCTTT  TTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCTTCCACTGAGCGTCAGA  CCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGC  TGCTTGCAAAACAAAAAACACCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAGAG  CTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAATACT  GTTCTTCTAGTGAGCCGTAGTTAGGCCACCACTTCAAGAATCTGTAGCACCGCCT  ACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG  TGTCTTACCGGGTTGGAATCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGG  CTGAACGGGGGTTCTGTGCACACGCCAGCTTGAGCGAACACCTACACCGCA  CTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAA  GGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA  GCTTCCAGGGGGAACGCCTGGTATCTTTATAGTCCTGTGCGGTTTCGCCACCTCTG  ACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGAAAAACG  CCAGCAACGCGGCCCTTTTTACGGTTCTTGCCCTTTTGCTGGCCTTTTGCTCACATGG  TCTTTCCTGCGTTATCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGC  TGATACCGCTCGCCGACGCCAAGCAGCGAGCGCAGCTAGTGAGCGAGGAA  GCGGAGAGCGCCCAATACGCAAAACCGCCTCTCCCGCGCGTTGGCCGATTCATTAA  TGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAA  TTAATGTGAGTTAGCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGGC  TCGTATGTTGTGTGGAATTGTGAGCGGATAACAAATTCACACAGGAAACAGCTATGA  CCATGATTACGCCAAGCGCGTCAATTAACCCCTCACTAAAGGGAACAAAAGCTGTAA  TTAA </p>
66	Matrice CD25 locus_IL12a_2A_IL12b pCLS30520 full sequence	<p> GTTTATTATTCCTGTTCCACAGCTATTGTCTGCCATATAAAAACTTAGGCCAGGCACA  GTGGCTCACACCTGTAATCCAGCACTTTGGAAGGCCGAGGCAGGCAGATCACAAAG  GTCAGGAGTTCGAGACCAGCCTGGCCAACATAGCAAAACCCCATCTCTACTAAAAAT  ACAAAAATTAGCCAGGCATGGTGGCGTGTGCACTGGTTTAGAGTGAGGACCACATTT  TTTTGGTGCCGTGTTACACATATGACCGTGACTTTGTTACACCACTACAGGAGGAAG  AGTAGAAGAACAATCGGTTCTGGCGTGAAACAGACTTTGAATTTTGACCTTCTCAAGT  TGGCGGGAGACGTGGAGTCCAACCCAGGGCCCATGTGGCCCCCTGGGTACGCCTC  CCAGCCACCGCCCTCACCTGCCGCGGCCACAGGTCTGCATCCAGCGGCTCGCCCT  GTGTCCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGCGCAGCCCTCCTCTTGCGC  TACCCTGGTCCTCTGGACCACCTCAGTTTGGCCAGAAACCTCCCGTGCGCACTC  CAGACCCAGGAATGTTCCCATGCCTTCACCACTCCCAAAACCTGCTGAGGGCCGTC  AGCAACATGCTCCAGAAGGCCAGACAAACTCTAGAATTTTACCCTTGCACTTCTGAA  GAGATTGATCATGAAGATATCACAAAAGATAAAACCAGCACAGTGGAGGCCTGTTTA  CCATTGGAATTAACCAAGAATGAGAGTTGCCTAAATTCAGAGAGACCTCTTTCATAA  CTAATGGGAGTTGCCTGGCCTCCAGAAAGACCTCTTTTATGATGGCCCTGTGCCTTA  GTAGTATTTATGAAGACTTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAA  AGCTTCTGATGGATCCTAAGAGGCAGATCTTTCTAGATCAAAACATGTCAGGTTA  TTGATGAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCT  CCCTTGAAGAACCGGATTTTTATAAACTAAAATCAAGCTCTGCATACTTCTTCATGC  TTTCAGAATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCGG  AAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACC  CTGGACCTATGTGTCACCAGCAGTTGGTCATCTTGGTTTTCCCTGGTTTTCTGG  CATCTCCCTCGTGCCCATATGGGAACCTGAAGAAAGATGTTTATGTCTGAGAATTGG </p>

		<p>ATTGGTATCCGGATGCCCTGGAGAAATGGTGGTCCTCACCTGTGACACCCCTGAA GAAGATGGTATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAA AACCCTGACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGTCACAA AGGAGGCGAGGTTCTAAGCCATTTCGCTCCTGCTGCTTCACAAAAAGGAAGATGGAA TTTGGTCCACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAG ATGCGAGGCCAAGAATTATTCTGGACGTTTCACCTGCTGGTGGCTGACGACAATCAG TACTGATTTGACATTCAGTGTCAAAGCAGCAGAGGCTCTTCTGACCCCAAGGGGT GACGTGCGGAGCTGCTACACTCTCTGCAGAGAGAGTCAGAGGGGACAAACAAGGAG TATGAGTACTCAGTGGAGTGCCAGGAGGACAGTGCCTGCCAGCTGCTGAGGAGA GTCTGCCCATTGAGGTCATGGTGGATGCCGTTTACAAGCTCAAGTATGAAACTACA CCAGCAGCTTCTTCATCAGGGACATCATCAAACCTGACCCACCCAAGAACTTGCAGC TGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTGAGCTGGGAGTACCCTGACACC TGGAGTACTCCACATTCCTACTTCTCCCTGACATTCTGCGTTCAGGTCCAGGGCAAG AGCAAGAGAGAAAAAGAAAGATAGAGTCTTCACGGACAAGACCTCAGCCACGGTCAT CTGCCGCAAAAAATGCCAGATTAGCTGCGGGGCCAGGCTACTACTACTCAT CTTGGAGCGAATGGGCATCTGTGCCCTGCAGTGAGGGCAGAGGCAGCCTGCTGAC CTGCGGCGACGTGAGGAGAACCCCGGGCCCATGGGGGCAGGTGCCACCGGCCG CGCCATGGACGGGGCCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCCTTGA GGTGCCAAGGAGGCATGCCCCACAGGCCTGTACACACACAGCGGTGAGTGCTGCA AAGCCTGCAACCTGGGCGAGGGTGTGGCCAGCCTTGTGGAGCCAACCAGACCGT GTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGGACCGAG CCGTGCAAGCCGTGCACCGAGTGCGTGGGGCTCCAGAGCATGTCGGCGCCGTGCG TGGAGGCCGATGACGCCGTGTGCCGCTGCGCCTACGGCTACTACCAGGATGAGAC GACTGGGCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTT CTCCTGCCAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTAT TCCGACGAGGCCAACACAGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACA CCGAGCGCCAGCTCCGCGAGTGCACACGCTGGGCCGACGCCGAGTGCGAGGAGA TCCCTGGCCGTTGGATTACACGGTCCACACCCCCAGAGGGCTCGGACAGCACAGC CCCCAGCACCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCATAGCCAGCAG GTGGCAGGTGTGGTGACACAGTGATGGGCAGCTCCAGCCCCGTGGTGACCCGAG GCACCACCGACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGTGG GTCTTGTGGCCTACATAGCCTTCAAGAGGTGAAAAACCAAAAGAACAAGATTTCTT GGTAAGAAGCCGGAACAGACAACAGAAGTCATGAAGCCCAAGTGAAATCAAAGGT GCTAAATGGTCGCCCAGGAGACATCCGTTGTGCTTGCCTGCGTTTTGGAAGCTCTG AAGTCACATCACAGGACACGGGGCAGTGGCAACCTTGCTCTATGCCAGCTCAGTC CCATCAGAGAGCGAGCGCTACCCACTTCTAAATAGCAATTTGCCGTTGAAGAGGAA GGGCAAAACCACTAGAACCTCCATCTTATTTTCATGTATGTGTTTCAGTCGATCGC TCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCACAGTCCCCGAGAAGTTGG GGGAGGGGTGCGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTG GGAAAGTGATGTCGTGACTGGCTCCGCTTTTTCCCGAGGGTGGGGGAGAACCGT ATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAA CACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTACGCGCCCCGCCGCCCTACC TGAGGCCGCCATCCACGCCGTTGAGTCGCGTTCTGCCGCTCCCGCCTGTGGTG CCTCCTGAAGTGCCTCGCCGTCTAGGTAAGTTTAAAGTTTAAAGTTCAGCTGAGG CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTG CCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCTGTTTCTGCTGCGCGTTAC AGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACCGGCGCCACCATGGCTTCTT ACCCTGGACACCAGCATGCTTCTGCCTTTGACCAGGCTGCCAGATCCAGGGGCCAC TCCAACAGGAGAACTGCCCTAAGACCCAGAAGACAGCAGGAAGCCACTGAGGTGAG GCCTGAGCAGAAGATGCCAACCTGCTGAGGGTGATGTTGATGAGCTCATGGCA TGGGCAAGACCACCACCACTCAACTGCTGGTGGCACTGGGCTCCAGGATGACATT GTGTATGTGCTGAGCCAATGACCTACTGGAGAGTGCTAGGAGCCTCTGAGACCAT TGCCAACATCTACACCACCCAGCACAGGCTGGACCAGGGAGAAATCTCTGCTGGAG ATGCTGCTGTGGTGATGACCTCTGCCCAGATCACAATGGGAATGCCCTATGCTGTGA CTGATGCTGTTCTGGCTCCTCACATTGGAGGAGAGGCTGGCTCTTCTCATGCCCTC CACCTGCCCTGACCCTGATCTTTGACAGACACCCCAATTGCAGCCCTGCTGTGCTACC CAGCAGCAAGGTACCTCATGGGCTCCATGACCCACAGGCTGTGCTGGCTTTTGTG GCCCTGATCCCTCCAACCTCCCTGGCACCAACATTGTTCTGGAGCACTGCCGTA AGACAGACACATTGACAGGCTGGCAAAGAGGCAGAGACCTGGAGAGAGACTGGAC CTGGCCATGCTGGCTGCAATCAGAAGGGTGTATGGACTGCTGGCAAACACTGTGAG ATACCTCCAGTGTGGAGGCTCTTGGAGAGAGGACTGGGGACAGCTCTCTGGAACAG CAGTGCCCCCTCAAGGAGCTGAGCCCCAGTCCAATGCTGGTCCAAGACCCACATT GGGGACACCCTGTTACCCCTGTTTCAAGGCCCTGAGCTGCTGGCTCCCAATGGAGA CCTGTACAATGTGTTTGCCTGGGCTCTGGATGTTCTAGCCAAGAGGCTGAGGTCCAT GCATGTGTTTCATCCTGGACTATGACCAGTCCCCTGCTGGATGAGATGCTCTGCT GCAACTAACCTCTGGCATGGTGCAGACCCATGTGACCACCCCTGGAGCAGTCCCCA CCATCTGTGACCTAGCCAGAACCTTTGCCAGGGAGATGGGAGAGGCCAACTAAGGC</p>
--	--	---

		<p> GCGCCACTCGAGCGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGAC  AAACCACAAGTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTAT  TGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTG  ATTTTATGTTTCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACC  TCTACAAATGTGGTATGGAAGGCGCGCCCAATTCGCCCTATAGTGAGTCGTATTACG  TCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCCTGGCGTTAC  CCAACTTAATCGCCTTGACGACATCCCCCTTCGCCAGCTGGCGTAATAGCGAAGA  GGCCCGCACCGAAACGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGA  GCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGTGTGGTGGTTACGCGCAGCGTGA  CCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTCCCTTCCTTTC  TCGCCACGTTCCGCCGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGG  TTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGATGGT  TGGCCTGTAGTGGGCCATAGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGT  CCACGTTCTTTAATAGTGGACTCTTGTCCAACTGGAACAACACTCAACCCTATCTC  GGTCTATTCTTTTGATTTATAAGGGATTTTGGCGATTTCGCCCTATTGGTAAAAAAT  GAGCTGATTTAAACAAAAATTTAACGCGAATTTTAAACAAAATATTAACGCTTACAATTA  GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTGTATTATTTTCTAAATAC  ATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGA  AAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCGCCTTATTCCTTTTTTTCGCG  CATTTTGCCTTCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAAGTAAAAGATGCTGA  AGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGA  TCCTTGAGAGTTTTTCGCCCGGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCT  GCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCC  GCATACACTATTCTCAGAATGACTTGGTTGAGTACTACCAGTCACAGAAAAGCATCT  TACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAA  CACTGCGGCCAATTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCCTT  TTTTGCACAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGA  ATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACA  ACGTTGCGCAACTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATAA  TAGACTGGATGGAGGCGGATAAAGTTGACAGGACCACTTCTGCGCTCGGCCCTTCGG  GCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGTTCTCGCGGTAT  CATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGA  CGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCC  TCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGA  TTTAAACTTCATTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCAT  GACCAAAATCCCTTAACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAA  GATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAACTGCTGCTTGGCAACA  AAAAAACCAACCGCTACCAGCGGTGGTTTGTGGCCGATCAAGAGCTACCAACTCTT  TTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAATACTGTTCTTCTAGTG  TAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT  CTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCGTGCTTACCGG  GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGGCTGAACGGGG  GGTTGCTGCACACAGCCAGCTTGAGCGAACGACCTACACCGAAGCTGAGATACCT  ACAGCGTGAGCTATGAGAAAGCGCCACGTTCCCGAAGGAGAAAGCTGGCAGG  TATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGG  GAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTC  GATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGAAAAACGCCAGCAACGCG  GCCTTTTTACGGTTCTTGCCCTTTTGTGGCCTTTTGTCTACATGGTCTTTCCTGCGT  TATCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTC  GCCGAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGAGAGCG  CCCAATACGCAAAACCGCTCTCCCGCGCGTGGCCGATTCAATGCGAGCTGGC  ACGACAGGTTTCCCGACTGGAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGT  TAGCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGT  GTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACG  CCAAGCGCGTCAATTAACCCTCACTAAAGGGAACAAAAGCTGTTAATTA </p>
67	Matrice PD1 locus_IL12a_2A_IL12b pCLS30511 full sequence	<p> TCGCGCGTTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACG  GTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGT  CAGCGGGTGTGGCGGGTGTGCGGGTGGCTTAATATGCGGCATCAGAGCAGAT  TGTAAGTGTGAGAGTGACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAA  AATACCGCATCAGGCGCCATTGCGCATTAGGCTGCGCAACTGTTGGGAAGGGCGA  TCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAA  GGCGATTAAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGTTGTAAAACGACG  GCCAGTGAATTCAGCTCGGTACCTCGCGAATGCATCTAGATGACTCCCGAGACAG  GCCCTGGAACCCCCCACCTTCTCCCGAGCCCTGCTCGTGGTGACCGAAGGGGAC  AACGCCACCTTCACCTGCAGCTTCTCAACACATCGGAGAGCTTCGTGCTAAACTGG </p>

	TACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCTTCCCCGAGGACC GCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTACACAAGTCCCAACGGGCG TGACTTCCACATGAGCGTGGTCAGGGCCCCGGCGCAATGACAGCGGCACCTACCTCT GTGGGGCCGGTTCTGGCGTGAAACAGACTTTGAATTTTACCTTCTCAAGTTGGCG GGAGACGTGGAGTCCAACCCAGGGCCCCATGTGGCCCCCTGGGTGAGCCTCCAGC CACCGCCCTCACCTGCCGCGGCCACAGGTCTGCATCCAGCGGCTCGCCCTGTGTC CCTGCAGTGCCGGCTCAGCATGTGTCCAGCGCGCAGCCTCCTCCTTGTGGCTACCC TGGTCCTCCTGGACCACCTCAGTTTGGCCAGAAACCTCCCCGTGGCCACTCCAGAC CCAGGAATGTTCCCATGCCTTCACCACTCCCAAAACCTGCTGAGGGCCGTCAGCAA CATGCTCCAGAAGGCCAGACAACTCTAGAATTTTACCCTTGCACTTCTGAAGAGAT TGATCATGAAGATATCACAAAAGATAAAACCAGCACAGTGGAGGCCTGTTTACCATT GGAATTAACCAAGAATGAGAGTTGCCTAAATTCAGAGAGACCTCTTTCATAACTAAT GGGAGTTGCCTGGCCTCCAGAAAGACCTCTTTTATGATGGCCCTGTGCCTTAGTAGT ATTTATGAAGACTTGAAGATGTACCAGGTGGAGTTCAAGACCATGAATGCAAAGCTT CTGATGGATCCTAAGAGGCAGATCTTTCTAGATCAAAACCTGCGCAGTTATTGAT GAGCTGATGCAGGCCCTGAATTTCAACAGTGAGACTGTGCCACAAAAATCCTCCCTT GAAGAACCGGATTTTTATAAACTAAAATCAAGCTCTGCATACTTCTTCATGCTTTCA GAATTCGGGCAGTGACTATTGATAGAGTGATGAGCTATCTGAATGCTTCCGGAAGCG GAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGA CCTATGTGTACCAGCAGTTGGTCATCTCTTGGTTTTCCCTGGTTTTTCTGGCATCTC CCCTCGTGGCCATATGGAACTGAAGAAAGATGTTTATGTCGTAGAATTGGATTGGT ATCCGGATGCCCTGGAGAAATGGTGGTCTCACCTGTGACACCCCTGAAGAAGAT GGTATCACCTGGACCTTGGACCAGAGCAGTGAGGTCTTAGGCTCTGGCAAAACCT GACCATCCAAGTCAAAGAGTTTGGAGATGCTGGCCAGTACACCTGTCACAAAGGAG GCGAGGTTCTAAGCCATTGCTCCTGCTGCTTACAAAAAGGAAGATGGAATTTGGT CCACTGATATTTTAAAGGACCAGAAAGAACCCAAAAATAAGACCTTTCTAAGATGCGA GGCCAAGAATTATTCTGGACGTTTACCTGCTGGTGGCTGACGACAATCAGTACTGA TTTGACATTCAAGTGTCAAAGCAGCAGAGGCTCTTCTGACCCCCAAGGGGTGACGT GCGGAGCTGCTACACTCTCTGCAGAGAGTCAAGGGGACAACAAGAGTAGTGA TACTCAGTGGAGTGCCAGGAGGACAGTGCCTGCCAGCTGCTGAGGAGTCTGC CCATTGAGGTCATGGTGGATGCCGTTCAACAGCTCAAGTATGAAAACCTACACCAGCA GCTTCTTCATCAGGGACATCATCAACCTGACCCACCAAGAAGTTCAGCTGAAGC CATTAAAGAATTCTCGGCAGGTGGAGGTGAGCTGGGAGTACCCTGACACCTGGAGT ACTCCACATTCTACTTCTCCCTGACATTCTGCGTTTCAGGTCCAGGGCAAGAGCAAG AGAGAAAAGAAAGATAGAGTCTTACGGACAAGACCTCAGCCACGGTCATCTGCCG CAAAAATGCCAGCATTAGCGTGGGGGCCAGGACCGCTACTAGCTCATCTTGGAG GCGAATGGGCATCTGTGCCCTGCAGTGAGGGCAGAGGCAGCTGCTGACCTGCGG CGACGTCGAGGAGAACCCCGGGGCCATGGGGGCAGGTGCCACCGGCCGCGCCAT GGACGGGCCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCTTGGAGGTGCC AAGGAGGCATGCCCCACAGGCCTGTACACACACAGCGGTGAGTGCTGCAAAGCCT GCAACCTGGGCGAGGGTGTGGCCAGCCTTGTGGAGCCAACCAGACCGTGTGTGA GCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCGACCGAGCCGTGC AAGCCGTGCACCGAGTGCGTGGGGCTCCAGAGCATGTCCGGCGCCGTGCGTGGAGG CCGATGACGCCGTGTGCCGCTGCGCTACGGCTACTACGAGCATGAGACGACTGCG GCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTCTCCTGC CAGGACAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACG AGGCCAACCACGTGGACCCGTGCCTGCCCTGCACCGTGTGCGAGGACACCGAGCG CCAGCTCCGCGAGTGACACGCTGGGCCGACGCGGAGTGCGAGGAGATCCCTGGC CGTTGGATTACACGTTCCACACCCCCAGAGGGCTCGGACAGCACAGCCCCCAGCA CCCAGGAGCCTGAGGCACCTCCAGAACAAGACCTCATAGCCAGCACGGTGCCAGG TGTGGTGACCACAGTGATGGGCAGCTCCAGCCCGTGGTGACCCGAGCACCACC GACAACCTCATCCCTGTCTATTGCTCCATCCTGGCTGCTGTGGTTGTGGGTCTTGTG GCCTACATAGCCTTCAAGAGGTGATCTAGAGGGCCCGTTTAAACCCGCTGATCAGC CTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCCGTGCCTTC CTTGACCCTGGAAGGTGCCACTCCCACTGTCTTTCTAATAAAATGAGGAAATTGC ATCGCATTGTCTGAGTAGGTGTATTCTATTCTGGGGGGTGGGGTGGGGCAGGACA GCAAGGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTC TATGACTAGTGCGGAATTGCGCGCAGATCAAAGAGAGCCTCGGGGAGGACGTGAGG GTGACAGGTGCGGCCTCGGAGGCCCCGGGGCAGGGGTGAGCTGAGCCGGTCTTG GGGTGGGTGTCCCTCCTGCACAGGATCAGGAGCTCCAGGGTCGTAGGGCAGGGA CCCCCAGCTCCAGTCCAGGGCTCTGTCTGCACCTGGGGAATGGTGACCGGCAT CTCTGTCTCTAGCTCTGGAAGCACCCAGCCCTCTAGTCTGCCCTACCCCTGA CCCTGACCCTCCACCCTGACCCCGTCTAACCCTGACCTTTGATCGGATCCCGGG CCCGTCGACTGCAGAGGCCTGCATGCAAGCTTGGCGTAATCATGGTCATAGCTGTT TCCTGTGTGAAATTGTTATCCGCTCACAATTCACACAACATACGAGCCGAAGCAT AAAGTGAAAGCCTGGGGTGCCTAATGAGTGAGTAACTCACATTAATTGCGTTGCG CTCACTGCCCGCTTCCAGTCGGGAAACCTGTCTGTGCCAGCTGCATTAATGAATCG
--	---

		<p> GCCAACGCGCGGGGAGAGGCGGTTTTCGTATTGGGCGCTCTTCCGCTTCCTCGCT  CACTGACTCGCTGCGCTCGGTCGTTCCGGCTGCGGCGAGCGGTATCAGCTCACTCAA  AGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAATGTGA  GCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTT  CCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGT  GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTC  GTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCT  TCGGGAAGCGTGGCGCTTTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTA  GGTCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTTCAGCCCGACCGCT  GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCCGTAAGACACGACTTATCGC  CACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCT  ACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGT  ATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCC  GGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAGCAGATTACG  CGCAGAAAAAAGGATCTCAAGAAGATCCCTTTGATCTTTACGGGTCTGACGCT  CAGTGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATC  TTCACCTAGATCCTTTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATATATGA  GTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGAT  CTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATA  CGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTC  ACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAA  GTGGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTA  GAGTAAGTAGTTCGCCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCA  TCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTACGCTCCGGTTCCCAACGAT  CAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTC  CTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAG  CACTGCATAATTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGA  GTAICTAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCC  GGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTAAAGAGTCTCATCT  TGAAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG  TTCGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTTTACTTTTACCAGC  GTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGC  GACACGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTATC  AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAAT  AGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTAT  TATCATGACATTAACCTATAAAAAATAGGCGTATCACGAGGCCCTTTCGTC </p>
68	HLAE trimer matrix (VMAPRTLFL peptide) inserted at the B2m locus	<p> cacttagcatctctggggccagctctgcaaagcgagggggcagccttaagtgtcctccagcctgaagtcttagaat  gagcgccgggtgtcccaagctggggCGCGCACCCAGATCGGAGGGCGCCGATGTACAGACA  GCAAACTCACCCAGTCTAGTGCATGCCTTCTTAAACATCACGAGACTCTAAGAAAAGG  AAACTGAAAACGGGAAAGTCCCTCTCTTAACCTGGCACTGCGTCGCTGGCTTGGAGA  CAGGTGACGGTCCCTGCGGGCCTTGTCTGATTGGCTGGGCACGCGTTTAAATATAAGT  GGAGGCGTCGCGCTGGCGGGCATTCTGAAGCTGACAGCATTGCGGCCGAGATGTCT  CGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTAT  GGCTCCGCGGACTTTATTCTTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTG  TGGCGGCTCCATCCAGCGTACGCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAG  AACGGCAAATCTAATTTCTGAACTGCTATGTATCAGGCTTTCACCTAGCGATATAGA  AGTGGACCTGCTGAAAAACGGAGAGAGGATAGAAAAGGTGCAACACAGCGACCTCT  CCTTTTCCAAGGACTGGAGCTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAA  AAAGATGAGTATGCGTGCCGAGTAAACCACGTACGCTGTACAGCCCAAAATAGTA  AAATGGGATCGCGACATGGGTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGG  AGGAAGCGGTGGTGGCGGTTCCGGATCTCACTCCTGAAGTATTTCCACACTTCCGTG  TCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCTGTGGGCTACGTGGACGACACC  CAGTTCGTGCGCTTCGACAACGACGCCGCGAGTCCGAGGATGGTGCCGCGGGCGCC  GTGGATGGAGCAGGAGGGGTGAGAGTATTGGGACCGGGAGACACGGAGCGCCAGG  GACACCGCACAGATTTTCCGAGTGAACCTGCGGACGCTGCGCGGCTACTACAATCAG  AGCGAGGCCGGGTCTCACACCTGCAGTGGATGCATGGCTGCGAGCTGGGGCCCGA  CAGGCGCTTCTCCGCGGGTATGAACAGTTCGCTACGACGGCAAGGATTATCTCACC  CTGAATGAGGACCTGCGCTCCTGGACCGCGGTGGACACGGCGGCTCAGATCTCCGAG  CAAAAGTCAAATGATGCCTCTGAGGCGGAGACCCAGAGAGCCTACCTGGAAGACACA </p>

		<p>             TCGGTGGAGTGGCTCCACAAATACCTGGAGAAGGGGAAGGAGACGCTGCTTCACCTG              GAGCCCCAAAGACACACGTGACTCACCACCCCATCTCTGACCATGAGGCCACCCTGA              GGTGCTGGGCTCTGGGCTTCTACCCTGCGGAGATCACTGACCTGGCAGCAGGATG              GGGAGGGCCATACCCAGGACACGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGG              AACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAGGAGCAGAGATACAC              GTGCCATGTGCAGCATGAGGGGCTACCCGAGCCCGTCACCCTGAGATGGAAGCCGGC              TTCCAGCCCACCATCCCCATCGTGGGCATCATTGCTGGCCTGGTTCTCCTTGGATCTG              TGGTCTCTGGAGCTGTGGTTGCTGCTGTGATATGGAGGAAGAAGAGCTCAGGTGGAA              AAGGAGGGAGCTACTATAAGGCTGAGTGGAGCGACAGTGCCCAGGGGTCTGAGTCT              CACAGCTTGTAAGTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCGTG              CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAAT              TGCATCGCATTGTCTGAGTAGGTGTATTCTATTCTGGGGGGTGGGGTGGGGCAGGA              CAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGC              TCTATGTCTCTTCTGGCCTGGAGGCTATCCAGCGTGAGTCTCTCCTACCCTCCCGCTCT              GGTCTTCTCTCCCGCTCTGCACCCTCTGTGGCCCTCGCTGTGCTCTCTCGCTCCGTG              ACTCCCTTCTCCAAGTTCTCCTTGGTGGCCCGCCGTGGGGCTAGTCCAGGGCTGGAT              CTCGGGGAAGCGGCGGGGTGGCCTGGGAGTGGGGAAGGGGGTGCACACCCGGGAC              GCGCGCTACTTGCCCTTTTCGGCGGGGAGCAGGGGAGACCTTTGGCCTACGGCGACG              GGAGGGTCTGGGACAAAAGtttagggcgctgataagcgctagagcgccgaggttgggggagggtttctctt              ccgctctttcgggggcctctggctccccagcgagctggagtgggg           </p>
69	HLAE trimer matrix (VMAPRTLFL peptide)	<p>             CGCGCACCCAGATCGGAGGGCGCCGATGTACAGACAGCAAACTCACCCAGTCTAGT              GCATGCCTTCTTAAACATCACGAGACTCTAAGAAAAGGAAACTGAAAACGGGAAAAGT              CCCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGACAGGTGACGGTCCCTGCGG              GCCTTGTCTGATTGGCTGGGCACGCGTTTAAATAAAGTGGAGGCGTCGCGCTGGCG              GGCATTCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTG              TGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTATGGCTCCGCGGACTTTATTC              TTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGGTGGCGGCTCCATCCAGCGT              ACGCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAGAACGGCAAATCTAATTTCC              TGAAGTGTATGTATCAGGCTTTCACCCCTAGCGATATAGAAGTGGACCTGCTGAAAAA              CGGAGAGAGGATAGAAAAGGTGGAACACAGCGACCTCTCCTTTTCCAAGGACTGGAG              CTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAAAAAGATGAGTATGCGTGCC              GAGTAAACCACGTCACGCTGTCACAGCCAAAATAGTAAAATGGGATCGCGACATGG              GTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGGAGGAAGCGGTGGTGGCGG              TTCCGGATCTCACTCCTGAAGTATTTCCACACTTCCGTGTCCCGGCCCGGCCGCGGG              GAGCCCCGCTTCATCTCTGTGGGCTACGTGGACGACCCAGTTCGTGCGCTTCGACA              ACGACGCCGCGAGTCCGAGGATGGTGCCGCGGGCGCCGTGGATGGAGCAGGAGGG              GTCAGAGTATTGGGACCGGGAGACACGGAGCGCCAGGGACACCGCACAGATTTTCC              GAGTGAACCTGCGGACGCTGCGCGGCTACTACAATCAGAGCGAGGCCGGGTCTCACA              CCCTGCAGTGGATGCATGGCTGCGAGCTGGGGCCCGACAGGCGCTTCTCCGCGGGT              ATGAACAGTTCGCCTACGACGGCAAGGATTATCTACCCTGAATGAGGACCTGCGCTC              CTGGACCGCGGTGGACACGGCGGCTCAGATCTCCGAGCAAAAGTCAAATGATGCCTC              TGAGGCGGAGCACCAGAGAGCCTACCTGGAAGACACATGCGTGGAGTGGCTCCACA              AATACCTGGAGAAGGGGAAGGAGACGCTGCTTACCTGGAGCCCCAAAGACACAC              GTGACTCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCTCTGGGCT              TCTACCCTGCGGAGATCACTGACCTGGCAGCAGGATGGGGAGGGCCATACCCAGG              ACACGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCA              GCTGTGGTGGTGCCTTCTGGAGAGGAGCAGAGATACACGTGCCATGTGCAGCATGA              GGGGCTACCCGAGCCCGTCACCCTGAGATGGAAGCCGGCTTCCAGCCCACCATCCC              CATCGTGGGCATCATTGCTGGCCTGGTTCTCCTTGGATCTGTGGTCTCTGGAGCTGTG              GTTGTGCTGTGATATGGAGGAAGAAGAGCTCAGGTGGAAAAGGAGGGAGCTACTA           </p>

		<p>TAAGGCTGAGTGGAGCGACAGTGCCAGGGGTCTGAGTCTCACAGCTTGTAAGTGTG CCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCGTGCCTTCCTGACCCTGGAA GGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGA GTAGGTGTCAATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGAT TGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGTCTCTTCTGCGC CTGGAGGCTATCCAGCGTGAGTCTCTCCTACCCTCCCGCTCTGGTCCTTCTCTCCCGC TCTGCACCCTCTGTGGCCCTCGCTGTGCTCTCTCGCTCCGTGACTTCCCTTCTCCAAGTT CTCCTTGGTGGCCCGCCGTGGGGCTAGTCCAGGGCTGGATCTCGGGGAAGCGGCGG GGTGGCCTGGGAGTGGGGAAGGGGGTGCACCCGGGACGCGCGCTACTTGCCCTT TTCGGCGGGGAGCAGGGGAGACCTTTGGCCTACGGCGACGGGAGGGTTCGGGACAA AG</p>
70	HLAE trimer matrix (VMAPRTLIL peptide) inserted at the B2m locus	<p>cacttagcatctctggggccagtctgcaaagcgagggggcagccttaatgtgcctccagcctgaagtcctagaat gagcgcccggtgtcccaagctggggCGCGCACCCAGATCGGAGGGCGCCGATGTACAGACA GCAAACCTACCCAGTCTAGTGCATGCCTTCTTAAACATCACGAGACTCTAAGAAAAGG AAACTGAAAACGGGAAAGTCCCTCTCTTAACCTGGCACTGCGTCGCTGGCTTGGAGA CAGGTGACGGTCCCTGCGGGCCTTGTCTGATTGGCTGGGCACGCGTTTAAATAAGT GGAGGCGTCGCGCTGGCGGGCATTCTGAAGCTGACAGCATTTCGGGCCGAGATGTCT CGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTAT GGCTCCGCGGACTTTAATTTTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGG TGGCGGCTCCATCCAGCGTACGCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAG AACGGCAAATCTAATTTCTGAAGTGTATGTATCAGGCTTTCACCTAGCGATATAGA AGTGGACCTGCTGAAAACGGAGAGAGGATAGAAAAGGTGAACACAGCGACCTCT CCTTTTCCAAGGACTGGAGCTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAA AAAGATGAGTATGCGTGCCGAGTAAACCACGTACGCTGTACAGCCAAAATAGTA AAATGGGATCGCGACATGGGTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGG AGGAAGCGGTGGTGGCGGTTCCGGATCTACTCCTTGAAGTATTTCCACACTTCCGTG TCCCGGCCCGGCCGCGGGAGCCCCGCTTCATCTCTGTGGGCTACGTGGACGACACC CAGTTCGTGCGCTTCGACAACGACGCCGCGAGTCCGAGGATGGTGGCGCGGGCGCC GTGGATGGAGCAGGAGGGGTGACAGTATTGGGACCGGGAGACACGGAGCGCCAGG GACACCGCACAGATTTTCCGAGTGAACCTGCGGACGCTGCGCGGCTACTACAATCAG AGCGAGGCCGGTCTCACACCCTGCAGTGGATGCATGGCTGCGAGCTGGGGCCCGA CAGGCGCTTCTCCGCGGGTATGAACAGTTCGCTACGACGGCAAGGATTATCTCACC CTGAATGAGGACCTGCGCTCCTGGACCGCGGTGGACACGGCGGCTCAGATCTCCGAG CAAAAGTCAAATGATGCCTCTGAGGCGGAGCACCAGAGAGCCTACCTGGAAGACACA TGCGTGGAGTGGCTCCACAAATACCTGGAGAAGGGGAAGGAGACGCTGCTTACCTG GAGCCCCAAAGACACACGTGACTCACCACCCATCTCTGACCATGAGGCCACCCTGA GGTGTGGGCTCTGGGCTTCTACCCTGCGGAGATCACTGACCTGGCAGCAGGATG GGGAGGGCCATACCCAGGACACGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGG AACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAGGAGCAGAGATACAC GTGCCATGTGCAGCATGAGGGGCTACCCGAGCCCGTACCCTGAGATGGAAGCCGGC TTCCAGCCACCATCCCATCGTGGGCATCATTGCTGGCCTGGTTCTCCTTGGATCTG TGGTCTCTGGAGCTGTGGTTGCTGTGCTGTGATATGGAGGAAGAAGAGCTCAGGTGGAA AAGGAGGGAGCTACTATAAGGCTGAGTGGAGCGACAGTGCCCAGGGGTCTGAGTCT CACAGCTTGTAAGTGTGCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCGTG CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAAT TGCATCGCATTGTCTGAGTAGGTGTATTCTATTCTGGGGGGTGGGGTGGGGCAGGA CAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGC TCTATGTCTCTTCTGGCCTGGAGGCTATCCAGCGTGAGTCTCTCCTACCCTCCCGCTCT GGTCCTTCTCTCCCGCTCTGCACCCTCTGTGGCCCTCGCTGTGCTCTCTCGCTCCGTG ACTTCCCTTCTCCAAGTTCTCCTTGGTGGCCCGCCGTGGGGCTAGTCCAGGGCTGGAT</p>

		CTCGGGGAAGCGGCGGGGTGGCCTGGGAGTGGGGAAGGGGGTGCGCACCCGGGAC GCGCGCTACTTGCCCCCTTCGGCGGGGAGCAGGGGAGACCTTTGGCCTACGGCGACG GGAGGGTCTGGGACAAAGtttagggcgtcgataagcgtcagagcgccgaggttgggggagggtttctctt ccgctctttcgggggcctctggctccccagcgagctggagtgggg
71	HLAE trimer matrix (VMAPRTLIL peptide)	CGCGCACCCCAGATCGGAGGGCGCCGATGTACAGACAGCAAACCTACCCAGTCTAGT GCATGCCTTCTTAACATCACGAGACTCTAAGAAAAGGAAACTGAAAACGGGAAAGT CCCTCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGACAGGTGACGGTCCCTGCGG GCCTTGTCTGATTGGCTGGGCACGCGTTTAATATAAGTGGAGGCGTCGCGCTGGCG GGCATTCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTG TGCTCGCGCTACTCTCTCTAGCGGCCTCGAAGCTGTTATGGCTCCGCGGACTTTAATT TTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGGTGGCGGCTCCATCCAGCGT ACGCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAGAACGGCAAATCTAATTTCC TGAAGTGTATGTATCAGGCTTTACCCTAGCGATATAGAAGTGGACCTGCTGAAAAA CGGAGAGAGGATAGAAAAGGTCGAACACAGCGACCTCTCTTTTCCAAGGACTGGAG CTTTTATCTTCTGTATTATACTGAATTTACCCACGGAAAAAGATGAGTATGCGTGCC GAGTAAACCACGTACGCTGTACAGCCAAAATAGTAAAATGGGATCGCGACATGG GTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGGAGGAAGCGGTGGTGGCGG TTCCGGATCTACTCCTGAAGTATTTCCACACTTCCGTGTCCCGGCCGCGCGCGGG GAGCCCCGCTTCATCTCTGTGGGCTACGTGGACGACACCCAGTTCGTGCGCTTCGACA ACGACGCCGCGAGTCCGAGGATGGTGCCGCGGGCGCCGTGGATGGAGCAGGAGGG GTCAGAGTATTGGGACCGGGAGACACGGAGCGCCAGGGACACCGCACAGATTTTCC GAGTGAACCTGCGGACGCTGCGCGGCTACTACAATCAGAGCGAGGCCGGGTCTCACA CCCTGCAGTGGATGCATGGCTGCGAGCTGGGGCCGACAGGCGCTTCTCCGCGGGT ATGAACAGTTCGCCTACGACGGCAAGGATTATCTACCCTGAATGAGGACCTGCGCTC CTGGACCGCGGTGGACACGGCGGCTCAGATCTCCGAGCAAAAAGTCAAATGATGCCTC TGAGGCGGAGCACCAGAGAGCCTACCTGGAAGACACATGCGTGGAGTGGCTCCACA AATACCTGGAGAAGGGGAAGGAGACGCTGCTTACCTGGAGCCCCCAAAGACACAC GTGACTACCAACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCTCTGGGCT TCTACCCTGCGGAGATCACACTGACCTGGCAGCAGGATGGGGAGGGGCCATACCCAGG ACACGGAGCTCGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCA GCTGTGGTGGTGCCTTCTGGAGAGGAGCAGAGATACACGTGCCATGTGCAGCATGA GGGGCTACCCGAGCCCGTCACCCTGAGATGGAAGCCGGCTTCCAGCCCACCATCCC CATCGTGGGCATCATTGCTGGCCTGGTTCTCCTTGGATCTGTGGTCTCTGGAGCTGTG GTTGCTGCTGTGATATGGAGGAAGAAGAGCTCAGGTGGAAAAGGAGGGAGCTACTA TAAGGCTGAGTGGAGCGACAGTGGCCAGGGGTCTGAGTCTCACAGCTTGAACTGTG CCTTCTAGTTGCCAGCCATCTGTTGTTGCCCTCCCCGTGCCTTCTTGACCCTGGAA GGTGCCACTCCCACTGTCCTTTCCTAATAAAAATGAGGAAATTGCATCGCATTGTCTGA GTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGAT TGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGTCTCTTCTGGC CTGGAGGCTATCCAGCGTGAGTCTCTCTACCCTCCCGCTCTGGTCTTCTCTCCCGC TCTGCACCCTCTGTGGCCCTCGCTGTGCTCTCTCGCTCCGTGACTTCCCTTCTCCAAGTT CTCCTTGGTGGCCCGCCGTGGGGCTAGTCCAGGGCTGGATCTCGGGGAAGCGGCGG GGTGGCCTGGGAGTGGGGAAGGGGGTGGCGACCCGGGACGCGCGCTACTTGCCCT TTCGGCGGGGAGCAGGGGAGACCTTTGGCCTACGGCGACGGGAGGGTGGGACAA AG
72	UL18Trimer matrix _Actine peptide	cacttagcatctctggggccagtctgcaaagcgagggggcagccttaatgtgcctccagcctgaagtccagaat gagcgcccggtgtcccaagctggggCGCGCACCCCAGATCGGAGGGCGCCGATGTACAGACA GCAAACCTACCCAGTCTAGTGCATGCCTTCTTAACATCACGAGACTCTAAGAAAAGG AAACTGAAAACGGGAAAGTCCCTCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGA

	inserted at the B2m locus	<p>CAGGTGACGGTCCCTGCGGGCCTTGTCCTGATTGGCTGGGCACGCGTTTAATATAAGT  GGAGGCGTCGCGCTGGCGGGCATTCTGAAGCTGACAGCATTGGGCCGAGATGTCT  CGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGCCCT  GCCCCACGCCATTTTGC GGCTCGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGG  TGGCGGCTCCATCCAGCGTACGCCCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAG  AACGGCAAATCTAATTTCTGAACTGCTATGTATCAGGCTTTCACCCTAGCGATATAGA  AGTGGACCTGCTGAAAAACGGAGAGAGGATAGAAAAGGTGCAACACAGCGACCTCT  CCTTTTCCAAGGACTGGAGCTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAA  AAAGATGAGTATGCGTGCCGAGTAAACCACGTCACGCTGTCACAGCCCAAATAGTA  AAATGGGATCGCGACATGGGTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGG  AGGAAGCGGTGGTGGCGGTTCCGGATCTATGCACGTGCTGAGATACGGATATACCG  GCATCTTCGACGATACATCCCATATGACTCTGACCGTGGTCGGGATTTTTCGACGGACA  GCACTTCTTTACATACCATGTGAACAGCTCCGATAAGGCTTCTAGTCGAGCAAATGGC  ACCATCTCATGGATGGCCAACGTGAGCGCAGCCTACCCACATATCTGGACGGAGAA  CGCGCTAAAGCGATCTGATCTTCAATCAGACCGAGCAGAACCTGCTGGAGCTGGAA  ATTGCTCTGGGGTACAGGTCTCAGAGTGTCTGACATGGACTCACGAATGTAATACCA  CAGAGAACGGGAGCTTCGTGGCAGGATATGAGGGCTTTGGGTGGGACGGAGAAACA  CTGATGGAGCTGAAGGATAATCTGACTCTGTGGACCGGCCCTAACTACGAAATCAGCT  GGCTGAAGCAGAACAAAGACTTACATCGACGGAAAGATCAAAAACATCAGCGAGGGC  GATACTACCATCCAGCGCAATTACCTGAAGGGCAACTGCACCCAGTGGAGCGTGATCT  ACTCTGGGTTCCAGACACCTGTCACTCACCCAGTGGTCAAAGGGGGAGTGCGAAACC  AGAATGACAACCGGGCCGAGGCCTTCTGTACATCCTACGGCTTCTTTCCCGGGGAGAT  CAATATTACTTTTATCCATTACGGCAACAAGGCCCCGACGATTCTGAGCCTCAGTGCA  ATCCCCTGCTGCCTACCTTCGATGGCACATTTACCAGGGGTGCTACGTCGCTATCTTC  TGCAATCAGAACTATACTTGCCGGGTGACCCATGGGAACTGGACTGTGGAAATCCCA  ATTTAGTCACCAGCCCCGACGATTCAAGCTCCGGAGAGGTGCCAGATCACCCACCG  CAAATAAGAGATACAACACCATGACAATCTCTAGTGTGCTGCTGGCCCTGCTGCTGTG  CGCACTGCTGTTGCTTTTCTGCATTACTTCACAACTCTGAAGCAGTATCTGCGGAACC  TGGCATTGCTGCTGGCGGTACAGAAAAGTGAGATCAAGCTGACTGTGCCTTCTAGTTGC  CAGCCATCTGTTGTTTGGCCCTCCCCCTGCCTTCTTGACCCTGGAAGGTGCCACTCC  CACTGTCCTTTCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATT  CTATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAA  TAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGTCTCTTTCTGGCCTGGAGGCTATC  CAGCGTGAGTCTCTCCTACCTCCCCCTCTGGTCTTCTCTCCCCTCTGCACCTCTG  TGGCCCTCGCTGTGCTCTCTCGCTCCGTGACTTCCCTTCTCCAAGTTCTCCTTGGTGGCC  CGCCGTGGGGCTAGTCCAGGGCTGGATCTCGGGGAAGCGGCGGGGTGGCCTGGGA  GTGGGGAAGGGGGTGCACCCGGGACGCGCGCTACTTGCCCTTTCGGCGGGGAG  CAGGGGAGACCTTTGGCCTACGGCGACGGGAGGGTCTGGGACAAAGGtttagggcgctgata  agcgtcagagcgccgaggttgggggaggggttctctccgctctttcgggggcctctggctccccagcgagct  ggagtgggg</p>
73	UL18Trimer matrix_Actine peptide	<p>CGCGCACCCCAGATCGGAGGGCGCCGATGTACAGACAGCAAACTCACCCAGTCTAGT  GCATGCCTTCTTAACATCACGAGACTCTAAGAAAAGGAACTGAAAACGGGAAAGT  CCCTCTCTCTAACCTGGCACTGCGTCGCTGGCTTGAGACAGGTGACGGTCCCTGCGG  GCCTTGTCCTGATTGGCTGGGCACGCGTTTAATATAAGTGGAGGCGTCGCGCTGGCG  GGCATTCTGAAGCTGACAGCATTGGGCCGAGATGTCTCGTCCGTGGCCTTAGCTG  TGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGCCCTGCCCCACGCCATTTGCGG  CTCGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGGTGGCGGCTCCATCCAGCGT  ACGCCCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAGAACGGCAAATCTAATTTCC  TGAAGTCTATGTATCAGGCTTTCACCCTAGCGATATAGAAGTGGACCTGCTGAAAAA  CGGAGAGAGGATAGAAAAGGTGCAACACAGCGACCTCTCCTTTTCCAAGGACTGGAG</p>

		<p>CTTTATCTTCTGTATTATACTGAATTTACACCCACGGAAAAAGATGAGTATGCGTGCC  GAGTAAACCACGTACGCTGTCACAGCCAAAATAGTAAAATGGGATCGCGACATGG  GTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGGAGGAAGCGGTGGTGGCGG  TTCCGGATCTATGCACGTGCTGAGATACGGATATACCGGCATCTTCGACGATACATCC  CATATGACTCTGACCGTGGTCGGGATTTTGGACGGACAGCACTTCTTTACATACCATGT  GAACAGCTCCGATAAGGCTTCTAGTCGAGCAAATGGCACCATCTCATGGATGGCCAA  CGTGAGCGCAGCCTACCCACATATCTGGACGGAGAACGCGCTAAAGGCGATCTGAT  CTTCAATCAGACCGAGCAGAACCTGCTGGAGCTGGAAATTGCTCTGGGGTACAGGTC  TCAGAGTGTCTGACATGGACTCACGAATGTAATACCACAGAGAACGGGAGCTTCGT  GGCAGGATATGAGGGCTTTGGGTGGGACGGAGAAACACTGATGGAGCTGAAGGATA  ATCTGACTCTGTGGACCGGCCCTAACTACGAAATCAGCTGGCTGAAGCAGAACAGA  CTTACATCGACGGAAAGATCAAAAACATCAGCGAGGGGCGATACTACCATCCAGCGCA  ATTACCTGAAGGGCAACTGCACCCAGTGGAGCGTGATCTACTCTGGGTTCAGACACC  TGCTACTACCCAGTGGTCAAAGGGGGAGTGCGAAACCAGAATGACAACCGGGCCG  AGGCCTTCTGTACATCTACGGCTTCTTTCCCGGGGAGATCAATATTACTTTTATCCATT  ACGGCAACAAGGCCCCCGACGATTCTGAGCCTCAGTGCAATCCCCTGCTGCCTACCTT  CGATGGCACATTTTACCAGGGGTGCTACGTCGCTATCTTCTGCAATCAGAACTATACTT  GCCGGGTGACCCATGGGAAGTGGACTGTGGAAATCCCAATTTAGTCACCAGCCCCG  ACGATTCAAGCTCCGGAGAGGTGCCAGATCACCCACCGCAAATAAGAGATACAACA  CCATGACAATCTCTAGTGTGCTGCTGGCCCTGCTGCTGTGCGCACTGCTGTTGCTTTT  CTGCATTACTTCACAACTCTGAAGCAGTATCTGCGGAACCTGGCATTGCTGGCGGT  ACAGAAAAGTGAGATCAAGCTGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC  CCCTCCCCCGTGCCTTCTTGACCCTGGAAGGTGCCACTCCACTGCTCTTCTCTAATA  AAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGG  GGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGG  GATGCGGTGGGCTCTATGTCTCTTCTGGCCTGGAGGCTATCCAGCGTGAGTCTCTCC  TACCCTCCCGCTCTGGTCCTTCTCTCCCGCTCTGCACCTCTGTGGCCCTCGCTGTGCT  CTCTCGCTCCGTGACTTCCCTTCTCCAAGTTCTCCTTGGTGGCCCGCCGTGGGGCTAGT  CCAGGGCTGGATCTCGGGGAAGCGGCGGGGTGGCCTGGGAGTGGGGAAGGGGGTG  CGCACCCGGGACGCGCGCTACTTGGCCCTTTCGGCGGGGAGCAGGGGAGACCTTTGG  CCTACGGCGACGGGAGGGTCGGGACAAAG</p>
74	UL18Trimer matrix _HLACw peptide inserted at the B2m locus	<p>cacttagcatctctggggccagctctgcaaagcgagggggcagccttaatgtgcctccagcctgaagtcctagaat  gagcgccccgtgtcccaagctggggCGCGCACCCAGATCGGAGGGCGCCGATGTACAGACA  GCAAACCTACCCAGTCTAGTGCATGCCTTCTTAAACATCACGAGACTCTAAGAAAAGG  AAACTGAAAACGGGAAAGTCCCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGA  CAGGTGACGGTCCCTGCGGGCCTTGTCTGATTGGCTGGGCACGCGTTTAAATATAAGT  GGAGGCGTCGCGCTGGCGGGCATTCTGAAGCTGACAGCATTCCGGGCCGAGATGTCT  CGCTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTAT  GGCTCCGCGGACTTTAATTTTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGG  TGGCGGCTCCATCCAGCGTACGCCCAAATTCAGTCTACAGCCGACATCCTGCAGAG  AACGGCAAATCTAATTTCTGAACTGCTATGTATCAGGCTTTCACCTAGCGATATAGA  AGTGGACCTGCTGAAAAACGGAGAGAGGATAGAAAAGGTGCAACACAGCGACCTCT  CCTTTTCAAGGACTGGAGCTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAA  AAAGATGAGTATGCGTGCCGAGTAAACCACGTACGCTGTCACAGCCAAAATAGTA  AAATGGGATCGCGACATGGGTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGG  AGGAAGCGGTGGTGGCGGTTCCGGATCTATGCACGTGCTGAGATACGGATATACCG  GCATCTTCGACGATACATCCCATATGACTCTGACCGTGGTCGGGATTTTGGACGGACA  GCACTTCTTTACATACCATGTGAACAGCTCCGATAAGGCTTCTAGTCGAGCAAATGGC  ACCATCTCATGGATGGCCAACGTGAGCGCAGCCTACCCACATATCTGGACGGAGAA  CGCGCTAAAGGCGATCTGATCTTCAATCAGACCGAGCAGAACCTGCTGGAGCTGGAA</p>

		<p>ATTGCTCTGGGGTACAGGTCTCAGAGTGTCTGACATGGACTCACGAATGTAATACCA  CAGAGAACGGGAGCTTCGTGGCAGGATATGAGGGCTTTGGGTGGGACGGAGAAACA  CTGATGGAGCTGAAGGATAATCTGACTCTGTGGACCGGCCCTAACTACGAAATCAGCT  GGCTGAAGCAGAACAAAGACTTACATCGACGGAAAGATCAAAAACATCAGCGAGGGC  GATACTACCATCCAGCGCAATTACCTGAAGGGCAACTGCACCCAGTGGAGCGTGATCT  ACTCTGGGTCCAGACACCTGTCACTACCCAGTGGTCAAAGGGGGAGTGCGAAACC  AGAATGACAACCGGGCCGAGGCCTTCTGTACATCCTACGGCTTCTTTCCCGGGGAGAT  CAATATTACTTTTATCCATTACGGCAACAAGGCCCCGACGATTCTGAGCCTCAGTGCA  ATCCCCTGCTGCCTACCTTCGATGGCACATTTACCAGGGGTGCTACGTCGCTATCTTC  TGCAATCAGAACTATACTTGCCGGGTGACCCATGGGAACTGGACTGTGGAAATCCCA  ATTTAGTCACAGCCCCGACGATTCAAGCTCCGGAGAGGTGCCAGATACCCCCACCG  CAAATAAGAGATACAACACCATGACAATCTCTAGTGTGCTGCTGGCCCTGCTGCTGTG  CGCACTGCTGTTGCTTTTCTGCATTACTTCACAACTCTGAAGCAGTATCTGCGGAACC  TGGCATTGCTGCGGTACAGAAAAGTGAGATCAAGCTGACTGTGCCTTCTAGTTGC  CAGCCATCTGTTGTTGCCCCCTCCCCGTGCCTTCTTGACCCTGGAAGGTGCCACTCC  CACTGTCCTTCTAATAAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATT  CTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAA  TAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGTCTCTTTCTGGCCTGGAGGCTATC  CAGCGTGAGTCTCTCTACCTCCCGCTCTGGTCCTTCTCTCCCGCTCTGCACCTCTG  TGGCCCTCGCTGTGCTCTCTCGCTCCGTGACTTCCCTTCTCCAAGTTCTCTTGGTGGCC  CGCCGTGGGGCTAGTCCAGGGCTGGATCTCGGGGAAGCGGCGGGGTGGCCTGGGA  GTGGGGAAGGGGGTGCACCCGGGACGCGCGCTACTTGCCCCTTTCGGCGGGGAG  CAGGGGAGACCTTTGGCCTACGGCGACGGGAGGGTCGGGACAAAGGtttagggcgatgata  agcgtagagcgccgaggttgggggaggggttctctccgctcttccggggctctggctccccagcgagct  ggagtgggg</p>
75	UL18Trimer matrix _HLAcw peptide	<p>CGCGCACCCCAGATCGGAGGGCGCCGATGTACAGACAGCAAACTCACCCAGTCTAGT  GCATGCCTTCTTAAACATCACGAGACTCTAAGAAAAGGAACTGAAAACGGGAAAGT  CCCTCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGACAGGTGACGGTCCCTGCGG  GCCTTGTCTGATTGGCTGGGCACGCGTTTAAATATAAGTGAGGCGTCGCGCTGGCG  GGCATTCTGAAGCTGACAGCATTGCGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTG  TGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTATGGCTCCGCGGACTTTAATT  TTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGGTGGCGGCTCCATCCAGCGT  ACGCCCCAAAATTCAAGTCTACAGCCGACATCCTGCAGAGAACGGCAAATCTAATTTCC  TGAAGTGTATGTATCAGGCTTTCACCCTAGCGATATAGAAGTGACCTGCTGAAAAA  CGGAGAGAGGATAGAAAAGTCTGAACACAGCGACCTCTCCTTTTCAAGGACTGGAG  CTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAAAAAGATGAGTATGCGTGCC  GAGTAAACCACGTCACGCTGTACAGCCAAAATAGTAAAATGGGATCGCGACATGG  GTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGGAGGAAGCGGTGGTGGCGG  TTCCGGATCTATGCACGTGCTGAGATACGGATATACCGGCATCTTCGACGATACATCC  CATATGACTCTGACCGTGGTGGGATTTTACGGACAGCACTTCTTTACATACCATGT  GAACAGCTCCGATAAGGCTTCTAGTCGAGCAAATGGCACCATCTCATGGATGGCCAA  CGTGAGCGCAGCCTACCCACATATCTGGACGGAGAACGCGCTAAAGGCGATCTGAT  CTTCAATCAGACCGAGCAGAACCTGCTGGAGCTGGAAATTGCTCTGGGGTACAGGTC  TCAGAGTGTCTGACATGGACTCACGAATGTAATACCACAGAGAACGGGAGCTTCGT  GGCAGGATATGAGGGCTTTGGGTGGGACGGAGAAACACTGATGGAGCTGAAGGATA  ATCTGACTCTGTGGACCGGCCCTAACTACGAAATCAGCTGGCTGAAGCAGAACAGA  CTTACATCGACGGAAAGATCAAAAACATCAGCGAGGGCGATACTACCATCCAGCGCA  ATTACCTGAAGGGCAACTGCACCCAGTGGAGCGTGATCTACTCTGGGTTCAGACACC  TGCTACTCACCCAGTGGTCAAAGGGGGAGTGCGAAACCAGAATGACAACCGGGCCG  AGGCCTTCTGTACATCCTACGGCTTCTTTCCCGGGGAGATCAATATTACTTTTATCCATT</p>

		<p>ACGGCAACAAGGCCCCGACGATTCTGAGCCTCAGTGCAATCCCCTGCTGCCTACCTT  CGATGGCACATTTACCAGGGGTGCTACGTCGCTATCTTCTGCAATCAGAACTATACTT  GCCGGGTGACCCATGGGAACTGGACTGTGGAAATCCCAATTTAGTCACCAGCCCCG  ACGATTCAAGCTCCGGAGAGGTGCCAGATCACCCACCGCAAATAAGAGATACAACA  CCATGACAATCTCTAGTGTGCTGCTGGCCCTGCTGCTGTGCGCACTGCTGTTGCTTTT  CTGCATTACTTCACAACTCTGAAGCAGTATCTGCGGAACCTGGCATTGCTGCTGGCGGT  ACAGAAAAGTGAGATCAAGCTGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC  CCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCTTTTCTAATA  AAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGG  GGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGG  GATGCGGTGGGCTCTATGTCTCTTCTGGCCTGGAGGCTATCCAGCGTGAGTCTCTCC  TACCCTCCCGCTCTGGTCTTCTCTCCCGCTCTGCACCCTCTGTGGCCCTCGCTGTGCT  CTCTCGCTCCGTGACTTCCCTTCTCCAAGTTCTCCTTGGTGGCCCCGCGTGGGGCTAGT  CCAGGGCTGGATCTCGGGGAAGCGGCGGGGTGGCCTGGGAGTGGGGAAGGGGGTG  CGACCCGGGACGCGCGCTACTTGCCCTTTGCGCGGGGAGCAGGGGAGACCTTTGG  CCTACGGCGACGGGAGGGTCGGGACAAAG</p>
76	UL18Trimer matrix _HLA peptide inserted at the B2m locus	<p>cacttagcatctctggggccagctctgcaaagcgagggggcagccttaatgtgcctccagcctgaagtcctagaat  gagcgcccggtgtcccaagctggggCGCGCACCCAGATCGGAGGGCGCCGATGTACAGACA  GCAAACTACCCAGTCTAGTGCATGCCTTCTTAAACATCACGAGACTCTAAGAAAAGG  AACTGAAAACGGGAAAGTCCCTCTCTAACCTGGCACTGCGTCGCTGGCTTGGAGA  CAGGTGACGGTCCCTGCGGGCCTTGTCTGATTGGCTGGGCACGCGTTTAAATATAAGT  GGAGGCGTCGCGCTGGCGGGCATTCTGAAGCTGACAGCATTGCGGCCGAGATGTCT  CGTCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTAT  GGCTCCGCGGACTTTATTCTTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGG  TGGCGGCTCCATCCAGCGTACGCCCAAATTCAAGTCTACAGCCGACATCCTGCAGAG  AACGGCAAATCTAATTTCTGAAGTCTATGTATCAGGCTTTCACCCTAGCGATATAGA  AGTGGACCTGCTGAAAACGGAGAGAGGATAGAAAAGGTGCAACACAGCGACCTCT  CCTTTTCCAAGGACTGGAGCTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAA  AAAGATGAGTATGCGTGCCGAGTAAACCACGTACGCTGTACAGCCCAAATAGTA  AAATGGGATCGCGACATGGGTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGG  AGGAAGCGGTGGTGGCGGTTCCGGATCTATGCACGTGCTGAGATACGGATATACCG  GCATCTTCGACGATACATCCCATATGACTCTGACCGTGGTGGGATTTTGGACGGACA  GCACTTCTTTACATACCATGTGAACAGCTCCGATAAGGCTTCTAGTCGAGCAAATGGC  ACCATCTCATGGATGGCCAACGTGAGCGCAGCCTACCCACATATCTGGACGGAGAA  CGCGCTAAAGGCGATCTGATCTTCAATCAGACCGAGCAGAACCTGCTGGAGCTGGAA  ATTGCTCTGGGGTACAGGTCTCAGAGTGTCTGACATGGACTCACGAATGTAATACCA  CAGAGAACGGGAGCTTCGTGGCAGGATATGAGGGCTTTGGGTGGGACGGAGAAACA  CTGATGGAGCTGAAGGATAATCTGACTCTGTGGACCGGCCCTAACTACGAAATCAGCT  GGCTGAAGCAGAACAAGACTTACATCGACGGAAGATCAAAAACATCAGCGAGGGC  GATACTACCATCCAGCGCAATTACCTGAAGGGCAACTGCACCCAGTGGAGCGTGATCT  ACTCTGGGTTCCAGACACCTGTCACTCACCCAGTGGTCAAAGGGGGAGTGCGAAACC  AGAATGACAACCGGGCCGAGGCCTTCTGTACATCCTACGGCTTCTTTCCCGGGGAGAT  CAATATTACTTTTATCCATTACGGCAACAAGGCCCCGACGATTCTGAGCCTCAGTGCA  ATCCCCTGCTGCCTACCTTCGATGGCACATTTACCAGGGGTGCTACGTCGCTATCTTC  TGCAATCAGAACTATACTTGCCGGGTGACCCATGGGAACTGGACTGTGGAAATCCCA  ATTCAGTCACCAGCCCCGACGATTCAAGCTCCGGAGAGGTGCCAGATCACCCACCG  CAAATAAGAGATACAACACCATGACAATCTCTAGTGTGCTGCTGGCCCTGCTGCTGTG  CGCACTGCTGTTGCTTTTCTGCATTACTTCACAACTCTGAAGCAGTATCTGCGGAACC  TGGCATTGCTGCTGGCGGTACAGAAAAGTGAGATCAAGCTGACTGTGCCTTCTAGTTGC  CAGCCATCTGTTGTTGCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCC</p>

		<p>CACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATT CTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAA TAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGTCTCTTCTGGCCTGGAGGCTATC CAGCGTGAGTCTCTCCTACCCTCCCCTCTGGTCTTCTCTCCCCTCTGCACCCTCTG TGGCCCTCGCTGTGCTCTCTCGTCCGTGACTTCCCTTCTCCAAGTTCTCCTTGGTGGCC CGCCGTGGGGCTAGTCCAGGGCTGGATCTCGGGGAAGCGGCGGGGTGGCCTGGGA GTGGGGAAGGGGGTGCACCCGGGACGCGCGCTACTTGCCCTTTCGGCGGGGAG CAGGGGAGACCTTTGGCCTACGGCGACGGGAGGGTCGGGACAAAGtttagggcgtcgata agcgtcagagcgccgaggttgggggaggggttctcttccgctctttcgggggcctctggctccccagcgagct ggagtgggg</p>
77	UL18Trimer matrix _HLA peptide	<p>CGCGCACCCAGATCGGAGGGCGCCGATGTACAGACAGCAAACTCACCCAGTCTAGT GCATGCCTTCTTAACATCACGAGACTCTAAGAAAAGGAAACTGAAAACGGGAAAGT CCCTCTCTTAACCTGGCACTGCGTCGCTGGCTTGGAGACAGGTGACGGTCCCTGCGG GCCTTGCTCTGATTGGCTGGGCACGCGTTTAATATAAGTGAGGCGTCGCGCTGGCG GGCATTCTGAAGCTGACAGCATTGCGGCCGAGATGTCTCGCTCCGTGGCCTTAGCTG TGCTCGCGCTACTCTCTTAGCGGCCTCGAAGCTGTTATGGCTCCGCGGACTTTATTC TTAGGTGGTGGCGGATCCGGTGGTGGCGGTTCTGGTGGTGGCGGCTCCATCCAGCGT ACGCCCCAAATTCAAGTCTACAGCCGACATCCTGCAGAGAACGGCAAATCTAATTTCC TGAAGTGTATGTATCAGGCTTTCACCTAGCGATATAGAAGTGACCTGCTGAAAAA CGGAGAGAGGATAGAAAAGGTGCAACACAGCGACCTCTCCTTTTCCAAGGACTGGAG CTTTTATCTTCTGTATTATACTGAATTTACACCCACGGAAAAAGATGAGTATGCGTGCC GAGTAAACCACGTACGCTGTACAGCCCAAAATAGTAAAATGGGATCGCGACATGG GTGGTGGCGGTTCTGGTGGTGGCGGTAGTGGCGGCGGAGGAAGCGGTGGTGGCGG TTCCGGATCTATGCACGTGCTGAGATACGGATATACCGGCATCTTCGACGATACATCC CATATGACTCTGACCGTGGTGGGATTTTTGACGGACAGCACTTCTTTACATACCATGT GAACAGCTCCGATAAGGCTTCTAGTCGAGCAAATGGCACCATCTCATGGATGGCCAA CGTGAGCGCAGCCTACCCACATATCTGGACGGAGAACGCGCTAAAGGCGATCTGAT CTTCAATCAGACCGAGCAGAACCTGCTGGAGCTGGAAATTGCTCTGGGGTACAGGTC TCAGAGTGTCTGACATGGACTCACGAATGTAATACCACAGAGAACGGGAGCTTCGT GGCAGGATATGAGGGCTTTGGGTGGGACGGAGAAACACTGATGGAGCTGAAGGATA ATCTGACTCTGTGGACCGGCCCTAACTACGAAATCAGCTGGCTGAAGCAGAACAAGA CTTACATCGACGGAAAGATCAAAAACATCAGCGAGGGCGATACTACCATCCAGCGCA ATTACCTGAAGGGCAACTGCACCCAGTGGAGCGTGATCTACTCTGGGTTCCAGACACC TGCTACTCACCCAGTGGTCAAAGGGGGAGTGCGAAACCAGAATGACAACCGGGCCG AGGCCTTCTGTACATCCTACGGCTTCTTCCCGGGGAGATCAATATTACTTTTATCCATT ACGGCAACAAGGCCCCCGACGATTCTGAGCCTCAGTGAATCCCCTGCTGCCTACCTT CGATGGCACATTTACCAGGGGTGCTACGTCGCTATCTTCTGCAATCAGAACTATACTT GCCGGGTGACCCATGGGAACTGGACTGTGGAAATCCCAATTTAGTCACCAGCCCCG ACGATTCAAGCTCCGGAGAGGTGCCAGATCACCCACCGCAAATAAGAGATAACA CCATGACAATCTCTAGTGTGCTGCTGGCCCTGCTGCTGTGCGCACTGCTGTTGCTTTT CTGCATTACTTCACAACTCTGAAGCAGTATCTGCGGAACCTGGCATTGCTGCTGGCGGT ACAGAAAAGTGAGATCAAGCTGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC CCCTCCCCCGTGCCTTCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATA AAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGG GGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGG GATGCGGTGGGCTCTATGTCTCTTCTGGCCTGGAGGCTATCCAGCGTGAGTCTCTCC TACCCTCCCCTCTGGTCTTCTCTCCGCTCTGCACCCTCTGTGGCCCTCGCTGTGCT CTCTCGTCCGTGACTTCCCTTCTCCAAGTTCTCCTTGGTGGCCCGCCGTGGGGCTAGT CCAGGGCTGGATCTCGGGGAAGCGGCGGGGTGGCCTGGGAGTGGGGAAGGGGGTG CGCACCCGGGACGCGCGCTACTTGCCCTTTCGGCGGGGAGCAGGGGAGACCTTTGG</p>

		CCTACGGCGACGGGAGGGTCGGGACAAAG
78	TALEN target B2m1	TCCGTGGCCTTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGA
79	TALEN target B2m2	TTAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA

**Table 5 (continued):** Sequences referred to in example 2 and 3.

		Polypeptide sequence
80	pCLS31134 right TALEN B2m1  RVD sequence :  HD-HD-NN-NG-NN- NN-HD-HD-NG-NG- NI-NN-HD-NG-NN- NG#	MGDPKKKRKVIDYPYDVPDYAIDIADLRTLGYSSQQQKEIKPKVRSTVAQHHEA LVGHGFTAHIVALSQHPAALGTAVVKYQDMIAALPEATHEAIVGVGKQWSGA RALEALLTVAGELRGPPLQLDTGQLLKIARGGVTAVEAVHAWRNALTGAPLNL TPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALET VQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQV VAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRL LPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS HDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLC QAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGG GKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHG LTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQAL ETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQ QVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGGRPALESIVA QLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSELEEKKS ELRHKLKYPHEYIELIEIARNSTQDRILEMKVMEFFMKVGYRGKHLGGSRKPD GAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNE WWKVYPSSVTEFKFLVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMI KAGTLTLEEVRKFNNGEINFAAD
81	pCLS31135 left TALEN B2m1  RVD sequence :  HD-HD-NI-NN-NN-HD- HD-NI-NN-NI-NI-NI- NN-NI-NN-NG#	MGDPKKKRKVIDYPYDVPDYAIDIADLRTLGYSSQQQKEIKPKVRSTVAQHHEA LVGHGFTAHIVALSQHPAALGTAVVKYQDMIAALPEATHEAIVGVGKQWSGA RALEALLTVAGELRGPPLQLDTGQLLKIARGGVTAVEAVHAWRNALTGAPLNL TPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALET VQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVV AIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLL PVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASH DGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQA HGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQ ALETVQALLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPE QVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNNGGKQALETVQ RLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAI ASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGGRPALESIVAQLSRP DPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSELEEKSELRHKL KYPHEYIELIEIARNSTQDRILEMKVMEFFMKVGYRGKHLGGSRKPDGAIYTV GSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWKVY PSSVTEFKFLVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLT LEEVRKFNNGEINFAAD

82	<p>pCLS31136 right TALEN B2m2</p> <p>RVD sequence :</p> <p>NG-NI-NN-HD-NG- NN-NG-NN-HD-NG- HD-NN-HD-NN-HD- NG#</p>	<p>MGDPKKKKRVIDYPYDVPDYAIDIADLRTLGYSSQQQKEIKPKVRSTVAQHHEA LVGHGFTAHIVALSQHPAALGTAVVKYQDMIAALPEATHEAIVGVGKQWWSGA RALEALLTVAGELRGPPLQLDTGQLLKIAGRGGVTAVEAVHAWRNALTGAPLNL TPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALET VQALLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQV VAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRL LPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIA SNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLC QAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGG GKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAH GLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQA LETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPE QVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGGRPALESIVA QLSRPDPALAALTNDHLVALACLGGPALDAVKKGLGDPISRSQLVKSELEEKKS ELRHKLKYPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPD GAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNE WWKVYPSSVTEFKFLVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMI KAGTLTLEEVRKFNNGEINFAAD</p>
83	<p>pCLS31137 left TALEN B2m2</p> <p>RVD sequence :</p> <p>NN-NN-NI-NG-NI- NN-HD-HD-NG-HD- HD-NI-NN-NN-HD- NG#</p>	<p>MGDPKKKKRVIDYPYDVPDYAIDIADLRTLGYSSQQQKEIKPKVRSTVAQHHEA LVGHGFTAHIVALSQHPAALGTAVVKYQDMIAALPEATHEAIVGVGKQWWSGA RALEALLTVAGELRGPPLQLDTGQLLKIAGRGGVTAVEAVHAWRNALTGAPLNL TPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALE TVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQV VAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALL PVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIAS HDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLC QAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGG KQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGL TPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNNGGKQALET VQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQV VAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGGRPALESIVAQL SRPDPALAALTNDHLVALACLGGPALDAVKKGLGDPISRSQLVKSELEEKSEL HKLKYPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAI YTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWW KVYPSSVTEFKFLVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAG TLTLEEVRKFNNGEINFAAD</p>
84	HLAG1	<p>MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASS HTLQWMIGCDLGSDGRLLRGYEYAYDGKDYALNEDLRSWTAADTAAQISKRCCEAA NVAEQRRAYLEGTCVEWLHRYLENGKEMLRADPPKTHVTHHPVFDYEATLRCWALGF YPAEIILTQQRDGEDQTQDVELVETRPAGDGTQKWA AVVVPSGEEQRYTCHVQHEGL PEPLMLRWKQSSLPTIPIMGIVAGLVVLA AVVTGA AVAVLWRKKSSD</p>
85	HLAG2	<p>MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEAKP PKTHVTHHPVFDYEATLRCWALGFYPAEIILTQQRDGEDQTQDVELVETRPAGDGTQK WA AVVVPSGEEQRYTCHVQHEGLPEPLMLRWKQSSLPTIPIMGIVAGLVVLA AVVTGA AAVLWRKKSSD</p>

86	HLAG3	MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEETRNTKAHAQTDRMNLQTLRGYYNQSEAKQ SSLPTIPIMGIVAGLVVLA AVVTGA AVA AVLWRKKSSD
87	HLAG4	MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEETRNTKAHAQTDRMNLQTLRGYYNQSEASS HTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAA NVAEQRRAYLEGTCVEWLHRYLENGKEMLQRAKQSSLPTIPIMGIVAGLVVLA AVVTGA AVA AVLWRKKSSD
88	HLAG5	MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEETRNTKAHAQTDRMNLQTLRGYYNQSEASS HTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKCEAA NVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDYEATLRCWALGF YPAEIILTWQRDGEDQTQDVELVETRPAGDGTGFKWA AVVVPSGEEQRYTCHVQHEGL PEPLMLRWSKEGDGGIMSVRESRSLSEDL
89	HLAG6	MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEETRNTKAHAQTDRMNLQTLRGYYNQSEAKP PKTHVTHHPVFDYEATLRCWALGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTGFK WA AVVVPSGEEQRYTCHVQHEGLPEPLMLRWSKEGDGGIMSVRESRSLSEDL
90	HLAG7	MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFVR FDSDSACPRMEPRAPWVEQEGPEYWEETRNTKAHAQTDRMNLQTLRGYYNQSEASE

### Example 3: TALEN®-mediated double targeted integration of NK inhibitor and CAR encoding matrices at the B2M and TRAC loci in primary T-cells.

This example describes methods to improve the therapeutic outcome of CAR T-cell therapies by extending their persistence in vivo. It consists in a simultaneous TALEN® mediated knock-out of B2M and TCR in the presence of AAV6 repair vectors delivering the CAR at the TRAC locus and an NK inhibitor at the B2M locus. This method prevents CAR T-cell to attack host tissues in a non-specific and TCR-mediated manner (graft versus host attack) and to divert host T- and NK-cells-mediated depletion of CAR T-cells.

The method developed to integrate a NK inhibitor at the B2m locus consisted in generating a double-strand break in one of the first B2M exons using TALEN® in the presence of a DNA repair matrix vectorized by AAV6. This matrix consists of two B2M homology arms embedding the NK inhibitor coding sequence separated by a 2A cis acting elements and regulatory elements (stop codon and polyA sequences). Because expression of B2M at the surface of CAR T-cells is likely to promote their depletion when

transfer in an allogeneic setting, insertion of the repair matrix was designed to inactivate B2M and promote expression of the NK inhibitor.

To illustrate this approach and demonstrate the feasibility of double targeted insertion in primary T-cells, two different matrices were designed (figure 19). The first one named CARm (SEQ ID NO 31) was designed to insert an anti-CD22 CAR cDNA at the TRAC locus in the presence of TRAC TALEN® (SEQ ID NO 16 and 17). The second one, HLAEm, under two variants (SEQ ID NO 69 and 71) was designed to integrate a single chain protein consisting of a fusion of B2M, HLAE and HLAG peptide moieties in the middle of the B2M open reading frame using B2M TALEN® (SEQ ID NO 80 and 81 or 82 and 83 – right and left dimers respectively). The two matrices contained an additional 2A cis-acting element located upstream expression cassettes to enable co-expression of the single chain B2M-HLAE-HLAG peptide and CAR with the endogenous gene targeted. Polynucleotide and polypeptides sequences are listed in Table 5.

We assessed the efficiency of double targeted insertion in T-cells by transfecting them with the TRAC and B2M TALEN® and subsequently transducing them with the AAV6 repair matrices encoding the anti-CD22 CAR and the single chain B2M-HLAE-HLAG peptide. Such treatment led to more than 88% of TCR and HLA-ABC double knockout, to the expression of about 68% of anti-CD22 CAR among the double knockout population and to about 68% of HLAE expression among the double knockout CAR expressing T-cells. Overall, this method enabled to generate about 40% of TCR/HLA-ABC negative, CAR/HLAE positive T-cells (figure 21).

These engineered cells can be assayed for their resistance to NK and alloresponsive T-cells attack. The same engineering approach can be used to generate TCR/HLA-ABC negative, CAR positive T-cell bearing NK cells inhibitors other than HLAE and assess their ability to resist to NK cells attack. Such assessment can be performed on a collection of TCR/HLA-ABC negative, CAR positive T-cell bearing different NK cells inhibitors as illustrated in figure 18. This approach can consist in transfecting T-cells, for instance, with TRAC and B2M TALEN® and subsequently transducing them with the AAV6 repair matrix encoding a CAR, such as anti-CD22 CAR and a library (or collection) of repair matrices encoding different NK inhibitors:

- HLAE trimer matrix comprising VMAPRTLFL peptide (SEQ ID NO.68), which can be inserted at the B2m locus (SEQ ID NO.69),

- HLAE trimer matrix comprising VMAPRTLIL peptide (SEQ ID NO.70), which can be inserted at the B2m locus (SEQ ID NO.71),

- UL18Trimer matrix\_Actine peptide (SEQ ID NO.72), which can be inserted at the B2m locus (SEQ ID NO.73),

- UL18Trimer matrix \_HLACw peptide (SEQ ID NO.74), which can be inserted at the B2m locus (SEQ ID NO.75),

5           - UL18Trimer matrix \_HLAG (SEQ ID NO.76), which can be inserted at the B2m locus (SEQ ID NO.77),

Trimers can also comprises HLAG peptides can be used to form these trimers, such as one selected from the following ones:

HLAG1 (SEQ ID NO.84)

10           HLAG2 (SEQ ID NO.85)

HLAG3 (SEQ ID NO.86)

HLAG4 (SEQ ID NO.87)

HLAG5 (SEQ ID NO.88)

HLAG6 (SEQ ID NO.89)

15           HLAG7 (SEQ ID NO.90)

HLAE or HLAG trimers can also comprise G peptides (as shown in figure 20) selected from the following ones (non limiting examples):

Peptide 1    VMAPRTLIL

Peptide 2    VMAPRTLLL

20           Peptide 3   VMAPRTLVL

Peptide 4    AMAPRTLIL

Peptide 5    VMAPRSLIL

Peptide 6    VMAPRSLLL

Peptide 7    VMAPRTLFL

25           Peptide 8   VMAPRILIL

Peptide 9    YLLPRRGPRL

peptide 10 ALPHAILRL.

The resulting library of TCR negative CAR and NK inhibitor positive T-cells would be cultivated in the presence of NK cells and the remaining viable cells could be recovered and analyzed by high throughput DNA sequence to identify the NK inhibitor (s) 5 responsible for resistance to NK cell attack.

22 Apr 2020

2018353112

**Table 6:** Preferred human endogenous gene loci responsive to T-cell activation

symbol	description	inductionRatio12hr	T.8Nve.Sp.OT1	T.8Eff.Sp.OT1. 12hr.LisOva	T.8Eff.Sp.OT1. 48hr.LisOva	T.8Eff.Sp.OT1. d6.LisOva
Il3	interleukin 21	16,4	12,8	208,9	18,4	13,6
Il2	interleukin 3	97,0	16,0	1554,4	17,7	18,1
Ccl4	isopentenyl-diphosphate delta isomerase 2	2,1	16,8	35,6	17,6	19,7
Il21	granzyme C	9,2	17,4	160,5	20,4	24,9
Gp49a	chemokine (C-C motif) receptor 8	5,9	18,5	108,4	31,5	20,9
Cxcl10	interleukin 2	58,4	21,1	1229,6	32,7	17,9
Nr4a3	interleukin 1 receptor, type I	2,6	21,2	54,6	35,5	21,7
Lilrb4	tumor necrosis factor (ligand) superfamily, member 4	4,1	21,8	88,8	29,3	20,0
Cd200	neuronal calcium sensor 1	4,5	24,1	109,6	46,3	23,2
Cdkn1a	CDK5 and Abl enzyme substrate 1	3,1	26,2	80,9	49,1	32,8
Gzmc	transmembrane and tetratricopeptide repeat containing 2	2,0	26,8	53,9	26,2	29,4
Nr4a2	LON peptidase N-terminal domain and ring finger 1	3,2	28,4	90,4	50,4	28,3
Cish	glycoprotein 49 A	15,0	31,6	472,4	30,6	212,5
Nr4a1	polo-like kinase 2	3,6	31,7	114,3	39,0	32,5
Tnf	lipase, endothelial	2,1	32,4	66,7	35,9	33,3
Ccr8	cyclin-dependent kinase inhibitor 1A (P21)	9,7	34,6	335,4	54,4	71,0
Lad1	grainyhead-like 1 (Drosophila)	2,1	35,1	73,4	52,0	44,1
Slamf1	cellular retinoic acid binding protein II	5,3	35,4	187,2	43,3	36,3
Crabp2	adenylate kinase 4	2,2	35,9	80,4	58,5	39,8
Furin	microtubule-associated protein 1B	2,1	36,2	77,7	36,4	38,4
Gadd45g	acyl-CoA synthetase long-chain family member 6	2,0	37,2	76,0	45,2	41,3

Bcl2l1	zinc finger E-box binding homeobox 2	2,1	38,6	80,7	44,9	455,4
Ncs1	CD200 antigen	9,8	41,2	404,3	70,4	36,8
Ciart	carboxypeptidase D	3,1	41,6	127,7	71,4	71,6
Ahr	thioredoxin reductase 3	3,6	43,4	157,8	61,7	28,8
Spry1	myosin IE	2,3	43,6	100,2	61,3	77,0
Tnfrsf4	RNA binding protein with multiple splicing 2	2,1	43,6	91,5	49,8	36,5
Myo10	mitogen-activated protein kinase kinase 3, opposite strand	2,9	44,8	127,9	66,4	43,1
Dusp5	PERP, TP53 apoptosis effector	2,8	44,9	127,2	78,4	72,4
Myc	myosin X	4,1	45,5	184,9	81,6	57,5
Psrc1	immediate early response 3	2,7	45,6	121,6	63,9	66,2
St6galnac4	folliculin interacting protein 2	2,6	47,5	124,2	87,4	96,6
Nfkbid	leukocyte immunoglobulin-like receptor, subfamily B, member 4	9,9	48,9	483,3	64,5	179,1
Bst2	circadian associated repressor of transcription	4,5	50,6	225,5	100,3	33,8
Txnrd3	RAR-related orphan receptor gamma	2,1	51,7	106,7	47,5	52,8
Plk2	proline/serine-rich coiled-coil 1	3,9	52,9	205,9	92,3	79,6
Gfi1	cysteine rich protein 2	2,4	54,2	127,7	90,3	182,9
Pim1	cAMP responsive element modulator	2,0	55,7	112,6	54,4	57,3
Pvt1	chemokine (C-C motif) ligand 4	20,2	55,8	1125,8	103,1	89,0
Nfkbib	nuclear receptor subfamily 4, group A, member 2	7,8	58,5	457,6	78,7	72,0
Gnl2	transglutaminase 2, C polypeptide	2,3	58,7	132,1	69,8	64,7
Cd69	synapse defective 1, Rho GTPase, homolog 2 (C, elegans)	2,1	62,5	132,7	111,3	31,0
Dgat2	sprouty homolog 1 (Drosophila)	4,2	63,8	268,5	76,8	61,4
Atf3	activating transcription factor 3	3,2	65,8	210,3	88,3	75,8
Tnfrsf21	pogo transposable element with KRAB domain	2,9	68,6	196,9	91,1	293,2
Lonrf1	tumor necrosis factor receptor superfamily,	3,2	70,6	224,5	126,5	72,9

	member 21						
Cables1	cytokine inducible SH2-containing protein		7,5	74,3	558,7	82,5	133,9
Cpd	lymphotoxin A		2,6	74,6	197,2	93,4	58,6
Qtrtd1	FBJ osteosarcoma oncogene		3,0	74,9	224,1	89,0	61,1
Polr3d	signaling lymphocytic activation molecule family member 1		5,4	75,6	412,0	108,4	190,4
Kcnq5	syndecan 3		2,4	76,0	180,0	77,2	85,3
Fos	mitochondrial ribosomal protein L47		2,1	77,2	161,7	152,0	72,3
Slc19a2	ladinin		5,5	77,3	423,2	152,5	70,4
Hif1a	E2F transcription factor 5		2,5	77,7	198,0	92,0	65,2
Il15ra	ISG15 ubiquitin-like modifier		2,8	77,9	221,0	88,9	45,1
Nfkb1	aryl-hydrocarbon receptor		4,2	78,7	333,2	145,7	91,4
Phlda3	diacylglycerol O-acyltransferase 2		3,2	81,0	259,2	150,0	84,4
Mtrr	FBJ osteosarcoma oncogene B		2,0	81,3	163,7	139,3	98,5
Pogk	pleckstrin homology-like domain, family A, member 3		2,9	84,8	244,5	126,9	83,8
Map2k3os	potassium voltage-gated channel, subfamily Q, member 5		3,0	86,3	261,0	118,1	63,4
Egr2	tumor necrosis factor receptor superfamily, member 10b		2,5	88,6	219,0	106,1	51,0
Isg15	Mir17 host gene 1 (non-protein coding)		2,1	90,4	190,1	120,0	51,2
Perp	glucose-fructose oxidoreductase domain containing 1		2,2	92,9	208,5	168,7	237,4
Ipo4	plexin A1		2,1	94,8	200,7	118,0	90,3
Mphosph10	heat shock factor 2		2,4	96,8	233,2	191,0	104,8
Plk3	carbohydrate sulfotransferase 11		2,4	96,8	235,1	180,8	385,7
Ifitm3	growth arrest and DNA-damage-inducible 45 gamma		4,8	104,6	504,8	109,3	95,0
Polr1b	solute carrier family 5 (sodium-dependent vitamin transporter), member 6		2,1	107,0	227,3	192,8	75,8
Usp18	interferon induced transmembrane protein 3		2,8	109,2	302,6	43,9	106,4

[illegible]

	member 11								
Ifi2712a	polymerase (RNA) III (DNA directed) polypeptide D	3,0	166,3	503,7	296,1	121,6			
Tnfrsf10b	early growth response 2	2,8	173,5	494,0	136,3	68,2			
Rpl7l1	DnaJ (Hsp40) homolog, subfamily C, member 2	2,1	173,6	369,4	346,2	254,3			
Eif1a	DNA topoisomerase 1, mitochondrial	2,7	182,2	498,2	338,6	114,4			
Nfkb2	tripartite motif-containing 30D	2,3	182,6	423,4	65,8	90,6			
Heatr1	DnaJ (Hsp40) homolog, subfamily C, member 21	2,0	190,1	389,4	285,5	228,2			
Utp20	SAM domain, SH3 domain and nuclear localization signals, 1	2,2	191,5	422,1	222,8	304,1			
Chst11	solute carrier family 5 (inositol transporters), member 3	2,1	191,6	400,2	210,0	123,4			
Ddx21	mitochondrial ribosomal protein L15	2,1	191,6	396,3	329,8	137,7			
Hsf2	dual specificity phosphatase 5	4,0	203,5	818,1	307,5	560,7			
Bccip	apoptosis enhancing nuclease	2,3	211,1	478,5	288,2	137,9			
Tagap	ets variant 6	2,3	218,3	508,1	220,5	297,3			
Sdc3	DIM1 dimethyladenosine transferase 1-like (S, cerevisiae)	2,2	218,4	486,0	356,0	129,7			
Sytl3	2'-5' oligoadenylate synthetase-like 1	2,1	229,0	473,3	130,7	124,3			
Gtpbp4	UTP18, small subunit (SSU) processome component, homolog (yeast)	2,1	232,0	494,3	384,9	189,5			
Crip2	BRCA2 and CDKN1A interacting protein	2,4	234,6	563,3	437,5	269,8			
Sh3rf1	synaptotagmin-like 3	2,4	242,4	572,9	316,7	700,7			
Nsf11c	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	2,9	245,7	706,5	334,6	150,6			
Gtf2f1	URB2 ribosome biogenesis 2 homolog (S, cerevisiae)	2,0	245,7	500,2	489,8	184,6			
Slc4a7	ubiquitin-conjugating enzyme E2C binding protein	2,1	251,2	530,5	288,2	85,2			
Etv6	lysine (K)-specific demethylase 2B	2,2	251,8	547,1	332,7	262,1			

Trim30d	queuine tRNA-ribosyltransferase domain containing 1	3,0	260,3	788,7	358,0	75,5
Ddx27	ubiquitin specific peptidase 31	2,0	265,2	533,2	277,1	176,2
Pwp2	eukaryotic translation initiation factor 2-alpha kinase 2	2,0	267,7	540,5	260,8	244,8
Chchd2	ATPase family, AAA domain containing 3A	2,5	268,8	679,7	523,1	147,1
Myo1e	adhesion molecule, interacts with CXADR antigen 1	2,3	269,5	610,9	272,9	182,8
Eif5b	SUMO/sentrin specific peptidase 3	2,0	272,5	548,7	544,5	298,4
Stat5a	ESF1, nucleolar pre-rRNA processing protein, homolog (S, cerevisiae)	2,2	276,3	610,4	482,2	266,5
Cops6	deoxynucleotidyltransferase, terminal, interacting protein 2	2,1	282,9	600,4	359,9	326,1
D19Bwg1357e	TGFB-induced factor homeobox 1	2,1	300,5	618,9	217,5	210,6
Aatf	eukaryotic translation initiation factor 1A	2,5	300,8	738,7	597,7	262,8
Aen	interferon-stimulated protein	2,1	305,7	651,2	144,3	138,4
Amica1	pleiomorphic adenoma gene-like 2	2,1	311,5	651,9	376,2	405,9
Wdr43	PWP2 periodic tryptophan protein homolog (yeast)	2,3	321,8	743,3	586,5	189,3
Cct4	furin (paired basic amino acid cleaving enzyme)	5,2	329,7	1728,3	271,7	421,5
Nifk	tumor necrosis factor	6,6	330,7	2188,4	489,9	213,3
Tgm2	apoptosis antagonizing transcription factor	2,3	331,4	754,8	523,1	221,5
Ero1l	interferon, alpha-inducible protein 27 like 2A	2,5	334,0	828,1	296,0	221,4
Gfod1	ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4	3,9	338,4	1311,3	636,0	298,2
Ak4	methyltransferase like 1	2,2	339,4	744,7	662,8	94,5
Sdad1	notchless homolog 1 (Drosophila)	2,0	339,4	690,3	610,3	158,1
Dimt1	mitochondrial ribosomal protein L3	2,1	340,0	725,5	651,4	359,8
Esf1	UBX domain protein 2A	2,1	343,8	732,9	532,1	428,5

Cd3eap	guanine nucleotide binding protein-like 2 (nucleolar)	3,2	347,6	1124,7	647,4	227,5
Samsn1	programmed cell death 11	2,0	353,9	711,8	435,9	287,4
Tnfrsf4	cyclin-dependent kinase 8	2,0	364,0	731,1	702,5	346,2
Mettl1	eukaryotic translation initiation factor 5B	2,3	365,1	838,2	544,5	355,5
Cd274	RNA terminal phosphate cyclase-like 1	2,5	373,3	948,8	746,4	155,8
Ubttd2	NSFL1 (p97) cofactor (p47)	2,3	374,1	876,1	725,9	369,7
Icos	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, delta	3,9	378,5	1465,1	389,9	224,0
Kdm2b	M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein)	2,8	379,8	1069,3	738,4	290,8
Larp4	GRAM domain containing 1B	2,5	382,7	949,6	363,4	659,2
Eif3d	ERO1-like (S, cerevisiae)	2,2	387,7	872,3	773,0	520,9
Tnfaip3	nuclear receptor subfamily 4, group A, member 1	6,8	387,8	2639,0	343,7	220,7
Map1b	surfeit gene 2	2,1	399,8	852,2	696,3	204,0
Cdv3	N(alpha)-acetyltransferase 25, NatB auxiliary subunit	2,1	405,7	847,3	669,5	194,1
Plac8	yrdC domain containing (E.coli)	2,0	406,7	830,8	635,3	267,0
Mrpl3	La ribonucleoprotein domain family, member 4	2,2	408,8	887,9	586,6	358,3
Surf2	SDA1 domain containing 1	2,2	419,8	939,9	631,4	284,7
Ubxn2a	importin 4	2,8	420,3	1183,6	777,8	173,5
Utp18	inducible T cell co-stimulator	2,2	423,9	920,9	818,8	796,9
Isg20	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1	2,1	439,4	934,4	842,6	344,6
Dnajc2	arsA arsenite transporter, ATP-binding, homolog 1 (bacterial)	2,6	446,6	1165,0	717,9	963,9
Jak2	polymerase (RNA) I polypeptide C	2,7	447,8	1208,4	854,0	295,9
Slc7a1	spermatogenesis associated 5	2,0	450,8	920,2	516,0	361,6
Syde2	ubiquitin specific peptidase 18	2,7	451,8	1240,5	296,0	250,7

Slc5a6	placenta-specific 8		2,1	452,4	967,3	888,6	590,8
Dnttip2	general transcription factor IIF, polypeptide 1		2,3	454,8	1063,9	890,0	680,8
Idi2	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta		3,4	456,4	1535,5	679,1	502,7
Dus2	PHD finger protein 6		2,5	462,0	1159,5	775,8	510,4
Pitrm1	RRN3 RNA polymerase I transcription factor homolog (yeast)		2,1	462,2	948,4	913,2	388,9
Plxna1	cytotoxic and regulatory T cell molecule		2,5	473,7	1177,8	586,8	431,8
Cdk5r1	COP9 (constitutive photomorphogenic) homolog, subunit 6 (Arabidopsis thaliana)		2,3	483,6	1101,9	947,8	560,3
Ube2cbp	asparagine-linked glycosylation 3 (alpha-1,3-mannosyltransferase)		2,1	485,9	1006,3	758,7	339,4
Tnfsf11	tryptophanyl-tRNA synthetase		2,0	486,1	987,1	897,1	504,7
Pop7	hypoxia up-regulated 1		2,0	494,3	996,6	802,4	690,3
Psme3	family with sequence similarity 60, member A		2,0	500,8	1002,1	834,7	417,6
Mir17hg	bone marrow stromal cell antigen 2		3,8	502,5	1922,9	925,5	246,0
Tsr1	nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100		2,4	503,2	1231,8	494,0	341,8
Rbpms2	UTP20, small subunit (SSU) processome component, homolog (yeast)		2,4	510,5	1240,2	696,4	245,8
Mirpl47	CD274 antigen		2,2	516,6	1128,7	246,9	220,2
Rab8b	proviral integration site 1		3,4	518,4	1766,4	676,9	970,0
Plagl2	signal transducer and activator of transcription 5A		2,3	530,0	1210,4	496,6	507,8
Grhl1	CD69 antigen		3,2	535,7	1725,8	289,5	153,9
Zeb2	pitrilysin metallopeptidase 1		2,1	544,9	1153,8	968,4	349,3
CDK6	cyclin-dependent kinase 6		2,7	550,3	1476,5	1064,0	642,1
Slc5a3	DEAD (Asp-Glu-Ala-Asp) box polypeptide 27		2,3	556,2	1286,9	987,2	480,4
Naa25	polymerase (RNA) I polypeptide B		2,8	556,2	1536,0	1070,4	201,3
Plaur	tumor necrosis factor, alpha-induced protein 3		2,2	560,6	1212,2	255,5	446,0

Metap1	nodal modulator 1	2,1	563,0	1161,0	988,9	439,8
Alg3	NOP14 nucleolar protein	2,5	570,9	1418,9	925,3	398,0
Mrpl15	ribosomal protein L7-like 1	2,5	586,7	1448,7	1030,2	687,2
Oasl1	methionyl aminopeptidase 1	2,1	597,5	1244,1	1139,3	433,4
Rorc	hypoxia inducible factor 1, alpha subunit	3,0	624,2	1854,6	809,4	838,4
Nomo1	Janus kinase 2	2,1	624,5	1328,7	390,6	917,8
Tgif1	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	2,9	661,5	1913,3	713,9	720,5
Lipg	reticuloendotheliosis oncogene	2,5	678,9	1686,4	409,8	580,5
Rrn3	septin 2	2,1	687,3	1436,0	1354,1	1181,3
Dnajc21	nucleolar protein interacting with the FHA domain of MKI67	2,3	733,4	1658,2	1280,0	407,2
Yrdc	elongation factor Tu GTP binding domain containing 2	2,0	739,3	1483,5	1439,0	904,3
Acs16	myelocytomatosis oncogene	4,0	761,0	3022,8	1064,0	211,5
Spata5	dyskeratosis congenita 1, dyskerin	2,7	778,2	2112,0	1549,5	484,2
Urb2	carnitine deficiency-associated gene expressed in ventricle 3	2,1	801,6	1718,2	1274,7	1010,3
Nle1	GTP binding protein 4	2,4	824,2	1942,6	1578,7	567,3
Wars	HEAT repeat containing 1	2,4	830,3	2020,6	1235,5	495,4
Crem	proteaseome (prosome, macropain) activator subunit 3 (PA28 gamma, Ki)	2,1	838,4	1763,5	1471,1	936,1
Larp1	La ribonucleoprotein domain family, member 1	2,0	861,7	1742,1	1250,9	854,3
Eif2ak2	DNA segment, Chr 19, Brigham & Women's Genetics 1357 expressed	2,3	868,6	1978,4	1218,0	653,4
Hyou1	eukaryotic translation initiation factor 3, subunit D	2,2	909,1	1971,6	1641,9	920,6
Senp3	TSR1 20S rRNA accumulation	2,1	913,9	1915,9	1474,6	477,2
Tmtc2	MYB binding protein (P160) 1a	2,6	1140,0	2962,9	2200,7	459,8
Fosb	T cell activation Rho GTPase activating	2,4	1176,7	2794,4	489,3	704,2

	protein						
Pdcd11	RAB8B, member RAS oncogene family	2,1	1189,5	2492,2	1671,3	2512,5	
Usp31	DEAD (Asp-Glu-Ala-Asp) box polypeptide 21	2,4	1210,2	2928,0	2221,1	1098,2	
Cdk8	chaperonin containing Tcp1, subunit 4 (delta)	2,3	1321,4	2989,7	2462,5	1294,8	
Eftud2	coiled-coil-helix-coiled-coil-helix domain containing 2	2,3	1374,2	3171,2	2636,9	1008,9	
Fam60a	WD repeat domain 43	2,3	1727,6	3912,6	2927,5	1014,9	

**Table 7:** Selection of preferred endogenous genes that are constantly active during immune cell activation (dependent or independent from T-cell activation).

Symbol	Gene description
CD3G	CD3 gamma
Rn28s1	28S ribosomal RNA
Rn18s	18S ribosomal RNA
Rn7sk	RNA, 7SK, nuclear
Actg1	actin, gamma, cytoplasmic 1
B2m	beta-2 microglobulin
Rpl18a	ribosomal protein L18A
Pabpc1	poly(A) binding protein, cytoplasmic 1
Gapdh	glyceraldehyde-3-phosphate dehydrogenase
Rpl19	ribosomal protein L19
Rpl17	ribosomal protein L17
Rplp0	ribosomal protein, large, P0
Cfl1	cofilin 1, non-muscle
Pfn1	profilin 1

**Table 8:** Selection of genes that are transiently upregulated upon T-cell activation.

Symbol	Gene description
Il3	interleukin 3
Il2	interleukin 2
Ccl4	chemokine (C-C motif) ligand 4
Il21	interleukin 21
Gp49a	glycoprotein 49 A
Nr4a3	nuclear receptor subfamily 4, group A, member 3
Lilrb4	leukocyte immunoglobulin-like receptor, subfamily B, member 4
Cd200	CD200 antigen
Cdkn1a	cyclin-dependent kinase inhibitor 1A (P21)
Gzmc	granzyme C
Nr4a2	nuclear receptor subfamily 4, group A, member 2
Cish	cytokine inducible SH2-containing protein
Ccr8	chemokine (C-C motif) receptor 8
Lad1	ladinin
Crabp2	cellular retinoic acid binding protein II

**Table 9:** Selection of genes that are upregulated over more than 24 hours upon T-cell activation.

Symbol	Description
Gzmb	granzyme B
Tbx21	T-box 21
Pdcd1	programmed cell death 1
Plek	pleckstrin
Chek1	checkpoint kinase 1
Slamf7	SLAM family member 7
Zbtb32	zinc finger and BTB domain containing 32
Tigit	T cell immunoreceptor with Ig and ITIM domains
Lag3	lymphocyte-activation gene 3
Gzma	granzyme A
Wee1	WEE 1 homolog 1 (S. pombe)
Il12rb2	interleukin 12 receptor, beta 2
Ccr5	chemokine (C-C motif) receptor 5
Eea1	early endosome antigen 1
Dtl	denticless homolog (Drosophila)

**Table 10:** Selection of genes that are down-regulated upon immune cell activation.

Symbol	Gene description
Spata6	spermatogenesis associated 6
Itga6	integrin alpha 6
Rcbtb2	regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2
Cd1d1	CD1d1 antigen
St8sia4	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4
Itgae	integrin alpha E, epithelial-associated
Fam214a	family with sequence similarity 214, member A
Slc6a19	solute carrier family 6 (neurotransmitter transporter), member 19
Cd55	CD55 antigen
Xkrx	X Kell blood group precursor related X linked
Mturn	maturin, neural progenitor differentiation regulator homolog (Xenopus)
H2-Ob	histocompatibility 2, O region beta locus
Cnr2	cannabinoid receptor 2 (macrophage)
Itgae	integrin alpha E, epithelial-associated
Raver2	ribonucleoprotein, PTB-binding 2
Zbtb20	zinc finger and BTB domain containing 20
Arrb1	arrestin, beta 1
Abca1	ATP-binding cassette, sub-family A (ABC1), member 1
Tet1	tet methylcytosine dioxygenase 1
Slc16a5	solute carrier family 16 (monocarboxylic acid transporters), member 5
Trav14-1	T cell receptor alpha variable 14-1
Ampd3	adenosine monophosphate deaminase 3

**Table 11:** Selection of human genes that are silent upon T-cell activation  
(safe harbor gene targeted integration loci).

Symbol	Gene description
Zfp640	zinc finger protein 640
LOC100038422	uncharacterized LOC100038422
Zfp600	zinc finger protein 600
Serpinb3a	serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 3A
Tas2r106	taste receptor, type 2, member 106
Magea3	melanoma antigen, family A, 3
Omt2a	oocyte maturation, alpha
Cpxcr1	CPX chromosome region, candidate 1
Hsf3	heat shock transcription factor 3
Pbsn	Probasin
Sbp	spermine binding protein
Wfdc6b	WAP four-disulfide core domain 6B
Meiob	meiosis specific with OB domains
Dnm3os	dynamin 3, opposite strand
Skint11	selection and upkeep of intraepithelial T cells 11

**Table 12:** List of gene loci upregulated in tumor exhausted infiltrating lymphocytes  
(compiled from multiple tumors) useful for gene integration  
of exogenous coding sequences as per the present invention

Gene names	Uniprot ID (human)
CXCL13	O43927
TNFRSF1B	P20333
RGS2	P41220
TIGIT	Q495A1
CD27	P26842
TNFRSF9	Q12933
SLA	Q13239
INPP5F	Q01968
XCL2	Q9UBD3
HLA-DMA	P28067
FAM3C	Q92520
WARS	P23381
EIF3L	Q9Y262
KCNK5	O95279
TMBIM6	P55061
CD200	P41217
C3H7A	O60880
SH2D1A	O60880
ATP1B3	P54709
THADA	Q6YHU6
PARK7	Q99497
EGR2	P11161
FDFT1	P37268
CRTAM	O95727
IFI16	Q16666

**Table 13:** List of gene loci upregulated in hypoxic tumor conditions useful for gene integration of exogenous coding sequences as per the present invention

<u>Gene names</u>	<u>Strategy</u>	
<u>CTLA-4</u>	<u>KO/KI</u>	Target shown to be upregulated in T-cells upon hypoxia exposure and T cell exhaustion
<u>LAG-3 (CD223)</u>	<u>KO/KI</u>	
<u>PD1</u>	<u>KO/KI</u>	
<u>4-1BB (CD137)</u>	<u>KI</u>	
<u>GITR</u>	<u>KI</u>	
<u>OX40</u>	<u>KI</u>	
<u>IL10</u>	<u>KO/KI</u>	
<u>ABCB1</u>	<u>KI</u>	HIF target
<u>ABCG2</u>	<u>KI</u>	
<u>ADM</u>	<u>KI</u>	
<u>ADRA1B</u>	<u>KI</u>	
<u>AK3</u>	<u>KI</u>	
<u>ALDOA</u>	<u>KI</u>	
<u>BHLHB2</u>	<u>KI</u>	
<u>BHLHB3</u>	<u>KI</u>	
<u>BNIP3</u>	<u>KI</u>	
<u>BNIP3L</u>	<u>KI</u>	
<u>CA9</u>	<u>KI</u>	
<u>CCNG2</u>	<u>KI</u>	
<u>CD99</u>	<u>KI</u>	
<u>CDKN1A</u>	<u>KI</u>	
<u>CITED2</u>	<u>KI</u>	
<u>COL5A1</u>	<u>KI</u>	
<u>CP</u>	<u>KI</u>	

<u>CTGF</u>	<u>KI</u>	
<u>CTSD</u>	<u>KI</u>	
<u>CXCL12</u>	<u>KI</u>	
<u>CXCR4</u>	<u>KI</u>	
<u>CYP2S1</u>	<u>KI</u>	
<u>DDIT4</u>	<u>KI</u>	
<u>DEC1</u>	<u>KI</u>	
<u>EDN1</u>	<u>KI</u>	
<u>EGLN1</u>	<u>KI</u>	
<u>EGLN3</u>	<u>KI</u>	
<u>ENG</u>	<u>KI</u>	
<u>ENO1</u>	<u>KI</u>	
<u>EPO</u>	<u>KI</u>	
<u>ETS1</u>	<u>KI</u>	
<u>FECH</u>	<u>KI</u>	
<u>FN1</u>	<u>KI</u>	
<u>FURIN</u>	<u>KI</u>	
<u>GAPDH</u>	<u>KI</u>	
<u>GPI</u>	<u>KI</u>	
<u>GPX3</u>	<u>KI</u>	
<u>HK1</u>	<u>KI</u>	
<u>HK2</u>	<u>KI</u>	
<u>HMOX1</u>	<u>KI</u>	
<u>HSP90B1</u>	<u>KI</u>	
<u>ID2</u>	<u>KI</u>	
<u>IGF2</u>	<u>KI</u>	
<u>IGFBP1</u>	<u>KI</u>	
<u>IGFBP2</u>	<u>KI</u>	
<u>IGFBP3</u>	<u>KI</u>	

<u>ITGB2</u>	<u>KI</u>	
<u>KRT14</u>	<u>KI</u>	
<u>KRT18</u>	<u>KI</u>	
<u>KRT19</u>	<u>KI</u>	
<u>LDHA</u>	<u>KI</u>	
<u>LEP</u>	<u>KI</u>	
<u>LOX</u>	<u>KI</u>	
<u>LRP1</u>	<u>KI</u>	
<u>MCL1</u>	<u>KI</u>	
<u>MET</u>	<u>KI</u>	
<u>MMP14</u>	<u>KI</u>	
<u>MMP2</u>	<u>KI</u>	
<u>MXI1</u>	<u>KI</u>	
<u>NOS2A</u>	<u>KI</u>	
<u>NOS3</u>	<u>KI</u>	
<u>NPM1</u>	<u>KI</u>	
<u>NR4A1</u>	<u>KI</u>	
<u>NT5E</u>	<u>KI</u>	
<u>PDGFA</u>	<u>KI</u>	
<u>PDK1</u>	<u>KI</u>	
<u>PFKFB3</u>	<u>KI</u>	
<u>PFKL</u>	<u>KI</u>	
<u>PGK1</u>	<u>KI</u>	
<u>PH-4</u>	<u>KI</u>	
<u>PKM2</u>	<u>KI</u>	
<u>PLAUR</u>	<u>KI</u>	
<u>PMAIP1</u>	<u>KI</u>	
<u>PPP5C</u>	<u>KI</u>	
<u>PROK1</u>	<u>KI</u>	

<u>SERPINE1</u>	<u>KI</u>	
<u>SLC2A1</u>	<u>KI</u>	
<u>TERT</u>	<u>KI</u>	
<u>TF</u>	<u>KI</u>	
<u>TFF3</u>	<u>KI</u>	
<u>TFRC</u>	<u>KI</u>	
<u>TGFA</u>	<u>KI</u>	
<u>TGFB3</u>	<u>KI</u>	
<u>TGM2</u>	<u>KI</u>	
<u>TPI1</u>	<u>KI</u>	
<u>VEGFA</u>	<u>KI</u>	
<u>VIM</u>	<u>KI</u>	
<u>TMEM45A</u>	<u>KI</u>	
<u>AKAP12</u>	<u>KI</u>	
<u>SEC24A</u>	<u>KI</u>	
<u>ANKRD37</u>	<u>KI</u>	
<u>RSBN1</u>	<u>KI</u>	
<u>GOPC</u>	<u>KI</u>	
<u>SAMD12</u>	<u>KI</u>	
<u>CRKL</u>	<u>KI</u>	
<u>EDEM3</u>	<u>KI</u>	
<u>TRIM9</u>	<u>KI</u>	
<u>GOSR2</u>	<u>KI</u>	
<u>MIF</u>	<u>KI</u>	
<u>ASPH</u>	<u>KI</u>	
<u>WDR33</u>	<u>KI</u>	
<u>DHX40</u>	<u>KI</u>	
<u>KLF10</u>	<u>KI</u>	
<u>R3HDM1</u>	<u>KI</u>	

<u>RARA</u>	<u>KI</u>	
<u>LOC162073</u>	<u>KI</u>	
<u>PGRMC2</u>	<u>KI</u>	
<u>ZWILCH</u>	<u>KI</u>	
<u>TPCN1</u>	<u>KI</u>	
<u>WSB1</u>	<u>KI</u>	
<u>SPAG4</u>	<u>KI</u>	
<u>GYS1</u>	<u>KI</u>	
<u>RRP9</u>	<u>KI</u>	
<u>SLC25A28</u>	<u>KI</u>	
<u>NTRK2</u>	<u>KI</u>	
<u>NARF</u>	<u>KI</u>	
<u>ASCC1</u>	<u>KI</u>	
<u>UFM1</u>	<u>KI</u>	
<u>TXNIP</u>	<u>KI</u>	
<u>MGAT2</u>	<u>KI</u>	
<u>VDAC1</u>	<u>KI</u>	
<u>SEC61G</u>	<u>KI</u>	
<u>SRP19</u>	<u>KI</u>	
<u>JMJD2C</u>	<u>KI</u>	
<u>SNRPD1</u>	<u>KI</u>	
<u>RASSF4</u>	<u>KI</u>	

**CLAIMS**

- 1) A method for preparing engineered primary T cells for cell immunotherapy, said method comprising:
  - providing a population of cells comprising primary T cells;
  - introducing into a proportion of said primary T-cells:
    - i) at least one nucleic acid comprising an exogenous polynucleotide sequence to be integrated at a selected endogenous locus to encode at least one NK cell inhibitor;
    - ii) at least one sequence-specific reagent that specifically targets said selected endogenous locus,wherein said exogenous polynucleotide sequence is inserted by targeted gene integration into said endogenous locus; and  
wherein said exogenous polynucleotide sequence comprises a sequence encoding at least one non polymorphic class I molecule or comprises a sequence encoding at least one viral evasin.
- 2) The method according to claim 1, wherein said sequence specific reagent is a nuclease.
- 3) The method according to claim 1 or 2, wherein said sequence-specific reagent is selected from a RNA or DNA-guided endonuclease, such as Cas9 or Cpf1, a TAL-endonuclease, a zing finger nuclease, a homing endonuclease or any combination thereof.
- 4) The method according to any one of claims 1 to 3, wherein the at least one non polymorphic class I molecule is HLA-G and/or HLA-E.
- 5) The method according to any one of claims 1 to 3, wherein the at least one viral evasin is UL16 or UL18.
- 6) The method according to any one of claims 1 to 3, wherein said exogenous polynucleotide sequence is integrated under transcriptional control of an endogenous promoter present at said locus, such as a locus expressing a MHC I component, such as  $\beta 2m$ .

- 7) The method according to claim 6, wherein said exogenous sequence comprises a sequence encoding HLA-G and/or HLA-E, and when integrated at  $\beta 2m$  endogenous locus results into the expression of a fusion of a HLA-E and/or HLA-G with  $\beta 2m$  fragments.
- 8) The method according to claim 6 or 7, wherein said insertion of said exogenous sequence inactivates  $\beta 2m$  expression at said endogenous locus.
- 9) The method according to any one of claims 1 to 8, wherein targeted gene integration into said endogenous locus is homology-directed repair (HDR)-based.
- 10) The method according to any one of claims 1 to 9, wherein said selected endogenous locus is responsive to T-cell activation, such as one selected from Il3, Il2, Ccl4, Il21, Gp49a, Cxcl10, Nr4a3, Lillrb4, Cd200, Cdkn1a, Gzmc, Nr4a2, Cish, Nr4a1, Tnf, Ccr8, Lad1, Slamf1, Crabp2, Furin, Gadd45g, Bcl2l1, Ncs1, Ciart, Ahr, Spry1, Tnfsf4, Myo10, Dusp5, Myc, Psrc1, St6galnac4, Nfkbid, Bst2, Txnrd3, Plk2, Gfi1, Pim1, Pvt1, Nfkbib, Gnl2, Cd69, Dgat2, Atf3, Tnfrsf21, Lonrf1, Cables1, Cpd, Qtrtd1, Polr3d, Kcnq5, Fos, Slc19a2, Hif1a, Il15ra, Nfkb1, Phlda3, Mtrr, Pogk, Map2k3os, Egr2, Isg15, Perp, Ipo4, Mphosph10, Plk3, Ifitm3, Polr1b, Usp18, Top1mt, Dkc1, Polr1c, Cdk6, Ier3, Lta, Ptpsr, Fnip2, Asna1, Mybbp1a, Il1r1, Dennd5a, E2f5, Rcl1, Fosl2, Atad3a, Bax, Phf6, Zfp52, Crtam, Nop14, Rel, Gramd1b, Ifi27l2a, Tnfrsf10b, Rpl7l1, Eif1a, Nfkb2, Heatr1, Utp20, Chst11, Ddx21, Hsf2, Bccip, Tagap, Sdc3, Sytl3, Gtpbp4, Crip2, Sh3rf1, Nsf1c, Gtf2f1, Slc4a7, Etv6, Trim30d, Ddx27, Pwp2, Chchd2, Myo1e, Eif5b, Stat5a, Cops6, D19Bwg1357e, Aatf, Aen, Amica1, Wdr43, Cct4, Nifk, Tgm2, Ero1l, Gfod1, Ak4, Sdad1, Dimt1, Esf1, Cd3eap, Samsn1, Tnfrsf4, Mettl1, Cd274, Ubtd2, Icos, Kdm2b, Larp4, Eif3d, Tnfaip3, Map1b, Cdv3, Plac8, Mrpl3, Surf2, Ubxn2a, Utp18, Isg20, Dnajc2, Jak2, Slc7a1, Syde2, Slc5a6, Dnttip2, Idi2, Dus2, Pitrm1, Plxna1, Cdk5r1, Ube2cbp, Tnfsf11, Pop7, Psme3, Mir17hg, Tsr1, Rbpms2, Mrpl47, Rab8b, Plagl2, Grhl1, Zeb2, CDK6, Slc5a3, Naa25, Plaur, Metap1, Alg3, Mrpl15, Oasl1, Rorc, Nomo1, Tgif1, Lipg, Rrn3, Dnajc21, Yrdc, Acsl6, Spata5, Urb2, Nle1, Wars, Crem, Larp1, Eif2ak2, Hyou1, Senp3, Tmtc2, Fosb, Pdcd11, Usp31, Cdk8, Eftud2, and Fam60a.
- 11) The method according to any one of claims 1 to 10, wherein said T-cells are endowed with chimeric antigen receptor (CAR).

- 12) The method according to claim 11, wherein said exogenous sequences encoding said chimeric antigen receptor (CAR) is integrated at a TCR locus thereby preventing the expression of the endogenous TCR sequences.
- 13) The method according to any one of claims 1 to 12, wherein said primary T-cells are human primary T-cells.
- 14) An engineered T-cell obtained by the method of any of claims 1 to 13.
- 15) An engineered T-cell, which comprises an exogenous sequence encoding HLA-E and/or HLA-G integrated at the  $\beta 2m$  locus, resulting in the expression of a fusion of a HLA-E and/or HLA-G with  $\beta 2m$  fragments.
- 16) The engineered T-cell according to claims 14 or 15, wherein said T- cell is endowed with a chimeric antigen receptor, and optionally having a genotype  $[TCR]^{neg}[\beta 2m]^{neg}$ .
- 17) The engineered T-cell according to claim 16, wherein the exogenous sequence encoding said CAR has been integrated at a TCR locus.
- 18) The engineered T-cell according to any one of claims 14 to 17, wherein said T-cell is a primary cell.
- 19) Use of an engineered T-cell according to any one of claims 14 to 18, in the manufacture of a medicament for the treatment of cancer or an infection.
- 20) A method for the treatment of cancer or an infection in a subject, comprising administering to said subject an engineered T-cell according to any one of claims 14 to 18.

**Collectis**

**Patent Attorneys for the Applicant/Nominated Person**

**SPRUSON & FERGUSON**




Figure 1




Figure 2




Figure 3

+ TALEN® TRAC  
+ TALEN® PD1  
+ CARm  
+IL15m-PD1

**B**




Figure 3 (cont.)

+ TALEN® TRAC  
+ TALEN® CD25  
+ CARm  
+IL15m-CD25

**C**




Figure 3 (cont.)




Figure 4




Figure 5




Figure 5 (cont.)

**LNGFR expression  
+ TALEN® TRAC and TALEN® CD25**




Figure 5 (cont.)

**LNGFR expression  
+ TALEN® TRAC and TALEN® CD25**




Figure 6

**LNGFR expression  
+ TALEN® TRAC and TALEN® CD25**




Figure 6 (cont.)

**LNGFR expression  
+ TALEN® TRAC and TALEN® CD25**




Figure 6 (cont.)

# Endogenous CD25 expression

+ TALEN® TRAC and TALEN® CD25




Figure 7

# Endogenous CD25 expression + TALEN® TRAC and TALEN® CD25




Figure 7 (cont.)

Endogenous CD25 expression  
+ TALEN® TRAC and TALEN® CD25




Figure 7 (cont.)

# Endogenous CD25 expression + TALEN® TRAC and TALEN® CD25




Figure 8

# Endogenous CD25 expression + TALEN® TRAC and TALEN® CD25




Figure 8 (cont.)

# Endogenous CD25 expression + TALEN® TRAC and TALEN® CD25




Figure 8 (cont.)




Figure 9




Figure 10




Figure 10 (cont.)

LNGFR expression  
+ TALEN® TRAC and TALEN® PD1




Figure 10 (cont.)





Figure 11

LNGFR expression  
+ TALEN® TRAC and TALEN® PD1

CARm + IL-15m-PD1

CARm

Anti CD3/CD28 activation



LNGFR expression  
+ TALEN® TRAC and TALEN® PD1

CARm + IL-15m-PD1

CARm

Raji tumor cells activation




Figure 11 (cont.)

# PD1 expression




Figure 12

PD1 expression

+ TALEN® TRAC and TALEN® PD1

No TALEN®

Anti CD3/CD28 activation




Figure 12 (cont.)

# PD1 expression

+ TALEN® TRAC and TALEN® PD1

No TALEN®

## Raji tumor cells activation




Figure 12 (cont.)




Figure 13




Figure 14




Figure 15



**A****B**

Figure 16




Figure 17




Figure 18




Figure 19




Figure 20

Figure 21

TRAC TALEN®+CAR




Figure 21 (cont.)

TRAC TALEN®+CAR





Figure 21 (cont.)

TRAC TALEN®+CAR



## SEQUENCE LISTING

&lt;110&gt; Cellectis

&lt;120&gt; TARGETED GENE INTEGRATION OF NK INHIBITORS GENES FOR IMPROVED IMMUNE CELLS THERAPY

&lt;130&gt; P81604915PCT02

&lt;150&gt; PCT/EP2017/076798

&lt;151&gt; 2017-10-19

&lt;150&gt; PCT/EP2018/053343

&lt;151&gt; 2018-02-09

&lt;160&gt; 90

&lt;170&gt; PatentIn version 3.5

&lt;210&gt; 1

&lt;211&gt; 1000

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; PD1 left homology

&lt;400&gt; 1

ccaagccctg	accctggcag	gcatatgttt	caggaggtcc	ttgtcttggg	agcccagggt	60
cgggggcccc	gtgtctgtcc	acatccgagt	caatggccca	tctcgtctct	gaagcatctt	120
tgctgtgagc	tctagtcccc	actgtcttgc	tggaaaatgt	ggaggcccca	ctgcccactg	180
cccagggcag	caatgccccat	accacgtggg	cccagctccg	agcttgtcct	gaaaaggggg	240
caaagactgg	accctgagcc	tgccaagggg	ccacactcct	cccagggtg	gggtctccat	300
gggcagcccc	ccaccacccc	agaccagtta	cactccccctg	tgccagagca	gtgcagacag	360
gaccaggcca	ggatgcccga	gggtcagggg	ctggggatgg	gtagcccca	aacagccctt	420
tctgggggaa	ctggcctcaa	cggggaaggg	ggtgaaggct	cttagtagga	aatcaggagg	480
acccaagtca	gagccagggtg	ctgtgcagaa	gctgcagcct	cacgtagaag	gaagaggctc	540
tgcagtggag	gccagtgtccc	atccccgggt	ggcagaggcc	ccagcagaga	cttctcaatg	600
acattccagc	tgggggtggcc	cttccagagc	ccttgctgcc	cgagggatgt	gagcagggtg	660
ccggggaggc	tttgtggggc	cacccagccc	cttcctcacc	tctctccatc	tctcagactc	720
cccagacagg	ccctggaacc	ccccacctt	ctccccagcc	ctgctcgtgg	tgaccgaagg	780
ggacaacgcc	accttcacct	gcagcttctc	caacacatcg	gagagcttcg	tgctaaactg	840
gtaccgcatg	agccccagca	accagacgga	caagctggcc	gccttccccg	aggaccgcag	900
ccagcccggc	caggactgcc	gcttccgtgt	cacacaactg	cccaacgggc	gtgacttcca	960
catgagcgtg	gtcagggccc	ggcgcaatga	cagcggcacc			1000

eolf-seql (10).txt

<210> 2

<211> 1000

<212> DNA

<213> artificial sequence

<220>

<223> PD1 right homology

<400> 2

gcctgcgggc	agagctcagg	gtgacaggtg	cggcctcgga	ggccccgggg	caggggtgag	60
ctgagccggg	cctgggggtg	gtgtcccctc	ctgcacagga	tcaggagctc	cagggtcgta	120
gggcagggac	ccccagctc	cagtccagg	ctctgtcctg	cacctgggga	atgggtgaccg	180
gcatctctgt	cctctagctc	tggaagcacc	ccagcccctc	tagtctgccc	tcaccctga	240
ccctgaccct	ccaccctgac	cccgtcctaa	cccctgacct	ttgtgccctt	ccagagagaa	300
gggcagaagt	gcccacagcc	caccccagcc	cctcaccag	gccagccggc	cagttccaaa	360
ccctgggtgg	tggtgtcgtg	ggcggcctgc	tgggcagcct	ggtgctgcta	gtctgggtcc	420
tggccgtcat	ctgtctccgg	gccgcacgag	gtaacgtcat	cccagcccct	cggcctgccc	480
tgccctaacc	ctgtggcgg	ccctcactcc	cgcctcccct	tcctccacc	ttccctcacc	540
ccaccccacc	tcccccatc	tccccgccag	gctaagtccc	tgatgaaggc	ccctggacta	600
agacccccca	cctaggagca	cggctcagg	tcggcctggg	gaccccaagt	gtgtttctct	660
gcagggacaa	taggagccag	gcgcaccggc	cagcccctgg	tgagtctcac	tcttttctctg	720
catgatccac	tgtgccttcc	ttcctgggtg	ggcagagggtg	gaaggacagg	ctgggaccac	780
acggcctgca	ggactcacat	tctattatag	ccaggacccc	acctccccag	ccccagggca	840
gcaacctcaa	tccctaaagc	catgatctgg	ggccccagcc	cacctgcggg	ctccgggggt	900
gcccggccca	tgtgtgtgcc	tgcctgcggg	ctccaggggt	gcctggccca	cgcgtgtgcc	960
cgcctgcggg	ctctgggggt	gcccggccca	catatgtgcc			1000

<210> 3

<211> 2781

<212> DNA

<213> artificial sequence

<220>

<223> PD1\_T3C-L2

<400> 3

atgggcgatc	ctaaaaagaa	acgtaaggct	atcgatatcg	ccgatctacg	cacgctcggc	60
tacagccagc	agcaacagga	gaagatcaaa	ccgaagggtc	gttcgacagt	ggcgcagcac	120
cacgaggcac	tggtcggcca	cgggtttaca	cacgcgcaca	tcgttgcggt	aagccaacac	180
ccggcagcgt	tagggaccgt	cgctgtcaag	tatcaggaca	tgatcgagc	gttgccagag	240
gcgacacacg	aagcgatcgt	tggcgtcggc	aaacagtggg	ccggcgcacg	cgctctggag	300
gccttgctca	cgggtggcggg	agagttgaga	ggtccaccgt	tacagttgga	cacaggccaa	360
cttctcaaga	ttgcaaaacg	tggcggcggt	accgcagtgg	aggcagtgca	tgcatggcgc	420
aatgcactga	cgggtgcccc	gctcaacttg	acccccgagc	aagtgggtggc	tatcgcttcc	480
aagctggggg	gaaagcaggc	cctggagacc	gtccaggccc	ttctcccagt	gctttgccag	540

eolf-seql (10).txt

gctcacggac	tgacccctga	acaggtgggtg	gcaattgcct	cacacgacgg	gggcaagcag	600
gcaactggaga	ctgtccagcg	gctgctgcct	gtcctctgcc	aggccacagg	actcactcct	660
gagcaggtcg	tggccattgc	cagccacgat	gggggcaaac	aggctctgga	gaccgtgcag	720
cgcctcctcc	cagtgtgtg	ccaggctcat	gggctgacct	cacagcaggt	cgtcgccatt	780
gccagtaacg	gcggggggaa	gcaggccctc	gaaacagtgc	agaggctgct	gcccgtcttg	840
tgccaagcac	acggcctgac	acccgagcag	gtggtggcca	tcgcctctca	tgacggcggc	900
aagcaggccc	ttgagacagt	gcagagactg	ttgcccgtgt	tgtgtcaggc	ccacgggttg	960
acaccccagc	aggtggctgc	catcgccagc	aatggcgggg	gaaagcaggc	ccttgagacc	1020
gtgcagcggg	tgcttccagt	gttgtgccag	gcacacggac	tgacccctca	acaggtgggtc	1080
gcaatcgcca	gctacaaggg	cggaaagcag	gctctggaga	cagtgcagcg	cctcctgccc	1140
gtgctgtgtc	aggctcacgg	actgacacca	cagcaggtgg	tcgccatcgc	cagtaacggg	1200
ggcggcaagc	aggctttgga	gaccgtccag	agactcctcc	ccgtcctttg	ccaggccac	1260
gggttgacac	ctcagcaggt	cgtcgccatt	gcctccaaca	acgggggcaa	gcaggccctc	1320
gaaactgtgc	agaggctgct	gcctgtgctg	tgccaggctc	atgggctgac	acccagcag	1380
gtggtggcca	ttgcctctaa	caacggcggc	aaacaggcac	tggagaccgt	gcaaaggctg	1440
ctgcccgtcc	tctgccaagc	ccacgggctc	actccacagc	aggctcgtggc	catcgctca	1500
aacaatggcg	ggaagcaggc	cctggagact	gtgcaaaggc	tgctccctgt	gctctgccag	1560
gcacacggac	tgacccctca	gcaggtgggtg	gcaatcgctt	ccaacaacgg	gggaaagcag	1620
gccctcgaaa	ccgtgcagcg	cctcctccca	gtgctgtgcc	aggcacatgg	cctcacaccc	1680
gagcaagtgg	tggctatcgc	cagccacgac	ggagggaagc	aggctctgga	gaccgtgcag	1740
aggctgtgc	ctgtcctgtg	ccaggccac	gggcttactc	cagagcaggt	cgtcgccatc	1800
gccagtcag	atggggggaa	gcaggccctt	gagacagtcc	agcggctgct	gccagtcctt	1860
tgccaggctc	acggcttgac	tcccagcag	gtcgtggcca	ttgcctcaaa	cattgggggc	1920
aaacaggccc	tggagacagt	gcaggccctg	ctgcccgtgt	tgtgtcaggc	ccacggcttg	1980
acaccccagc	aggtggctgc	cattgcctct	aatggcggcg	ggagaccgc	cctggagagc	2040
attgttgccc	agttatctcg	ccctgatccg	gcgttgggcg	cgttgaccaa	cgaccacctc	2100
gtgccttg	cctgcctcgg	cgggcgtcct	gcgctggatg	cagtgaaaaa	gggattgggg	2160
gatcctatca	gccgttccca	gctgggtgaag	tccgagctgg	aggagaagaa	atccgagttg	2220
aggcacaagc	tgaagtacgt	gccccacgag	tacatcgagc	tgatcgagat	cgcccggaac	2280
agcaccacag	accgtatcct	ggagatgaag	gtgatggagt	tcttcatgaa	ggtgtacggc	2340
tacaggggca	agcacctggg	cggctccagg	aagcccagc	gcgccatcta	caccgtgggc	2400
tccccatcg	actacggcgt	gatcgtggac	accaaggcct	actccggcgg	ctacaacctg	2460
cccacggcc	aggccgacga	aatgcagagg	tacgtggagg	agaaccagac	caggaacaag	2520
cacatcaacc	ccaacgagtg	gtggaagggtg	taccctcca	gcgtgaccga	gttcaagttc	2580
ctgttcgtgt	ccggccactt	caagggaac	tacaaggccc	agctgaccag	gctgaaccac	2640
atcaccaact	gcaacggcgc	cgtgctgtcc	gtggaggagc	tcctgatcgg	cggcgagatg	2700
atcaaggccg	gcacccctgac	cctggaggag	gtgaggagga	agttcaacaa	cggcgagatc	2760
aacttcgcgg	ccgactgata	a				2781

<210> 4

<211> 2778

<212> DNA

<213> artificial sequence

<220>

<223> PD1T3R

eolf-seql (10).txt

<400> 4

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgatatcg	ccgatctacg	cacgctcggc	60
tacagccagc	agcaacagga	gaagatcaaa	ccgaaggttc	gttcgacagt	ggcgcagcac	120
cacgaggcac	tggtcggcca	cgggtttaca	cacgcgcaca	tcgttgcggt	aagccaacac	180
ccggcagcgt	tagggaccgt	cgctgtcaag	tatcaggaca	tgatcgagc	gttgccagag	240
gcgacacacg	aagcgatcgt	tggcgtcggc	aaacagtggg	ccggcgcacg	cgctctggag	300
gccttgctca	cgggtggcggg	agagttgaga	gggtccaccgt	tacagttgga	cacaggccaa	360
cttctcaaga	ttgcaaaacg	tggcggcgtg	accgcagtgg	aggcagtgca	tgcatggcgc	420
aatgcactga	cgggtgcccc	gctcaacttg	acccccgagc	aagtcgtcgc	aatcgccagc	480
catgatggag	ggaagcaagc	cctcgaaacc	gtgcagcggg	tgcttcctgt	gctctgccag	540
gcccacggcc	ttaccctca	gcaggtgggtg	gccatcgcaa	gtaacggagg	aggaaagcaa	600
gccttgagaga	cagtgcagcg	cctgttgccc	gtgctgtgcc	aggcacacgg	cctcacacca	660
gagcaggtcg	tggccattgc	ctcccatgac	ggggggaaac	aggctctgga	gaccgtccag	720
aggctgctgc	ccgtcctctg	tcaagctcac	ggcctgactc	ccaacaagt	ggtcgccatc	780
gcctctaattg	gcggcgggaa	gcaggcactg	gaaacagtgc	agagactgct	ccctgtgctt	840
tgccaagctc	atgggttgac	cccccaacag	gtcgtcgcta	ttgcctcaaa	cggggggggc	900
aagcaggccc	ttgagactgt	gcagaggctg	ttgccagtgc	tgtgtcaggc	tcacgggctc	960
actccacaac	aggtggctgc	aattgccagc	aacggcggcg	gaaagcaagc	tcttgaaacc	1020
gtgcaacgcc	tcctgcccgt	gctctgtcag	gctcatggcc	tgacaccaca	acaagtcgtg	1080
gccatcgcca	gtaataatgg	cgggaaacag	gctcttgaga	ccgtccagag	gctgctccca	1140
gtgctctgcc	aggcacacgg	gctgaccccc	gagcaggtgg	tggctatcgc	cagcaatatt	1200
gggggcaagc	aggccctgga	aacagtccag	gccctgctgc	cagtgccttg	ccaggctcac	1260
gggctcactc	cccagcaggt	cgtggcaatc	gcctccaacg	gcggagggaa	gcaggctctg	1320
gagaccgtgc	agagactgct	gcccgtcttg	tgccaggccc	acggactcac	acctgaacag	1380
gtcgtcgcca	ttgcctctca	cgatgggggc	aaacaagccc	tggagacagt	gcagcggctg	1440
ttgcctgtgt	tgtgccaagc	ccacggcttg	actcctcaac	aagtggctgc	catcgctca	1500
aatggcggcg	gaaaacaagc	tctggagaca	gtgcagaggt	tgtgcccgt	cctctgcca	1560
gcccacggcc	tgactcccca	acaggtcgtc	gccattgcca	gcaacaacgg	aggaaagcag	1620
gctctcgaaa	ctgtgcagcg	gctgcttcct	gtgctgtgtc	aggctcatgg	gctgaccccc	1680
gagcaagtgg	tggctattgc	ctctaattgga	ggcaagcaag	cccttgagac	agtccagagg	1740
ctgttgccag	tgctgtgcca	ggccacggg	ctcacacccc	agcaggtggg	cgccatcgcc	1800
agtaacaacg	ggggcaaaca	ggcattggaa	accgtccagc	gcctgcttcc	agtgtctgtc	1860
caggcacacg	gactgacacc	cgaacaggtg	gtggccattg	catcccatga	tgggggcaag	1920
caggccctgg	agaccgtgca	gagactcctg	ccagtgttgt	gccaagctca	cggcctcacc	1980
cctcagcaag	tcgtggccat	cgcctcaaac	ggggggggcc	ggcctgcact	ggagagcatt	2040
gttgcccagt	tatctcgccc	tgatccggcg	ttggccgcgt	tgaccaacga	ccacctcgtc	2100
gccttgggcct	gcctcggcgg	gcgtcctgcg	ctggatgcag	tgaaaaaggg	attgggggat	2160
cctatcagcc	gttcccagct	ggtgaagtcc	gagctggagg	agaagaaatc	cgagttgagg	2220
cacaagctga	agtacgtgcc	ccacgagtac	atcgagctga	tcgagatcgc	ccggaacagc	2280
accaggacc	gtatcctgga	gatgaaggtg	atggagttct	tcatgaaggt	gtacggctac	2340
aggggcaagc	acctgggcgg	ctccaggaag	cccgcggcg	ccatctacac	cgtgggctcc	2400
cccacgact	acggcgtgat	cgtggacacc	aaggcctact	ccggcggcta	caacctgccc	2460
atcggccagg	ccgacgaaat	gcagaggtac	gtggaggaga	accagaccag	gaacaagcac	2520
atcaacccca	acgagtgggtg	gaaggtgtac	ccctccagcg	tgaccgagtt	caagttcctg	2580
ttcgtgtccg	gccacttcaa	gggcaactac	aaggcccagc	tgaccaggct	gaaccacatc	2640
accaactgca	acggcgccgt	gctgtccgtg	gaggagctcc	tgatcggcgg	cgagatgatc	2700
aaggccggca	ccctgaccct	ggaggaggtg	aggaggaagt	tcaacaacgg	cgagatcaac	2760

ttcgcggccg actgataa

2778

&lt;210&gt; 5

&lt;211&gt; 49

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; PD1-T3

&lt;400&gt; 5

tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagaga

49

&lt;210&gt; 6

&lt;211&gt; 60

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; 2A-element

&lt;400&gt; 6

tccggtgagg gcagaggaag tcttctaaca tgcggtgacg tggaggagaa tccgggcccc

60

&lt;210&gt; 7

&lt;211&gt; 1989

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; apoptosis CAR

&lt;400&gt; 7

gctttgcctg	tactgcctt	gctgcttcca	cttgctctgt	tgttgacgc	cgcaagaccc	60
gaggtcaagc	tccaggaaag	cggaccaggg	ctggtggccc	ctagtcagtc	attgagcgtc	120
acttgacccg	tcagcggcgt	gtctctgccc	gattacggcg	tgagctggat	cagacagccc	180
ccaaggaagg	gactggagt	gctgggcgtc	atctggggga	gcgagactac	ctactacaac	240
agcgccctga	agagcaggct	gaccatcatt	aaggacaact	ccaagtccca	ggtctttctg	300
aaaatgaaca	gcctgcagac	tgatgacact	gccatctact	actgcgcca	gcattactac	360
tacgggggca	gctacgctat	ggactactgg	gggcagggga	cctctgtcac	agtgtaagt	420
ggcggaggag	gcagtggcgg	agggggaagt	gggggcggcg	gcagcgacat	ccagatgacc	480
cagacaacat	ccagcctctc	cgctctctg	ggcgacagag	tgacaatcag	ctgccgggcc	540

eolf-seql (10).txt

agtcaggaca	tcagcaagta	tctcaattgg	taccagcaga	aaccagacgg	gacagtga	600
ttgctgatct	accacacatc	caggctgcac	tcaggagtcc	ccagcagggt	ttccggctcc	660
ggctccggga	cagattacag	tctgaccatt	tccaacctgg	agcaggagga	tattgccaca	720
tacttttgcc	agcaaggcaa	cactctgccc	tataccttcg	gcggaggcac	aaaactggag	780
attactcggg	cggatcccga	gccccaatct	cctgacaaaa	ctcacacatg	cccaccgtgc	840
ccagcacctc	ccgtggccgg	cccgtcagtg	ttcctcttcc	ccccaaaacc	caaggacacc	900
ctcatgatcg	cccggacccc	tgaggtcaca	tgctgtgggg	tggacgtgag	ccacgaggac	960
cctgagggtca	agttcaactg	gtacgtggac	ggcgtggagg	tgcataatgc	caagacaaag	1020
ccgcggggagg	agcagtacaa	cagcacgtac	cgtgtgggtca	gcgtcctcac	cgtcctgcac	1080
caggactggc	tgaatggcaa	ggagtacaag	tgcaagggtgt	ccaacaaagc	cctcccagcc	1140
cccacgcaga	aaaccatctc	caaagccaaa	gggcagcccc	gagaaccaca	ggtgtacacc	1200
ctgcccccat	cccgggatga	gctgaccaag	aaccagggtca	gcctgacctg	cctggtcaaa	1260
ggcttctatc	ccagcgacat	cgccgtggag	tgggagagca	atgggcaacc	ggagaacaac	1320
tacaagacca	cgctccccgt	gctggactcc	gacggctcct	tcttcctcta	cagcaagctc	1380
accgtggaca	agagcagggtg	gcagcagggg	aacgtgttct	catgctccgt	gatgcatgag	1440
gccctgcaca	atcactatac	ccagaaatct	ctgagtctga	gcccaggcaa	gaaggatatt	1500
ttgggggtggc	tttgccttct	tcttttgcca	attccactaa	ttgtttgggt	gaagagaaaag	1560
gaagtacaga	aaacatgcag	aaagcacaga	aaggaaaacc	aaggttctca	tgaatctcca	1620
accttaaatac	ctgaaacagt	ggcaataaat	ttatctgatg	ttgacttgag	taaatatatc	1680
accactattg	ctggagtcac	gacactaagt	caagttaaag	gctttgttcg	aaagaatggt	1740
gtcaatgaag	ccaaaataga	tgagatcaag	aatgacaatg	tccaagacac	agcagaacag	1800
aaagttcaac	tgcttcgtaa	ttggcatcaa	cttcatggaa	agaaagaagc	gtatgacaca	1860
ttgattgcag	atctcaaaaa	agccaatctt	tgtactcttg	cagagaaaat	tcagactatc	1920
atcctcaagg	acattactag	tgactcagaa	aattcaaact	tcagaaatga	aatccagagc	1980
ttggtcgaa						1989

<210> 8

<211> 276

<212> DNA

<213> artificial sequence

<220>

<223> BGH polyA

<400> 8

tctagagggc	ccgttttaaac	ccgctgatca	gcctcgactg	tgctttctag	ttgccagcca	60
tctgttgttt	gccccctccc	cgtgccttcc	ttgaccctgg	aagggtgccac	tcccactgtc	120
ctttccta	aaaatgagga	aattgcatcg	cattgtctga	gtaggtgtca	ttctattctg	180
gggggtgggg	tggggcagga	cagcaagggg	gaggattggg	aagacaatag	caggcatgct	240
ggggatgcgg	tgggctctat	gactagtggc	gaattc			276

<210> 9

<211> 1000

<212> DNA

eolf-seql (10).txt

<213> artificial sequence

<220>

<223> Lck left homology

<400> 9

gggatagggg	gtgcctctgt	gtgtgtgtgt	gagagtgtgt	gtgtgtaggg	tgtgtatatg	60
tataggggtg	gtgtgagtg	gtgtgtgtga	gagagtgtgt	gtgtggcaga	atagactgcg	120
gaggtggatt	tcatcttgat	atgaaaggct	tggaatgcat	ggtacattaa	actttgagga	180
cagcgctttc	caagcactct	gaggagcagc	cctagagaag	gaggagctgc	agggactccg	240
ggggcttcaa	agtgagggcc	ccactctgct	tcaggcaaaa	caggcacaca	tttatcactt	300
tatctatgga	gttctgcttg	atttcatcag	acaaaaaatt	tccactgcta	aaacaggcaa	360
ataaacaaaa	aaaaagttat	ggccaacaga	gtcactggag	ggttttctgc	tggggagaag	420
caagcccgtg	tttgaaggaa	ccctgtgaga	tgactgtggg	ctgtgtgagg	ggaacagcgg	480
gggcttgatg	gtggacttcg	ggagcagaag	cctctttctc	agcctcctca	gctagacagg	540
ggaattataa	taggaggtgt	ggcgtgcaca	cctctccagt	aggggagggg	ctgataagtc	600
aggtctctcc	caggcttggg	aaagtgtgtg	tcatctctag	gaggtggtcc	tcccaacaca	660
gggtactggc	agagggagag	ggagggggca	gaggcaggaa	gtgggtaact	agactaacia	720
aggtgcctgt	ggcggtttgc	ccatcccagg	tgggaggggt	gggctagggc	tcaggggccg	780
tgtgtgaatt	tacttgtagc	ctgagggctc	agagggagca	ccggtttgga	gctgggaccc	840
cctattttag	cttttctgtg	gctggtgaat	ggggatccca	ggatctcaca	atctcaggta	900
cttttggaac	tttccagggc	aaggcccat	tatatctgat	gttgggggag	cagatcttgg	960
gggagcccct	tcagccccct	cttcattcc	ctcagggacc			1000

<210> 10

<211> 219

<212> PRT

<213> artificial sequence

<220>

<223> Interleukin-12 subunit alpha

<400> 10

Met	Cys	Pro	Ala	Arg	Ser	Leu	Leu	Leu	Val	Ala	Thr	Leu	Val	Leu	Leu
1				5					10					15	
Asp	His	Leu	Ser	Leu	Ala	Arg	Asn	Leu	Pro	Val	Ala	Thr	Pro	Asp	Pro
		20					25						30		
Gly	Met	Phe	Pro	Cys	Leu	His	His	Ser	Gln	Asn	Leu	Leu	Arg	Ala	Val
	35					40						45			
Ser	Asn	Met	Leu	Gln	Lys	Ala	Arg	Gln	Thr	Leu	Glu	Phe	Tyr	Pro	Cys
50						55					60				

eolf-seql (10).txt

Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys Thr Ser  
65 70 75 80

Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu Ser Cys  
85 90 95

Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys Leu Ala  
100 105 110

Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser Ile Tyr  
115 120 125

Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn Ala Lys  
130 135 140

Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn Met Leu  
145 150 155 160

Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser Glu Thr  
165 170 175

Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys Thr Lys  
180 185 190

Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala Val Thr  
195 200 205

Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser  
210 215

<210> 11

<211> 328

<212> PRT

<213> artificial sequence

eolf-seql (10).txt

<220>

<223> Interleukin-12 subunit beta

<400> 11

Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu  
1 5 10 15

Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val  
20 25 30

Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu  
35 40 45

Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln  
50 55 60

Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys  
65 70 75 80

Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val  
85 90 95

Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp  
100 105 110

Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe  
115 120 125

Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp  
130 135 140

Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg  
145 150 155 160

Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser  
165 170 175

eolf-seql (10).txt

Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu  
180 185 190

Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile  
195 200 205

Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr  
210 215 220

Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn  
225 230 235 240

Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp  
245 250 255

Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr  
260 265 270

Phe Cys Val Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg  
275 280 285

Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala  
290 295 300

Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser  
305 310 315 320

Glu Trp Ala Ser Val Pro Cys Ser  
325

<210> 12

<211> 1000

<212> DNA

<213> artificial sequence

<220>

<223> lck right homology

eolf-seql (10).txt

<400> 12

ggctgtggct	gcagctcaca	cccggaagat	gactggatgg	aaaacatcga	tgtgtgtgag	60
aactgccatt	atcccatagt	cccactggat	ggcaagggca	cggtaagagg	cgagacaggg	120
gccttggtga	gggagttggg	tagagaatgc	aaccacaggag	aaagaaatga	ccagcactac	180
aggcccttga	aagaatagag	tggccctctc	ccctgaaata	cagaaaggaa	aagaggccca	240
gagaggggaa	gggaatctcc	taagatcaca	cagaaagtag	ttggtaaact	cagggataac	300
atctaaccag	gctggagagg	ctgagagcag	agcagggggg	aagggggcca	gggtctgacc	360
caatcttctg	ctttctgacc	ccaccctcat	ccccactcc	acagctgctc	atccgaaatg	420
gctctgaggt	gcgggaccca	ctggttacct	acgaaggctc	caatccgccg	gcttccccac	480
tgcaaggtga	ccccaggcag	cagggcctga	aagacaaggc	ctgcggatcc	ctggctgttg	540
gcttccacct	ctccccacc	tactttctcc	ccggtcttgc	cttccttgct	ccccaccctg	600
taactccagg	cttcctgccg	atcccagctc	ggttctccct	gatgcccctt	gtctttacag	660
acaacctggg	tatcgctctg	cacagctatg	agccctctca	cgacggagat	ctgggctttg	720
agaaggggga	acagctccgc	atcctggagc	agtgagtcct	tctccacctt	gctctggcgg	780
agtccgtgag	ggagcggcga	tctccgcgac	ccgcagccct	cctgcggccc	ttgaccagct	840
cgggggtggc	gcccttggga	caaaattcga	ggctcagtat	tgctgagcca	gggttggggg	900
aggctggctt	aaggggtgga	ggggtctttg	agggagggtc	tcaggtcgac	ggctgagcga	960
gccacactga	cccacctccg	tggcgcagga	gcggcgagtg			1000

<210> 13

<211> 1992

<212> DNA

<213> artificial sequence

<220>

<223> apoptosis CAR

<400> 13

atggctttgc	ctgtcactgc	cttgctgctt	ccacttgctc	tgttgttgca	cgccgcaaga	60
cccgaggtca	agctccagga	aagcggacca	gggctggtgg	cccctagtca	gtcattgagc	120
gtcacttgca	ccgtcagcgg	cgtgtctctg	cccgattacg	gcgtgagctg	gatcagacag	180
cccccaagga	agggactgga	gtggctgggc	gtcatctggg	ggagcagagc	tacctactac	240
aacagcgccc	tgaagagcag	gctgaccatc	attaaggaca	actccaagtc	ccaggtcttt	300
ctgaaaaatga	acagcctgca	gactgatgac	actgccatct	actactgcgc	caagcattac	360
tactacgggg	gcagctacgc	tatggactac	tgggggcagg	ggacctctgt	cacagtgtca	420
agtggcggag	gaggcagtgg	cggaggggga	agtgggggcg	gcggcagcga	catccagatg	480
accagacaaa	catccagcct	ctccgcctct	ctgggcgaca	gagtgacaat	cagctgccgg	540
gccagtcagg	acatcagcaa	gtatctcaat	tggtaccagc	agaaaccaga	cgggacagtg	600
aaattgctga	tctaccacac	atccaggctg	cactcaggag	tccccagcag	gttttccggc	660
tccggctccg	ggacagatta	cagtctgacc	atttccaacc	tggagcagga	ggatattgcc	720
acatactttt	gccagcaagg	caacactctg	ccctatacct	tcggcggagg	cacaaaactg	780
gagattactc	ggtcggatcc	cgagcccaaa	tctcctgaca	aaactcacac	atgccaccg	840
tgcccagcac	ctcccgtggc	cggcccgtca	gtgttctctt	tcccccaaaa	acccaaggac	900
accctcatga	tcgcccggac	ccctgaggtc	acatgcgtgg	tggtggacgt	gagccacgag	960
gacctgagg	tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	1020
aagccgcggg	aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	1080

eolf-seql (10).txt

caccaggact	ggctgaatgg	caaggagtag	aagtgcgaagg	tgtccaacaa	agccctccca	1140
gcccccatcg	agaaaacat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	1200
accctgcccc	catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	1260
aaaggcttct	atcccagcga	catcgccgtg	gagtgggaga	gcaatgggca	accggagAAC	1320
aactacaaga	ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	1380
ctcaccgtgg	acaagagcag	gtggcagcag	gggaacgtgt	tctcatgctc	cgtgatgcat	1440
gaggccctgc	acaatcacta	taccagaaa	tctctgagtc	tgagcccagg	caagaaggat	1500
attttggggt	ggctttgcct	tcttcttttg	ccaattccac	taattgtttg	ggtgaagaga	1560
aaggaaagtac	agaaaacatg	cagaaagcac	agaaaggaaa	accaaggttc	tcatgaatct	1620
ccaaccttaa	atcctgaaac	agtggcaata	aatttatctg	atgttgactt	gagtaaataat	1680
atcaccacta	ttgctggagt	catgacacta	agtcaagtta	aaggctttgt	tcgaaagaat	1740
ggtgtcaatg	aagccaaaat	agatgagatc	aagaatgaca	atgtccaaga	cacagcagaa	1800
cagaaagttc	aactgcttcg	taattggcat	caacttcatg	gaaagaaaga	agcgtatgac	1860
acattgattg	cagatctcaa	aaaagccaat	ctttgtactc	ttgcagagaa	aattcagact	1920
atcatcctca	aggacattac	tagtgactca	gaaaattcaa	acttcagaaa	tgaaatccag	1980
agcttggtcg	aa					1992

<210> 14

<211> 1000

<212> DNA

<213> artificial sequence

<220>

<223> Lck left homology

<400> 14

ctcataacaa	ttctatgagg	taggaacagt	tatttactct	attttcctaaa	taaggaaact	60
gggctcgccc	aaggttccac	aactaacatg	tgtgtattat	tgagcattta	atttacacca	120
gggaagcagg	ttgtgggtgt	gtgcacctgt	tgtccagcta	tttaggaggc	tgaggtgaaa	180
ggatcacttg	aacggaggag	ttcaaatttg	caatgtgcta	tgattgtgcc	tgtgaacagc	240
tgctgcactc	cagcctgggc	aacatagtga	gatcccttat	ctaaaacatt	ttttttaagt	300
aaataatcag	gtgggcacgg	tggctcacgc	ctgtaatcca	gcactttggg	aggctgaggc	360
gggcggatca	cctgagggtca	ggagttcaag	accagcctga	ccaacatgga	gaaaccgctc	420
tctactaaaa	atacaaaatt	agcttggcgt	ggtggtgcat	gcctgtaatc	ccagctactc	480
gagaagctga	ggcaggagaa	ttgtttgaac	ctgggagggtg	gaggttgcgg	tgagccgaga	540
tcgcaccatt	gcactccagc	ctgggcaaca	agagtgaat	tgcatctcaa	aaaaaaagaa	600
aaggaaaataa	tctataaccag	gcactccaag	tggtgtgact	gatattcaac	aagtacctct	660
agtgtgacct	taccattgat	gaagaccaag	attcttttgg	attggtgctc	acactgtgcc	720
agttaaatat	tccgaacatt	acccttgccct	gtgggcttcc	agtgcctgac	cttgatgtcc	780
tttcacccat	caacccttag	ggatgaccaa	cccggagggtg	attcagaacc	tgagcgagg	840
ctaccgcatg	gtgcgccctg	acaactgtcc	agaggagctg	taccaactca	tgaggctgtg	900
ctggaaggag	cgcccagagg	accggccac	ctttgactac	ctgcgcagtg	tgctggagga	960
cttcttcacg	gccacagagg	gccagtacca	gcctcagcct			1000

<210> 15

eolf-seql (10).txt

<211> 1000  
<212> DNA  
<213> artificial sequence

<220>  
<223> lck right homology

<400> 15  
gaggccttga gaggccctgg ggttctcccc ctttctctcc agcctgactt ggggagatgg 60  
agttcttgtg ccatagtcac atggcctatg cacatatgga ctctgcacat gaatcccacc 120  
cacatgtgac acatatgcac cttgtgtctg tacacgtgtc ctgtagttgc gtggactctg 180  
cacatgtctt gtacatgtgt agcctgtgca tgtatgtctt ggacactgta caaggtaccc 240  
ctttctggct ctcccatttc ctgagaccac agagagaggg gagaagcctg ggattgacag 300  
aagcttctgc ccacctactt ttctttcctc agatcatcca gaagttcctc aagggccagg 360  
actttatcta atacctctgt gtgctcctcc ttgggtgcctg gcctggcaca catcaggagt 420  
tcaataaatg tctgttgatg actgttgtag atctctttgc tgtccactct ttgtgggtgg 480  
gcagtggggg ttaagaaaat ggtaattagg tcaccctgag ttggggtgaa agatgggatg 540  
agtggatgtc tggaggctct gcagaccctc tcaaatggga cagtgtcctc caccctccc 600  
caaaggattc agggtgactc ctacctggaa tcccttaggg aatgggtgcg tcaaaggacc 660  
ttcctcccca ttataaaaagg gcaacagcat tttttactga ttcaagggtc atatttgacc 720  
tcagattttg tttttttaag gctagtcaaa tgaagcggcg ggaatggagg aggaacaaat 780  
aaatctgtaa ctatcctcag attttttttt ttttttgaga ctgggtctca ctttttcatt 840  
caggctggag tgcagtcgca tgatcacggc tcactgtagc ctcaacctct ccagctcaaa 900  
tgctcctcct gtctcagcct cccgagtacc tgggactact ttcttgaggc caggaattca 960  
agaacagagt aagatcctgg tctccaaaaa aagttttaaa 1000

<210> 16  
<211> 936  
<212> PRT  
<213> artificial sequence

<220>  
<223> TALEN TRAC

<400> 16  
Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
1 5 10 15  
  
Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
20 25 30  
  
Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
35 40 45

eolf-seql (10).txt

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
50 55 60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
65 70 75 80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
85 90 95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
100 105 110

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val  
130 135 140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
145 150 155 160

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys  
165 170 175

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
225 230 235 240

eolf-seql (10).txt

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
260 265 270

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
290 295 300

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
325 330 335

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val  
340 345 350

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
355 360 365

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu  
370 375 380

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

eolf-seql (10).txt

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
485 490 495

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
500 505 510

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
530 535 540

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
545 550 555 560

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
565 570 575

Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala  
580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
595 600 605

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
610 615 620

eolf-seql (10).txt

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
625 630 635 640

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
645 650 655

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ala Leu Ala  
690 695 700

Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala Cys Leu Gly Gly Arg  
705 710 715 720

Pro Ala Leu Asp Ala Val Lys Lys Gly Leu Gly Asp Pro Ile Ser Arg  
725 730 735

Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys Lys Ser Glu Leu Arg  
740 745 750

His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile Glu Leu Ile Glu Ile  
755 760 765

Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu Met Lys Val Met Glu  
770 775 780

Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys His Leu Gly Gly Ser  
785 790 795 800

Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly Ser Pro Ile Asp Tyr  
805 810 815

eolf-seql (10).txt

Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly Gly Tyr Asn Leu Pro  
820 825 830

Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val Glu Glu Asn Gln Thr  
835 840 845

Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp Lys Val Tyr Pro Ser  
850 855 860

Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser Gly His Phe Lys Gly  
865 870 875 880

Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His Ile Thr Asn Cys Asn  
885 890 895

Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile Gly Gly Glu Met Ile  
900 905 910

Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg Arg Lys Phe Asn Asn  
915 920 925

Gly Glu Ile Asn Phe Ala Ala Asp  
930 935

<210> 17

<211> 942

<212> PRT

<213> artificial sequence

<220>

<223> TALEN TRAC

<400> 17

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Lys Glu Thr Ala  
1 5 10 15

eolf-seql (10).txt

Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser Ile Asp Ile Ala Asp  
20 25 30

Leu Arg Thr Leu Gly Tyr Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro  
35 40 45

Lys Val Arg Ser Thr Val Ala Gln His His Glu Ala Leu Val Gly His  
50 55 60

Gly Phe Thr His Ala His Ile Val Ala Leu Ser Gln His Pro Ala Ala  
65 70 75 80

Leu Gly Thr Val Ala Val Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro  
85 90 95

Glu Ala Thr His Glu Ala Ile Val Gly Val Gly Lys Gln Trp Ser Gly  
100 105 110

Ala Arg Ala Leu Glu Ala Leu Leu Thr Val Ala Gly Glu Leu Arg Gly  
115 120 125

Pro Pro Leu Gln Leu Asp Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg  
130 135 140

Gly Gly Val Thr Ala Val Glu Ala Val His Ala Trp Arg Asn Ala Leu  
145 150 155 160

Thr Gly Ala Pro Leu Asn Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
165 170 175

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
180 185 190

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
195 200 205

eolf-seql (10).txt

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
210 215 220

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
225 230 235 240

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val  
245 250 255

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
260 265 270

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu  
275 280 285

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
290 295 300

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala  
305 310 315 320

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
325 330 335

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys  
340 345 350

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
355 360 365

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly  
370 375 380

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
385 390 395 400

eolf-seql (10).txt

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
405 410 415

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
420 425 430

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
435 440 445

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
450 455 460

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
465 470 475 480

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
485 490 495

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
500 505 510

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val  
515 520 525

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
530 535 540

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
545 550 555 560

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
565 570 575

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala  
580 585 590

eolf-seql (10).txt

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly  
595 600 605

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys  
610 615 620

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
625 630 635 640

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
645 650 655

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
660 665 670

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
675 680 685

Gly Gly Gly Arg Pro Ala Leu Glu Ser Ile Val Ala Gln Leu Ser Arg  
690 695 700

Pro Asp Pro Ala Leu Ala Ala Leu Thr Asn Asp His Leu Val Ala Leu  
705 710 715 720

Ala Cys Leu Gly Gly Arg Pro Ala Leu Asp Ala Val Lys Lys Gly Leu  
725 730 735

Gly Asp Pro Ile Ser Arg Ser Gln Leu Val Lys Ser Glu Leu Glu Glu  
740 745 750

Lys Lys Ser Glu Leu Arg His Lys Leu Lys Tyr Val Pro His Glu Tyr  
755 760 765

Ile Glu Leu Ile Glu Ile Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu  
770 775 780

eolf-seql (10).txt

Glu Met Lys Val Met Glu Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly  
785 790 795 800

Lys His Leu Gly Gly Ser Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val  
805 810 815

Gly Ser Pro Ile Asp Tyr Gly Val Ile Val Asp Thr Lys Ala Tyr Ser  
820 825 830

Gly Gly Tyr Asn Leu Pro Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr  
835 840 845

Val Glu Glu Asn Gln Thr Arg Asn Lys His Ile Asn Pro Asn Glu Trp  
850 855 860

Trp Lys Val Tyr Pro Ser Ser Val Thr Glu Phe Lys Phe Leu Phe Val  
865 870 875 880

Ser Gly His Phe Lys Gly Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn  
885 890 895

His Ile Thr Asn Cys Asn Gly Ala Val Leu Ser Val Glu Glu Leu Leu  
900 905 910

Ile Gly Gly Glu Met Ile Lys Ala Gly Thr Leu Thr Leu Glu Glu Val  
915 920 925

Arg Arg Lys Phe Asn Asn Gly Glu Ile Asn Phe Ala Ala Asp  
930 935 940

<210> 18

<211> 913

<212> PRT

<213> artificial sequence

<220>

<223> TALEN CD25

eolf-seql (10).txt

<400> 18

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
1 5 10 15

Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
20 25 30

Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
35 40 45

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
50 55 60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
65 70 75 80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
85 90 95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
100 105 110

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val  
130 135 140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
145 150 155 160

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys  
165 170 175

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

eolf-seql (10).txt

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
225 230 235 240

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
260 265 270

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
290 295 300

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
325 330 335

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
340 345 350

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
355 360 365

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu  
370 375 380

eolf-seql (10).txt

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
485 490 495

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
500 505 510

Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
530 535 540

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
545 550 555 560

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
565 570 575

eolf-seql (10).txt

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
595 600 605

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
610 615 620

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
625 630 635 640

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
645 650 655

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ser Gly Ser  
690 695 700

Gly Ser Gly Gly Asp Pro Ile Ser Arg Ser Gln Leu Val Lys Ser Glu  
705 710 715 720

Leu Glu Glu Lys Lys Ser Glu Leu Arg His Lys Leu Lys Tyr Val Pro  
725 730 735

His Glu Tyr Ile Glu Leu Ile Glu Ile Ala Arg Asn Ser Thr Gln Asp  
740 745 750

Arg Ile Leu Glu Met Lys Val Met Glu Phe Phe Met Lys Val Tyr Gly  
755 760 765

eolf-seql (10).txt

Tyr Arg Gly Lys His Leu Gly Gly Ser Arg Lys Pro Asp Gly Ala Ile  
770 775 780

Tyr Thr Val Gly Ser Pro Ile Asp Tyr Gly Val Ile Val Asp Thr Lys  
785 790 795 800

Ala Tyr Ser Gly Gly Tyr Asn Leu Pro Ile Gly Gln Ala Asp Glu Met  
805 810 815

Gln Arg Tyr Val Glu Glu Asn Gln Thr Arg Asn Lys His Ile Asn Pro  
820 825 830

Asn Glu Trp Trp Lys Val Tyr Pro Ser Ser Val Thr Glu Phe Lys Phe  
835 840 845

Leu Phe Val Ser Gly His Phe Lys Gly Asn Tyr Lys Ala Gln Leu Thr  
850 855 860

Arg Leu Asn His Ile Thr Asn Cys Asn Gly Ala Val Leu Ser Val Glu  
865 870 875 880

Glu Leu Leu Ile Gly Gly Glu Met Ile Lys Ala Gly Thr Leu Thr Leu  
885 890 895

Glu Glu Val Arg Arg Lys Phe Asn Asn Gly Glu Ile Asn Phe Ala Ala  
900 905 910

Asp

<210> 19

<211> 913

<212> PRT

<213> artificial sequence

eolf-seql (10).txt

<220>

<223> TALEN CD25

<400> 19

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
1 5 10 15

Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
20 25 30

Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
35 40 45

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
50 55 60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
65 70 75 80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
85 90 95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
100 105 110

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val  
130 135 140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
145 150 155 160

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys  
165 170 175

eolf-seql (10).txt

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
225 230 235 240

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
260 265 270

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
290 295 300

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
325 330 335

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val  
340 345 350

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
355 360 365

eolf-seql (10).txt

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu  
370 375 380

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys  
485 490 495

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
500 505 510

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
530 535 540

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu  
545 550 555 560

eolf-seql (10).txt

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
565 570 575

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
595 600 605

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
610 615 620

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
625 630 635 640

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu  
645 650 655

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ser Gly Ser  
690 695 700

Gly Ser Gly Gly Asp Pro Ile Ser Arg Ser Gln Leu Val Lys Ser Glu  
705 710 715 720

Leu Glu Glu Lys Lys Ser Glu Leu Arg His Lys Leu Lys Tyr Val Pro  
725 730 735

His Glu Tyr Ile Glu Leu Ile Glu Ile Ala Arg Asn Ser Thr Gln Asp  
740 745 750

eolf-seql (10).txt

Arg Ile Leu Glu Met Lys Val Met Glu Phe Phe Met Lys Val Tyr Gly  
755 760 765

Tyr Arg Gly Lys His Leu Gly Gly Ser Arg Lys Pro Asp Gly Ala Ile  
770 775 780

Tyr Thr Val Gly Ser Pro Ile Asp Tyr Gly Val Ile Val Asp Thr Lys  
785 790 795 800

Ala Tyr Ser Gly Gly Tyr Asn Leu Pro Ile Gly Gln Ala Asp Glu Met  
805 810 815

Gln Arg Tyr Val Glu Glu Asn Gln Thr Arg Asn Lys His Ile Asn Pro  
820 825 830

Asn Glu Trp Trp Lys Val Tyr Pro Ser Ser Val Thr Glu Phe Lys Phe  
835 840 845

Leu Phe Val Ser Gly His Phe Lys Gly Asn Tyr Lys Ala Gln Leu Thr  
850 855 860

Arg Leu Asn His Ile Thr Asn Cys Asn Gly Ala Val Leu Ser Val Glu  
865 870 875 880

Glu Leu Leu Ile Gly Gly Glu Met Ile Lys Ala Gly Thr Leu Thr Leu  
885 890 895

Glu Glu Val Arg Arg Lys Phe Asn Asn Gly Glu Ile Asn Phe Ala Ala  
900 905 910

Asp

<210> 20

<211> 936

<212> PRT

eolf-seql (10).txt

<213> artificial sequence

<220>

<223> TALEN PD1

<400> 20

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
1 5 10 15

Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
20 25 30

Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
35 40 45

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
50 55 60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
65 70 75 80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
85 90 95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
100 105 110

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val  
130 135 140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
145 150 155 160

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Lys Leu Gly Gly Lys  
165 170 175

eolf-seql (10).txt

Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His  
225 230 235 240

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
260 265 270

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
290 295 300

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
325 330 335

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
340 345 350

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
355 360 365

eolf-seql (10).txt

Gln Val Val Ala Ile Ala Ser Tyr Lys Gly Gly Lys Gln Ala Leu Glu  
370 375 380

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
485 490 495

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
500 505 510

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
530 535 540

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
545 550 555 560

eolf-seql (10).txt

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
565 570 575

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
595 600 605

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val  
610 615 620

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
625 630 635 640

Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu  
645 650 655

Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ala Leu Ala  
690 695 700

Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala Cys Leu Gly Gly Arg  
705 710 715 720

Pro Ala Leu Asp Ala Val Lys Lys Gly Leu Gly Asp Pro Ile Ser Arg  
725 730 735

Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys Lys Ser Glu Leu Arg  
740 745 750

eolf-seql (10).txt

His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile Glu Leu Ile Glu Ile  
755 760 765

Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu Met Lys Val Met Glu  
770 775 780

Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys His Leu Gly Gly Ser  
785 790 795 800

Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly Ser Pro Ile Asp Tyr  
805 810 815

Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly Gly Tyr Asn Leu Pro  
820 825 830

Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val Glu Glu Asn Gln Thr  
835 840 845

Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp Lys Val Tyr Pro Ser  
850 855 860

Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser Gly His Phe Lys Gly  
865 870 875 880

Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His Ile Thr Asn Cys Asn  
885 890 895

Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile Gly Gly Glu Met Ile  
900 905 910

Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg Arg Lys Phe Asn Asn  
915 920 925

Gly Glu Ile Asn Phe Ala Ala Asp  
930 935

eolf-seql (10).txt

<210> 21

<211> 941

<212> PRT

<213> artificial sequence

<220>

<223> TALEN PD1

<400> 21

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Lys Glu Thr Ala  
1 5 10 15

Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser Ile Asp Ile Ala Asp  
20 25 30

Leu Arg Thr Leu Gly Tyr Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro  
35 40 45

Lys Val Arg Ser Thr Val Ala Gln His His Glu Ala Leu Val Gly His  
50 55 60

Gly Phe Thr His Ala His Ile Val Ala Leu Ser Gln His Pro Ala Ala  
65 70 75 80

Leu Gly Thr Val Ala Val Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro  
85 90 95

Glu Ala Thr His Glu Ala Ile Val Gly Val Gly Lys Gln Trp Ser Gly  
100 105 110

Ala Arg Ala Leu Glu Ala Leu Leu Thr Val Ala Gly Glu Leu Arg Gly  
115 120 125

Pro Pro Leu Gln Leu Asp Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg  
130 135 140

eolf-seql (10).txt

Gly Gly Val Thr Ala Val Glu Ala Val His Ala Trp Arg Asn Ala Leu  
145 150 155 160

Thr Gly Ala Pro Leu Asn Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
165 170 175

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
180 185 190

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
195 200 205

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
210 215 220

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
225 230 235 240

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val  
245 250 255

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
260 265 270

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu  
275 280 285

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
290 295 300

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala  
305 310 315 320

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
325 330 335

eolf-seql (10).txt

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys  
340 345 350

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
355 360 365

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
370 375 380

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
385 390 395 400

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
405 410 415

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
420 425 430

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
435 440 445

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
450 455 460

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
465 470 475 480

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
485 490 495

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
500 505 510

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
515 520 525

eolf-seql (10).txt

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
530 535 540

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu  
545 550 555 560

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
565 570 575

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Gly Gly Lys Gln Ala Leu  
580 585 590

Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu  
595 600 605

Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln  
610 615 620

Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His  
625 630 635 640

Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly  
645 650 655

Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln  
660 665 670

Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly  
675 680 685

Gly Gly Arg Pro Ala Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro  
690 695 700

Asp Pro Ala Leu Ala Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala  
705 710 715 720

eolf-seql (10).txt

Cys Leu Gly Gly Arg Pro Ala Leu Asp Ala Val Lys Lys Gly Leu Gly  
725 730 735

Asp Pro Ile Ser Arg Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys  
740 745 750

Lys Ser Glu Leu Arg His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile  
755 760 765

Glu Leu Ile Glu Ile Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu  
770 775 780

Met Lys Val Met Glu Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys  
785 790 795 800

His Leu Gly Gly Ser Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly  
805 810 815

Ser Pro Ile Asp Tyr Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly  
820 825 830

Gly Tyr Asn Leu Pro Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val  
835 840 845

Glu Glu Asn Gln Thr Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp  
850 855 860

Lys Val Tyr Pro Ser Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser  
865 870 875 880

Gly His Phe Lys Gly Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His  
885 890 895

Ile Thr Asn Cys Asn Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile  
900 905 910

eolf-seql (10).txt

Gly Gly Glu Met Ile Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg  
 915 920 925

Arg Lys Phe Asn Asn Gly Glu Ile Asn Phe Ala Ala Asp  
 930 935 940

<210> 22

<211> 2814

<212> DNA

<213> artificial sequence

<220>

<223> TALEN TRAC pCLS11370

<400> 22

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tcgccgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgagc	caccacgagg	caactggcgg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	caccggcgag	cgtaggggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggctccggcg	acgcgctctg	gaggccttgc	tcacgggtggc	gggagagttg	360
agagggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaaac	480
ttgaccccc	agcaggtggt	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	600
gtggccatcg	ccagcaataa	tgggtggcaag	caggcgctgg	agacgggtcca	gctgctgttg	660
ccgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tgggtggccat	cgccagcaat	720
ggcgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	780
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccgag	900
caggtggtgg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgaccccgg	agcaggtggt	ggccatcgcc	1020
agccacgatg	gcggcaagca	ggcgctggag	acggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ggagcaggtg	gtggccatcg	ccagcaatat	tgggtggcaag	1140
caggcgctgg	agacgggtgca	ggcgctgttg	ccgggtgctgt	gccaggccca	cggcttgacc	1200
ccggagcagg	tgggtggccat	cgccagccac	gatggcggca	agcaggcgct	ggagacggtc	1260
cagcggctgt	tgccgggtgct	gtgccaggcc	cacggcttga	ccccggagca	ggtggtggcc	1320
atcgccagca	atattggtgg	caagcaggcg	ctggagacgg	tgcaggcgct	gttgccgggtg	1380
ctgtgccagg	cccacggctt	gacccccag	caggtggtgg	ccatcgccag	caataatggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgaccccgg	agcaggtggt	ggccatcgcc	agcaatatgt	gtggcaagca	ggcgctggag	1560
acgggtgcagg	cgctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	1620
gtggccatcg	ccagcaatgg	cgggtggcaag	caggcgctgg	agacgggtcca	gctgctgttg	1680
ccgggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tgggtggccat	cgccagcaat	1740

eolf-seql (10).txt

attggtggca	agcaggcgct	ggagacggtg	caggcgctgt	tgccggtgct	gtgccaggcc	1800
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcggtgg	caagcaggcg	1860
ctggagacgg	tccagcggtc	gttgccggtg	ctgtgccagg	cccacggctt	gaccccggag	1920
cagggtggtg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	1980
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgacccctc	agcagggtgt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgcccctgat	2100
ccggcggttg	ccgcgttgac	caacgaccac	ctcgtcgcct	tggcctgcct	cggcgggcgt	2160
cctgcgtgg	atgcagtga	aaagggttg	ggggatccta	tcagccgttc	ccagctggtg	2220
aagtccgagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgatcga	gatcgcccgg	aacagcaccc	aggaccgtat	cctggagatg	2340
aagggtgatg	agttcttcat	gaagggtgtac	ggctacaggg	gcaagcacct	gggcggctcc	2400
aggaagccc	acggcgccat	ctacaccgtg	ggctccccc	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacg	gccaggccga	cgaatgcag	2520
aggtagctgg	aggagaacca	gaccaggaac	aagcacatca	acccaacga	gtggtggaag	2580
gtgtaccct	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcacct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 23

<211> 2832

<212> DNA

<213> artificial sequence

<220>

<223> TALEN TRAC pCLS11369

<400> 23

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgataagg	agaccgccgc	tgccaagttc	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgttcgacag	tggcgagca	ccacgaggca	180
ctggctggcc	acgggtttac	acacgcgcac	atcggtgcgt	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgag	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtgg	tccggcgcac	gcgctctgga	ggccttgctc	360
acgggtggcg	gagagttgag	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggcgt	gaccgcagtg	gaggcagtcg	atgcatggcg	caatgcactg	480
acgggtgccc	cgctcaactt	gaccccgagg	cagggtggtg	ccatcgccag	ccacgatggc	540
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcca	ggcccacggc	600
ttgaccccc	agcagggtgt	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	660
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	720
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacggtcca	gcggctgttg	780
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tgggtggccat	cgcagcaat	840
attggtggca	agcaggcgct	ggagacggtg	caggcgctgt	tgccggtgct	gtgccaggcc	900
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	960
ctggagacgg	tccagcggtc	gttgccggtg	ctgtgccagg	cccacggctt	gaccccggag	1020
cagggtggtg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	1080

eolf-seql (10).txt

ctgttgccgg	tgctgtgcc	ggcccacggc	ttgaccccc	agcaggtggt	ggccatcgcc	1140
agcaatggcg	gtggcaagca	ggcgctggag	acgggtccagc	ggctgttgcc	ggtgctgtgc	1200
caggccccacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaataa	tggtggcaag	1260
caggcgctgg	agacgggtcca	gctggctgtg	ccgggtgctgt	gccaggccca	cggcttgacc	1320
ccccagcagg	tggtggccat	cgccagcaat	aatgggtggca	agcaggcgct	ggagacggtc	1380
cagcggctgt	tgccggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1440
atgccagca	atggcggtgg	caagcaggcg	ctggagacgg	tccagcggt	gttgccgggtg	1500
ctgtgccagg	cccacggctt	gaccccggag	caggtggtgg	ccatcgccag	caatattggt	1560
ggcaagcagg	cgctggagac	ggtgcaggcg	ctgttgccgg	tgctgtgcc	ggcccacggc	1620
ttgaccccgg	agcaggtggt	ggccatcgcc	agccacgatg	gctggcaagca	ggcgctggag	1680
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	1740
gtggccatcg	ccagcaatat	tggtggcaag	caggcgctgg	agacggtgca	ggcgctgttg	1800
ccgggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tggtggccat	cgccagccac	1860
gatggcggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccggtgct	gtgccaggcc	1920
cacggcttga	ccccccagca	ggtggtggcc	atgccagca	ataatggtgg	caagcaggcg	1980
ctggagacgg	tccagcggt	gttgccgggtg	ctgtgccagg	cccacggctt	gacccctcag	2040
caggtggtgg	ccatcgccag	caatggcggc	ggcaggccgg	cgctggagag	cattgttgcc	2100
cagttatctc	gccctgatcc	ggcgttggtg	gcgttgacca	acgaccacct	cgctgccttg	2160
gcctgcctcg	gcgggcgtcc	tgcgctggat	gcagtgaata	agggattggg	ggatcctatc	2220
agccgttccc	agctggtgaa	gtccgagctg	gaggagaaga	aatccgagtt	gaggcacaag	2280
ctgaagtacg	tgccccacga	gtacatcgag	ctgatcgaga	tcgcccggaa	cagcaccacg	2340
gaccgtatcc	tggagatgaa	ggtgatggag	ttcttcatga	aggtgtacgg	ctacaggggc	2400
aagcacctgg	gcggctccag	gaagcccagc	ggcgccatct	acaccgtggg	ctccccatc	2460
gactacggcg	tgatcgtgga	caccaaggcc	tactccggcg	gctacaacct	gcccacggc	2520
caggccgacg	aaatgcagag	gtacgtggag	gagaaccaga	ccaggaacaa	gcacatcaac	2580
cccaacgagt	ggtggaagg	gtacccctcc	agcgtgaccg	agttcaagtt	cctgttcgtg	2640
tccggccact	tcaagggcaa	ctacaaggcc	cagctgacca	ggctgaacca	catcaccaac	2700
tgcaacggcg	ccgtgctgtc	cgtggaggag	ctcctgatcg	gcggcgagat	gatcaaggcc	2760
ggcaccctga	ccctggagga	ggtgaggagg	aagttcaaca	acggcgagat	caacttcgcg	2820
gccgactgat	aa					2832

<210> 24

<211> 2745

<212> DNA

<213> artificial sequence

<220>

<223> TALEN CD25 pCLS30480

<400> 24

atgggcgatc	ctaaaaagaa	acgtaaggct	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tcgccgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	cacccggcag	cgttaggagc	cgctcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggtccggcgc	acgcgctctg	gaggccttgc	tcacggtggc	gggagagttg	360

eolf-seql (10).txt

agaggtccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgaccccc	agcaggtggt	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	540
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	600
gtggccatcg	ccagcaatgg	cgggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	660
ccgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtggccat	cgccagcaat	720
ggcgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	780
cacggcttga	ccccggagca	ggtggtggcc	atcgccagcc	acgatggcgg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccgggt	ctgtgccagg	cccacggctt	gacccccag	900
caggtggtgg	ccatcgccag	caatggcgggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcc	ggcccacggc	ttgaccccc	agcaggtggt	ggccatcgcc	1020
agcaatggcg	gtggcaagca	ggcgctggag	acgggtccagc	ggctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaatgg	cgggtggcaag	1140
caggcgctgg	agacgggtcca	gcggctgttg	ccgggtgctgt	gccaggccca	cggcttgacc	1200
ccccagcagg	tggtggccat	cgccagcaat	ggcgggtggca	agcaggcgct	ggagacggtc	1260
cagcggctgt	tgccgggtgct	gtgccaggcc	cacggcttga	ccccccagca	ggtggtggcc	1320
atcgccagca	ataatggtgg	caagcaggcg	ctggagacgg	tccagcggct	gttgccgggtg	1380
ctgtgccagg	cccacggctt	gacccccag	caggtggtgg	ccatcgccag	caataatggt	1440
ggcaagcagg	cgctggagac	ggtccagcgg	ctgttgccgg	tgctgtgcc	ggcccacggc	1500
ttgaccccc	agcaggtggt	ggccatcgcc	agcaatggcg	gtggcaagca	ggcgctggag	1560
acgggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ccagcaggtg	1620
gtggccatcg	ccagcaatgg	cgggtggcaag	caggcgctgg	agacgggtcca	gcggctgttg	1680
ccgggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tggtggccat	cgccagcaat	1740
ggcgggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccgggtgct	gtgccaggcc	1800
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcgggtg	caagcaggcg	1860
ctggagacgg	tccagcggct	gttgccgggtg	ctgtgccagg	cccacggctt	gaccccggag	1920
caggtggtgg	ccatcgccag	ccacgatggc	ggcaagcagg	cgctggagac	ggtccagcgg	1980
ctgttgccgg	tgctgtgcc	ggcccacggc	ttgacccctc	agcaggtggt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccgagtggca	gcggaagtgg	cggggatcct	atcagccgtt	cccagctggt	gaagtccgag	2160
ctggaggaga	agaaatccga	gttgaggcac	aagctgaagt	acgtgcccc	cgagtacatc	2220
gagctgatcg	agatcgccc	gaacagcacc	caggaccgta	tcctggagat	gaaggtgatg	2280
gagttcttca	tgaagggtga	cggctacagg	ggcaagcacc	tgggcggctc	caggaagccc	2340
gacggcgcca	tctacaccgt	gggctcccc	atcgactacg	gcgtgatcgt	ggacaccaag	2400
gcctactccg	gcggctacaa	cctgcccac	ggccaggccg	acgaaatgca	gaggtacgtg	2460
gaggagaacc	agaccaggaa	caagcacatc	aaccccaacg	agtgggtggaa	ggtgtacccc	2520
tccagcgtga	ccgagttcaa	gttcctgttc	gtgtccggcc	acttcaaggg	caactacaag	2580
gcccagctga	ccaggctgaa	ccacatcacc	aactgcaacg	gcgccgtgct	gtccgtggag	2640
gagctcctga	tcggcggcga	gatgatcaag	gccggcaccc	tgaccctgga	ggaggtgagg	2700
aggaagttca	acaacggcga	gatcaacttc	gcggccgact	gataa		2745

<210> 25

<211> 2745

<212> DNA

<213> artificial sequence

eolf-seql (10).txt

<220>

<223> TALEN CD25 pCLS30479

<400> 25

atgggcgatc	ctaaaaagaa	acgtaaggct	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tcgccgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggctcg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	caccggcgag	cgtagggac	cgctcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggctccggcg	acgcgctctg	gaggccttgc	tcacgggtgg	gggagagttg	360
agaggccac	cgttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaac	480
ttgacccgg	agcaggtggt	ggccatcgcc	agcaatattg	gtggcaagca	ggcgctggag	540
acggtgcagg	cgctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	600
gtggccatcg	ccagccacga	tggcggcaag	caggcgctgg	agacggtcca	gcggctgttg	660
ccggtgctgt	gccaggccca	cggcttgacc	ccggagcagg	tgggtggccat	cgccagcaat	720
attggtggca	agcaggcgct	ggagacggtg	caggcgctgt	tgccggtgct	gtgccaggcc	780
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	ataatggtgg	caagcaggcg	840
ctggagacgg	tccagcggct	gttgccggtg	ctgtgccagg	cccacggctt	gacccccag	900
caggtggtgg	ccatcgccag	caataatggt	ggcaagcagg	cgctggagac	ggtccagcgg	960
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgaccccg	agcaggtggt	ggccatcgcc	1020
agcaatattg	gtggcaagca	ggcgctggag	acggtgcagg	cgctgttgcc	ggtgctgtgc	1080
caggcccacg	gcttgacccc	ccagcaggtg	gtggccatcg	ccagcaataa	tgggtggcaag	1140
caggcgctgg	agacggtcca	gcggctgttg	ccggtgctgt	gccaggccca	cggcttgacc	1200
ccccagcagg	tgggtggccat	cgccagcaat	aatggtggca	agcaggcgct	ggagacggct	1260
cagcggctgt	tgccggtgct	gtgccaggcc	cacggcttga	ccccggagca	ggtggtggcc	1320
atcgccagca	atattggtgg	caagcaggcg	ctggagacgg	tgacggcgct	gttgccggtg	1380
ctgtgccagg	cccacggctt	gaccccgag	caggtggtgg	ccatcgccag	caatattggt	1440
ggcaagcagg	cgctggagac	ggtgcaggcg	ctgttgccgg	tgctgtgcca	ggcccacggc	1500
ttgaccccc	agcaggtggt	ggccatcgcc	agcaataatg	gtggcaagca	ggcgctggag	1560
acggtccagc	ggctgttgcc	ggtgctgtgc	caggcccacg	gcttgacccc	ggagcaggtg	1620
gtggccatcg	ccagcaatat	tgggtggcaag	caggcgctgg	agacggtgca	ggcgctgttg	1680
ccggtgctgt	gccaggccca	cggcttgacc	ccccagcagg	tgggtggccat	cgccagcaat	1740
aatggtggca	agcaggcgct	ggagacggtc	cagcggctgt	tgccggtgct	gtgccaggcc	1800
cacggcttga	ccccccagca	ggtggtggcc	atcgccagca	atggcgggtg	caagcaggcg	1860
ctggagacgg	tccagcggct	gttgccggtg	ctgtgccagg	cccacggctt	gaccccgag	1920
caggtggtgg	ccatcgccag	caatattggt	ggcaagcagg	cgctggagac	ggtgcaggcg	1980
ctgttgccgg	tgctgtgcca	ggcccacggc	ttgacccctc	agcaggtggt	ggccatcgcc	2040
agcaatggcg	gcggcaggcc	ggcgctggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccgagtggca	gcgggaagtgg	cggggatcct	atcagccgtt	cccagctggt	gaagtcagag	2160
ctggaggaga	agaaatccga	gttgaggcac	aagctgaagt	acgtgcccc	cgagtacatc	2220
gagctgatcg	agatcgccc	gaacagcacc	caggaccgta	tcctggagat	gaaggtgatg	2280
gagttcttca	tgaaggtgta	cggctacagg	ggcaagcacc	tgggcggctc	caggaagccc	2340
gacggcgcca	tctacaccgt	gggctcccc	atcgactacg	gcgtgatcgt	ggacaccaag	2400
gcctactccg	gcggctacaa	cctgcccac	ggccaggccg	acgaaatgca	gaggtacgtg	2460
gaggagaacc	agaccaggaa	caagcacatc	aaccccaacg	agtgggtgaa	ggtgtacccc	2520
tccagcgtga	ccgagttcaa	gttcctgttc	gtgtccggcc	acttcaaggg	caactacaag	2580
gccagctga	ccaggctgaa	ccacatcacc	aactgcaacg	gcgccgtgct	gtccgtggag	2640

eolf-seql (10).txt

gagctcctga	tcggcggcga	gatgatcaag	gccggcaccc	tgaccctgga	ggaggtgagg	2700
aggaagttca	acaacggcga	gatcaacttc	gcggccgact	gataa		2745

<210> 26

<211> 2814

<212> DNA

<213> artificial sequence

<220>

<223> TALEN PD1 pCLS28959

<400> 26

atgggcgatc	ctaaaaagaa	acgtaaggtc	atcgattacc	catacgatgt	tccagattac	60
gctatcgata	tcgccgatct	acgcacgctc	ggctacagcc	agcagcaaca	ggagaagatc	120
aaaccgaagg	ttcgttcgac	agtggcgag	caccacgagg	cactggtcgg	ccacgggttt	180
acacacgcgc	acatcgttgc	gttaagccaa	cacccggcag	cgttagggac	cgtcgctgtc	240
aagtatcagg	acatgatcgc	agcgttgcca	gaggcgacac	acgaagcgat	cgttggcgctc	300
ggcaaacagt	ggcccggcgc	acgcgctctg	gaggccttgc	tcacgggtggc	gggagagttg	360
agaggtccac	cggttacagtt	ggacacaggc	caacttctca	agattgcaaa	acgtggcggc	420
gtgaccgcag	tggaggcagt	gcatgcatgg	cgcaatgcac	tgacgggtgc	cccgtcaaac	480
ttgacccccg	agcaagtggg	ggctatcgct	tccaagctgg	ggggaaagca	ggccctggag	540
accgtccagg	cccttctccc	agtgccttgc	caggctcacg	gactgacccc	tgaacagggtg	600
gtggcaattg	cctcacacga	cgggggcaag	caggcactgg	agactgtcca	gcggctgctg	660
cctgtcctct	gccaggccca	cggactcact	cctgagcagg	tcgtggccat	tgccagccac	720
gatgggggca	aacaggctct	ggagaccgtg	cagcgctcc	tcccagtgct	gtgccaggct	780
catgggctga	ccccacagca	ggctgctgcc	attgccagta	acggcggggg	gaagcaggcc	840
ctcgaacag	tgcagaggct	gctgcccgtc	ttgtgccaa	cacacggcct	gacaccgag	900
cagggtgggtg	ccatcgctct	tcattgacggc	ggcaagcagg	cccttgagac	agtgcagaga	960
ctgttgccccg	tgttggtgtca	ggccacggg	ttgacacccc	agcaggtggg	cgccatcgcc	1020
agcaatggcg	ggggaaagca	ggcccttgag	accgtgcagc	ggttgcttcc	agtgttgctg	1080
caggcacacg	gactgacccc	tcaacagggtg	gtcgcaatcg	ccagctacaa	gggcggaaag	1140
caggctcttg	agacagtga	gcgcctcctg	cccgtgctgt	gtcaggctca	cggactgaca	1200
ccacagcagg	tggctgccat	cgccagtaac	ggggcgggca	agcaggcttt	ggagaccgtc	1260
cagagactcc	tccccgtcct	ttgccaggcc	cacgggttga	cacctcagca	ggtcgtcgcc	1320
attgcctcca	acaacggggg	caagcaggcc	ctcgaaactg	tgacagaggct	gctgcctgtg	1380
ctgtgccagg	ctcatgggct	gacaccccag	cagggtgggtg	ccattgcctc	taacaacggc	1440
ggcaaacagg	cactggagac	cgtagcaagg	ctgctgcccg	tcctctgcca	agcccacggg	1500
ctcactccac	agcaggctgt	ggccatcgcc	tcaaacatg	gcgggaagca	ggccctggag	1560
actgtgcaaa	ggctgctccc	tgtgctctgc	caggcacacg	gactgacccc	tcagcagggtg	1620
gtggcaatcg	cttccaacaa	cgggggaaag	caggccctcg	aaaccgtgca	gcgcctcctc	1680
ccagtgtgtg	gccaggcaca	tggcctcaca	cccagcaag	tgggtggctat	cgccagccac	1740
gacggaggga	agcaggctct	ggagaccgtg	cagaggctgc	tgctgtcct	gtgccaggcc	1800
cacgggctta	ctccagagca	ggctgctgcc	atcgccagtc	atgatggggg	gaagcaggcc	1860
cttgagacag	tccagcggtc	gctgccagtc	ctttgccagg	ctcacggctt	gactcccagag	1920
caggctgtgg	ccattgcctc	aaacattggg	ggcaaacagg	ccctggagac	agtgcaggcc	1980
ctgctgccccg	tgttggtgtca	ggccacggc	ttgacacccc	agcaggtggg	cgccattgcc	2040

eolf-seql (10).txt

tctaattggcg	gcgggagacc	cgccttggag	agcattgttg	cccagttatc	tcgccctgat	2100
ccggcggttg	ccgcgttgac	caacgaccac	ctcgtcgcct	tggcctgcct	cggcgggct	2160
cctgcgctgg	atgcagtga	aaagggattg	ggggatccta	tcagccgttc	ccagctgggtg	2220
aagtccgagc	tggaggagaa	gaaatccgag	ttgaggcaca	agctgaagta	cgtgccccac	2280
gagtacatcg	agctgacga	gatcgcccgg	aacagcacc	aggaccgtat	cctggagatg	2340
aaggtgatgg	agttcttcat	gaaggtgtac	ggctacaggg	gcaagcacct	gggcggctcc	2400
aggaagcccc	acggcgccat	ctacaccgtg	ggctcccca	tcgactacgg	cgtgatcgtg	2460
gacaccaagg	cctactccgg	cggctacaac	ctgcccacg	gccaggccga	cgaatgacag	2520
aggtagctgg	aggagaacca	gaccaggaac	aagcacatca	acccaacga	gtggtggaag	2580
gtgtaccccc	ccagcgtgac	cgagttcaag	ttcctgttcg	tgtccggcca	cttcaagggc	2640
aactacaagg	cccagctgac	caggctgaac	cacatcacca	actgcaacgg	cgccgtgctg	2700
tccgtggagg	agctcctgat	cggcggcgag	atgatcaagg	ccggcaccct	gaccctggag	2760
gaggtgagga	ggaagttcaa	caacggcgag	atcaacttcg	cggccgactg	ataa	2814

<210> 27

<211> 2829

<212> DNA

<213> artificial sequence

<220>

<223> TALEN PD1 pCLS18792

<400> 27

atgggcgatc	ctaaaaagaa	acgtaaggct	atcgataagg	agaccgccgc	tgccaagtct	60
gagagacagc	acatggacag	catcgatatc	gccgatctac	gcacgctcgg	ctacagccag	120
cagcaacagg	agaagatcaa	accgaagggt	cgttcgacag	tggcgcagca	ccacgaggca	180
ctggctcggc	acgggtttac	acacgcgcac	atcgttgcgt	taagccaaca	cccggcagcg	240
ttagggaccg	tcgctgtcaa	gtatcaggac	atgatcgagc	cgttgccaga	ggcgacacac	300
gaagcgatcg	ttggcgtcgg	caaacagtgg	tccggcgcac	gcgctctgga	ggccttgctc	360
acgggtggcgg	gagagttagg	aggtccaccg	ttacagttgg	acacaggcca	acttctcaag	420
attgcaaaac	gtggcggcgt	gaccgcagtg	gaggcagtg	atgcatggcg	caatgcaactg	480
acgggtgccc	cgctcaactt	gacccccgag	caagtcgtcg	caatcgccag	ccatgatgga	540
gggaagcaag	ccctcgaaac	cgtgcagcgg	ttgcttctctg	tgctctgcca	ggcccacggc	600
cttaccctc	agcaggtggg	ggccatcgca	agtaacggag	gaggaaaagca	agccttgag	660
acagtgcagc	gcctgttgcc	cgtgctgtgc	caggcacacg	gcctcacacc	agagcaggctc	720
gtggccattg	cctcccatga	cgggggggaaa	caggctctgg	agaccgtcca	gaggctgctg	780
cccgtcctct	gtcaagctca	cggcctgact	ccccaaacaag	tggctcgccat	cgcctctaata	840
ggcggcggga	agcaggcact	ggaaacagtg	cagagactgc	tccctgtgct	ttgccaagct	900
catgggttga	cccccaaca	ggtcgtcgct	attgcctcaa	acggggggggg	caagcaggcc	960
cttgagactg	tgagagggct	gttgccagtg	ctgtgtcagg	ctcacgggct	cactccacaa	1020
caggtggctg	caattgccag	caacggcggc	ggaaagcaag	ctcttgaaac	cgtgcaacgc	1080
ctcctgccc	tgctctgtca	ggctcatggc	ctgacaccac	aacaagtcgt	ggccatcgcc	1140
agtaataatg	gcgggaaaca	ggctcttgag	accgtccaga	ggctgctccc	agtgtctgtc	1200
caggcacacg	ggctgacccc	cgagcaggtg	gtggctatcg	ccagcaatat	tgggggcaag	1260
caggccctgg	aaacagtcca	ggccctgctg	ccagtgtctt	gccaggctca	cgggctcact	1320
cccagcagg	tcgtggcaat	cgcctccaac	ggcggaggga	agcaggctct	ggagaccgtg	1380

eolf-seql (10).txt

cagagactgc	tgcccgtctt	gtgccaggcc	cacggactca	cacctgaaca	ggtcgtcgcc	1440
attgcctctc	acgatggggg	caaacaagcc	ctggagacag	tgacagggct	gttgctgtg	1500
ttgtgccaag	cccacggctt	gactcctcaa	caagtggtcg	ccatcgctc	aaatggcggc	1560
ggaaaacaag	ctctggagac	agtgcagagg	ttgctgccc	tcctctgcca	agcccacggc	1620
ctgactcccc	aacaggctgt	cgccattgcc	agcaacaacg	gaggaaagca	ggctctcgaa	1680
actgtgcagc	ggctgcttcc	tgtgctgtgt	caggctcatg	ggctgacccc	cgagcaagtg	1740
gtggctattg	cctctaattg	aggcaagcaa	gcccttgaga	cagtccagag	gctgttgcca	1800
gtgctgtgcc	aggcccacgg	gctcacaccc	cagcaggtgg	tcgccatcgc	cagtaacaac	1860
gggggcaaac	aggcattgga	aaccgtccag	cgcttgcttc	cagtgtcttg	ccaggcacac	1920
ggactgacac	ccgaacaggt	ggtggccatt	gcatcccatg	atgggggcaa	gcaggccctg	1980
gagaccgtgc	agagactcct	gccagtggtg	tgccaagctc	acggcctcac	ccctcagcaa	2040
gtcgtggcca	tcgcctcaaa	cggggggggc	cggcctgcac	tgagagagcat	tggtgcccag	2100
ttatctcgcc	ctgatccggc	gttggccgcg	ttgaccaacg	accacctcgt	cgcttgggcc	2160
tgcttcggcg	ggcgtcctgc	gctggatgca	gtgaaaaagg	gattggggga	tcctatcagc	2220
cgttcccagc	tggtgaagtc	cgagctggag	gagaagaaat	ccgagttgag	gcacaagctg	2280
aagtacgtgc	cccacgagta	catcgagctg	atcgagatcg	cccggaacag	caccaggac	2340
cgtatcctgg	agatgaaggt	gatggagttc	ttcatgaagg	tgtacggcta	caggggcaag	2400
cacctgggcg	gctccaggaa	gcccgcggc	gccatctaca	ccgtgggctc	ccccatcgac	2460
tacggcgtga	tcgtggacac	caaggcctac	tccggcggct	acaacctgcc	catcggccag	2520
gccgacgaaa	tgagaggtga	cgtggaggag	aaccagacca	ggaacaagca	catcaacccc	2580
aacgagtggg	ggaaggtgta	cccctccagc	gtgaccgagt	tcaagttcct	gttcgtgtcc	2640
ggccacttca	agggcaacta	caaggcccag	ctgaccaggc	tgaaccacat	caccaactgc	2700
aacggcgccg	tgctgtccgt	ggaggagctc	ctgatcggcg	gcgagatgat	caaggccggc	2760
accctgaccc	tggaggaggt	gaggaggaag	ttcaacaacg	gcgagatcaa	cttcgcggcc	2820
gactgataa						2829

<210> 28

<211> 49

<212> DNA

<213> artificial sequence

<220>

<223> TALEN target TRAC

<400> 28

ttgtcccaca gatattcaga accctgaccc tgccgtgtac cagctgaga

49

<210> 29

<211> 45

<212> DNA

<213> artificial sequence

<220>

<223> TALEN target CD25

eolf-seql (10).txt

<400> 29  
tacaggagga agagtagaag aacaatctag aaaacaaaa gaaca 45

<210> 30

<211> 49

<212> DNA

<213> artificial sequence

<220>

<223> TALEN target PD1

<400> 30  
tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagaga 49

<210> 31

<211> 2897

<212> DNA

<213> artificial sequence

<220>

<223> Matrice TRAC locus\_CubiCAR CD22 pCLS30056

<400> 31  
ttgctgggcc tttttcccat gcctgccttt actctgccag agttatatg ctggggtttt 60  
gaagaagatc ctattaaata aaagaataag cagtattatt aagtagccct gcatttcagg 120  
tttccttgag tggcaggcca ggcctggccg tgaacgttca ctgaaatcat ggcctcttgg 180  
ccaagattga tagcttgtgc ctgtccctga gtcccagtc atcacgagca gctggtttct 240  
aagatgctat ttcccgtata aagcatgaga ccgtgacttg ccagccccac agagccccgc 300  
ccttgctccat cactggcatc tggactccag cctgggttgg ggcaaagagg gaaatgagat 360  
catgtcctaa ccctgatcct cttgtccac agatatccag taccctacg acgtgcccga 420  
ctacgcctcc ggtgaggga gaggaagtct tctaacatgc ggtgacgtgg aggagaatcc 480  
gggccccgga tccgctctgc ccgtcaccgc tctgctgctg ccactggcac tgctgctgca 540  
cgctgctagg cccggagggg gaggcagctg cccctacagc aaccccagcc tgtgcagcgg 600  
aggcggcggc agcggcggag ggggtagcca ggtgcagctg cagcagagcg gccctggcct 660  
ggtgaagcca agccagacac tgtccctgac ctgcgccatc agcggcgatt ccgtgagctc 720  
caactccgcc gcctggaatt ggatcaggca gtccccttct cggggccttg agtggctggg 780  
aaggacatac tatcggctta agtggtacaa cgattatgcc gtgtctgtga agagcagaat 840  
cacaatcaac cctgacacct ccaagaatca gttctctctg cagctgaata gcgtgacacc 900  
agaggacacc gccgtgtact attgcgccag ggaggtgacc ggcgacctgg aggatgcctt 960  
tgacatctgg ggccagggca caatggtgac cgtgagctcc ggaggcggcg gatctggcgg 1020  
aggaggaagt gggggcggcg ggagtgatat ccagatgaca cagtcccat cctctctgag 1080  
cgctccgtg ggcgacagag tgacaatcac ctgtagggcc tccagacca tctggtctta 1140  
cctgaactgg tatcagcaga ggcccggcaa ggccccta atctgctgatct acgcagcaag 1200

eolf-seql (10).txt

ctccctgcag	agcggagtg	catccagatt	ctctggcagg	ggctccggca	cagacttcac	1260
cctgaccatc	tctagcctgc	aggccgagga	cttcgccacc	tactattgcc	agcagtctta	1320
tagcatcccc	cagacatttg	gccagggcac	caagctggag	atcaagtcgg	atcccggag	1380
cggaggggga	ggcagctgcc	cctacagcaa	ccccagcctg	tgcagcggag	gcggcggcag	1440
cgagctgccc	acccagggca	ccttctccaa	cgtgtccacc	aacgtgagcc	cagccaagcc	1500
caccaccacc	gcctgtcctt	attccaatcc	ttccctgtgt	gctcccacca	caacccccgc	1560
tccaaggccc	cctacccccg	caccaactat	tgctctccag	ccactctcac	tgcggcctga	1620
ggcctgtcgg	cccgtgtctg	gaggcgagct	gcatacaagg	ggcctcgatt	tcgcctgcga	1680
tatttacatc	tgggcacccc	tcgccggcac	ctgcgggggtg	cttctcctct	ccctgggtgat	1740
taccctgtat	tgcagacggg	gccggaagaa	gctcctctac	atttttaagc	agcctttcat	1800
gcggccagtg	cagacaaccc	aagaggagga	tgggtgttcc	tgcagattcc	ctgaggaaga	1860
ggaaggcggg	tgcgagctga	gagtgaagtt	ctccaggagc	gcagatgccc	ccgcctatca	1920
acagggccag	aaccagctct	acaacgagct	taacctcggg	aggcgcgaag	aatacgacgt	1980
gttgataaag	agaagggggc	gggaccccga	gatgggagga	aagccccgga	ggaagaaccc	2040
tcaggagggc	ctgtacaacg	agctgcagaa	ggataagatg	gccgaggcct	actcagagat	2100
cgggatgaag	ggggagcggc	gccgcgggaa	ggggcacgat	gggctctacc	aggggctgag	2160
cacagccaca	aaggacacat	acgacgcctt	gcacatgcag	gcccttccac	cccgggaata	2220
gtctagaggg	cccgtttaaa	cccgtgatc	agcctcgact	gtgccttcta	gttgccagcc	2280
atctgttgtt	tgcccctccc	ccgtgccttc	cttgaccctg	gaagggtgcca	ctcccactgt	2340
cctttcctaa	taaaatgagg	aaattgcatc	gcattgtctg	agtaggtgtc	attctattct	2400
gggggggtggg	gtggggcagg	acagcaaggg	ggaggattgg	gaagacaata	gcaggcatgc	2460
tggggatgcg	gtgggctcta	tgactagtgg	cgaattcccg	tgtaccagct	gagagactct	2520
aaatccagtg	acaagtctgt	ctgcctattc	accgattttg	attctcaaac	aaatgtgtca	2580
caaagtaagg	attctgatgt	gtatatcaca	gacaaaactg	tgctagacat	gagggtctatg	2640
gacttcaaga	gcaacagtgc	tgtggcctgg	agcaacaaat	ctgactttgc	atgtgcaaac	2700
gccttcaaca	acagcattat	tccagaagac	accttcttcc	ccagcccagg	taagggcagc	2760
tttggtgcct	tcgcaggctg	tttccttgct	tcaggaatgg	ccaggttctg	cccagagctc	2820
tggatcaatga	tgtctaaaac	tcctctgatt	ggtggtctcg	gccttatcca	ttgccaccaa	2880
aaccctcttt	ttactaa					2897

<210> 32

<211> 2688

<212> DNA

<213> artificial sequence

<220>

<223> Matrice CD25 locus\_IL15\_2A\_sIL15Ra pCLS30519

<400> 32

gtttattatt	cctgttccac	agctattgtc	tgccatataa	aaacttaggc	caggcacagt	60
ggctcacacc	tgtaatccca	gcactttgga	aggccgaggc	aggcagatca	caaggtcagg	120
agttcgagac	cagcctggcc	aacatagcaa	aaccccatct	ctactaaaaa	tacaaaaatt	180
agccaggcat	ggtggcgtgt	gcactggttt	agagttagga	ccacattttt	ttggtgccgt	240
gttacacata	tgaccgtgac	tttgttacac	cactacagga	ggaagagtag	aagaacaatc	300
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaaccag	ggcccgtac	cgggtccgcc	accatggact	ggacctggat	tctgttcctc	420

eolf-seql (10).txt

gtggctgctg	ctacaagagt	gcacagcggc	attcatgtct	tcattttggg	ctgtttcagt	480
gcagggcttc	ctaaaacaga	agccaactgg	gtgaatgtaa	taagtgattt	gaaaaaaatt	540
gaagatctta	ttcaatctat	gcatattgat	gctactttat	atacggaag	tgatgttcac	600
cccagttgca	aagtaacagc	aatgaagtgc	tttctcttgg	agttacaagt	tatttcactt	660
gagtccggag	atgcaagtat	tcatgataca	gtagaaaatc	tgatcatcct	agcaaacaac	720
agtttgtctt	ctaattgggaa	tgtaacagaa	tctggatgca	aagaatgtga	ggaactggag	780
gaaaaaaata	ttaaagaatt	tttgcaagat	tttgtacata	ttgtccaaat	gttcatcaac	840
acttctggaa	gcggagctac	taacttcagc	ctgctgaagc	aggctggaga	cgtggaggag	900
aaccctggac	ctgggaccgg	ctctgcaacc	atggattgga	cgtggatcct	gtttctcgtg	960
gcagctgcca	caagagttca	cagtatcacg	tgccctcccc	ccatgtccgt	ggaacacgca	1020
gacatctggg	tcaagagcta	cagcttgtag	tccagggagc	ggtacatttg	taactctggt	1080
ttcaagcgta	aagccggcac	gtccagcctg	acggagtgcg	tggtgaacaa	ggccacgaat	1140
gtcgcccact	ggacaacccc	cagtctcaaa	tgcattagag	accctgccct	ggttcaccaa	1200
aggccagcgc	caccctccac	agtaacgacg	gcaggggtga	ccccacagcc	agagagcctc	1260
tcccccttctg	gaaaagagcc	cgcagcttca	tctcccagct	caaacaacac	agcggccaca	1320
acagcagcta	ttgtcccggg	ctcccagctg	atgccttcaa	aatcaccttc	cacaggaacc	1380
acagagataa	gcagtcatga	gtcctcccac	ggcaccctct	ctcagacaac	agccaagaac	1440
tgggaactca	cagcatccgc	ctcccaccag	ccgccaggtg	tgtatccaca	gggccacagc	1500
gacaccactg	agggcagagg	cagcctgctg	acctgcggcg	acgtcgagga	gaaccccggg	1560
cccatggggg	caggtgccac	cggccgcgcc	atggacgggc	cgcgcctgct	gctgttgctg	1620
cttctggggg	tgtcccttgg	aggtgccaa	gaggcatgcc	ccacaggcct	gtacacacac	1680
agcggtgagt	gctgcaaagc	ctgcaacctg	ggcgagggtg	tggcccagcc	ttgtggagcc	1740
aaccagaccg	tgtgtgagcc	ctgcctggac	agcgtgacgt	tctccgacgt	ggtgagcgcg	1800
accgagccgt	gcaagccgtg	caccgagtgc	gtggggctcc	agagcatgtc	ggcgccgtgc	1860
gtggaggccg	atgacgccgt	gtgccgctgc	gcctacggct	actaccagga	tgagacgact	1920
gggcgctgcg	aggcgtgccg	cgtgtgagag	gcgggctcgg	gcctcgtgtt	ctcctgccag	1980
gacaagcaga	acaccgtgtg	cgaggagtgc	cccagcggca	cgtattccga	cgaggccaac	2040
cacgtggacc	cgtgcctgcc	ctgcaccgtg	tgcaggagca	ccgagcgcca	gctccgcgag	2100
tgcacacgct	gggccgacgc	cgagtgcgag	gagatccctg	gccgttggtg	tacacggtcc	2160
acacccccag	agggtcggga	cagcacagcc	cccagcacc	aggagcctga	ggcacctcca	2220
gaacaagacc	tcatagccag	cacggtggca	ggtgtggtga	ccacagtgat	gggcagctcc	2280
cagcccgtgg	tgacccgagg	caccaccgac	aacctcatcc	ctgtctattg	ctccatcctg	2340
gctgctgtgg	ttgtgggtct	tgtggcctac	atagccttca	agaggtgaaa	aaccaaaga	2400
acaagaattt	cttggtgaaga	agccgggaac	agacaacaga	agtcatgaag	cccaagtga	2460
atcaaagggtg	ctaaatggtc	gcccaggaga	catccgttgt	gcttgccctgc	gttttgaag	2520
ctctgaagtc	acatcacagg	acacggggca	gtggcaacct	tgtctctatg	ccagctcagt	2580
cccatcagag	agcgagcgct	acccacttct	aaatagcaat	ttcgccgttg	aagaggaagg	2640
gcaaaaccac	tagaactctc	catcttattt	tcatgtatat	gtgttcat		2688

<210> 33

<211> 2964

<212> DNA

<213> artificial sequence

<220>

<223> Matrice PD1 locus\_IL15\_2A\_sIL15Ra pCLS30513

eolf-seql (10).txt

<400> 33

gactccccag	acaggccctg	gaaccccccc	accttctccc	cagccctgct	cgtggtgacc	60
gaaggggaca	acgccacctt	cacctgcagc	ttctccaaca	catcggagag	cttcgtgcta	120
aactggtacc	gcatgagccc	cagcaaccag	acggacaagc	tggccgcctt	ccccgaggac	180
cgcagccagc	ccggccagga	ctgccgcttc	cgtgtcacac	aactgccccaa	cgggcgtgac	240
ttccacatga	gcgtggtcag	ggccccggcg	aatgacagcg	gcacctacct	ctgtggggcc	300
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaacccag	ggcccggtag	cgggtccgcc	accatggact	ggacctggat	tctgttcctc	420
gtggctgctg	ctacaagagt	gcacagcggc	attcatgtct	tcattttggg	ctgtttcagt	480
gcagggttc	ctaaaacaga	agccaactgg	gtgaatgtaa	taagtgattt	gaaaaaaatt	540
gaagatctta	ttcaatctat	gcatattgat	gctactttat	atacggaag	tgatgttcac	600
cccagttgca	aagtaacagc	aatgaagtgc	tttctcttgg	agttacaagt	tatttcactt	660
gagtccggag	atgcaagtat	tcatgataca	gtagaaaatc	tgatcatcct	agcaaacaac	720
agtttgtctt	ctaattggga	tgtaacagaa	tctggatgca	aagaatgtga	ggaactggag	780
gaaaaaaata	ttaaagaatt	tttgagagt	ttgtacata	ttgtccaaat	gttcatcaac	840
acttctggaa	gcggagctac	taacttcagc	ctgctgaagc	aggctggaga	cgtggaggag	900
aaccttgga	ctgggaccgg	ctctgcaacc	atggattgga	cgtggatcct	gtttctcgtg	960
gcagctgcca	caagagttca	cagtatcacg	tgccctcccc	ccatgtccgt	ggaacacgca	1020
gacatctggg	tcaagagcta	cagcttgtag	tccaggaggc	ggtacatttg	taactctggt	1080
ttcaagcgta	aagccggcac	gtccagcctg	acggagtgcg	tggtgaacaa	ggccacgaat	1140
gtcggccact	ggacaacccc	cagtctcaaa	tgcattagag	accctgccct	ggttcaccaa	1200
aggccagcgc	cacctccac	agtaacgacg	gcaggggtga	ccccacagcc	agagagcctc	1260
tcccccttctg	gaaaagagcc	cgcagcttca	tctcccagct	caaacaacac	agcggccaca	1320
acagcagcta	ttgtcccggg	ctcccagctg	atgccttcaa	aatcaccttc	cacaggaacc	1380
acagagataa	gcagtcatga	gtcctccccc	ggcaccctct	ctcagacaac	agccaagaac	1440
tgggaactca	cagcatccgc	ctcccaccag	ccgccagggtg	tgtatccaca	gggccacagc	1500
gacaccactg	agggcagagg	cagcctgctg	acctgcggcg	acgtcgagga	gaaccccggg	1560
cccatggggg	caggtgccac	cggccgcgcc	atggacgggc	cgcgcctgct	gctgttgctg	1620
cttctggggg	tgtcccttgg	aggtgccaag	gaggcatgcc	ccacaggcct	gtacacacac	1680
agcggtgagt	gctgcaaagc	ctgcaacctg	ggcgagggtg	tggcccagcc	ttgtggagcc	1740
aaccagaccg	tgtgtgagcc	ctgcctggac	agcgtgacgt	tctccgacgt	ggtgagcgcg	1800
accgagccgt	gcaagccgtg	caccgagtgc	gtggggctcc	agagcatgtc	ggcgccgtgc	1860
gtggaggccg	atgacgccgt	gtgccgctgc	gcctacggct	actaccagga	tgagacgact	1920
gggcgctgcg	aggcgtgccg	cgtgtgcgag	gcgggctcgg	gcctcgtgtt	ctcctgccag	1980
gacaagcaga	acaccgtgtg	cgaggagtgc	cccagcggca	cgtattccga	cgaggccaac	2040
cacgtggacc	cgtgcctgcc	ctgcaccgtg	tgagaggaca	ccgagcgcca	gctccgcgag	2100
tgacacacgt	gggccgacgc	cgagtgcgag	gagatccctg	gccgttggat	tacacggtcc	2160
acacccccag	agggctcgga	cagcacagcc	cccagcaccc	aggagcctga	ggcacctcca	2220
gaacaagacc	tcatagccag	cacggtggca	ggtgtggtga	ccacagtgat	gggcagctcc	2280
cagcccgtgg	tgacccgagg	caccaccgac	aacctcatcc	ctgtctattg	ctccatcctg	2340
gctgctgtgg	ttgtgggtct	tgtggcctac	atagccttca	agaggtgatc	tagagggccc	2400
gtttaaaacc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	tggtgtttgc	2460
ccctcccccg	tgctttcctt	gacctggaa	ggtgccactc	ccactgtcct	ttcctaataa	2520
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	2580
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	2640
ggctctatga	ctagtggcga	attcggcgca	gatcaaagag	agcctgcggg	cagagctcag	2700
ggtgacaggt	gcggcctcgg	aggccccggg	gcaggggtga	gctgagccgg	tcctgggggtg	2760

eolf-seql (10).txt

ggtgtccccct	cctgcacagg	atcaggagct	ccagggtcgt	agggcaggga	ccccccagct	2820
ccagtccagg	gctctgtcct	gcacctgggg	aatgggtgacc	ggcatctctg	tcctctagct	2880
ctggaagcac	cccagcccct	ctagtctgcc	ctcaccctg	accctgaccc	tccaccctga	2940
ccccgtccta	accctgacc	tttg				2964

<210> 34

<211> 3363

<212> DNA

<213> artificial sequence

<220>

<223> Matrice CD25 locus\_IL12a\_2A\_IL12b pCLS30520

<400> 34

gtttattatt	cctgttccac	agctattgtc	tgccatataa	aaacttaggc	caggcacagt	60
ggctcacacc	tgtaatccca	gcactttgga	aggccgaggc	aggcagatca	caaggtcagg	120
agttcgagac	cagcctggcc	aacatagcaa	aaccccatct	ctactaaaaa	tacaaaaatt	180
agccaggcat	ggtggcgtgt	gcactggttt	agagtgagga	ccacattttt	ttggtgccgt	240
gttacacata	tgaccgtgac	tttgttacac	cactacagga	ggaagagtag	aagaacaatc	300
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaaccag	ggcccatgtg	gccccctggg	tcagcctccc	agccaccgcc	ctcacctgcc	420
gcggccacag	gtctgcatcc	agcggctcgc	cctgtgtccc	tgcaagtccg	gctcagcatg	480
tgtccagcgc	gcagcctcct	ccttgtggct	accctgggtc	tcctggacca	cctcagtttg	540
gccagaaacc	tccccgtggc	cactccagac	ccaggaatgt	tcccatgcct	tcaccactcc	600
caaaacctgc	tgagggccgt	cagcaacatg	ctccagaagg	ccagacaaac	tctagaattt	660
tacccttgca	cttctgaaga	gattgatcat	gaagatatca	caaaagataa	aaccagcaca	720
gtggaggcct	gtttaccatt	ggaattaacc	aagaatgaga	gttgccctaaa	ttccagagag	780
acctctttca	taactaatgg	gagttgcctg	gcctccagaa	agacctcttt	tatgatggcc	840
ctgtgcctta	gtagtattta	tgaagacttg	aagatgtacc	aggtggagtt	caagaccatg	900
aatgcaaagc	ttctgatgga	tcctaagagg	cagatctttc	tagatcaaaa	catgctggca	960
gttattgatg	agctgatgca	ggccctgaat	ttcaacagtg	agactgtgcc	acaaaaatcc	1020
tcccttgaag	aaccggattt	ttataaaact	aaaatcaagc	tctgcatact	tcttcatgct	1080
ttcagaattc	gggcagtgc	tattgataga	gtgatgagct	atctgaatgc	ttccggaagc	1140
ggagctacta	acttcagcct	gctgaagcag	gctggagacg	tgaggagaaa	ccctggacct	1200
atgtgtcacc	agcagttggt	catctcttgg	ttttccctgg	tttttctggc	atctcccctc	1260
gtggccatat	gggaactgaa	gaaagatgtt	tatgtcgtag	aattggattg	gtatccggat	1320
gcccctggag	aaatggtggt	cctcacctgt	gacaccctg	aagaagatgg	tatcacctgg	1380
accttggacc	agagcagtga	ggtcttaggc	tctggcaaaa	ccctgaccat	ccaagtcaaa	1440
gagtttggag	atgctggcca	gtacacctgt	cacaaaggag	gcgaggttct	aagccattcg	1500
ctcctgctgc	ttcacaaaaa	ggaagatgga	atgtgttcca	ctgatatttt	aaaggaccag	1560
aaagaacca	aaaataagac	ctttctaaga	tgcgaggcca	agaattattc	tggaagtgtt	1620
acctgctggt	ggctgacgac	aatcagtact	gatttgacat	tcagtgtcaa	aagcagcaga	1680
ggctcttctg	acccccaagg	ggtgacgtgc	ggagctgcta	cactctctgc	agagagagtc	1740
agagggggaca	acaaggagta	tgagtactca	gtggagtgcc	aggaggacag	tgctgcccc	1800
gctgctgagg	agagtctgcc	cattgaggtc	atggtggatg	ccgttcacaa	gctcaagtat	1860
gaaaactaca	ccagcagctt	cttcacagg	gacatcatca	aacctgaccc	acccaagaac	1920

eolf-seql (10).txt

ttgcagctga	agccattaaa	gaattctcgg	caggtggagg	tcagctggga	gtaccctgac	1980
acctggagta	ctccacattc	ctacttctcc	ctgacattct	gcgttcaggt	ccagggcaag	2040
agcaagagag	aaaagaaaga	tagagtcttc	acggacaaga	cctcagccac	ggcatctgct	2100
cgcaaaaatg	ccagcattag	cgtgcggggc	caggaccgct	actatagctc	atcttgagac	2160
gaatgggcat	ctgtgccctg	cagtgagggc	agaggcagcc	tgctgacctg	cggcgacgtc	2220
gaggagaacc	ccggggccat	gggggcaggt	gccaccggcc	gcgccatgga	cggggccgcgc	2280
ctgctgctgt	tgctgcttct	gggggtgtcc	cttgagggtg	ccaaggaggc	atgccccaca	2340
ggcctgtaca	cacacagcgg	tgagtgtctg	aaagcctgca	acctgggcga	gggtgtggcc	2400
cagccttgct	gagccaacca	gaccgtgtgt	gagccctgcc	tggacagcgt	gacgttctcc	2460
gacgtgggtg	gcgcgaccga	gccgtgcaag	ccgtgcaccg	agtgcgtggg	gctccagagc	2520
atgtcggcgc	cgtgcgtgga	ggccgatgac	gccgtgtgcc	gctgcgccta	cggctactac	2580
caggatgaga	cgactgggcg	ctgcgaggcg	tgccgcgtgt	gcgaggcggg	ctcgggcctc	2640
gtgttctcct	gccaggacaa	gcagaacacc	gtgtgcgagg	agtgccccga	cggcacgtat	2700
tccgacgagg	ccaaccacgt	ggacccgtgc	ctgccctgca	ccgtgtgcga	ggacaccgag	2760
cgccagctcc	gcgagtgcac	acgctggggc	gacgccgagt	gcgaggagat	ccctggccgt	2820
tggattacac	ggtccacacc	cccagagggc	tcggacagca	cagccccag	caccaggag	2880
cctgaggcac	ctccagaaca	agacctcata	gccagcacgg	tggcaggtgt	ggtgaccaca	2940
gtgatgggca	gtccccagcc	cgtgggtgacc	cgaggcacca	ccgacaacct	catccctgtc	3000
tattgtctca	tcctggctgc	tgtgggtgtg	ggtcttgtgg	cctacatagc	cttcaagagg	3060
tgaaaaacca	aaagaacaag	aatttcttgg	taagaagccg	ggaacagaca	acagaagtca	3120
tgaagcccaa	gtgaaatcaa	aggtgctaaa	tggtcgccca	ggagacatcc	gttgtgcttg	3180
cctgcgtttt	ggaagctctg	aagtcacatc	acaggacacg	gggcagtggc	aaccttgtct	3240
ctatgccagc	tcagtcccat	cagagagcga	gcgctaccca	cttctaaata	gcaatttcgc	3300
cgttgaagag	gaagggcaaa	accactagaa	ctctccatct	tattttcatg	tatatgtgtt	3360
cat						3363

<210> 35

<211> 3639

<212> DNA

<213> artificial sequence

<220>

<223> Matrice PD1 locus\_IL12a\_2A\_IL12b pCLS30511

<400> 35

gactccccag	acaggccctg	gaaccccccc	accttctccc	cagccctgct	cgtggtgacc	60
gaagggggaca	acgccacctt	cacctgcagc	ttctccaaca	catcggagag	cttcgtgcta	120
aactggtacc	gcatgagccc	cagcaaccag	acggacaagc	tggccgcctt	ccccgaggac	180
cgcagccagc	ccggccagga	ctgccgcttc	cgtgtcacac	aactgccccaa	cgggcgtgac	240
ttccacatga	gcgtggctag	ggcccggcgc	aatgacagcg	gcacctacct	ctgtggggcc	300
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaacccag	ggcccatgtg	gccccctggg	tcagcctccc	agccaccgcc	ctcacctgcc	420
gcggccacag	gtctgcatcc	agcggctcgc	cctgtgtccc	tgcaagtccg	gctcagcatg	480
tgtccagcgc	gcagcctcct	ccttgtggct	accctggtcc	tcctggacca	cctcagtttg	540
gccagaaacc	tccccgtggc	cactccagac	ccaggaatgt	tcccatgcct	tcaccactcc	600
caaaacctgc	tgagggccgt	cagcaacatg	ctccagaagg	ccagacaaac	tctagaattt	660

eolf-seql (10).txt

tacccttgca	cttctgaaga	gattgatcat	gaagatatca	caaaagataa	aaccagcaca	720
gtggaggcct	gtttaccatt	ggaattaacc	agaatgaga	gttgcctaaa	ttccagagag	780
acctctttca	taactaatgg	gagttgcctg	gcctccagaa	agacctcttt	tatgatggcc	840
ctgtgcctta	gtagtattta	tgaagacttg	aagatgtacc	aggtggagtt	caagaccatg	900
aatgcaaagc	ttctgatgga	tcctaagagg	cagatctttc	tagatcaaaa	catgctggca	960
gttattgatg	agctgatgca	ggccctgaat	ttcaacagt	agactgtgcc	acaaaaatcc	1020
tcccttgaag	aaccggat	ttataaaact	aaaatcaagc	tctgcatact	tcttcatgct	1080
ttcagaattc	gggcagt	tattgataga	gtgatgagct	atctgaatgc	ttccggaagc	1140
ggagctacta	acttcagcct	gctgaagcag	gctggagacg	tggaggagaa	ccctggacct	1200
atgtgtcacc	agcagttggt	catctcttgg	ttttccctgg	tttttctggc	atctcccctc	1260
gtggccatat	gggaactgaa	gaaagatgtt	tatgtcgtag	aattggattg	gtatccggat	1320
gccccctggag	aaatggtggt	cctcacctgt	gacaccctg	aagaagatgg	tatcacctgg	1380
accttggacc	agagcagtga	ggtcttaggc	tctggcaaaa	ccctgaccat	ccaagtcaaa	1440
gagtttggag	atgctggcca	gtacacctgt	cacaaaggag	gcgaggttct	aagccattcg	1500
ctcctgctgc	ttcacaaaaa	ggaagatgga	atgttggtcca	ctgatatttt	aaaggaccag	1560
aaagaaccca	aaaataagac	ctttctaaga	tgcgaggcca	agaattattc	tggacgtttc	1620
acctgctggt	ggctgacgac	aatcagtact	gatttgacat	tcagtgtcaa	aagcagcaga	1680
ggctcttctg	acccccaagg	ggtgacgtgc	ggagctgcta	cactctctgc	agagagagtc	1740
agagggggaca	acaaggagta	tgagtactca	gtggagtgcc	aggaggacag	tgctgcccc	1800
gctgtgagg	agagtctgcc	cattgaggtc	atggtggatg	ccgttcacaa	gctcaagtat	1860
gaaaactaca	ccagcagctt	cttcatcagg	gacatcatca	aacctgacc	acccaagaac	1920
ttgcagctga	agccattaaa	gaattctcgg	caggtggagg	tcagctggga	gtaccctgac	1980
acctggagta	ctccacattc	ctacttctcc	ctgacattct	gcgttcaggt	ccagggcaag	2040
agcaagagag	aaaagaaaga	tagagtcttc	acggacaaga	cctcagccac	ggtcatctgc	2100
cgcaaaaatg	ccagcattag	cgtgcggggc	caggaccgct	actatagctc	atcttggagc	2160
gaatgggcat	ctgtgccctg	cagtgagggc	agaggcagcc	tgctgacctg	cggcgacgtc	2220
gaggagaacc	ccggggccat	gggggcaggt	gccaccggcc	gcgccatgga	cgggcccgcgc	2280
ctgctgctgt	tgctgcttct	gggggtgtcc	cttggaggtg	ccaaggaggc	atgccccaca	2340
ggcctgtaca	cacacagcgg	tgagtgtgtc	aaagcctgca	acctgggcga	gggtgtggcc	2400
cagccttgtg	gagccaacca	gaccgtgtgt	gagccctgcc	tggacagcgt	gacgttctcc	2460
gacgtggtga	gcgcgaccga	gccgtgcaag	ccgtgcaccg	agtgcgtggg	gctccagagc	2520
atgtcggcgc	cgtgcgtgga	ggccgatgac	gccgtgtgcc	gctgcgccta	cggctactac	2580
caggatgaga	cgactgggcg	ctgcgaggcg	tgccgcgtgt	gcgaggcggg	ctcgggcctc	2640
gtgttctcct	gccaggacaa	gcagaacacc	gtgtgcgagg	agtgcccga	cggcacgtat	2700
tccgacgagg	ccaaccacgt	ggaccctgtc	ctgcccctgca	ccgtgtgcga	ggacaccgag	2760
cgccagctcc	gcgagtgcac	acgctggggc	gacgccaggt	gcgaggagat	ccctggccgt	2820
tggattacac	ggtccacacc	cccagagggc	tcggacagca	cagccccag	caccaggag	2880
cctgaggcac	ctccagaaca	agacctcata	gccagcacgg	tggcaggtgt	ggtgaccaca	2940
gtgatgggca	gtccccagcc	cgtggtgacc	cgaggcacca	ccgacaacct	catccctgtc	3000
tattgtcca	tcctggctgc	tgtggttgtg	ggtccttgtg	cctacatagc	cttcaagagg	3060
tgatctagag	ggcccgttta	aaccgctga	tcagcctcga	ctgtgccttc	tagttgccag	3120
ccatctgttg	tttgcccctc	ccccgtgcct	tccttgacc	tggaaaggtgc	cactcccact	3180
gtcctttcct	aataaaatga	ggaaattgca	tcgcattgtc	tgagtaggtg	tcattctatt	3240
ctgggggggtg	gggtggggca	ggacagcaag	ggggaggatt	gggaagacaa	tagcaggcat	3300
gctgggggatg	cggtgggctc	tatgactagt	ggcgaattcg	gcgcagatca	aagagagcct	3360
gcgggcagag	ctcagggtga	caggtgcggc	ctcggaggcc	ccggggcagg	ggtgagctga	3420
gccggtcctg	gggtgggtgt	ccccctctgc	acaggatcag	gagctccagg	gtcgtagggc	3480
agggaccccc	cagctccagt	ccagggtctc	gtcctgcacc	tggggaatgg	tgaccggcat	3540

eolf-seql (10).txt

ctctgtcctc	tagctctgga	agcaccacag	cccctctagt	ctgccctcac	ccctgaccct	3600
gaccctccac	cctgaccccg	tcctaaccac	tgacctttg			3639

<210> 36

<211> 3017

<212> DNA

<213> artificial sequence

<220>

<223> Inserted matrice TRAC locus\_CubiCAR CD22 (60 nucleotides upstream and downstream)

<400> 36

atgagatcat	gtcctaacc	tgatcctctt	gtccacaga	tatccagaac	cctgaccctg	60
ttgctggg	ccat	gcctgccttt	actctgccag	agttatattg	ctgggggttt	120
gaagaagatc	ctattaaata	aaagaataag	cagtattatt	aagtagccct	gcatttcagg	180
tttccttgag	tgaggagcca	ggcctggccg	tgaacgttca	ctgaaatcat	ggcctcttgg	240
ccaagattga	tagcttgtgc	ctgtccctga	gtcccagtc	atcacgagca	gctgggtttct	300
aagatgctat	ttcccgata	aagcatgaga	ccgtgacttg	ccagcccccac	agagccccgc	360
ccttgccat	cactggcatc	tggactccag	cctgggttgg	ggcaaagagg	gaaatgagat	420
catgtcctaa	ccctgatcct	cttgtccac	agatatccag	taccctacg	acgtgcccga	480
ctacgcctcc	ggtgagggca	gaggaagtct	tctaacatgc	ggtgacgtgg	aggagaatcc	540
gggccccgga	tccgctctgc	ccgtcacccg	tctgctgctg	ccactggcac	tgctgctgca	600
cgctgctagg	cccggagggg	gaggcagctg	cccctacagc	aaccccagcc	tgtgcagcgg	660
aggcggcggc	agcggcggag	ggggtagcca	ggtgcagctg	cagcagagcg	gccctggcct	720
ggtgaagcca	agccagacac	tgtccctgac	ctgcgccatc	agcggcgatt	ccgtgagctc	780
caactccgcc	gcctggaatt	ggatcaggca	gtccccttct	cggggcctgg	agtggctggg	840
aaggacatac	tatcggtcta	agtgggtaca	cgattatgcc	gtgtctgtga	agagcagaat	900
cacaatcaac	cctgacacct	ccaagaatca	gttctctctg	cagctgaata	gcgtgacacc	960
agaggacacc	gccgtgtact	attgcgccag	ggaggtgacc	ggcgacctgg	aggatgcctt	1020
tgacatctgg	ggccagggca	caatggtgac	cgtgagctcc	ggaggcggcg	gatctggcgg	1080
aggagggaagt	gggggcggcg	ggagtgatat	ccagatgaca	cagtcccat	cctctctgag	1140
cgctccgtg	ggcgacagag	tgacaatcac	ctgtagggcc	tcccagacca	tctggtctta	1200
cctgaactgg	tatcagcaga	ggcccggcaa	ggccccta	ctgctgatct	acgcagcaag	1260
ctccctgcag	agcggagtgc	catccagatt	ctctggcagg	ggctccggca	cagacttcac	1320
cctgaccatc	tctagcctgc	aggccgagga	cttcgccacc	tactattgcc	agcagtctta	1380
tagcatcccc	cagacatttg	gccagggcac	caagctggag	atcaagtcgg	atcccggaag	1440
cggaggggga	ggcagctgcc	cctacagcaa	ccccagcctg	tgacagcgag	gcggcggcag	1500
cgagctgccc	accagggca	ccttctccaa	cgtgtccacc	aacgtgagcc	cagccaagcc	1560
caccaccacc	gcctgtcctt	attccaatcc	ttccctgtgt	gtcccacca	caacccccgc	1620
tccaaggccc	cctacccccg	caccaactat	tgctctccag	ccactctcac	tgcggcctga	1680
ggcctgtcgg	cccgtgctg	gaggcgagct	gcatacaagg	ggcctcgatt	tcgcctgcga	1740
tattttacatc	tgggcacccc	tcgccggcac	ctgcgggggtg	cttctcctct	ccctgggtgat	1800
taccctgtat	tgacagcggg	gccggaagaa	gctcctctac	atttttaagc	agcctttcat	1860
gcggccagtg	cagacaaccc	aagaggagga	tggtgttcc	tgacagattcc	ctgaggaaga	1920
ggaaggcggg	tgcgagctga	gagtgaagtt	ctccaggagc	gcagatgccc	ccgcctatca	1980

eolf-seql (10).txt

acagggccag	aaccagctct	acaacgagct	taacctcggg	aggcgcggaag	aatacgacgt	2040
gttggataag	agaagggggc	gggaccccga	gatgggagga	aagccccgga	ggaagaaccc	2100
tcaggagggc	ctgtacaacg	agctgcagaa	ggataagatg	gccgaggcct	actcagagat	2160
cgggatgaag	ggggagcggc	gccgcgggaa	ggggcacgat	gggctctacc	aggggctgag	2220
cacagccaca	aaggacacat	acgacgcctt	gcacatgcag	gcccttccac	cccgggaata	2280
gtctagaggg	cccgtttaaa	cccgtgatc	agcctcgact	gtgccttcta	gttgccagcc	2340
atctgttgtt	tgcccctccc	ccgtgccttc	cttgaccctg	gaaggtgcca	ctcccactgt	2400
cctttcctaa	taaaatgagg	aaattgcatc	gcattgtctg	agtaggtgtc	attctattct	2460
gggggggtggg	gtggggcagg	acagcaaggg	ggaggattgg	gaagacaata	gcaggcatgc	2520
tggggatgcg	gtgggctcta	tgactagtgg	cgaattcccg	tgtaccagct	gagagactct	2580
aaatccagtg	acaagtctgt	ctgcctattc	accgattttg	attctcaaac	aaatgtgtca	2640
caaagtaagg	attctgatgt	gtatatcaca	gacaaaactg	tgctagacat	gaggtctatg	2700
gacttcaaga	gcaacagtgc	tgtggcctgg	agcaacaaat	ctgactttgc	atgtgcaaac	2760
gccttcaaca	acagcattat	tccagaagac	accttcttcc	ccagcccagg	taagggcagc	2820
tttggtgcct	tcgcaggctg	tttccttgct	tcaggaatgg	ccaggttctg	cccagagctc	2880
tggtaaatga	tgtctaaaac	tcctctgatt	ggtggtctcg	gccttatcca	ttgccaccaa	2940
aaccctcttt	ttactaagaa	acagtgagcc	ttgttctggc	agtccagaga	atgacacggg	3000
aaaaaagcag	atgaaga					3017

<210> 37

<211> 2808

<212> DNA

<213> artificial sequence

<220>

<223> Inserted matrice CD25 locus\_IL15\_2A\_sIL15Ra (60 nucleotides upstream and downstream)

<400> 37

agtgtctggct	agaaaccaag	tgctttactg	catgcacatc	atttagcaca	gttagttgct	60
gtttattatt	cctgttccac	agctattgtc	tgccatataa	aaacttaggc	caggcacagt	120
ggctcacacc	tgtaatccca	gcactttgga	aggccgaggc	aggcagatca	caaggtcagg	180
agttcgagac	cagcctggcc	aacatagcaa	aaccccatct	ctactaaaaa	tacaaaaatt	240
agccaggcat	ggtggcgtgt	gcactggttt	agagtgagga	ccacattttt	ttggtgccgt	300
gttacacata	tgaccgtgac	tttgttacac	cactacagga	ggaagagtag	aagaacaatc	360
ggttctggcg	tgaaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	420
tccaacccag	ggcccggtag	cgggtccgcc	accatggact	ggacctggat	tctgttcctc	480
gtggctgctg	ctacaagagt	gcacagcggc	attcatgtct	tcattttggg	ctgtttcagt	540
gcagggcctt	ctaaaacaga	agccaactgg	gtgaatgtaa	taagtgattt	gaaaaaaatt	600
gaagatctta	ttcaatctat	gcatattgat	gctactttat	atacgaaaag	tgatgttcac	660
cccagttgca	aagtaacagc	aatgaagtgc	tttctcttgg	agttacaagt	tattttcactt	720
gagtcgggag	atgcaagtat	tcatgataca	gtagaaaatc	tgatcatcct	agcaaacaac	780
agtttgtctt	ctaatgggaa	tgtaacagaa	tctggatgca	aagaatgtga	ggaactggag	840
gaaaaaaata	ttaaagaatt	tttgagagat	ttgtacata	ttgtccaaat	gttcatcaac	900
acttctggaa	gcggagctac	taacttcagc	ctgctgaagc	aggctggaga	cgtggaggag	960
aaccctggac	ctgggaccgg	ctctgcaacc	atggattgga	cgtggatcct	gtttctcgtg	1020

eolf-seql (10).txt

gcagctgcca	caagagttca	cagtatcacg	tgccctcccc	ccatgtccgt	ggaacacgca	1080
gacatctggg	tcaagagcta	cagcttgtag	tccagggagc	ggtacatttg	taactctggt	1140
ttcaagcgta	aagccggcac	gtccagcctg	acggagtgcg	tgttgaacaa	ggccacgaat	1200
gtcgcccact	ggacaacccc	cagtctcaaa	tgcattagag	accctgccct	ggttcaccaa	1260
aggccagcgc	caccctccac	agtaacgacg	gcaggggtga	ccccacagcc	agagagcctc	1320
tccccttctg	gaaaagagcc	cgagcttca	tctcccagct	caaacaacac	agcggccaca	1380
acagcagcta	ttgtcccggg	ctcccagctg	atgccttcaa	aatcaccttc	cacaggaacc	1440
acagagataa	gcagtcatga	gtcctccac	ggcacccttc	ctcagacaac	agccaagaac	1500
tgggaactca	cagcatccgc	ctcccaccag	ccgccaggtg	tgtatccaca	gggccacagc	1560
gacaccactg	agggcagagg	cagcctgctg	acctgcggcg	acgtcgagga	gaaccccggg	1620
cccatggggg	caggtgccac	cggccgcgcc	atggacgggc	cgcgctgct	gctgttgctg	1680
cttctggggg	tgtcccttgg	aggtgccaa	gaggcatgcc	ccacaggcct	gtacacacac	1740
agcggtgagt	gctgcaaagc	ctgcaacctg	ggcgagggtg	tggcccagcc	ttgtggagcc	1800
aaccagaccg	tgtgtgagcc	ctgcctggac	agcgtgacgt	tctccgacgt	ggtgagcgcg	1860
accgagccgt	gcaagccgtg	caccgagtgc	gtggggctcc	agagcatgtc	ggcgccgtgc	1920
gtggaggccg	atgacgccgt	gtgccgctgc	gcctacggct	actaccagga	tgagacgact	1980
gggcgctgcg	aggcgtgccg	cgtgtgagag	gcgggctcgg	gcctcgtgtt	ctcctgccag	2040
gacaagcaga	acaccgtgtg	cgaggagtgc	cccgcaggca	cgtattccga	cgaggccaac	2100
cacgtggacc	cgtgcctgcc	ctgcaccgtg	tgcgaggaca	ccgagcgcca	gctccgcgag	2160
tgcacacgct	gggccgacgc	cgagtgcgag	gagatccctg	gccgttggtg	tacacggtcc	2220
acacccccag	agggtcggga	cagcacagcc	cccagcacc	aggagcctga	ggcacctcca	2280
gaacaagacc	tcatagccag	cacggtggca	ggtgtggtga	ccacagtgat	gggcagctcc	2340
cagcccgtgg	tgacccgagg	caccaccgac	aacctcatcc	ctgtctattg	ctccatcctg	2400
gctgctgtgg	ttgtgggtct	tgtggcctac	atagccttca	agaggtgaaa	aacaaaaaga	2460
acaagaattt	cttggtgaaga	agccgggaac	agacaacaga	agtcatgaag	cccaagtga	2520
atcaaagggtg	ctaaatgggtc	gcccaggaga	catccgttgt	gcttgccctgc	gtttttggaag	2580
ctctgaagtc	acatcacagg	acacggggca	gtggcaacct	tgtctctatg	ccagctcagt	2640
cccatcagag	agcgagcgct	acccacttct	aaatagcaat	ttcgccgttg	aagaggaagg	2700
gcaaaaccac	tagaactctc	catcttattt	tcatgtatat	gtgttcatta	aagcatgaat	2760
ggtatggaac	tctctccacc	ctatatgtag	tataaagaaa	agtaggtt		2808

<210> 38

<211> 3084

<212> DNA

<213> artificial sequence

<220>

<223> Inserted matrice PD1 locus\_IL15\_2A\_sIL15Ra (60 nucleotides upstream and downstream)

<400> 38

ggtggccggg	gaggctttgt	ggggccaccc	agccccttcc	tcacctctct	ccatctctca	60
gactccccag	acaggccctg	gaaccccccc	accttctccc	cagccctgct	cgtggtgacc	120
gaaggggaca	acgccacctt	cacctgcagc	ttctccaaca	catcgagag	cttcgtgcta	180
aactggtacc	gcatgagccc	cagcaaccag	acggacaagc	tggccgcctt	ccccgaggac	240
cgcagccagc	ccggccagga	ctgccgcttc	cgtgtcacac	aactgcccc	cgggcgtgac	300

eolf-seql (10).txt

ttccacatga	gcgtgggtcag	ggccccggcgc	aatgacagcg	gcacctacct	ctgtgggggcc	360
ggtttctggcg	tgaacagac	tttgaattttt	gaccttctca	agttggcggg	agacgtggag	420
tccaacccag	ggccccgtac	cgggtccgcc	accatggact	ggacctggat	tctgttcctc	480
gtggctgctg	ctacaagagt	gcacagcggc	attcatgtct	tcattttggg	ctgtttcagt	540
gcagggcctt	ctaaaacaga	agccaactgg	gtgaatgtaa	taagtgattt	gaaaaaaatt	600
gaagatctta	ttcaatctat	gcatattgat	gtacttttat	atacgaaaag	tgatgttcac	660
cccagttgca	aagtaacagc	aatgaagtgc	tttctcttgg	agttacaagt	tattttcactt	720
gagtcgggag	atgcaagtat	tcatgataca	gtagaaaatc	tgatcatcct	agcaaacaac	780
agtttgtctt	ctaattgggaa	tgtaacagaa	tctggatgca	aagaatgtga	ggaactggag	840
gaaaaaaaata	ttaaagaatt	tttgacagagt	tttgtacata	ttgtccaaat	gttcatcaac	900
acttctggaa	gcggagctac	taacttcagc	ctgctgaagc	aggctggaga	cgtggaggag	960
aaccttggac	ctgggaccgg	ctctgcaacc	atggattgga	cgtggatcct	gtttctcgtg	1020
gcagctgcca	caagagttca	cagtatcacg	tgccctcccc	ccatgtccgt	ggaacacgca	1080
gacatctggg	tcaagagcta	cagcttgtag	tccagggagc	ggtacatttg	taactctggt	1140
ttcaagcgta	aagccggcac	gtccagcctg	acggagtgcg	tgttgaacaa	ggccacgaat	1200
gtcgcctact	ggacaacccc	cagtctcaaa	tgcattagag	accctgccct	ggttcaccaa	1260
aggccagcgc	cacctccac	agtaacgacg	gcaggggtga	ccccacagcc	agagagcctc	1320
tccccctctg	gaaaagagcc	cgcagcttca	tctcccagct	caaacaacac	agcggccaca	1380
acagcagcta	ttgtcccggg	ctcccagctg	atgccttcaa	aatcaccttc	cacaggaacc	1440
acagagataa	gcagtcatga	gtcctccac	ggcaccctct	ctcagacaac	agccaagaac	1500
tgggaactca	cagcatccgc	ctcccaccag	ccgccaggtg	tgtatccaca	gggccacagc	1560
gacaccactg	agggcagagg	cagcctgctg	acctgcggcg	acgtcgagga	gaaccccggg	1620
cccatggggg	caggtgccac	cggccgcgcc	atggacgggc	cgcgcctgct	gctgttgctg	1680
cttctggggg	tgtcccttgg	aggtgccaaag	gaggcatgcc	ccacaggcct	gtacacacac	1740
agcggtgagt	gtcgaaaagc	ctgcaacctg	ggcgagggtg	tggcccagcc	ttgtggagcc	1800
aaccagaccg	tgtgtgagcc	ctgcctggac	agcgtgacgt	tctccgacgt	ggtgagcgcg	1860
accgagccgt	gcaagccgtg	caccgagtgc	gtggggctcc	agagcatgtc	ggcgccgtgc	1920
gtggaggccg	atgacgccgt	gtgccgctgc	gcctacggct	actaccagga	tgagacgact	1980
gggcgctgcg	aggcgtgccg	cgtgtgcgag	gcgggctcgg	gcctcgtgtt	ctcctgccag	2040
gacaagcaga	acaccgtgtg	cgaggagtgc	ccgacggca	cgtattccga	cgaggccaac	2100
cacgtggacc	cgtgcctgcc	ctgcaccgtg	tgcgaggaca	ccgagcgcca	gctccgcgag	2160
tgcacacgct	gggccgacgc	cgagtgcgag	gagatccctg	gccgttggat	tacacggtcc	2220
acacccccag	agggtctgga	cagcacagcc	cccagcacc	aggagcctga	ggcacctcca	2280
gaacaagacc	tcatagccag	cacggtggca	ggtgtggtga	ccacagtgat	gggcagctcc	2340
cagcccgtgg	tgacccgagg	caccaccgac	aacctcatcc	ctgtctattg	ctccatcctg	2400
gctgctgtgg	ttgtgggtct	tgtggcctac	atagccttca	agaggtgatc	tagagggccc	2460
gtttaaaccc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	tgttgtttgc	2520
ccctcccccg	tgccttctct	gacctggaa	ggtgccactc	ccactgtcct	ttcctaataa	2580
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	2640
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	2700
ggctctatga	ctagtggcga	attcggcgca	gatcaaagag	agcctgcggg	cagagctcag	2760
ggtgacaggt	gcggcctcgg	aggccccggg	gcaggggtga	gctgagccgg	tcctgggggtg	2820
ggtgtcccct	cctgcacagg	atcaggagct	ccagggtcgt	agggcaggga	ccccccagct	2880
ccagtccagg	gctctgtcct	gcacctgggg	aatggtgacc	ggcatctctg	tcctctagct	2940
ctggaagcac	cccagcccct	ctagtctgcc	ctcacccttg	accctgacct	tccaccctga	3000
ccccgtccta	accctgacc	tttgtgccct	tccagagaga	agggcagaag	tgcccacagc	3060
ccaccccagc	ccctcaccca	ggcc				3084

eolf-seql (10).txt

<210> 39

<211> 3475

<212> DNA

<213> artificial sequence

<220>

<223> Inserted matrice CD25 locus\_IL12a\_2A\_IL12b (60 nucleotides upstream and downstream)

<400> 39

agtgctggct	agaaaccaag	tgctttactg	catgcacatc	atttagcaca	gttagttgct	60
gtttattatt	cctgttccac	agctattgtc	tgccatataa	aaacttaggc	caggcacagt	120
ggctcacacc	tgtaatccca	gcactttgga	aggccgaggc	aggcagatca	caaggtcagg	180
agttcgagac	cagcctggcc	aacatagcaa	aaccccatct	ctactaaaaa	tacaaaaatt	240
agccaggcat	ggtggcgtgt	gcactggttt	agagttagga	ccacattttt	ttggtgccgt	300
gttacacata	tgaccgtgac	tttgttacac	cactacagga	ggaagagtag	aagaacaatc	360
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	420
tccaaccag	ggcccatgtg	gccccctggg	tcagcctccc	agccaccgcc	ctcacctgcc	480
gcggccacag	gtctgcatcc	agcggctcgc	cctgtgtccc	tgcaagtgcc	gctcagcatg	540
tgtccagcgc	gcagcctcct	ccttgtggct	accctggctc	tcctggacca	cctcagtttg	600
gccagaaacc	tccccgtggc	cactccagac	ccaggaatgt	tcccatgcct	tcaccactcc	660
caaaacctgc	tgagggccgt	cagcaacatg	ctccagaagg	ccagacaaac	tctagaatth	720
tacccttgca	cttctgaaga	gattgatcat	gaagatatca	caaaagataa	aaccagcaca	780
gtggaggcct	gtttaccatt	ggaattaacc	aagaatgaga	gttgccctaaa	ttccagagag	840
acctctttca	taactaatgg	gagttgcctg	gcctccagaa	agacctcttt	tatgatggcc	900
ctgtgcctta	gtagtattta	tgaagacttg	aagatgtacc	aggtggagtt	caagaccatg	960
aatgcaaagc	ttctgatgga	tcctaagagg	cagatctttc	tagatcaaaa	catgctggca	1020
gttattgatg	agctgatgca	ggccctgaat	ttcaacagtg	agactgtgcc	acaaaaatcc	1080
tcccttgaag	aaccggatth	ttataaaact	aaaatcaagc	tctgcatact	tcttcatgct	1140
ttcagaattc	gggcagtgac	tattgataga	gtgatgagct	atctgaatgc	ttccggaagc	1200
ggagctacta	acttcagcct	gctgaagcag	gctggagacg	tgaggagagaa	ccctggacct	1260
atgtgtcacc	agcagttggg	catctcttgg	ttttccctgg	tttttctggc	atctcccctc	1320
gtggccatat	gggaactgaa	gaaagatgtt	tatgtcgtag	aattggattg	gtatccggat	1380
gcccctggag	aaatgggtgg	cctcacctgt	gacacccctg	aagaagatgg	tatcacctgg	1440
accttggacc	agagcagtga	ggtcttaggc	tctggcaaaa	ccctgaccat	ccaagtcaaa	1500
gagtttggag	atgctggcca	gtacacctgt	cacaaaggag	gcgaggttct	aagccattcg	1560
ctcctgctgc	ttcacaaaaa	ggaagatgga	atttgggtcca	ctgatatttt	aaaggaccag	1620
aaagaacca	aaaataagac	ctttctaaga	tgcgaggcca	agaattattc	tggacgtttc	1680
acctgctggg	ggctgacgac	aatcagtact	gatttgacat	tcagtgtcaa	aagcagcaga	1740
ggctcttctg	acccccaagg	ggtgacgtgc	ggagctgcta	cactctctgc	agagagagtc	1800
agagggggaca	acaaggagta	tgagtactca	gtggagtgcc	aggaggacag	tgcttgccca	1860
gctgctgagg	agagtctgcc	cattgaggtc	atgggtggatg	ccgttcacaa	gctcaagtat	1920
gaaaactaca	ccagcagctt	cttcatcagg	gacatcatca	aacctgaccc	acccaagaac	1980
ttgcagctga	agccattaaa	gaattctcgg	caggtggagg	tcagctggga	gtaccctgac	2040
acctggagta	ctccacattc	ctacttctcc	ctgacattct	gcgttcaggt	ccagggaag	2100
agcaagagag	aaaagaaaga	tagagtcttc	acggacaaga	cctcagccac	ggtcatctgc	2160

eolf-seql (10).txt

cgcaaaaatg	ccagcattag	cgtgcggggc	caggaccgct	actatagctc	atcttggagc	2220
gaatgggcat	ctgtgccctg	cagtgagggc	agaggcagcc	tgctgacctg	cggcgacgtc	2280
gaggagaacc	ccggggcccat	gggggcaggt	gccaccggcc	gcgccatgga	cgggcccgcgc	2340
ctgctgctgt	tgctgcttct	gggggtgtcc	cttgagggtg	ccaaggaggc	atgccccaca	2400
ggcctgtaca	cacacagcgg	tgagtgtctg	aaagcctgca	acctgggcga	gggtgtggcc	2460
cagccttgtg	gagccaacca	gaccgtgtgt	gagccctgcc	tggacagcgt	gacgttctcc	2520
gacgtggtga	gcgcgaccga	gccgtgcaag	ccgtgcaccg	agtgcgtggg	gctccagagc	2580
atgtcggcgc	cgtgcgtgga	ggccgatgac	gccgtgtgcc	gctgcgccta	cggctactac	2640
caggatgaga	cgactgggcg	ctgcgaggcg	tgccgcgtgt	gcgaggcggg	ctcgggcctc	2700
gtgttctcct	gccaggacaa	gcagaacacc	gtgtgcgagg	agtgccccga	cggcacgtat	2760
tccgacgagg	ccaaccacgt	ggacccgtgc	ctgccctgca	ccgtgtgcga	ggacaccgag	2820
cgccagctcc	gcgagtgcac	acgctggggc	gacgccgagt	gcgaggagat	ccctggccgt	2880
tggattacac	ggtccacacc	cccagagggc	tcggacagca	cagccccag	caccagagg	2940
cctgaggcac	ctccagaaca	agacctcata	gccagcacgg	tggcaggtgt	ggtgaccaca	3000
gtgatgggca	gctcccagcc	cgtggtgacc	cgaggcacca	ccgacaacct	catccctgtc	3060
tattgctcca	tcctggctgc	tgtggttgtg	ggtcttgtgg	cctacatagc	cttcaagagg	3120
tgaaaaacca	aaagaacaag	aatttcttgg	taagaagccg	ggaacagaca	acagaagtca	3180
tgaagcccaa	gtgaaatcaa	aggtgctaaa	tggtcgcccc	ggagacatcc	gttgtgcttg	3240
cctgcgtttt	ggaagctctg	aagtcacatc	acaggacacg	gggcagtggc	aaccttgtct	3300
ctatgccagc	tcagtcccat	cagagagcga	gcgctaccca	cttctaaata	gcaatttcgc	3360
cgttgaagag	gaagggcaaa	accactagaa	ctctccatct	tattttcatg	tatatgtgtt	3420
catgaatggt	atggaactct	ctccacccta	tatgtagtat	aaagaaaagt	aggtt	3475

<210> 40

<211> 3759

<212> DNA

<213> artificial sequence

<220>

<223> Inserted matrice PD1 locus\_IL12a\_2A\_IL12b (60 nucleotides upstream and downstream)

<400> 40

ggtggccggg	gaggctttgt	ggggccaccc	agcccccttc	tcacctctct	ccatctctca	60
gactccccag	acaggccctg	gaaccccccc	accttctccc	cagccctgct	cgtggtgacc	120
gaagggggaca	acgccacctt	cacctgcagc	ttctccaaca	catcggagag	cttcgtgcta	180
aactggtacc	gcatgagccc	cagcaaccag	acggacaagc	tggccgcctt	ccccgaggac	240
cgcagccagc	ccggccagga	ctgccgcttc	cgtgtcacac	aactgcccaa	cgggcgtgac	300
ttccacatga	gcgtggtcag	ggcccggcgc	aatgacagcg	gcacctacct	ctgtggggcc	360
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	420
tccaaccag	ggcccatgtg	gccccctggg	tcagcctccc	agccaccgcc	ctcacctgcc	480
gcggccacag	gtctgcatcc	agcggctcgc	cctgtgtccc	tgcagtgccg	gctcagcatg	540
tgtccagcgc	gcagcctcct	ccttgtggct	accctggtcc	tcctggacca	cctcagtttg	600
gccagaaacc	tccccgtggc	cactccagac	ccaggaatgt	tcccatgcct	tcaccactcc	660
caaaacctgc	tgagggccgt	cagcaacatg	ctccagaagg	ccagacaaac	tctagaattt	720
tacccttgca	cttctgaaga	gattgatcat	gaagatatca	caaaaagataa	aaccagcaca	780

eolf-seql (10).txt

gtggaggcct	gtttaccatt	ggaattaacc	aagaatgaga	gttgcctaaa	ttccagagag	840
acctctttca	taactaatgg	gagttgcctg	gcctccagaa	agacctcttt	tatgatggcc	900
ctgtgcctta	gtagtattta	tgaagacttg	aagatgtacc	aggtggagtt	caagaccatg	960
aatgcaaagc	ttctgatgga	tcctaagagg	cagatctttc	tagatcaaaa	catgctggca	1020
gttattgatg	agctgatgca	ggccctgaat	ttcaacagtg	agactgtgcc	acaaaaatcc	1080
tcccttgaag	aaccggatth	ttataaaact	aaaatcaagc	tctgcatact	tcttcatgct	1140
ttcagaattc	gggcagtgac	tattgataga	gtgatgagct	atctgaatgc	ttccggaagc	1200
ggagctacta	acttcagcct	gctgaagcag	gctggagacg	tggaggagaa	ccctggacct	1260
atgtgtcacc	agcagttggt	catctcttgg	ttttccctgg	tttttctggc	atctcccctc	1320
gtggccatat	gggaactgaa	gaaagatgtt	tatgtcgtag	aattggattg	gtatccggat	1380
gcccctggag	aaatggtggt	cctcacctgt	gacacccctg	aagaagatgg	tatcacctgg	1440
accttgacc	agagcagtg	ggtcttaggc	tctggcaaaa	ccctgacct	ccaagtcaaa	1500
gagtttgag	atgctggcca	gtacacctgt	cacaaaggag	gcgaggttct	aagccattcg	1560
ctcctgctgc	ttcacaaaa	ggaagatgga	atgttggtcca	ctgatatttt	aaaggaccag	1620
aaagaacca	aaaataagac	ctttctaaga	tgcgaggcca	agaattattc	tggacgtttc	1680
acctgctggt	ggctgacgac	aatcagtact	gatttgacat	tcagtgtcaa	aagcagcaga	1740
ggctcttctg	acccccaagg	ggtgacgtgc	ggagctgcta	cactctctgc	agagagagtc	1800
agagggggaca	acaaggagta	tgagtactca	gtggagtgcc	aggaggacag	tgctgcccc	1860
gctgtgagg	agagtctgcc	cattgaggtc	atggtggatg	ccgttcacaa	gctcaagtat	1920
gaaaactaca	ccagcagctt	cttcatcagg	gacatcatca	aacctgacct	acccaagaac	1980
ttgcagctga	agccattaaa	gaattctcgg	caggtggagg	tcagctggga	gtaccctgac	2040
acctggagta	ctccacattc	ctacttctcc	ctgacattct	gcgttcaggt	ccagggaag	2100
agcaagagag	aaaagaaaga	tagagtcttc	acggacaaga	cctcagccac	ggtcatctgc	2160
cgcaaaaaatg	ccagcattag	cgtgcggggc	caggaccgct	actatagctc	atcttgagac	2220
gaatgggcat	ctgtgccctg	cagtggggc	agaggcagcc	tgctgacctg	cggcgacgtc	2280
gaggagaacc	ccggggccat	gggggcaggt	gccaccggcc	gcgccatgga	cgggcccgc	2340
ctgctgctgt	tgctgcttct	gggggtgtcc	cttgagggtg	ccaaggaggc	atgccccaca	2400
ggcctgtaca	cacacagcgg	tgagtgtctg	aaagcctgca	acctgggcga	gggtgtggcc	2460
cagccttgtg	gagccaacca	gaccgtgtgt	gagccctgcc	tggacagcgt	gacgttctcc	2520
gacgtggtga	gcgcgaccga	gccgtgcaag	ccgtgcaccg	agtgcgtggg	gctccagagc	2580
atgtcggcgc	cgtgcgtgga	ggccgatgac	gccgtgtgcc	gctgcgccta	cggctactac	2640
caggatgaga	cgactgggcg	ctgcgaggcg	tgccgcgtgt	gcgaggcggg	ctcgggcctc	2700
gtgttctcct	gccaggacaa	gcagaacacc	gtgtgcgagg	agtgcccga	cggcacgtat	2760
tccgacgagg	ccaaccacgt	ggaccctgtc	ctgccctgca	ccgtgtgcga	ggacaccgag	2820
cgccagctcc	gcgagtgcac	acgctggggc	gacgccaggt	gcgaggagat	ccctggccgt	2880
tggattacac	ggtccacacc	cccagagggc	tcggacagca	cagccccag	caccaggag	2940
cctgaggcac	ctccagaaca	agacctcata	gccagcacgg	tggcaggtgt	ggtgaccaca	3000
gtgatgggca	gctcccagcc	cgtggtgacc	cgaggcacca	ccgacaacct	catccctgtc	3060
tattgctcca	tcctggctgc	tgtggttgtg	ggtcttgtgg	cctacatagc	cttcaagagg	3120
tgatctagag	ggcccgttta	aaccgctga	tcagcctcga	ctgtgccttc	tagttgccag	3180
ccatctgttg	tttgcccctc	ccccgtgcct	tccttgacct	tggaaaggtgc	cactcccact	3240
gtcctttcct	aataaaatga	ggaaattgca	tcgcattgtc	tgagtaggtg	tcattctatt	3300
ctgggggggtg	gggtggggca	ggacagcaag	ggggaggatt	gggaagacaa	tagcaggcat	3360
gctgggggatg	cggtggggctc	tatgactagt	ggcgaattcg	gcgcagatca	aagagagcct	3420
gcggggcagag	ctcagggtga	caggtgcggc	ctcggaggcc	ccggggcagg	ggtgagctga	3480
gccggtcctg	gggtgggtgt	cccctcctgc	acaggatcag	gagctccagg	gtcgtagggc	3540
agggaccccc	cagctccagt	ccagggtctc	gtcctgcacc	tggggaatgg	tgaccggcat	3600
ctctgtcctc	tagctctgga	agcaccacag	cccctctagt	ctgccctcac	ccctgacctc	3660

eolf-seql (10).txt

gaccctccac cctgaccccc tcctaacccc tgacctttgt gcccttccag agagaagggc 3720  
agaagtgtccc acagcccacc ccagcccctc acccaggcc 3759

<210> 41

<211> 60

<212> DNA

<213> artificial sequence

<220>

<223> upstream TRAC locus polynucleotide sequence

<400> 41

atgagatcat gtcctaaccc tgatcctctt gtccacaga tatccagaac cctgaccctg 60

<210> 42

<211> 60

<212> DNA

<213> artificial sequence

<220>

<223> downstream TRAC locus polynucleotide sequence

<400> 42

gaaacagtga gccttggtct ggacgtccag agaatgacac gggaaaaaag cagatgaaga 60

<210> 43

<211> 60

<212> DNA

<213> artificial sequence

<220>

<223> upstream CD25 locus polynucleotide sequence

<400> 43

agtgtgggct agaaaccaag tgctttactg catgcacatc atttagcaca gttagttgct 60

<210> 44

<211> 52

<212> DNA

<213> artificial sequence

eolf-seql (10).txt

<220>

<223> downstream CD25 locus polynucleotide sequence

<400> 44

gaatggtatg gaactctctc caccctatat gtagtataaa gaaaagtagg tt 52

<210> 45

<211> 60

<212> DNA

<213> artificial sequence

<220>

<223> upstream PD1 locus polynucleotide sequence

<400> 45

ggtggccggg gaggctttgt ggggccaccc agccccttcc tcacctctct ccatctctca 60

<210> 46

<211> 60

<212> DNA

<213> artificial sequence

<220>

<223> downstream PD1 locus polynucleotide sequence

<400> 46

tgcccttcca gagagaaggg cagaagtgcc cacagcccac cccagcccct caccagggcc 60

<210> 47

<211> 759

<212> DNA

<213> artificial sequence

<220>

<223> IL-12a polynucleotide

<400> 47

atgtggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg 60  
catccagcgg ctgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 120  
ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 180  
gtggccactc cagaccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 240

eolf-seql (10).txt

gccgtcagca	acatgctcca	gaaggccaga	caaactctag	aatttttacc	ttgcacttct	300
gaagagattg	atcatgaaga	tatcacaaaa	gataaaacca	gcacagtgga	ggcctgttta	360
ccattggaat	taaccaagaa	tgagagttgc	ctaaattcca	gagagacctc	tttcataact	420
aatgggagtt	gcctggcctc	cagaaagacc	tcttttatga	tggccctgtg	ccttagtagt	480
atztatgaag	acttgaagat	gtaccaggtg	gagttcaaga	ccatgaatgc	aaagcttctg	540
atggatccta	agaggcagat	ctttctagat	caaaacatgc	tggcagttat	tgatgagctg	600
atgcaggccc	tgaatttcaa	cagtgagact	gtgccacaaa	aatcctccct	tgaagaaccg	660
gatttttata	aaactaaaat	caagctctgc	atacttcttc	atgctttcag	aattcgggca	720
gtgactattg	atagagtgat	gagctatctg	aatgctttcc			759

<210> 48

<211> 984

<212> DNA

<213> artificial sequence

<220>

<223> IL12b polynucleotide

<400> 48

atgtgtcacc	agcagttggt	catctcttgg	ttttccctgg	tttttctggc	atctcccctc	60
gtggccatat	gggaactgaa	gaaagatgtt	tatgtcgtag	aattggattg	gtatccggat	120
gcccttgagg	aaatggtggt	cctcacctgt	gacacccctg	aagaagatgg	tatcacctgg	180
accttggaac	agagcagtga	ggtcttaggc	tctggcaaaa	ccctgaccat	ccaagtcaaa	240
gagtttgagg	atgctggcca	gtacacctgt	cacaaaggag	gcgaggttct	aagccattcg	300
ctcctgctgc	ttcacaaaaa	ggaagatgga	atgttggtcca	ctgatatttt	aaaggaccag	360
aaagaaccca	aaaataagac	ctttctaaga	tgcgaggcca	agaattattc	tggaacgtttc	420
acctgctggt	ggctgacgac	aatcagtact	gatttgacat	tcagtgtcaa	aagcagcaga	480
ggctcttctg	acccccaagg	ggtgacgtgc	ggagctgcta	cactctctgc	agagagagtc	540
agagggggaca	acaaggagta	tgagtactca	gtggagtggc	aggaggacag	tgcttgccca	600
gctgctgagg	agagtctgcc	cattgaggtc	atgggtggatg	ccgttcacaa	gctcaagtat	660
gaaaactaca	ccagcagctt	cttcacagg	gacatcatca	aacctgaccc	acccaagaac	720
ttgcagctga	agccattaaa	gaattctcgg	caggtggagg	tcagctggga	gtaccctgac	780
acctggagta	ctccacattc	ctacttctcc	ctgacattct	gcgttcaggt	ccagggcaag	840
agcaagagag	aaaagaaaaga	tagagtcttc	acggacaaga	cctcagccac	ggtcatctgc	900
cgcaaaaatg	ccagcattag	cgtgcggggc	caggaccgct	actatagctc	atcttgagagc	960
gaatgggcat	ctgtgccctg	cagt				984

<210> 49

<211> 399

<212> DNA

<213> artificial sequence

<220>

<223> IL15 polynucleotide

eolf-seql (10).txt

```
<400> 49
ggcattcatg tcttcatttt gggctgtttc agtgcagggc ttcctaaaac agaagccaac 60
tgggtgaatg taataagtga ttgaaaaaa attgaagatc ttattcaatc tatgcatatt 120
gatgctactt tatatacgga aagtgatgtt caccacagtt gcaaagtaac agcaatgaag 180
tgctttctct tggagttaca agttatttca cttgagtccg gagatgcaag tattcatgat 240
acagtagaaa atctgatcat cctagcaaac aacagtttgt cttctaattg gaatgtaaca 300
gaatctggat gcaaagaatg tgaggaactg gaggaaaaaa atattaaaga atttttgcag 360
agttttgtac atattgtcca aatgttcac c aacacttct 399
```

<210> 50

<211> 525

<212> DNA

<213> artificial sequence

<220>

<223> sIL15ra polynucleotide

```
<400> 50
atcacgtgcc ctccccccat gtccgtggaa cacgcagaca tctgggtcaa gagctacagc 60
ttgtactcca gggagcggta catttgtaac tctggtttca agcgtaaagc cggcacgtcc 120
agcctgacgg agtgcgtgtt gaacaaggcc acgaatgtcg cccactggac aacccccagt 180
ctcaaagtca ttagagaccc tgccctgggt caccaaaggc cagcgccacc ctccacagta 240
acgacggcag gggtgacccc acagccagag agcctctccc cttctggaaa agagcccgca 300
gcttcatctc ccagctcaaa caacacagcg gccacaacag cagctattgt cccgggctcc 360
cagctgatgc cttcaaaatc accttcaca ggaaccacag agataagcag tcatgagtcc 420
tcccacggca cccctctca gacaacagcc aagaactggg aactcacagc atccgcctcc 480
caccagccgc caggtgtgta tccacagggc cacagcgaca ccact 525
```

<210> 51

<211> 1818

<212> DNA

<213> artificial sequence

<220>

<223> soluble GP130 polynucleotide

```
<400> 51
atgctgacac tgcagacttg gctgggtgcag gcactgttta tttttctgac tactgaatca 60
actggcgaac tgctggaccc ttgtggctac atcagccctg agtccccagt ggtgcagctg 120
cacagcaact tcaccgccgt gtgcgtgctg aaggagaagt gtatggacta ctttcacgtg 180
aacgccaatt atatcgtgtg gaaaaccaac cacttcacaa tcccaagga gcagtacacc 240
atcatcaata ggacagccag ctccgtgacc ttacagaca tcgcctccct gaacatccag 300
ctgacctgca atatcctgac attcggccag ctggagcaga acgtgtatgg catcaccatc 360
```

eolf-seql (10).txt

atctctggcc	tgccccctga	gaagcctaag	aacctgagct	gcatacgtgaa	tgagggcaag	420
aagatgcggt	gtgagtggga	cggcggcaga	gagacacacc	tgagagacaaa	cttcaccctg	480
aagtccgagt	gggccacaca	caagtttgcc	gactgcaagg	ccaagcgcgga	tacccaaca	540
tcctgtaccg	tggtattactc	tacagtgtat	tttgtgaaca	tcgaagtgtg	ggtggaggcc	600
gagaatgccc	tgggcaaggt	gacctccgac	cacatcaact	tcgatcccgt	gtacaagggtg	660
aagcctaacc	caccccacaa	tctgagcgtg	atcaattccg	aggagctgtc	tagcatcctg	720
aagctgacct	ggacaaaccc	atctatcaag	agcgtgatca	tcctgaagta	caatatccag	780
tatcggacca	aggacgcctc	cacatggagc	cagatccctc	cagaggatac	cgccagcaca	840
agatcctctt	tcaccgtgca	ggacctgaag	cccttcacag	agtacgtgtt	tcggatcaga	900
tgtatgaagg	aggacggcaa	gggctactgg	agcgattggt	ccgaggaggc	cagcggcatc	960
acctatgagg	acaggccttc	taaggccccc	agcttctggt	acaagatcga	tccatcccac	1020
accaggggct	atcgcacagt	gcagctggtg	tggaacaccc	tgcccccttt	cgaggccaac	1080
ggcaagatcc	tggactacga	ggtgaccctg	acacggtgga	agtcccacct	gcagaactat	1140
accgtgaatg	ccaccaagct	gacagtgaac	ctgacaaatg	atcggtacct	ggccaccctg	1200
acagtgaaga	acctggtggg	caagtctgac	gccgccgtgc	tgaccatccc	tgcttgcgat	1260
ttccaggcca	cacaccagct	gatggacctg	aaggcctttc	ccaaggataa	tatgctgtgg	1320
gtggagtggg	ccacacctag	agagtccgtg	aagaagtaca	tcctggagtg	gtgcgtgctg	1380
tctgacaagg	ccccatgtat	caccgactgg	cagcaggagg	atggcacctg	gcacaggaca	1440
tatctgcgcg	gcaacctggc	cgagtctaag	tggtacctga	tcaccgtgac	accctgttat	1500
gcagacggac	caggctctcc	tgagagcatc	aaggcctacc	tgaagcaggc	accaccaagc	1560
aagggaacca	ccgtgcggac	aaagaaggtc	ggcaagaatg	aggccgtgct	ggagtgggac	1620
cagctgcctg	tggatgtgca	gaacggcttc	atcaggaatt	acaccatctt	ttatcgacac	1680
atcatcggca	acgagacagc	cgtgaatgtg	gacagctccc	acaccgagta	tacactgtct	1740
agcctgacct	ccgatacact	gtacatggtg	aggatggccg	cctatacaga	cgagggcggc	1800
aaggatggcc	ccgagttt					1818

<210> 52

<211> 72

<212> DNA

<213> artificial sequence

<220>

<223> IgE signal sequence

<400> 52

ggtaccgggt	ccgccacat	ggactggacc	tggattctgt	tcctcgtggc	tgctgctaca	60
agagtgcaca	gc					72

<210> 53

<211> 75

<212> DNA

<213> artificial sequence

<220>

eolf-seql (10).txt

<223> F2A

<400> 53

ggttctggcg tgaaacagac tttgaatttt gaccttctca agttggcggg agacgtggag 60  
tccaaccag ggccc 75

<210> 54

<211> 66

<212> DNA

<213> artificial sequence

<220>

<223> P2A

<400> 54

ggaagcggag ctactaactt cagcctgctg aagcaggctg gagacgtgga ggagaaccct 60  
ggacct 66

<210> 55

<211> 54

<212> DNA

<213> artificial sequence

<220>

<223> T2A

<400> 55

gagggcagag gcagcctgct gacctgcggc gacgtcgagg agaaccccgg gccc 54

<210> 56

<211> 825

<212> DNA

<213> artificial sequence

<220>

<223> LNGFR

<400> 56

atgggggagc gtgccaccgg ccgcgccatg gacggggccgc gcctgctgct gttgctgctt 60  
ctgggggtgt cccttgagg tgccaaggag gcatgcccc caggcctgta cacacacagc 120  
ggtgagtgt gcaaagcctg caacctgggc gaggtgtgg cccagccttg tggagccaac 180  
cagaccgtgt gtgagccctg cctggacagc gtgacgttct ccgacgtggt gagcgcgacc 240

eolf-seql (10).txt

```

gagccgtgca agccgtgcac cgagtgcgtg gggctccaga gcatgtcggc gccgtgcgtg 300
gaggccgatg acgccgtgtg ccgctgcgcc tacggctact accaggatga gacgactggg 360
cgctgcgagg cgtgccgcgt gtgcgaggcg ggctcgggcc tcgtgttctc ctgccaggac 420
aagcagaaca ccgtgtgcga ggagtgcccc gacggcacgt attccgacga ggccaaccac 480
gtggacccgt gcctgccctg caccgtgtgc gaggacaccg agcgccagct ccgcgagtgc 540
acacgctggg ccgacgccga gtgcgaggag atccctggcc gttggattac acggtccaca 600
ccccagagg gctcggacag cacagcccc agcaccagg agcctgaggc acctccagaa 660
caagacctca tagccagcac ggtggcaggt gtggtgacca cagtgatggg cagctcccag 720
cccgtggtga cccgaggcac caccgacaac ctcatccctg tctattgctc catcctggct 780
gctgtgggtg tgggtcttgt ggcctacata gccttcaaga ggtga 825

```

<210> 57

<211> 253

<212> PRT

<213> artificial sequence

<220>

<223> IL-12a polypeptide

<400> 57

```

Met Trp Pro Pro Gly Ser Ala Ser Gln Pro Pro Pro Ser Pro Ala Ala
1           5           10           15

```

```

Ala Thr Gly Leu His Pro Ala Ala Arg Pro Val Ser Leu Gln Cys Arg
          20           25           30

```

```

Leu Ser Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val
          35           40           45

```

```

Leu Leu Asp His Leu Ser Leu Ala Arg Asn Leu Pro Val Ala Thr Pro
          50           55           60

```

```

Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Arg
65           70           75           80

```

```

Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr
          85           90           95

```

```

Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys
          100          105          110

```

eolf-seql (10).txt

Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu  
115 120 125

Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys  
130 135 140

Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser  
145 150 155 160

Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn  
165 170 175

Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn  
180 185 190

Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser  
195 200 205

Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys  
210 215 220

Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala  
225 230 235 240

Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser  
245 250

<210> 58

<211> 328

<212> PRT

<213> artificial sequence

<220>

<223> IL12b polypeptide

<400> 58

eolf-seql (10).txt

Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu  
1 5 10 15

Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val  
20 25 30

Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu  
35 40 45

Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln  
50 55 60

Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys  
65 70 75 80

Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val  
85 90 95

Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp  
100 105 110

Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe  
115 120 125

Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp  
130 135 140

Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg  
145 150 155 160

Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser  
165 170 175

Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu  
180 185 190

eolf-seql (10).txt

Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile  
195 200 205

Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr  
210 215 220

Ser Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn  
225 230 235 240

Leu Gln Leu Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp  
245 250 255

Glu Tyr Pro Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr  
260 265 270

Phe Cys Val Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg  
275 280 285

Val Phe Thr Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala  
290 295 300

Ser Ile Ser Val Arg Ala Gln Asp Arg Tyr Tyr Ser Ser Ser Trp Ser  
305 310 315 320

Glu Trp Ala Ser Val Pro Cys Ser  
325

245

250

<210> 59

<211> 133

<212> PRT

<213> artificial sequence

<220>

<223> IL15 polypeptide

eolf-seql (10).txt

<400> 59

Gly Ile His Val Phe Ile Leu Gly Cys Phe Ser Ala Gly Leu Pro Lys  
1 5 10 15

Thr Glu Ala Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu  
20 25 30

Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser  
35 40 45

Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu  
50 55 60

Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp  
65 70 75 80

Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn  
85 90 95

Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu  
100 105 110

Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met  
115 120 125

Phe Ile Asn Thr Ser  
130

<210> 60

<211> 175

<212> PRT

<213> artificial sequence

<220>

<223> sIL15ra polypeptide

<400> 60

eolf-seql (10).txt

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val  
1 5 10 15

Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly  
20 25 30

Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn  
35 40 45

Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile  
50 55 60

Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val  
65 70 75 80

Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly  
85 90 95

Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr  
100 105 110

Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro  
115 120 125

Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr  
130 135 140

Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser  
145 150 155 160

His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr  
165 170 175

<210> 61

<211> 606

<212> PRT

eolf-seql (10).txt

<213> artificial sequence

<220>

<223> soluble gp130

<400> 61

Met Leu Thr Leu Gln Thr Trp Leu Val Gln Ala Leu Phe Ile Phe Leu  
1 5 10 15

Thr Thr Glu Ser Thr Gly Glu Leu Leu Asp Pro Cys Gly Tyr Ile Ser  
20 25 30

Pro Glu Ser Pro Val Val Gln Leu His Ser Asn Phe Thr Ala Val Cys  
35 40 45

Val Leu Lys Glu Lys Cys Met Asp Tyr Phe His Val Asn Ala Asn Tyr  
50 55 60

Ile Val Trp Lys Thr Asn His Phe Thr Ile Pro Lys Glu Gln Tyr Thr  
65 70 75 80

Ile Ile Asn Arg Thr Ala Ser Ser Val Thr Phe Thr Asp Ile Ala Ser  
85 90 95

Leu Asn Ile Gln Leu Thr Cys Asn Ile Leu Thr Phe Gly Gln Leu Glu  
100 105 110

Gln Asn Val Tyr Gly Ile Thr Ile Ile Ser Gly Leu Pro Pro Glu Lys  
115 120 125

Pro Lys Asn Leu Ser Cys Ile Val Asn Glu Gly Lys Lys Met Arg Cys  
130 135 140

Glu Trp Asp Gly Gly Arg Glu Thr His Leu Glu Thr Asn Phe Thr Leu  
145 150 155 160

Lys Ser Glu Trp Ala Thr His Lys Phe Ala Asp Cys Lys Ala Lys Arg  
165 170 175

eolf-seql (10).txt

Asp Thr Pro Thr Ser Cys Thr Val Asp Tyr Ser Thr Val Tyr Phe Val  
180 185 190

Asn Ile Glu Val Trp Val Glu Ala Glu Asn Ala Leu Gly Lys Val Thr  
195 200 205

Ser Asp His Ile Asn Phe Asp Pro Val Tyr Lys Val Lys Pro Asn Pro  
210 215 220

Pro His Asn Leu Ser Val Ile Asn Ser Glu Glu Leu Ser Ser Ile Leu  
225 230 235 240

Lys Leu Thr Trp Thr Asn Pro Ser Ile Lys Ser Val Ile Ile Leu Lys  
245 250 255

Tyr Asn Ile Gln Tyr Arg Thr Lys Asp Ala Ser Thr Trp Ser Gln Ile  
260 265 270

Pro Pro Glu Asp Thr Ala Ser Thr Arg Ser Ser Phe Thr Val Gln Asp  
275 280 285

Leu Lys Pro Phe Thr Glu Tyr Val Phe Arg Ile Arg Cys Met Lys Glu  
290 295 300

Asp Gly Lys Gly Tyr Trp Ser Asp Trp Ser Glu Glu Ala Ser Gly Ile  
305 310 315 320

Thr Tyr Glu Asp Arg Pro Ser Lys Ala Pro Ser Phe Trp Tyr Lys Ile  
325 330 335

Asp Pro Ser His Thr Gln Gly Tyr Arg Thr Val Gln Leu Val Trp Lys  
340 345 350

Thr Leu Pro Pro Phe Glu Ala Asn Gly Lys Ile Leu Asp Tyr Glu Val  
355 360 365

eolf-seql (10).txt

Thr Leu Thr Arg Trp Lys Ser His Leu Gln Asn Tyr Thr Val Asn Ala  
370 375 380

Thr Lys Leu Thr Val Asn Leu Thr Asn Asp Arg Tyr Leu Ala Thr Leu  
385 390 395 400

Thr Val Arg Asn Leu Val Gly Lys Ser Asp Ala Ala Val Leu Thr Ile  
405 410 415

Pro Ala Cys Asp Phe Gln Ala Thr His Pro Val Met Asp Leu Lys Ala  
420 425 430

Phe Pro Lys Asp Asn Met Leu Trp Val Glu Trp Thr Thr Pro Arg Glu  
435 440 445

Ser Val Lys Lys Tyr Ile Leu Glu Trp Cys Val Leu Ser Asp Lys Ala  
450 455 460

Pro Cys Ile Thr Asp Trp Gln Gln Glu Asp Gly Thr Val His Arg Thr  
465 470 475 480

Tyr Leu Arg Gly Asn Leu Ala Glu Ser Lys Cys Tyr Leu Ile Thr Val  
485 490 495

Thr Pro Val Tyr Ala Asp Gly Pro Gly Ser Pro Glu Ser Ile Lys Ala  
500 505 510

Tyr Leu Lys Gln Ala Pro Pro Ser Lys Gly Pro Thr Val Arg Thr Lys  
515 520 525

Lys Val Gly Lys Asn Glu Ala Val Leu Glu Trp Asp Gln Leu Pro Val  
530 535 540

Asp Val Gln Asn Gly Phe Ile Arg Asn Tyr Thr Ile Phe Tyr Arg Thr  
545 550 555 560

eolf-seql (10).txt

Ile Ile Gly Asn Glu Thr Ala Val Asn Val Asp Ser Ser His Thr Glu  
565 570 575

Tyr Thr Leu Ser Ser Leu Thr Ser Asp Thr Leu Tyr Met Val Arg Met  
580 585 590

Ala Ala Tyr Thr Asp Glu Gly Gly Lys Asp Gly Pro Glu Phe  
595 600 605

<210> 62

<211> 836

<212> PRT

<213> artificial sequence

<220>

<223> soluble gp130 fused to a Fc

<400> 62

Met Leu Thr Leu Gln Thr Trp Leu Val Gln Ala Leu Phe Ile Phe Leu  
1 5 10 15

Thr Thr Glu Ser Thr Gly Glu Leu Leu Asp Pro Cys Gly Tyr Ile Ser  
20 25 30

Pro Glu Ser Pro Val Val Gln Leu His Ser Asn Phe Thr Ala Val Cys  
35 40 45

Val Leu Lys Glu Lys Cys Met Asp Tyr Phe His Val Asn Ala Asn Tyr  
50 55 60

Ile Val Trp Lys Thr Asn His Phe Thr Ile Pro Lys Glu Gln Tyr Thr  
65 70 75 80

Ile Ile Asn Arg Thr Ala Ser Ser Val Thr Phe Thr Asp Ile Ala Ser  
85 90 95

eolf-seql (10).txt

Leu Asn Ile Gln Leu Thr Cys Asn Ile Leu Thr Phe Gly Gln Leu Glu  
100 105 110

Gln Asn Val Tyr Gly Ile Thr Ile Ile Ser Gly Leu Pro Pro Glu Lys  
115 120 125

Pro Lys Asn Leu Ser Cys Ile Val Asn Glu Gly Lys Lys Met Arg Cys  
130 135 140

Glu Trp Asp Gly Gly Arg Glu Thr His Leu Glu Thr Asn Phe Thr Leu  
145 150 155 160

Lys Ser Glu Trp Ala Thr His Lys Phe Ala Asp Cys Lys Ala Lys Arg  
165 170 175

Asp Thr Pro Thr Ser Cys Thr Val Asp Tyr Ser Thr Val Tyr Phe Val  
180 185 190

Asn Ile Glu Val Trp Val Glu Ala Glu Asn Ala Leu Gly Lys Val Thr  
195 200 205

Ser Asp His Ile Asn Phe Asp Pro Val Tyr Lys Val Lys Pro Asn Pro  
210 215 220

Pro His Asn Leu Ser Val Ile Asn Ser Glu Glu Leu Ser Ser Ile Leu  
225 230 235 240

Lys Leu Thr Trp Thr Asn Pro Ser Ile Lys Ser Val Ile Ile Leu Lys  
245 250 255

Tyr Asn Ile Gln Tyr Arg Thr Lys Asp Ala Ser Thr Trp Ser Gln Ile  
260 265 270

Pro Pro Glu Asp Thr Ala Ser Thr Arg Ser Ser Phe Thr Val Gln Asp  
275 280 285

eolf-seql (10).txt

Leu Lys Pro Phe Thr Glu Tyr Val Phe Arg Ile Arg Cys Met Lys Glu  
290 295 300

Asp Gly Lys Gly Tyr Trp Ser Asp Trp Ser Glu Glu Ala Ser Gly Ile  
305 310 315 320

Thr Tyr Glu Asp Arg Pro Ser Lys Ala Pro Ser Phe Trp Tyr Lys Ile  
325 330 335

Asp Pro Ser His Thr Gln Gly Tyr Arg Thr Val Gln Leu Val Trp Lys  
340 345 350

Thr Leu Pro Pro Phe Glu Ala Asn Gly Lys Ile Leu Asp Tyr Glu Val  
355 360 365

Thr Leu Thr Arg Trp Lys Ser His Leu Gln Asn Tyr Thr Val Asn Ala  
370 375 380

Thr Lys Leu Thr Val Asn Leu Thr Asn Asp Arg Tyr Leu Ala Thr Leu  
385 390 395 400

Thr Val Arg Asn Leu Val Gly Lys Ser Asp Ala Ala Val Leu Thr Ile  
405 410 415

Pro Ala Cys Asp Phe Gln Ala Thr His Pro Val Met Asp Leu Lys Ala  
420 425 430

Phe Pro Lys Asp Asn Met Leu Trp Val Glu Trp Thr Thr Pro Arg Glu  
435 440 445

Ser Val Lys Lys Tyr Ile Leu Glu Trp Cys Val Leu Ser Asp Lys Ala  
450 455 460

Pro Cys Ile Thr Asp Trp Gln Gln Glu Asp Gly Thr Val His Arg Thr  
465 470 475 480

eolf-seql (10).txt

Tyr Leu Arg Gly Asn Leu Ala Glu Ser Lys Cys Tyr Leu Ile Thr Val  
485 490 495

Thr Pro Val Tyr Ala Asp Gly Pro Gly Ser Pro Glu Ser Ile Lys Ala  
500 505 510

Tyr Leu Lys Gln Ala Pro Pro Ser Lys Gly Pro Thr Val Arg Thr Lys  
515 520 525

Lys Val Gly Lys Asn Glu Ala Val Leu Glu Trp Asp Gln Leu Pro Val  
530 535 540

Asp Val Gln Asn Gly Phe Ile Arg Asn Tyr Thr Ile Phe Tyr Arg Thr  
545 550 555 560

Ile Ile Gly Asn Glu Thr Ala Val Asn Val Asp Ser Ser His Thr Glu  
565 570 575

Tyr Thr Leu Ser Ser Leu Thr Ser Asp Thr Leu Tyr Met Val Arg Met  
580 585 590

Ala Ala Tyr Thr Asp Glu Gly Gly Lys Asp Gly Pro Glu Phe Arg Ser  
595 600 605

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu  
610 615 620

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
625 630 635 640

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
645 650 655

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu  
660 665 670

eolf-seql (10).txt

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr  
675 680 685

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn  
690 695 700

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro  
705 710 715 720

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln  
725 730 735

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val  
740 745 750

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val  
755 760 765

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro  
770 775 780

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr  
785 790 795 800

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val  
805 810 815

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu  
820 825 830

Ser Pro Gly Lys  
835

<210> 63

eolf-seql (10).txt

<211> 7711

<212> DNA

<213> artificial sequence

<220>

<223> Matrice TRAC locus\_CubiCAR CD22 pCLS30056 full sequence

<400> 63

gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	taaatacatt	60
caaatatgta	tccgctcatg	agacaataac	cctgataaat	gcttcaataa	tattgaaaaa	120
ggaagagtat	gagtattcaa	catttccgtg	tcgcccttat	tccctttttt	gcggcatttt	180
gccttcctgt	ttttgctcac	ccagaaacgc	tggtgaaagt	aaaagatgct	gaagatcagt	240
tgggtgcacg	agtgggttac	atcgaactgg	atctcaacag	cggttaagatc	cttgagagtt	300
ttcgccccga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	tgtggcgcgg	360
tattatccccg	tattgacgcc	gggcaagagc	aaactcggtcg	ccgcatacac	tattctcaga	420
atgacttgggt	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	atgacagtaa	480
gagaattatg	cagtgcctgcc	ataaccatga	gtgataacac	tgcggccaac	ttacttctga	540
caacgatcgg	aggaccgaag	gagctaaccg	cttttttgca	caacatgggg	gatcatgtaa	600
ctcgccctga	tcgttgggaa	ccggagctga	atgaagccat	accaaacgac	gagcgtgaca	660
ccacgatgcc	tgtagcaatg	gcaacaacgt	tcgcgaaact	attaactggc	gaactactta	720
ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	ggataaagt	gcaggaccac	780
ttctgcgctc	ggcccttcgg	gctggctgggt	ttattgctga	taaatctgga	gccggtgagc	840
gtggttctcg	cggatatcatt	gcagcactgg	ggccagatgg	taagccctcc	cgtatcgtag	900
ttatctacac	gacggggagt	caggcaacta	tggtgaacg	aaatagacag	atcgctgaga	960
taggtgcctc	actgattaag	cattggtaac	tgtcagacca	agtttactca	tatatacttt	1020
agattgattt	aaaacttcat	ttttaattta	aaaggatcta	ggtgaagatc	ctttttgata	1080
atctcatgac	caaaatccct	taacgtgagt	tttcgttcca	ctgagcgtca	gaccccgtag	1140
aaaagatcaa	aggatcttct	tgagatcctt	tttttctgcg	cgtaatctgc	tgcttgcaaa	1200
caaaaaaacc	accgctacca	gcggtgggtt	gtttgccgga	tcaagagcta	ccaactcttt	1260
ttccgaaggt	aactggcttc	agcagagcgc	agataccaaa	tactgttctt	ctagtgtagc	1320
cgtagttagg	ccaccacttc	aagaactctg	tagcaccgcc	tacatacctc	gctctgctaa	1380
tcctgttacc	agtggctgct	gccagtggcg	ataagtctgt	tcttaccggg	ttggactcaa	1440
gacgatagtt	accggataag	gcgcagcggg	cggttggaac	gggggggttcg	tgcacacagc	1500
ccagcttgga	gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	ctatgagaaa	1560
gcgccacgct	tcccgaaggg	agaaaaggcg	acaggtatcc	ggttaagcggc	agggtcggaa	1620
caggagagcg	cacgaggagg	cttccagggg	gaaacgcctg	gtatctttat	agtcctgtcg	1680
ggtttcgcca	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	gggcggagcc	1740
tatggaaaaa	cgccagcaac	gcggcctttt	tacggttcct	ggcctttttg	tgccctttttg	1800
ctcacatgggt	ctttcctgcg	ttatcccctg	attctgtgga	taaccgtatt	accgcctttg	1860
agtgagctga	taccgctcgc	cgcagccgaa	cgaccgagcg	cagcgagtca	gtgagcgagg	1920
aagcggagag	cgccaatac	gcaaaccgcc	tctccccgcg	cgttggccga	ttcattaatg	1980
cagctggcac	gacaggtttc	ccgactggaa	agcgggcagt	gagcgcaacg	caattaatgt	2040
gagttagctc	actcattagg	caccccaggc	tttacacttt	atgcttccgg	ctcgtatgtt	2100
gtgtggaatt	gtgagcggat	aacaatttca	cacaggaaac	agctatgacc	atgattacgc	2160
caagcgcgtc	aattaaccct	cactaaaggg	aacaaaagct	gttaattaat	tgctgggcct	2220
ttttcccatg	cctgccttta	ctctgccaga	gttatattgc	tggggttttg	aagaagatcc	2280
tattaaataa	aagaataagc	agtattatta	agtagccctg	catttcagggt	ttccttgagt	2340
ggcaggccag	gcctggccgt	gaacgttcac	tgaaatcatg	gcctcttggc	caagattgat	2400

eolf-seql (10).txt

agcttgtgcc	tgtccctgag	tcccagtgcca	tcacgagcag	ctggtttcta	agatgctatt	2460
tcccgtataa	agcatgagac	cgtgacttgc	cagccccaca	gagccccgcc	cttgtccatc	2520
actggcatct	ggactccagc	ctgggttggg	gcaaagaggg	aaatgagatc	atgtcctaac	2580
cctgatcctc	ttgtcccaca	gatatccagt	acccttacga	cgtgcccga	tacgcctccg	2640
gtgagggcag	aggaagtctt	ctaacaatgcg	gtgacgtgga	ggagaatccg	ggccccggat	2700
ccgctctgcc	cgtcaccgct	ctgctgctgc	cactggcact	gctgctgcac	gctgctaggc	2760
ccggaggggg	aggcagctgc	ccctacagca	accccagcct	gtgcagcgga	ggcggcggca	2820
gcggcggagg	gggtagccag	gtgcagctgc	agcagagcgg	ccctggcctg	gtgaagccaa	2880
gccagacact	gtccctgacc	tgcgccatca	gcggcgattc	cgtgagctcc	aactccgccg	2940
cctggaattg	gatcaggcag	tccccttctc	ggggcctgga	gtggctggga	aggacatact	3000
atcggcttaa	gtggtacaac	gattatgccg	tgtctgtgaa	gagcagaatc	acaatcaacc	3060
ctgacacctc	caagaatcag	ttctctctgc	agctgaatag	cgtgacacca	gaggacaccg	3120
ccgtgtacta	ttgcgccagg	gaggtgaccg	gcgacctgga	ggatgccttt	gacatctggg	3180
gccagggcac	aatggtgacc	gtgagctccg	gaggcggcgg	atctggcgga	ggaggaagtg	3240
ggggcggcgg	gagtgatatc	cagatgacac	agtccccatc	ctctctgagc	gcctccgtgg	3300
gcgacagagt	gacaatcacc	tgtagggcct	cccagaccat	ctggtcttac	ctgaactggt	3360
atcagcagag	gcccggcaag	gcccctaata	tgctgatcta	cgcagcaagc	tccctgcaga	3420
gcggagtgcc	atccagattc	tctggcaggg	gctccggcac	agacttcacc	ctgaccatct	3480
ctagcctgca	ggccgaggac	ttcgccacct	actattgcca	gcagtcttat	agcatcccc	3540
agacatttgg	ccagggcacc	aagctggaga	tcaagtcgga	tcccggaagc	ggagggggag	3600
gcagctgccc	ctacagcaac	cccagcctgt	gcagcggagg	cggcggcagc	gagctgcccc	3660
cccagggcac	cttctccaac	gtgtccacca	acgtgagccc	agccaagccc	accaccaccg	3720
cctgtcctta	ttccaatcct	tccctgtgtg	ctcccaccac	aacccccgct	ccaaggcccc	3780
ctacccccgc	accaactatt	gcctcccagc	cactctcact	gcggcctgag	gcctgtcggc	3840
ccgctgctgg	aggcgcagtg	catacaaggg	gcctcgattt	cgcctgcgat	atttacatct	3900
gggcacccct	cgccggcacc	tgcgggggtgc	ttctcctctc	cctggtgatt	accctgtatt	3960
gcagacgggg	ccggaagaag	ctcctctaca	tttttaagca	gcctttcatg	cggccagtgc	4020
agacaacca	agaggaggat	gggtgttcct	gcagattccc	tgaggaagag	gaaggcgggt	4080
gcgagctgag	agtgaagttc	tccaggagcg	cagatgcccc	cgcctatcaa	cagggccaga	4140
accagctcta	caacgagctt	aacctcggga	ggcgcgaaga	atacgacgtg	ttggataaga	4200
gaagggggcg	ggaccccagag	atgggaggaa	agccccggag	gaagaaccct	caggaggggc	4260
tgtacaacga	gctgcagaag	gataagatgg	ccgaggccta	ctcagagatc	gggatgaagg	4320
gggagcggcg	ccgcgggaag	gggcacgatg	ggctctacca	ggggctgagc	acagccacaa	4380
aggacacata	cgacgccttg	cacatgcagg	cccttcacc	ccgggaatag	tctagagggc	4440
ccgtttaaac	ccgctgatca	gcctcgactg	tgcttcttag	ttgccagcca	tctgttgttt	4500
gccccctccc	cgtgccttcc	ttgacctggg	aaggtgccac	tcccactgtc	ctttccta	4560
aaaatgagga	aattgcatcg	cattgtctga	gtaggtgtca	ttctattctg	gggggtgggg	4620
tggggcagga	cagcaagggg	gaggattggg	aagacaatag	caggcatgct	ggggatgcgg	4680
tgggctctat	gactagtggc	gaattcccgt	gtaccagctg	agagactcta	aatccagtga	4740
caagtctgtc	tgcttattca	ccgattttga	ttctcaaaca	aatgtgtcac	aaagtaagga	4800
ttctgatgtg	tatatcacag	acaaaactgt	gctagacatg	aggtctatgg	acttcaagag	4860
caacagtgtc	gtggcctgga	gcaacaaatc	tgactttgca	tgtgcaaacg	ccttcaacaa	4920
cagcattatt	ccagaagaca	ccttcttccc	cagcccaggt	aagggcagct	ttggtgcctt	4980
cgcaggctgt	ttccttgctt	caggaatggc	caggttctgc	ccagagctct	ggtcaatgat	5040
gtctaaaaact	cctctgattg	gtggtctcgg	ccttatccat	tgccacaaaa	accctctttt	5100
tactaagcga	tcgctccggt	gcccgtcagt	gggcagagcg	cacatcgccc	acagtccccg	5160
agaagtggg	gggaggggtc	ggcaattgaa	cgggtgccta	gagaaggtgg	cgcggggtaa	5220
actgggaaag	tgatgtcgtg	tactggctcc	gcctttttcc	cgagggtggg	ggagaaccgt	5280

eolf-seql (10).txt

atataagtgc	agtagtcgcc	gtgaacgttc	tttttcgcaa	cgggtttgcc	gccagaacac	5340
agctgaagct	tcgaggggct	cgcattcttc	cttcacgcgc	ccgccgcct	acctgaggcc	5400
gccatccacg	ccggttgagt	cgcgttctgc	cgcctcccgc	ctgttggtgcc	tcctgaactg	5460
cgtccgccgt	ctaggtaagt	ttaaagctca	ggctgagacc	gggcctttgt	ccggcgctcc	5520
cttgagagcct	acctagactc	agccggctct	ccacgctttg	cctgaccctg	cttgctcaac	5580
tctacgtctt	tgtttcgttt	tctgttctgc	gccgttacag	atccaagctg	tgaccggcgc	5640
ctacctgaga	tcaccggcgc	caccatggct	tcttaccctg	gacaccagca	tgcttctgcc	5700
tttgaccagg	ctgccagatc	cagggggcac	tccaacagga	gaactgccct	aagaccaga	5760
agacagcagg	aagccactga	ggtgaggcct	gagcagaaga	tgccaaccct	gctgagggtg	5820
tacattgatg	gacctcatgg	catgggcaag	accaccacca	ctcaactgct	ggtggcactg	5880
ggctccaggg	atgacattgt	gtatgtgcct	gagccaatga	cctactggag	agtgttagga	5940
gcctctgaga	ccattgccaa	catctacacc	accagcaca	ggctggacca	gggagaaatc	6000
tctgctggag	atgctgctgt	ggtgatgacc	tctgcccaga	tcacaatggg	aatgccctat	6060
gctgtgactg	atgctgttct	ggctcctcac	attggaggag	aggctggctc	ttctcatgcc	6120
cctccacctg	ccctgaccct	gatctttgac	agacacccca	ttgcagccct	gctgtgctac	6180
ccagcagcaa	ggtacctcat	gggctccatg	acccacagg	ctgtgctggc	ttttgtggcc	6240
ctgatccctc	caaccctccc	tggcaccaac	attgttctgg	gagcactgcc	tgaagacaga	6300
cacattgaca	ggctggcaaa	gaggcagaga	cctggagaga	gactggacct	ggccatgctg	6360
gctgcaatca	gaaggggtga	tggactgctg	gcaaactg	tgagatacct	ccagtgtgga	6420
ggctcttgga	gagaggactg	gggacagctc	tctggaacag	cagtgcctcc	tcaaggagct	6480
gagccccagt	ccaatgctgg	tccaagacc	cacattgggg	acacctgtt	cacctgttc	6540
agagcccctg	agctgctggc	tcccaatgga	gacctgtaca	atgtgtttgc	ctgggctctg	6600
gatgttctag	ccaagaggct	gaggtccatg	catgtgttca	tcctggacta	tgaccagtcc	6660
cctgctggat	gcagagatgc	tctgctgcaa	ctaacctctg	gcatggtgca	gacctatgtg	6720
accacccctg	gcagcatccc	caccatctgt	gacctagcca	gaacctttgc	caggagatg	6780
ggagaggcca	actaaggcgc	gccactcgag	cgctagctgg	ccagacatga	taagatacat	6840
tgatgagttt	ggacaaacca	caactagaat	gcagtgaata	aaatgcttta	tttgtgaaat	6900
ttgtgatgct	attgctttat	ttgtaaccat	tataagctgc	aataaacaag	ttaacaacaa	6960
caattgcatt	cattttatgt	ttcagggtca	gggggagggtg	tgggagggtt	tttaaagcaa	7020
gtaaaacctc	tacaaatgtg	gtatggaagg	cgcgcccaat	tcgccctata	gtgagtcgta	7080
ttacgtcgcg	ctactggcc	gtcgtttttac	aacgtcgtga	ctgggaaaac	cctggcgtta	7140
cccaacttaa	tcgccttgca	gcacatcccc	ctttcgccag	ctggcgtaat	agcgaagagg	7200
cccgcaccga	aacgcccttc	ccaacagttg	cgcagcctga	atggcggaatg	ggagcgccct	7260
gtagcggcgc	attaagcgcg	gcgggtgtgg	tggttacgcg	cagcgtgacc	gctacacttg	7320
ccagcgccct	agcgccgct	cctttcgctt	tcttcccttc	ctttctcgcc	acgttcgccg	7380
gctttccccg	tcaagctcta	aatcgggggc	tccctttagg	gttccgattt	agtgttttac	7440
ggcacctcga	ccccaaaaaa	cttgattagg	gtgatggttg	gcctgtagtg	ggccatagcc	7500
ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	ttcttttaata	gtggactctt	7560
gttccaaact	ggaacaacac	tcaaccctat	ctcggcttat	tcttttgatt	tataagggat	7620
tttgccgatt	tcggcctatt	ggttaaaaaa	tgagctgatt	taacaaaaat	ttaacgcgaa	7680
ttttaacaaa	atattaacgc	ttacaattta	g			7711

<210> 64

<211> 7502

<212> DNA

<213> artificial sequence

eolf-seql (10).txt

<220>

<223> Matrice CD25 locus\_IL15\_2A\_sIL15Ra pCLS30519 full sequence

<400> 64

gtttattatt	cctgttccac	agctattgtc	tgccatataa	aaacttaggc	caggcacagt	60
ggctcacacc	tgtaatccca	gcactttgga	aggccgaggc	aggcagatca	caaggtcagg	120
agttcgagac	cagcctggcc	aacatagcaa	aaccccatct	ctactaaaaa	tacaaaaatt	180
agccaggcat	ggtggcggtg	gcactggttt	agagttagga	ccacattttt	ttggtgccgt	240
gttacacata	tgaccgtgac	tttgttacac	cactacagga	ggaagagtag	aagaacaatc	300
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaacccag	ggcccgtac	cgggtccgcc	accatggact	ggacctggat	tctgttcctc	420
gtggctgctg	ctacaagagt	gcacagcggc	attcatgtct	tcattttggg	ctgtttcagt	480
gcagggttc	ctaaaacaga	agccaactgg	gtgaatgtaa	taagtgattt	gaaaaaaatt	540
gaagatctta	ttcaatctat	gcatattgat	gctactttat	atacgaaaag	tgatgttcac	600
cccagttgca	aagtaacagc	aatgaagtgc	tttctcttgg	agttacaagt	tatttcactt	660
gagtcaggag	atgcaagtat	tcatagata	gtagaaaatc	tgatcatcct	agcaaacaac	720
agtttgtctt	ctaatgggaa	tgtaacagaa	tctggatgca	aagaatgtga	ggaactggag	780
gaaaaaaata	ttaaagaatt	tttgagaggt	ttgtacata	ttgtccaaat	gttcatcaac	840
acttctggaa	gcggagctac	taacttcagc	ctgctgaagc	aggctggaga	cgtggaggag	900
aaccctggac	ctgggaccgg	ctctgcaacc	atggattgga	cgtggatcct	gtttctcgtg	960
gcagctgcca	caagagttca	cagtatcacg	tgccctcccc	ccatgtccgt	ggaacacgca	1020
gacatctggg	tcaagagcta	cagcttgtag	tccaggaggc	ggtacatttg	taactctggt	1080
ttcaagcgta	aagccggcac	gtccagcctg	acggagtgcg	tgttgaacaa	ggccacgaat	1140
gtcgcccact	ggacaacccc	cagtctcaaa	tgcattagag	accctgccct	ggttcaccaa	1200
aggccagcgc	caccctccac	agtaacgacg	gcagggggtga	ccccacagcc	agagagcctc	1260
tccccttctg	gaaaagagcc	cgcagcttca	tctcccagct	caaacaacac	agcggccaca	1320
acagcagcta	ttgtcccggg	ctcccagctg	atgccttcaa	aatcaccttc	cacaggaacc	1380
acagagataa	gcagtcatga	gtcctccac	ggcaccctct	ctcagacaac	agccaagaac	1440
tgggaactca	cagcatccgc	ctcccaccag	ccgccagggtg	tgtatccaca	gggccacagc	1500
gacaccactg	agggcagagg	cagcctgctg	acctgcggcg	acgtcgagga	gaaccccggg	1560
cccatggggg	caggtgccac	cggccgcgcc	atggacgggc	cgcgcctgct	gctgttgctg	1620
cttctggggg	tgtcccttgg	aggtgccaag	gaggcatgcc	ccacaggcct	gtacacacac	1680
agcggtagt	gctgcaaagc	ctgcaacctg	ggcgagggtg	tggcccagcc	ttgtggagcc	1740
aaccagaccg	tgtgtgagcc	ctgcctggac	agcgtgacgt	tctccgacgt	ggtgagcgcg	1800
accgagccgt	gcaagccgtg	caccgagtgc	gtggggctcc	agagcatgtc	ggcgccgtgc	1860
gtggaggccg	atgacgccgt	gtgccgctgc	gcctacggct	actaccagga	tgagacgact	1920
gggcgctgcg	aggcgtgccg	cgtgtgagag	gcgggctcgg	gcctcgtgtt	ctcctgccag	1980
gacaagcaga	acaccgtgtg	cgaggagtgc	cccagcggca	cgtattccga	cgaggccaac	2040
cacgtggacc	cgtgcctgcc	ctgcaccgtg	tgcaggagca	ccgagcgcca	gctccgcgag	2100
tgcacacgct	gggccgacgc	cgagtgcgag	gagatccctg	gccgttggat	tacacggtcc	2160
acacccccag	agggtctgga	cagcacagcc	cccagcacc	aggagcctga	ggcacctcca	2220
gaacaagacc	tcatagccag	cacgggtggca	ggtgtggtga	ccacagtgat	gggcagctcc	2280
cagcccgtgg	tgacccgagg	caccaccgac	aacctcatcc	ctgtctattg	ctccatcctg	2340
gctgctgtgg	ttgtgggtct	tgtggcctac	atagccttca	agagggtgaaa	aacaaaaaga	2400
acaagaattt	cttggtgaaga	agccgggaac	agacaacaga	agtcatgaag	cccaagtga	2460
atcaaagggtg	ctaaatgggtc	gcccaggaga	catccgttgt	gcttgccctgc	gttttgggaag	2520
ctctgaagtc	acatcacagg	acacggggca	gtggcaacct	tgtctctatg	ccagctcagt	2580

## eolf-seql (10).txt

cccatcagag	agcgagcgct	accactttct	aaatagcaat	ttcgccgttg	aagaggaagg	2640
gcaaaaccac	tagaactctc	catcttattt	tcatgtatat	gtgttcatgc	gatcgctccg	2700
gtgcccgtca	gtgggcagag	cgcacatcgc	ccacagtccc	cgagaagttg	gggggagggg	2760
tcggcaattg	aacgggtgcc	tagagaaggt	ggcgcggggt	aaactgggaa	agtgatgtcg	2820
tgtactggct	ccgccttttt	cccgagggtg	ggggagaacc	gtatataagt	gcagtagtcg	2880
ccgtgaacgt	tctttttcgc	aacgggtttg	ccgccagaac	acagctgaag	cttcgagggg	2940
ctcgcacttc	tccttcacgc	gcccgccgcc	ctacctgagg	ccgccatcca	cggcggttga	3000
gtcgcgttct	gccgcctccc	gcctgtgggt	cctcctgaac	tgcgtccgcc	gtctaggtaa	3060
gtttaaagct	caggtcgaga	ccgggccttt	gtccggcgct	cccttgagac	ctacctagac	3120
tcagccgggt	ctccacgctt	tgcctgacct	tgcttgctca	actctacgtc	tttgtttcgt	3180
tttctgttct	gcgccgttac	agatccaagc	tgtgaccggc	gcctacctga	gatcacccggc	3240
gccaccatgg	cttcttacct	tggacaccag	catgcttctg	cctttgacca	ggctgccaga	3300
tccagggggc	actccaacag	gagaactgcc	ctaagaccca	gaagacagca	ggaagccact	3360
gaggtgaggc	ctgagcagaa	gatgccaaac	ctgctgaggg	tgtacattga	tggacctcat	3420
ggcatgggca	agaccaccac	cactcaactg	ctgggtggcac	tgggctccag	ggatgacatt	3480
gtgtatgtgc	ctgagccaat	gacctactgg	agagtgtctg	gagcctctga	gaccattgcc	3540
aacatctaca	ccaccagca	caggctggac	caggagaaaa	tctctgctgg	agatgctgct	3600
gtgggtgatga	cctctgcccc	gatcacaatg	ggaatgccct	atgctgtgac	tgatgctggt	3660
ctggctcctc	acattggagg	agaggctggc	tcttctcatg	cccctccacc	tgccctgacc	3720
ctgatctttg	acagacaccc	cattgcagcc	ctgctgtgct	accagcagc	aaggtacctc	3780
atgggctcca	tgacccaca	ggctgtgctg	gcttttgtgg	ccctgatccc	tccaaccctc	3840
cctggcacca	acattgttct	gggagcactg	cctgaagaca	gacacattga	caggctggca	3900
aagaggcaga	gacctggaga	gagactggac	ctggccatgc	tggctgcaat	cagaaggggtg	3960
tatggactgc	tggcaaacac	tgtgagatac	ctccagtgtg	gaggctcttg	gagagaggac	4020
tggggacagc	tctctggaac	agcagtgtcc	cctcaaggag	ctgagcccca	gtccaatgct	4080
ggtccaagac	cccacattgg	ggacaccctg	ttcacctgt	tcagagcccc	tgagctgctg	4140
gctcccaatg	gagacctgta	caatgtgttt	gcctgggctc	tggatgttct	agccaagagg	4200
ctgagggtcca	tgcatgtgtt	catcctggac	tatgaccagt	cccctgctgg	atgcagagat	4260
gctctgctgc	aactaacctc	tggcatgggt	cagacccatg	tgaccacccc	tggcagcatc	4320
cccaccatct	gtgacctagc	cagaaccttt	gccagggaga	tgggagaggc	caactaaggc	4380
gcgccactcg	agcgctagct	ggccagacat	gataagatac	attgatgagt	ttggacaaac	4440
cacaactaga	atgcagtga	aaaaatgctt	tatttgtgaa	atttgtgatg	ctattgcttt	4500
atttgaacc	attataagct	gcaataaaca	agttaacaac	aacaattgca	ttcattttat	4560
gtttcagggt	cagggggagg	tgtgggaggt	tttttaaagc	aagtaaaacc	tctacaaatg	4620
tggatatgga	ggcgcgcca	attcgcccta	tagtgagtcg	tattacgtcg	cgctcactgg	4680
ccgtcgtttt	acaacgtcgt	gactgggaaa	accctggcgt	tacccaactt	aatcgccttg	4740
cagcacatcc	ccctttcgcc	agctggcgta	atagcgaaga	ggcccgacc	gaaacgccct	4800
tcccaacagt	tgcgcagcct	gaatggcgaa	tgggagcgcc	ctgtagcggc	gcattaagcg	4860
cggcggggtg	ggtggttacg	cgcagcgtga	ccgctacact	tgccagcgcc	ctagcgcccg	4920
ctcctttcgc	tttcttccct	tcctttctcg	ccacgttcgc	cggctttccc	cgtcaagctc	4980
taaatcgggg	gctcccttta	gggttccgat	ttagtgcttt	acggcacctc	gaccccaaaa	5040
aacttgatta	gggtgatggt	tggcctgtag	tgggccatag	ccctgataga	cggtttttcg	5100
ccctttgacg	ttggagtcca	cgttctttta	tagtggactc	ttgttccaaa	ctggaacaac	5160
actcaaccct	atctcggtct	attcttttga	tttataaggg	attttgccga	tttcggccta	5220
ttggttaaaa	aatgagctga	tttaacaaaa	atttaacgcg	aattttaaca	aaatatatac	5280
gcttacaatt	taggtggcac	ttttcgggga	aatgtgcgcg	gaacccttat	ttgtttatatt	5340
ttctaaatac	attcaaatat	gtatccgctc	atgagacaat	aaccctgata	aatgcttcaa	5400
taatattgaa	aaaggaagag	tatgagtatt	caacatttcc	gtgtcgccct	tattcccttt	5460

eolf-seql (10).txt

```

tttgcggcat tttgccttcc tgttttttgct caccagaaa cgctggtgaa agtaaaagat 5520
gctgaagatc agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag 5580
atccttgaga gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg 5640
ctatgtggcg cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata 5700
cactattctc agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat 5760
ggcatgacag taagagaatt atgcagtgct gccataacca tgagtataa cactgcggcc 5820
aacttacttc tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg 5880
ggggatcatg taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac 5940
gacgagcgtg acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact 6000
ggcgaactac ttactctagc ttcccggcaa caattaatag actggatgga ggcgataaa 6060
gttgaggac cacttctgcg ctccggccctt ccggctggct ggtttattgc tgataaatct 6120
ggagccgggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc 6180
tcccgtatcg tagttatcta cacgacgggg agtcaggcaa ctatggatga acgaaataga 6240
cagatcgctg agataggtgc ctactgatt aagcattggt aactgtcaga ccaagtttac 6300
tcatatatac tttagattga tttaaaactt cttttttaat ttaaaaggat ctaggtgaag 6360
atcctttttg ataatctcat gacaaaatc ctttaacgtg agttttcgtt ccactgagcg 6420
tcagaccccg tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc 6480
tgctgcttgc aaacaaaaaa accaccgcta ccagcgggtg tttgtttgcc ggatcaagag 6540
ctaccaactc tttttccgaa ggtaactggc ttcagcagag cgagataacc aaatactgtt 6600
cttctagtgt agccgtagt aggccaccac ttcaagaact ctgtagcacc gcctacatac 6660
ctcgtctgct taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc 6720
gggttgact caagacgata gttaccggat aaggcgagc ggtcgggctg aacggggggt 6780
tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt 6840
gagctatgag aaagcgccac gcttcccga gggagaaagg cggacaggta tccggtaagc 6900
ggcagggctg gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt 6960
tatagtcctg tcgggtttcg ccacctctga cttgagcgtc gatTTTTtTg atgctcgtca 7020
ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt 7080
tgctggcctt ttgctcacat ggtcttttct gcgttatccc ctgattctgt ggataaccgt 7140
attaccgcct ttgagttagc tgataaccgt cgccgcagcc gaacgaccga gcgcagcgag 7200
tcagttagcg aggaagcgga gagcgcccaa tacgaaacc gcctctcccc gcgcgttggc 7260
cgattcatta atgcagctgg cacgacaggt ttcccactg gaaagcgggc agtgagcgca 7320
acgcaattaa tgtgagttag ctactcatt aggcacccca ggcttttacac tttatgcttc 7380
cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg 7440
accatgatta cgccaagcgc gtcaattaac ctcactaaa gggaacaaaa gctgttaatt 7500
aa 7502

```

<210> 65

<211> 7778

<212> DNA

<213> artificial sequence

<220>

<223> Matrice PD1 locus\_IL15\_2A\_sIL15Ra pCLS30513 full sequence

<400> 65

```

gactccccag acaggccctg gaaccccccc accttctccc cagccctgct cgtggtgacc 60

```

eolf-seql (10).txt

gaaggggaca	acgccacctt	cacctgcagc	ttctccaaca	catcggagag	cttcgtgcta	120
aactgggtacc	gcatgagccc	cagcaaccag	acggacaagc	tggccgcctt	ccccgaggac	180
cgcagccagc	ccggccagga	ctgccgcttc	cgtgtcacac	aactgcccac	cgggcgtgac	240
ttccacatga	gcgtgggtcag	ggcccggcgc	aatgacagcg	gcacctacct	ctgtggggcc	300
ggttctggcg	tgaacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaaccag	ggcccgttac	cgggtccgcc	accatggact	ggacctggat	tctgttcctc	420
gtggctgctg	ctacaagagt	gcacagcggc	attcatgtct	tcattttggg	ctgtttcagt	480
gcagggcctt	ctaaaacaga	agccaactgg	gtgaatgtaa	taagtgattt	gaaaaaaatt	540
gaagatctta	ttcaatctat	gcatattgat	gctactttat	atacgaaaag	tgatgttcac	600
cccagttgca	aagtaacagc	aatgaagtgc	tttctcttgg	agttacaagt	tatttcactt	660
gagtcgggag	atgcaagtat	tcatgataca	gtagaaaatc	tgatcatcct	agcaaacaac	720
agtttgtctt	ctaattggga	tgtaacagaa	tctggatgca	aagaatgtga	ggaactggag	780
gaaaaaaata	ttaaagaatt	tttgagagct	tttgtacata	ttgtccaaat	gttcatcaac	840
acttctggaa	gcggagctac	taacttcagc	ctgctgaagc	aggctggaga	cgtggaggag	900
aaccttggac	ctgggaccgg	ctctgcaacc	atggattgga	cgtggatcct	gtttctcgtg	960
gcagctgcca	caagagttca	cagtatcacg	tgccctcccc	ccatgtccgt	ggaacacgca	1020
gacatctggg	tcaagagcta	cagcttgtac	tccagggagc	ggtacatttg	taactctggt	1080
ttcaagcgta	aagccggcac	gtccagcctg	acggagtgcg	tggtgaacaa	ggccacgaat	1140
gtcggccact	ggacaacccc	cagtctcaaa	tgcattagag	accctgccct	ggttcaccaa	1200
aggccagcgc	caccctccac	agtaacgacg	gcaggggtga	ccccacagcc	agagagcctc	1260
tccccttctg	gaaaagagcc	cgcagcttca	tctcccagct	caaacaacac	agcggccaca	1320
acagcagcta	ttgtcccggg	ctcccagctg	atgccttcaa	aatcaccttc	cacaggaacc	1380
acagagataa	gcagtcatga	gtcctcccac	ggcaccctct	ctcagacaac	agccaagaac	1440
tgggaactca	cagcatccgc	ctcccaccag	ccgccaggtg	tgtatccaca	gggccacagc	1500
gacaccactg	agggcagagg	cagcctgctg	acctgcggcg	acgtcgagga	gaaccccggg	1560
cccatggggg	caggtgccac	cggccgcgcc	atggacgggc	cgcgcctgct	gctgttgctg	1620
cttctggggg	tgtcccttgg	aggtgccaa	gaggcatgcc	ccacaggcct	gtacacacac	1680
agcggtgagt	gctgcaaagc	ctgcaacctg	ggcgagggtg	tggcccagcc	ttgtggagcc	1740
aaccagaccg	tgtgtgagcc	ctgcctggac	agcgtgacgt	tctccgacgt	ggtgagcgcg	1800
accgagccgt	gcaagccgtg	caccgagtgc	gtggggctcc	agagcatgtc	ggcgccgtgc	1860
gtggaggccg	atgacgccgt	gtgccgctgc	gcctacggct	actaccagga	tgagacgact	1920
gggcgctgcg	aggcgtgccg	cgtgtgagag	gcgggctcgg	gcctcgtgtt	ctcctgccag	1980
gacaagcaga	acaccgtgtg	cgaggagtgc	cccagcggca	cgtattccga	cgaggccaac	2040
cacgtggacc	cgtgcctgcc	ctgcaccgtg	tgcgaggaca	ccgagcgcca	gctccgcgag	2100
tgacacgct	gggcccagc	cagtgccgag	gagatccctg	gccgttggat	tacacggtcc	2160
acacccccag	agggtcggga	cagcacagcc	cccagcacc	aggagcctga	ggcacctcca	2220
gaacaagacc	tcatagccag	cacggtggca	ggtgtggtga	ccacagtgat	gggcagctcc	2280
cagcccgtgg	tgacccgagg	caccaccgac	aacctcatcc	ctgtctattg	ctccatcctg	2340
gctgctgtgg	ttgtgggtct	tgtggcctac	atagccttca	agagggtgat	tagaggggcc	2400
gtttaaaccc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	tgttgtttgc	2460
ccctcccccg	tgcttctctt	gaccctggaa	ggtgccactc	ccactgtcct	ttcctaataa	2520
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	2580
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	2640
ggctctatga	ctagtggcga	attcggcgca	gatcaaagag	agcctgcggg	cagagctcag	2700
ggtgacaggt	gcggcctcgg	aggccccggg	gcaggggtga	gctgagccgg	tcctgggggtg	2760
ggtgtccctt	cctgcacagg	atcaggagct	ccagggtcgt	agggcaggga	ccccccagct	2820
ccagtccagg	gctctgtcct	gcacctgggg	aatggtgacc	ggcatctctg	tcctctagct	2880
ctggaagcac	cccagcccct	ctagtctgcc	ctcacccttg	accctgaccc	tccaccctga	2940

eolf-seql (10).txt

ccccgtccta	acccttgacc	tttggcgatc	gctccggtgc	ccgtcagtgg	gcagagcgca	3000
catcgccac	agtccccgag	aagttggggg	gaggggtcgg	caattgaacg	ggtgcctaga	3060
gaaggtggcg	cggggtaaac	tgggaaagt	atgtcgtgta	ctggctccgc	ctttttcccg	3120
aggggtgggg	agaaccgtat	ataagtgcag	tagtcgccgt	gaacgttctt	tttcgcaacg	3180
ggtttgccgc	cagaacacag	ctgaagcttc	gaggggctcg	catctctcct	tcacgcgccc	3240
gccgccctac	ctgaggccgc	catccacgcc	ggttgagtcg	cgttctgccg	cctcccgctt	3300
gtggtgcctc	ctgaactgcg	tccgccgtct	aggtaagttt	aaagctcagg	tcgagaccgg	3360
gcctttgtcc	ggcgctccct	tggagcctac	ctagactcag	ccggctctcc	acgctttgcc	3420
tgaccctgct	tgctcaactc	tacgtctttg	tttcgttttc	tgttctgcgc	cgttacagat	3480
ccaagctgtg	accggcgccct	acctgagatc	accggcgcca	ccatggcttc	ttaccctgga	3540
caccagcatg	cttctgcctt	tgaccaggct	gccagatcca	ggggccactc	caacaggaga	3600
actgccctaa	gaccagaag	acagcaggaa	gccactgagg	tgaggcctga	gcagaagatg	3660
ccaacctgct	tgagggtgta	cattgatgga	cctcatggca	tgggcaagac	caccaccact	3720
caactgctgg	tggcactggg	ctccagggat	gacatttgtt	atgtgcctga	gccaatgacc	3780
tactggagag	tgctaggagc	ctctgagacc	attgccaaca	tctacaccac	ccagcacagg	3840
ctggaccagg	gagaaatctc	tgctggagat	gctgctgtgg	tgatgacctc	tgcccagatc	3900
acaatgggaa	tgccctatgc	tgtgactgat	gctgttctgg	ctcctcacat	tgaggagagag	3960
gctggctctt	ctcatgcccc	tccacctgcc	ctgaccctga	tctttgacag	acacccatt	4020
gcagccctgc	tgtgtacctc	agcagcaagg	tacctcatgg	gctccatgac	cccacaggct	4080
gtgctggctt	ttgtggccct	gatccctcca	accctccctg	gcaccaacat	tgttctggga	4140
gactgcctg	aagacagaca	cattgacagg	ctggcaaaga	ggcagagacc	tgagagagaga	4200
ctggacctgg	ccatgctggc	tgcaatcaga	aggggtgtat	gactgctggc	aaacactgtg	4260
agatacctcc	agtgtggagg	ctcttgagga	gaggactggg	gacagctctc	tggaacagca	4320
gtgccccctc	aaggagctga	gccccagtcc	aatgctgggt	caagacccca	cattggggac	4380
accctgttca	ccctgttcag	agccccctgag	ctgctggctc	ccaatggaga	cctgtacaat	4440
gtgtttgcct	gggctctgga	tgttctagcc	aagaggctga	ggtccatgca	tgtgttcatc	4500
ctggactatg	accagtcccc	tgctggatgc	agagatgctc	tgctgcaact	aacctctggc	4560
atggtgcaga	cccatgtgac	cacccctggc	agcatcccca	ccatctgtga	cctagccaga	4620
acctttgcca	gggagatggg	agaggccaac	taaggcgcg	cactcgagcg	ctagctggcc	4680
agacatgata	agatacattg	atgagtttgg	acaaaccaca	actagaatgc	agtgaaaaaa	4740
atgctttatt	tgtgaaattt	gtgatgctat	tgctttattt	gtaaccatta	taagctgcaa	4800
taaacaagtt	aacaacaaca	attgcattca	ttttatgttt	caggttcagg	gggaggtgtg	4860
ggagggtttt	taaagcaagt	aaaacctcta	caaatgtggt	atggaaggcg	cgcccaattc	4920
gccctatagt	gagtcgtatt	acgtcgcgct	cactggccgt	cgttttacaa	cgtcgtgact	4980
gggaaaacc	tggcgttacc	caacttaatc	gccttgccgc	acatccccct	ttcgccagct	5040
ggcgtaatat	cgaagaggcc	cgcaccgaaa	cgcccttccc	aacagttgcg	cagcctgaat	5100
ggcgaatggg	agcgccctgt	agcggcgcat	taagcgcggc	gggtgtggtg	gttacgcgca	5160
gcgtgaccgc	tacacttgcc	agcgccctag	cgcccgtctc	tttcgctttc	ttcccttcct	5220
ttctcgccac	gttcgccggc	tttccccgtc	aagctctaaa	tcgggggctc	cctttagggt	5280
tccgatttag	tgctttacgg	cacctcgacc	caaaaaaact	tgattagggt	gatggttggc	5340
ctgtagtggg	ccatagccct	gatagacggg	ttttcgccct	ttgacgttgg	agtccacgtt	5400
ctttaatagt	ggactcttgt	tccaaactgg	aacaacactc	aaccctatct	cggtctattc	5460
ttttgattta	taagggtatt	tgccgatttc	ggcctatttg	ttaaaaaatg	agctgattta	5520
acaaaaattt	aacgcgaatt	ttaacaaaat	attaacgctt	acaatttagg	tggcactttt	5580
cggggaaatg	tgcgcggaac	ccctatttgt	ttatttttct	aaatacattc	aaatatgtat	5640
ccgctcatga	gacaataacc	ctgataaatg	cttcaataat	attgaaaaag	gaagagtatg	5700
agtattcaac	atttccgtgt	cgcccttatt	cccttttttg	cggcattttg	ccttcctgtt	5760
tttgctcacc	cagaaacgct	ggtgaaagta	aaagatgctg	aagatcagtt	gggtgcacga	5820

eolf-seql (10).txt

gtgggttaca	tcgaactgga	tctcaacagc	ggtaagatcc	ttgagagttt	tcgccccgaa	5880
gaacgttttc	caatgatgag	cactttttaa	gttctgctat	gtggcgcggt	attatcccgt	5940
attgacgccg	ggcaagagca	actcggtcgc	cgcatacact	attctcagaa	tgacttggtt	6000
gagtactcac	cagtcacaga	aaagcatctt	acggatggca	tgacagtaag	agaattatgc	6060
agtgtgcca	taaccatgag	tgataacact	gcggccaact	tacttctgac	aacgatcgga	6120
ggaccgaagg	agctaaccgc	ttttttgcac	aacatggggg	atcatgtaac	tcgccttgat	6180
cgttggggaa	cggagctgaa	tgaagccata	ccaaacgacg	agcgtgacac	cacgatgcct	6240
gtagcaatgg	caacaacgtt	gcgcaaacta	ttaactggcg	aactacttac	tctagcttcc	6300
cggcaacaat	taatagactg	gatggaggcg	gataaagttg	caggaccact	tctgcgctcg	6360
gcccttccgg	ctggctggtt	tattgctgat	aaatctggag	ccggtgagcg	tggttctcgc	6420
ggtatcattg	cagcactggg	gccagatggg	aagccctccc	gtatcgtagt	tatctacacg	6480
acggggagtc	aggcaactat	ggatgaacga	aatagacaga	tcgctgagat	aggtgcctca	6540
ctgattaagc	attggtaact	gtcagaccaa	gtttactcat	atatacttta	gattgattta	6600
aaacttcatt	tttaatttaa	aaggatctag	gtgaagatcc	tttttgataa	tctcatgacc	6660
aaaatccctt	aacgtgagtt	ttcgttccac	tgagcgtcag	accccgtaga	aaagatcaaa	6720
ggatcttctt	gagatccttt	ttttctgcgc	gtaatctgct	gcttgcaaac	aaaaaaacca	6780
ccgctaccag	cgggtggtttg	tttgccggat	caagagctac	caactctttt	tccgaaggta	6840
actggcttca	gcagagcgca	gataccaaat	actgttcttc	tagtgtagcc	gtagttaggc	6900
caccacttca	agaactctgt	agcaccgcct	acatacctcg	ctctgctaata	cctgtttacca	6960
gtggctgctg	ccagtggcga	taagtcgtgt	cttaccgggt	tgactcaag	acgatagtta	7020
ccggataagg	cgagcggtc	gggctgaacg	gggggttcgt	gcacacagcc	cagcttgag	7080
cgaacgacct	acaccgaact	gagataccta	cagcgtgagc	tatgagaaaag	cgccacgctt	7140
cccgaaggga	gaaaggcgga	caggatatccg	gtaagcggca	gggtcgggaa	aggagagcgc	7200
acgaggggagc	ttccagggggg	aaacgcctgg	tatctttata	gtcctgtcgg	gtttcgccac	7260
ctctgacttg	agcgtcgatt	tttgtgatgc	tcgtcagggg	ggcggagcct	atggaaaaac	7320
gccagcaacg	cggccttttt	acggttcctg	gccttttgc	ggccttttgc	tcacatgggtc	7380
tttctgcgt	tatcccctga	ttctgtggat	aaccgtatta	ccgcctttga	gtgagctgat	7440
accgctcgcc	gcagccgaac	gaccgagcgc	agcgagtcag	tgagcgagga	agcggagagc	7500
gccaataacg	caaaccgcct	ctccccgcgc	gttggccgat	tcattaatgc	agctggcacg	7560
acaggtttcc	cgactggaaa	gcgggcagtg	agcgcaacgc	aattaatgtg	agtttagctca	7620
ctcattaggc	accccaggct	ttacacttta	tgcttccggc	tcgtatgttg	tgtggaattg	7680
tgagcgggata	acaatttcac	acaggaaaca	gctatgacca	tgattacgcc	aagcgcgtca	7740
attaaccctc	actaaaggga	acaaaagctg	ttaattaa			7778

<210> 66

<211> 8177

<212> DNA

<213> artificial sequence

<220>

<223> Matrice CD25 locus\_IL12a\_2A\_IL12b pCLS30520 full sequence

<400> 66

gtttattatt	cctgttccac	agctattgtc	tgccatataa	aaacttaggc	caggcacagt	60
ggctcacacc	tgtaatccca	gcactttgga	aggccgaggc	aggcagatca	caaggtcagg	120
agttcgagac	cagcctggcc	aacatagcaa	aaccccatct	ctactaaaaa	tacaaaaatt	180

eolf-seql (10).txt

agccaggcat	ggtggcgtgt	gcactggttt	agagttagga	ccacattttt	ttggtgccgt	240
gttacacata	tgaccgtgac	tttgttacac	cactacagga	ggaagagtag	aagaacaatc	300
ggttctggcg	tgaacacagac	tttgaatttt	gaccttctca	agttggcggg	agacgtggag	360
tccaaccag	ggcccatgtg	gccccctggg	tcagcctccc	agccaccgcc	ctcacctgcc	420
gcggccacag	gtctgcatcc	agcggctcgc	cctgtgtccc	tgcagtgccg	gctcagcatg	480
tgtccagcgc	gcagcctcct	ccttgtggct	accctgggcc	tcctggacca	cctcagtttg	540
gccagaaacc	tccccgtggc	cactccagac	ccaggaatgt	tcccatgcct	tcaccactcc	600
caaaacctgc	tgagggccgt	cagcaacatg	ctccagaagg	ccagacaaac	tctagaatth	660
tacccttgca	cttctgaaga	gattgatcat	gaagatatca	caaaagataa	aaccagcaca	720
gtggaggcct	gtttaccatt	ggaattaacc	aagaatgaga	gttgcctaaa	ttccagagag	780
acctctttca	taactaatgg	gagttgcctg	gcctccagaa	agacctcttt	tatgatggcc	840
ctgtgcctta	gtagtattta	tgaagacttg	aagatgtacc	aggtggagtt	caagaccatg	900
aatgcaaagc	ttctgatgga	tcctaagagg	cagatctttc	tagatcaaaa	catgctggca	960
gttattgatg	agctgatgca	ggccctgaat	ttcaacagtg	agactgtgcc	acaaaaatcc	1020
tcccttgaag	aaccggatth	ttataaaact	aaaatcaagc	tctgcatact	tcttcatgct	1080
ttcagaattc	gggcagtgc	tattgataga	gtgatgagct	atctgaatgc	ttccggaagc	1140
ggagctacta	acttcagcct	gctgaagcag	gctggagacg	tggaggagaa	ccctggacct	1200
atgtgtcacc	agcagttggt	catctcttgg	ttttccctgg	tttttctggc	atctcccctc	1260
gtggccatat	gggaactgaa	gaaagatgth	tatgtcgtag	aattggattg	gtatccggat	1320
gcccctggag	aaatggtggt	cctcacctgt	gacacccctg	aagaagatgg	tatcacctgg	1380
accttgacc	agagcagtga	ggtcttaggc	tctggcaaaa	ccctgaccat	ccaagtcaaa	1440
gagtttgag	atgctggcca	gtacacctgt	cacaaaggag	gcgaggttct	aagccattcg	1500
ctcctgtgc	ttcacaaaaa	ggaagatgga	atthggtcca	ctgatattth	aaaggaccag	1560
aaagaaccca	aaaataagac	ctthctaaga	tgcgaggcca	agaattattc	tggacgtthc	1620
acctgctggt	ggctgacgac	aatcagtact	gatttgacat	tcagtgtcaa	aagcagcaga	1680
ggctcttctg	acccccaagg	ggtgacgtgc	ggagctgcta	cactctctgc	agagagagtc	1740
agagggggaca	acaaggagta	tgagtactca	gtggagtgcc	aggaggacag	tgcttgccca	1800
gctgctgagg	agagtctgcc	cattgaggtc	atggtggatg	ccgttcacaa	gctcaagtat	1860
gaaaactaca	ccagcagctt	cttcatcagg	gacatcatca	aacctgacct	acccaagaac	1920
ttgcagctga	agccattaaa	gaattctcgg	caggtggagg	tcagctggga	gtaccctgac	1980
acctggagta	ctccacattc	ctacttctcc	ctgacattct	gcgttcaggt	ccagggcaag	2040
agcaagagag	aaaagaaaaga	tagagtcttc	acggacaaga	cctcagccac	ggtcatctgc	2100
cgcaaaaatg	ccagcattag	cgtgcggggc	caggaccgct	actatagctc	atcttgagac	2160
gaatgggcat	ctgtgccctg	cagtgagggc	agaggcagcc	tgctgacctg	cggcgacgtc	2220
gaggagaacc	ccggggccat	gggggcaggt	gccaccggcc	gcgccatgga	cgggccgcgc	2280
ctgctgctgt	tgctgcttct	gggggtgtcc	cttggagggtg	ccaaggaggc	atgccccaca	2340
ggcctgtaca	cacacagcgg	tgagtgtgtc	aaagcctgca	acctgggcga	gggtgtggcc	2400
cagccttggtg	gagccaacca	gaccgtgtgt	gagccctgcc	tggacagcgt	gacgttctcc	2460
gacgtgggtga	gcgcgaccga	gccgtgcaag	ccgtgcaccg	agtgcgtggg	gctccagagc	2520
atgtcggcgc	cgtgcgtgga	ggccgatgac	gccgtgtgcc	gctgcgccta	cggctactac	2580
caggatgaga	cgactgggcg	ctgcgaggcg	tgccgcgtgt	gcgaggcggg	ctcgggcctc	2640
gtgttctcct	gccaggacaa	gcagaacacc	gtgtgcgagg	agtgcctcga	cggcacgtat	2700
tccgacgagg	ccaaccacgt	ggacctgtgc	ctgccctgca	ccgtgtgcga	ggacaccgag	2760
cgccagctcc	gcgagtgcac	acgtggggcc	gacgccgagt	gcgaggagat	ccctggccgt	2820
tggattacac	ggtccacacc	cccagagggc	tcggacagca	cagccccag	caccagggag	2880
cctgaggcac	ctccagaaca	agacctcata	gccagcacgg	tggcaggtgt	ggtgaccaca	2940
gtgatgggca	gtcccagcc	cgtgggtgacc	cgaggcacca	ccgacaacct	catccctgtc	3000
tattgtctca	tcctggctgc	tgtgggtgtg	ggtcttgtgg	cctacatagc	cttcaaggagg	3060

eolf-seql (10).txt

tgaaaaacca	aaagaacaag	aattttcttgg	taagaagccg	ggaacagaca	acagaagtca	3120
tgaagcccaa	gtgaaatcaa	aggtgctaaa	tggtcgccca	ggagacatcc	gttgtgcttg	3180
cctgcgtttt	ggaagctctg	aagtcacatc	acaggacacg	gggcagtggc	aaccttgctt	3240
ctatgccagc	tcagtcccat	cagagagcga	gcgctaccca	cttctaaata	gcaatttcgc	3300
cgttgaagag	gaagggcaaa	accactagaa	ctctccatct	tattttcatg	tatatgtgtt	3360
catgcgatcg	ctccggtgcc	cgtcagtggg	cagagcgcac	atcgcccaca	gtccccgaga	3420
agttgggggg	aggggtcggc	aattgaacgg	gtgcctagag	aaggtggcgc	ggggtaaact	3480
gggaaagtga	tgtcgtgtac	tggctccgcc	tttttcccga	gggtggggga	gaaccgtata	3540
taagtgcagt	agtcgccgtg	aacgttcttt	ttcgcaacgg	gtttgccgcc	agaacacagc	3600
tgaagcttcg	aggggctcgc	atctctcctt	cacgcgcccg	ccgccctacc	tgaggccgcc	3660
atccacgccg	gttgagtcgc	gttctgccgc	ctccgcctg	tggtgcctcc	tgaactgcgt	3720
ccgccgtcta	ggtaagttta	aagctcaggt	cgagaccggg	cctttgtccg	gcgctccctt	3780
ggagcctacc	tagactcagc	cggctctcca	cgctttgcct	gacctgctt	gctcaactct	3840
acgtctttgt	ttcgttttct	gttctgcgcc	gttacagatc	caagctgtga	ccggcgccta	3900
cctgagatca	ccggcgccac	catggcttct	tacctggac	accagcatgc	ttctgccttt	3960
gaccaggctg	ccagatccag	gggccactcc	aacaggagaa	ctgccctaag	accagaaga	4020
cagcaggaag	ccactgaggt	gaggcctgag	cagaagatgc	caaccctgct	gagggtgtac	4080
attgatggac	ctcatggcat	gggcaagacc	accaccactc	aactgctggg	ggcactgggc	4140
tccagggatg	acattgtgta	tgtgcctgag	ccaatgacct	actggagagt	gctaggagcc	4200
tctgagacca	ttgccaacat	ctacaccacc	cagcacaggc	tggaccaggg	agaaatctct	4260
gctggagatg	ctgctgtggg	gatgacctct	gcccagatca	caatgggaat	gccctatgct	4320
gtgactgatg	ctgttctggc	tcctcacatt	ggaggagagg	ctggctcttc	tcatgcccct	4380
ccacctgccc	tgacctgat	ctttgacaga	cacccattg	cagccctgct	gtgctaccca	4440
gcagcaaggt	acctcatggg	ctccatgacc	ccacaggctg	tgctggcttt	tgtggccctg	4500
atccctccaa	ccctccctgg	caccaacatt	gttctgggag	cactgcctga	agacagacac	4560
attgacaggc	tggcaaagag	gcagagacct	ggagagagac	tggacctggc	catgctggct	4620
gcaatcagaa	gggtgtatgg	actgctggca	aacactgtga	gatacctcca	gtgtggaggc	4680
tcttggagag	aggactgggg	acagctctct	ggaacagcag	tgccccctca	aggagctgag	4740
ccccagtcca	atgctggctc	aagacccac	attggggaca	ccctgttcac	cctgttcaga	4800
gcccctgagc	tgctggctcc	caatggagac	ctgtacaatg	tgtttgcctg	ggctctggat	4860
gttctagcca	agaggctgag	gtccatgcat	gtgttcatcc	tggactatga	ccagtcccct	4920
gctggatgca	gagatgctct	gctgcaacta	acctctggca	tgggtgcagac	ccatgtgacc	4980
accctggca	gcatccccac	catctgtgac	ctagccagaa	cctttgccag	ggagatggga	5040
gaggccaact	aaggcgcgcc	actcgagcgc	tagctggcca	gacatgataa	gatacattga	5100
tgagtttgga	caaaccacaa	ctagaatgca	gtgaaaaaaa	tgctttattt	gtgaaatttg	5160
tgatgctatt	gctttatttg	taaccattat	aagctgcaat	aaacaagtta	acaacaacaa	5220
ttgcattcat	tttatgtttc	aggttcaggg	ggaggtgtgg	gagggttttt	aaagcaagta	5280
aaacctctac	aaatgtggta	tgggaaggcgc	gcccatttcg	ccctatagtg	agtcgtatta	5340
cgtcgcgctc	actggccgtc	gttttacaac	gtcgtgactg	ggaaaaccct	ggcgttaccc	5400
aacttaatcg	ccttgacgca	catccccctt	tcgccagctg	gcgtaatagc	gaagaggccc	5460
gcaccgaaac	gcccttccca	acagttgcgc	agcctgaatg	gcgaatggga	gcgccctgta	5520
gcggcgcat	aagcgcggcg	ggtgtgggtg	ttacgcgcag	cgtgaccgct	acacttgcca	5580
gcgccctagc	gcccgtctct	ttcgctttct	ttccttcctt	tctcgccacg	ttcgccggct	5640
ttccccgtca	agctctaaat	cgggggctcc	ctttagggtt	ccgatttagt	gctttacggc	5700
acctcgaccc	caaaaaactt	gattaggggtg	atggttggcc	tgtagtgggc	catagccctg	5760
atagacgggt	tttcgccctt	tgacgttgga	gtccacgttc	tttaatagtg	gactcttggt	5820
ccaaactgga	acaacactca	accctatctc	ggtctattct	tttgatttat	aagggatttt	5880
gccgatttcg	gcctattgggt	taaaaaatga	gctgatttaa	caaaaattta	acgcgaattt	5940

eolf-seql (10).txt

taacaaaata	ttaacgctta	caatttaggt	ggcacttttc	ggggaaatgt	gcgcggaacc	6000
cctatttgtt	tatttttcta	aatacattca	aatatgtatc	cgctcatgag	acaataaccc	6060
tgataaatgc	ttcaataata	ttgaaaaagg	aagagtatga	gtattcaaca	tttccgtgtc	6120
gcccttattc	ccttttttgc	ggcattttgc	cttcctgttt	ttgctcacc	agaaacgctg	6180
gtgaaagtaa	aagatgctga	agatcagttg	ggtgcacgag	tgggttacat	cgaactggat	6240
ctcaacagcg	gtaagatcct	tgagagtttt	cgccccgaag	aacgttttcc	aatgatgagc	6300
acttttaaa	ttctgctatg	tggcgcggta	ttatcccgt	ttgacgccgg	gcaagagcaa	6360
ctcggtcgcc	gcatacacta	ttctcagaat	gacttggttg	agtactcacc	agtcacagaa	6420
aagcatctta	cggatggcat	gacagtaaga	gaattatgca	gtgctgccat	aaccatgagt	6480
gataacactg	cggccaactt	acttctgaca	acgatcggag	gaccgaagga	gctaaccgct	6540
tttttgcaca	acatggggga	tcatgtaact	cgccttgatc	gttggggaacc	ggagctgaat	6600
gaagccatac	caaacgacga	gcgtgacacc	acgatgcctg	tagcaatggc	aacaacgttg	6660
cgcaaacctat	taactggcga	actacttact	ctagcttccc	ggcaacaatt	aatagactgg	6720
atggaggcgg	ataaagttgc	aggaccactt	ctgcgctcgg	cccttcgccc	tggctggttt	6780
attgctgata	aatctggagc	cggtgagcgt	ggttctcgcg	gtatcattgc	agcactgggg	6840
ccagatggta	agccctccc	tatcgtagtt	atctacacga	cggggagtc	ggcaactatg	6900
gatgaacgaa	atagacagat	cgctgagata	ggtgcctcac	tgattaagca	ttggtaactg	6960
tcagaccaag	tttactcata	tatacttttag	attgatttaa	aacttcattt	ttaatttaaa	7020
aggatctagg	tgaagatcct	ttttgataat	ctcatgacca	aaatccctta	acgtgagttt	7080
tcgttccact	gagcgtcaga	ccccgtagaa	aagatcaaag	gatcttcttg	agatcctttt	7140
tttctgcgcg	taatctgctg	cttgcaaaca	aaaaaaccac	cgctaccagc	ggtgggtttgt	7200
ttgccggatc	aagagctacc	aactcttttt	ccgaaggtaa	ctggcttcag	cagagcgcag	7260
ataccaaaata	ctgttcttct	agtgtagccg	tagttaggcc	accacttcaa	gaactctgta	7320
gcaccgccta	catacctcgc	tctgctaata	ctgttaccag	tggctgctgc	cagtggcgat	7380
aagtcgtgtc	ttaccggggt	ggactcaaga	cgatagttac	cggataaggc	gcagcggtcg	7440
ggctgaacgg	ggggttcgtg	cacacagccc	agcttggagc	gaacgacct	caccgaactg	7500
agatacctac	agcgtgagct	atgagaaagc	gccacgcttc	ccgaaggag	aaaggcggac	7560
aggatccgg	taagcggcag	ggtcgggaaca	ggagagcgca	cgaggagct	tccaggggga	7620
aacgcctgg	atctttatag	tcctgtcggg	tttcgccacc	tctgacttga	gcgtcgattt	7680
ttgtgatgct	cgtcaggggg	gcggagccta	tggaaaaacg	ccagcaacgc	ggccttttta	7740
cggttcctgg	ccttttgctg	gccttttgct	cacatggtct	ttcctgcgtt	atcccctgat	7800
tctgtggata	accgtattac	cgcctttgag	tgagctgata	ccgctcgccg	cagccgaacg	7860
accgagcgca	gcgagtcagt	gagcgaggaa	gcggagagcg	ccaataacgc	aaaccgcctc	7920
tccccgcgcg	ttggccgatt	cattaatgca	gctggcacga	caggtttccc	gactggaaag	7980
cgggcagtga	gcgcaacgca	attaatgtga	gttagctcac	tcattaggca	ccccaggcct	8040
tacactttat	gcttccggct	cgtatgttgt	gtggaattgt	gagcggataa	caatttcaca	8100
caggaaacag	ctatgacat	gattacgcca	agcgcgtcaa	ttaaccctca	ctaaagggaa	8160
caaaagctgt	taatttaa					8177

<210> 67

<211> 6349

<212> DNA

<213> artificial sequence

<220>

<223> Matrice PD1 locus\_IL12a\_2A\_IL12b pCLS30511 full sequence

eolf-seql (10).txt

<400> 67

tcgcgcttt	cggtgatgac	ggtgaaaacc	tctgacacat	gcagctccc	gagacggtca	60
cagcttgct	gtaagcggat	gccgggagca	gacaagccc	tcagggcgcg	tcagcgggtg	120
ttggcgggtg	tcggggctgg	cttaactatg	cggcatcaga	gcagattgta	ctgagagtgc	180
accatatgcg	gtgtgaaata	ccgcacagat	gcgtaaggag	aaaataccgc	atcaggcgcc	240
attcgccatt	caggctgctg	aactgttggg	aagggcgatc	ggtgcggggc	tcttcgctat	300
tacgccagct	ggcgaaaggg	ggatgtgctg	caaggcgatt	aagttgggta	acgccagggt	360
tttcccagtc	acgacgttgt	aaaacgacgg	ccagtgaatt	cgagctcggt	acctcgcgaa	420
tgcattctaga	tgactcccca	gacaggccct	ggaaccccc	caccttctcc	ccagccctgc	480
tcgtggtgac	cgaaggggac	aacgccacct	tcacctgcag	cttctccaac	acatcggaga	540
gcttcgtgct	aaactggtac	cgcattgagcc	ccagcaacca	gacggacaag	ctggccgcct	600
tccccgagga	ccgcagccag	cccggccagg	actgccgctt	ccgtgtcaca	caactgcccc	660
acgggcgtga	cttccacatg	agcgtggtca	ggggccggcg	caatgacagc	ggcacctacc	720
tctgtggggc	cggttctggc	gtgaaacaga	ctttgaattt	tgaccttctc	aagttggcgg	780
gagacgtgga	gtccaaccca	gggcccattg	ggccccctgg	gtcagcctcc	cagccaccgc	840
cctcacctgc	cgcgggccaca	ggtctgcatc	cagcggctcg	ccctgtgtcc	ctgcagtgcc	900
ggctcagcat	gtgtccagcg	cgcagcctcc	tccttgtggc	taccctggtc	ctcctggacc	960
acctcagttt	ggccagaaac	ctccccgtgg	ccactccaga	cccaggaatg	ttcccatgcc	1020
ttcaccactc	ccaaaacctg	ctgagggccg	tcagcaacat	gctccagaag	gccagacaaa	1080
ctctagaatt	ttaccttgct	acttctgaag	agattgatca	tgaagatatc	acaaaagata	1140
aaaccagcac	agtggaggcc	tgtttaccat	tggaaattaac	caagaatgag	agttgcctaa	1200
attccagaga	gacctctttc	ataactaatg	ggagttgcct	ggcctccaga	aagacctctt	1260
ttatgatggc	cctgtgcctt	agtagtattt	atgaagactt	gaagatgtac	caggtggagt	1320
tcaagaccat	gaatgcaaag	cttctgatgg	atcctaagag	gcagatcttt	ctagatcaaa	1380
acatgctggc	agttattgat	gagctgatgc	aggccctgaa	tttcaacagt	gagactgtgc	1440
cacaaaaatc	ctcccttgaa	gaaccggatt	tttataaaac	taaaatcaag	ctctgcatac	1500
ttcttcatgc	tttcagaatt	cgggcagtga	ctattgatag	agtgatgagc	tatctgaatg	1560
cttccggaag	cggagctact	aacttcagcc	tgctgaagca	ggctggagac	gtggaggaga	1620
accctggacc	tatgtgtcac	cagcagttgg	tcattctctg	gttttccctg	gtttttctgg	1680
catctcccct	cgtggccata	tgggaactga	agaaagatgt	ttatgtcgta	gaattggatt	1740
ggtatccgga	tgcccctgga	gaaatggtgg	tcctcacctg	tgacaccctt	gaagaagatg	1800
gtatcacctg	gaccttgga	cagagcagtg	aggtcttagg	ctctggcaaa	accctgacca	1860
tccaagtcaa	agagtttggg	gatgtggcc	agtacacctg	tcacaaaagg	ggcgaggttc	1920
taagccattc	gctcctgctg	cttcacaaaa	aggaagatgg	aatttggtcc	actgatattt	1980
taaaggacca	gaaagaacct	aaaaataaga	cctttctaag	atgcgaggcc	aagaattatt	2040
ctggacgttt	cacctgctgg	tggctgacga	caatcagtag	tgatttgaca	ttcagtgtca	2100
aaagcagcag	aggctcttct	gacccccaa	gggtgacgtg	cggagctgct	acactctctg	2160
cagagagagt	cagaggggac	aacaaggagt	atgagtactc	agtggagtgc	caggaggaca	2220
gtgcctgccc	agctgctgag	gagagtctgc	ccattgaggt	catggtggat	gccgttcaca	2280
agctcaagta	tgaaaactac	accagcagct	tcttcatcag	ggacatcatc	aaacctgacc	2340
cacccaagaa	cttgacagct	aagccattaa	agaattctcg	gcaggtggag	gtcagctggg	2400
agtaccctga	cacctggagt	actccacatt	cctacttctc	cctgacattc	tgcgttcagg	2460
tccagggcaa	gagcaagaga	gaaaagaaag	atagagtctt	cacggacaag	acctcagcca	2520
cggatcatctg	ccgcaaaaat	gccagcatta	gcgtgcgggc	ccaggaccgc	tactatagct	2580
catcttggag	cgaatgggca	tctgtgccct	gcagtggagg	cagaggcagc	ctgctgacct	2640
gcggcgacgt	cgaggagaac	cccggggcca	tgggggcagg	tgccaccggc	cgcgccatgg	2700
acgggcccgc	cctgctgctg	ttgctgcttc	tgggggtgtc	ccttggagggt	gccaaggagg	2760

## eolf-seql (10).txt

catgccccac	aggcctgtac	acacacagcg	gtgagtgtctg	caaagcctgc	aacctggggcg	2820
agggtgtggc	ccagccttgt	ggagccaacc	agaccgtgtg	tgagccctgc	ctggacagcg	2880
tgacgttctc	cgacgtgggtg	agcgcgaccg	agccgtgcaa	gccgtgcacc	gagtgcgtgg	2940
ggctccagag	catgtcggcg	ccgtgcgtgg	aggccgatga	cgccgtgtgc	cgctgcgcct	3000
acggctacta	ccaggatgag	acgactgggc	gctgcgaggc	gtgccgcgtg	tgcgaggcgg	3060
gctcgggcct	cgtgttctcc	tgccaggaca	agcagaacac	cgtgtgcgag	gagtgcctcg	3120
acggcacgta	ttccgacgag	gccaaccacg	tggaccctgt	cctgccctgc	accgtgtgctg	3180
aggacaccga	gcgccagctc	cgcgagtgc	cacgctgggc	cgacgccgag	tgcgaggaga	3240
tccctggccg	ttggattaca	cgggtccacac	ccccagaggg	ctcggacagc	acagccccc	3300
gcaccagga	gcctgaggca	cctccagaac	aagacctcat	agccagcacg	gtggcagggtg	3360
tggtgaccac	agtgatgggc	agctcccagc	ccgtgggtgac	ccgaggcacc	accgacaacc	3420
tcattccctgt	ctattgtctc	atcctggctg	ctgtgggtgtg	gggtcttctg	gcctacatag	3480
ccttcaagag	gtgatctaga	gggcccgttt	aaaccgcgtg	atcagcctcg	actgtgcctt	3540
ctagttgcca	gccatctgtt	gtttgcccct	ccccgtgcc	ttccttgacc	ctggaagggtg	3600
ccactcccac	tgtcctttcc	taataaaatg	aggaaattgc	atcgcatgtt	ctgagtaggt	3660
gtcatttctat	tctgggggggt	gggggtggggc	aggacagcaa	gggggaggat	tgggaagaca	3720
atagcaggca	tgctgggggat	gcggtgggct	ctatgactag	tggcgaattc	ggcgcagatc	3780
aaagagagcc	tgccgggcaga	gctcagggtg	acagggtgcg	cctcggaggc	cccggggcag	3840
gggtgagctg	agccgggtcct	gggggtgggtg	tcccttcctg	cacaggatca	ggagctccag	3900
ggtcgtaggg	cagggacccc	ccagctccag	tccagggtc	tgtcctgcac	ctggggaatg	3960
gtgaccggca	tctctgtcct	ctagctctgg	aagcacccca	gccccctctag	tctgccctca	4020
cccctgaccc	tgaccctcca	ccctgacccc	gtcctaacc	ctgacctttg	atcggatccc	4080
gggcccgtcg	actgcagagg	cctgcatgca	agcttggcgt	aatcatgggtc	atagctgttt	4140
cctgtgtgaa	attgtttatcc	gctcacaatt	ccacacaaca	tacgagccgg	aagcataaag	4200
tgtaaaagcct	gggggtgccta	atgagtgcgc	taactcacat	taattgcgtt	gcgctcactg	4260
cccgttttcc	agtcgggaaa	cctgtcgtgc	cagctgcatt	aatgaatcgg	ccaacgcgcg	4320
gggagaggcg	gtttgcgtat	tgggcgctct	tccgcttcct	cgctcactga	ctcgctgcgc	4380
tcggctggtc	ggctgcggcg	agcgggtatca	gctcactcaa	aggcggtaat	acggttatcc	4440
acagaatcag	gggataacgc	aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	4500
aaccgtaaaa	aggccgcgtt	gctggcggtt	ttccataggc	tccgcccccc	tgacgagcat	4560
cacaaaaatc	gacgctcaag	tcagaggtgg	cgaaaccgga	caggactata	aagataccag	4620
gcgtttcccc	ctggaagctc	cctcgtgcgc	tctcctgttc	cgaccctgcc	gcttacccga	4680
tacctgtccg	cctttctccc	ttcggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	4740
tatctcagtt	cgggtgtaggt	cggtcgtcc	aagctgggct	gtgtgcacga	acccccgtt	4800
cagcccagcc	gctgcgcctt	atccggtaac	tatcgtcttg	agtccaacc	ggtaagacac	4860
gacttatcgc	cactggcagc	agccactgg	aacaggatta	gcagagcgag	gtatgtaggc	4920
gggtgctacag	agttcttgaa	gtgggtggcct	aactacggct	acactagaag	aacagtattt	4980
ggtatctgcg	ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	5040
ggcaaaaacaa	ccaccgctgg	tagcgggtgg	ttttttgttt	gcaagcagca	gattacgcgc	5100
agaaaaaaag	gatctcaaga	agatcctttg	atcttttcta	cggggtctga	cgctcagtgg	5160
aacgaaaact	cacgttaagg	gattttgggtc	atgagattat	caaaaaggat	cttcacctag	5220
atccttttaa	attaaaaatg	aagttttaaa	tcaatctaaa	gtatatatga	gtaaacttgg	5280
tctgacagtt	accaatgctt	aatcagtgcg	gcacctatct	cagcgatctg	tctatttcgt	5340
tcattccatag	ttgcctgact	ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	5400
tctggcccca	gtgctgcaat	gataccgcga	gaccacgcct	caccggctcc	agatttatca	5460
gcaataaacc	agccagccgg	aagggccgag	cgcagaagtg	gtcctgcaac	tttatccgcc	5520
tccatccagt	ctattaattg	ttgccgggaa	gctagagtaa	gtagtctgcc	agttaatagt	5580
ttgcgcaacg	ttgttgccat	tgctacaggc	atcgtgggtg	cacgctcgtc	gtttgggtatg	5640

eolf-seql (10).txt

gcttcattca	gctccggttc	ccaacgatca	aggcgagtta	catgatcccc	catgtttgtgc	5700
aaaaaagcgg	ttagctcctt	cggctcctccg	atcgttgtca	gaagtaagtt	ggccgcagtg	5760
ttatcactca	tggttatggc	agcactgcat	aattctctta	ctgtcatgcc	atccgtaaga	5820
tgcttttctg	tgactgggtga	gtactcaacc	aagtcatctt	gagaatagtg	tatgcggcga	5880
ccgagttgct	cttgcccggc	gtcaatacgg	gataatacgg	cgccacatag	cagaacttta	5940
aaagtgtca	tcattggaaa	acgttcttcg	gggcgaaaac	tctcaaggat	cttaccgctg	6000
ttgagatcca	gttcgatgta	accactcgt	gcacccaact	gatcttcagc	atcttttact	6060
ttcaccagcg	tttctgggtg	agcaaaaaca	ggaaggcaaa	atgccgcaaa	aaagggaata	6120
agggcgacac	ggaaatgttg	aatactcata	ctcttccttt	ttcaatatta	ttgaagcatt	6180
tatcagggtt	attgtctcat	gagcggatac	atatttgaat	gtatttagaa	aaataaacia	6240
ataggggttc	cgcgcacatt	tccccgaaaa	gtgccacctg	acgtctaaga	aaccattatt	6300
atcatgacat	taacctataa	aaataggcgt	atcacagggc	cctttcgtc		6349

<210> 68

<211> 2489

<212> DNA

<213> artificial sequence

<220>

<223> HLA-E trimer matrix (VMAPRTLFL peptide) inserted at the B2m locus

<400> 68

cacttagcat	ctctggggcc	agtctgcaaa	gcgagggggc	agccttaatg	tgctccagc	60
ctgaagtcct	agaatgagcg	cccgggtgtcc	caagctgggg	cgcgaccccc	agatcggagg	120
gcgccgatgt	acagacagca	aactcaccca	gtctagtga	tgcttctta	aacatcacga	180
gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	ctctaacctg	gactgcgtc	240
gctggcttgg	agacaggtga	cggctccctgc	gggccttgct	ctgattggct	gggcacgcgt	300
ttaatataag	tggaggcgtc	gcgctggcgg	gcattcctga	agctgacagc	attcgggccg	360
agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	ctctcttagc	ggcctcgaag	420
ctgttatggc	tccgaggact	ttattcttag	gtggtggcgg	atccgggtgg	ggcggttctg	480
gtggtggcgg	ctccatccag	cgtacgccc	aaattcaagt	ctacagccga	catcctgcag	540
agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	ctttcacct	agcgatatag	600
aagtggacct	gctgaaaaac	ggagagagga	tagaaaaggt	cgaacacagc	gacctctcct	660
tttccaagga	ctggagcttt	tatcttctgt	attatactga	atttacaccc	acggaaaaag	720
atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	gccccaaaata	gtaaaatggg	780
atcgcgacat	gggtgggtgg	ggttctggtg	gtggcggtag	tggcgggcga	ggaagcgggtg	840
gtggcggttc	cggatctcac	tccttgaagt	atttccacac	ttccgtgtcc	cggcccggcc	900
gcggggagcc	ccgcttcac	tctgtgggct	acgtggacga	caccagttc	gtgcgcttcg	960
acaacgacgc	cgcgagtccg	aggatggtgc	cgcgggcgcc	gtggatggag	caggaggggt	1020
cagagtattg	ggaccgggag	acacggagcg	ccaggacac	cgcacagatt	ttccgagtga	1080
acctgcggac	gctgcgcggc	tactacaatc	agagcgaggc	cgggtctcac	acctgcagt	1140
ggatgcatgg	ctgcgagctg	gggcccga	ggcgcttcct	ccgcgggtat	gaacagttcg	1200
cctacgacgg	caaggattat	ctcacctga	atgaggacct	gcgctcctgg	accgcggtgg	1260
acacggcggc	tcagatctcc	gagcaaaagt	caaatgatgc	ctctgaggcg	gagcaccaga	1320
gagcctacct	ggaagacaca	tgctgggagt	ggctccacaa	atacctggag	aagggaagg	1380
agacgctgct	tcacctggag	ccccaaaga	cacacgtgac	tcaccacccc	atctctgacc	1440

eolf-seql (10).txt

atgaggccac	cctgaggtgc	tgggctctgg	gcttctaccc	tgcggagatc	acactgacct	1500
ggcagcagga	tggggagggc	catacccagg	acacggagct	cgtggagacc	aggcctgcag	1560
gggatggaac	cttccagaag	tgggcagctg	tgggtggtgc	ttctggagag	gagcagagat	1620
acacgtgcca	tgtgcagcat	gaggggctac	ccgagcccgt	caccctgaga	tggaagccgg	1680
cttcccagcc	caccatcccc	atcgtgggca	tcattgctgg	cctggttctc	cttggatctg	1740
tggctctctg	agctgtggtt	gctgctgtga	tatggaggaa	gaagagctca	ggtggaaaag	1800
gagggagcta	ctataaggct	gagtggagcg	acagtgccca	ggggtctgag	tctcacagct	1860
tgtaaactgt	ccttctagtt	gccagccatc	tggtgtttgc	ccctcccccg	tgctttcctt	1920
gaccctggaa	ggtgccactc	ccactgtcct	ttcctaataa	aatgaggaaa	ttgcatcgca	1980
ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggt	gggcaggaca	gcaaggggga	2040
ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggt	ggctctatgt	ctctttctgg	2100
cctggaggct	atccagcgtg	agtctctcct	accctcccgc	tctggctcct	cctctcccgc	2160
tctgcaccct	ctgtggccct	cgctgtgctc	tctcgctccg	tgactttcct	tctccaagtt	2220
ctccttggtg	gcccgccgtg	gggctagtcc	agggtgggat	ctcggggaag	cggcgggggt	2280
gcctgggagt	ggggaagggg	gtgcgcaccc	gggacgcgcg	ctacttgccc	ctttcggcgg	2340
ggagcagggg	agacctttgg	cctacggcga	cgggaggggt	gggacaaagt	ttagggcgct	2400
gataagcgtc	agagcgccga	ggttggggga	gggtttctct	tccgctcttt	cgcggggcct	2460
ctggctcccc	cagcgcagct	ggagtgggg				2489

<210> 69

<211> 2289

<212> DNA

<213> artificial sequence

<220>

<223> HLA-E trimer matrix (VMAPRTLFL peptide)

<400> 69

cgcgaccccc	agatcggagg	gcgccgatgt	acagacagca	aactcaccca	gtctagtgc	60
tgcttcttta	aacatcacga	gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	120
ctctaacctg	gcactgcgtc	gctggcttgg	agacaggtga	cgggtccctgc	gggccttgtc	180
ctgattggct	gggcacgcgt	ttaataataag	tggaggcgtc	gcgctggcgg	gcattcctga	240
agctgacagc	attcggggccg	agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	300
ctctcttagc	ggcctcgaag	ctgttatggc	tccgcggact	ttattcttag	gtggtggcgg	360
atccggtggt	ggcggttctg	gtggtggcgg	ctccatccag	cgtacgcca	aaattcaagt	420
ctacagccga	catcctgcag	agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	480
ctttcaccct	agcgatatag	aagtggacct	gctgaaaaac	ggagagagga	tagaaaaggt	540
cgaacacagc	gacctctcct	tttccaagga	ctggagcttt	tatcttctgt	attatactga	600
atttacaccc	acggaaaaag	atgagtatgc	gtgccagagta	aaccacgtca	cgctgtcaca	660
gccccaaaata	gtaaaatggg	atcgcgacat	gggtggtggc	ggttctggtg	gtggcggtag	720
tggcggcgga	ggaagcgggt	gtggcggttc	cggatctcac	tccttgaagt	atttccacac	780
ttccgtgtcc	cggcccgcc	gcggggagcc	ccgcttcac	tctgtgggct	acgtggacga	840
cacccagttc	gtgcgcttcg	acaacgacgc	cgcgagtccg	aggatggtgc	cgcgggcgcc	900
gtggatggag	caggaggggt	cagagtattg	ggaccgggag	acacggagcg	ccagggacac	960
cgcacagatt	ttccgagtga	acctgcggac	gctgcgcggc	tactacaatc	agagcgaggc	1020
cgggtctcac	accctgcagt	ggatgcattg	ctgcgagctg	gggcccagca	ggcgcttctt	1080

eolf-seql (10).txt

ccgcgggtat	gaacagttcg	cctacgacgg	caaggattat	ctcaccctga	atgaggacct	1140
gcgctcctgg	accgcggtgg	acacggcggc	tcagatctcc	gagcaaaaagt	caaagtatgc	1200
ctctgaggcg	gagcaccaga	gagcctacct	ggaagacaca	tgctgggagt	ggctccacaa	1260
atacctggag	aaggggaagg	agacgctgct	tcacctggag	cccccaaaga	cacacgtgac	1320
tcaccacccc	atctctgacc	atgaggccac	cctgaggtgc	tgggctctgg	gcttctaccc	1380
tgcgagatc	acactgacct	ggcagcagga	tggggagggc	catacccagg	acacggagct	1440
cgtggagacc	aggcctgcag	gggatggaac	cttccagaag	tgggcagctg	tggtggtgcc	1500
ttctggagag	gagcagagat	acacgtgcca	tgtgcagcat	gaggggctac	ccgagcccgt	1560
caccctgaga	tggaagccgg	cttcccagcc	caccatcccc	atcgtgggca	tcattgctgg	1620
cctggttctc	cttggatctg	tggtctctgg	agctgtggtt	gctgctgtga	tatggaggaa	1680
gaagagctca	ggtggaaaag	gagggagcta	ctataaggct	gagtggagcg	acagtgccca	1740
ggggctctgag	tctcacagct	tgtaaactgtg	ccttctagtt	gccagccatc	tgttgtttgc	1800
ccctcccccg	tgcttctctt	gacctggaa	ggtgccactc	ccactgtcct	ttcctaataa	1860
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	1920
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	1980
ggctctatgt	ctctttctgg	cctggaggct	atccagcgtg	agtctctcct	accctcccgc	2040
tctggtcctt	cctctcccgc	tctgcaccct	ctgtggccct	cgctgtgctc	tctcgctccg	2100
tgacttccct	tctccaagtt	ctccttggtg	gcccgccgtg	gggctagtcc	agggtgggat	2160
ctcggggaag	cggcggggtg	gcctgggagt	ggggaagggg	gtgcgcaccc	gggacgcgcg	2220
ctacttgccc	ctttcggcgg	ggagcagggg	agacctttgg	cctacggcga	cgggagggtc	2280
gggacaaaag						2289

<210> 70

<211> 2489

<212> DNA

<213> artificial sequence

<220>

<223> HLA-E trimer matrix (VMAPRTLIL peptide) inserted at the B2m locus

<400> 70

cacttagcat	ctctggggcc	agtctgcaaa	gcgagggggc	agccttaatg	tgcttccagc	60
ctgaagtcct	agaatgagcg	cccgggtgtcc	caagctgggg	cgcgcacccc	agatcggagg	120
gcgccgatgt	acagacagca	aactcaccca	gtctagtga	tgcttcttta	aacatcacga	180
gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	ctctaacctg	gactgcgtc	240
gctggcttgg	agacaggtga	cgggtccctgc	gggccttgtc	ctgattggct	gggcacgcgt	300
ttaatatag	tggaggcgtc	gcgctggcgg	gcattcctga	agctgacagc	attcggggccg	360
agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	ctctcttagc	ggcctcgaag	420
ctgttatggc	tccgcggact	ttaatttttag	gtggtggcgg	atccggtggt	ggcggttctg	480
gtggtggcgg	ctccatccag	cgtacgccc	aaattcaagt	ctacagccga	catcctgcag	540
agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	ctttcacccct	agcgatatag	600
aagtggacct	gctgaaaaac	ggagagagga	tagaaaagg	cgaacacagc	gacctctcct	660
tttccaagga	ctggagcttt	tatcttctgt	attatactga	atttacaccc	acggaaaaag	720
atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	gccccaaaata	gtaaaatggg	780
atcgcgacat	gggtgggtggc	ggttctggtg	gtggcggtag	tggcggcgga	ggaagcgggtg	840
gtggcggttc	cggatctcac	tccttgaagt	atttccacac	ttccgtgtcc	cggcccggcc	900

eolf-seql (10).txt

gcggggagcc	ccgcttcac	tctgtgggct	acgtggacga	cacccagttc	gtgcgcttcg	960
acaacgacgc	cgcgagtcgc	aggatgggtgc	cgcgggcgcc	gtggatggag	caggaggggt	1020
cagagtattg	ggaccgggag	acacggagcg	ccagggacac	cgcacagatt	ttccgagtga	1080
acctgcggac	gctgcgcggc	tactacaatc	agagcgaggc	cgggtctcac	accctgcagt	1140
ggatgcatgg	ctgcgagctg	gggcccgcga	ggcgcttcct	ccgcgggtat	gaacagttcg	1200
cctacgacgg	caaggattat	ctcaccctga	atgaggacct	gcgctcctgg	accgcggtgg	1260
acacggcggc	tcagatctcc	gagcaaaagt	caaagtatgc	ctctgaggcg	gagcaccaga	1320
gagcctacct	ggaagacaca	tgcgtggagt	ggctccacaa	atacctggag	aaggggaagg	1380
agacgctgct	tcacctggag	cccccaaaga	cacacgtgac	tcaccacccc	atctctgacc	1440
atgaggccac	cctgaggtgc	tgggctctgg	gcttctaccc	tgcggagatc	acactgacct	1500
ggcagcagga	tggggagggc	catacccagg	acacggagct	cgtggagacc	aggcctgcag	1560
gggatggaac	cttcagaag	tgggcagctg	tgggtgggtgc	ttctggagag	gagcagagat	1620
acacgtgcca	tgtgcagcat	gaggggctac	ccgagcccgt	caccttgaga	tggaagccgg	1680
cttcccagcc	caccatcccc	atcgtgggca	tcattgctgg	cctggttctc	cttgatctg	1740
tggctctctg	agctgtggtt	gctgctgtga	tatggaggaa	gaagagctca	ggtggaaaag	1800
gagggagcta	ctataaggct	gagtggagcg	acagtgccca	ggggtctgag	tctcacagct	1860
tgtaaactgt	ccttctagtt	gccagccatc	tgttgtttgc	ccctcccccg	tgcttctctt	1920
gaccttgga	ggtgccactc	ccactgtcct	ttcctaataa	aatgaggaaa	ttgcatcgca	1980
ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	gggcaggaca	gcaaggggga	2040
ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	ggctctatgt	ctctttctgg	2100
cctggaggct	atccagcgtg	agtctctcct	accctcccgc	tctggtcctt	cctctcccgc	2160
tctgcaccct	ctgtggccct	cgctgtgctc	tctcgctccg	tgacttccct	tctccaagtt	2220
ctccttggtg	gcccgccgtg	gggctagtcc	agggtggtat	ctcggggaag	cggcgggggtg	2280
gcctgggagt	ggggaagggg	gtgcgcaccc	gggacgcgcg	ctacttgccc	ctttcggcgg	2340
ggagcagggg	agacctttgg	cctacggcga	cgggaggggtc	gggacaaaagt	ttagggcgctc	2400
gataagcgtc	agagcgccga	ggttggggga	gggtttctct	tccgctcttt	cgcggggcct	2460
ctggctcccc	cagcgagct	ggagtgggg				2489

<210> 71

<211> 2289

<212> DNA

<213> artificial sequence

<220>

<223> HLA-E trimer matrix (VMAPRTLIL peptide)

<400> 71

cgcgcacccc	agatcggagg	gcgccgatgt	acagacagca	aactcaccca	gtctagtgca	60
tgcttcttta	aacatcacga	gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	120
ctctaacctg	gcactgcgtc	gctggcttgg	agacaggtga	cggtccctgc	gggccttgctc	180
ctgattggct	gggcacgcgt	ttaatataga	tggaggcgctc	gcgctggcgg	gcattcctga	240
agctgacagc	attcggggcg	agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	300
ctctcttagc	ggcctcgaag	ctgttatggc	tccgcggact	ttaatttttag	gtggtggcgg	360
atccgggtgg	ggcggttctg	gtggtggcgg	ctccatccag	cgtacgcca	aaattcaagt	420
ctacagccga	catcctgcag	agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	480
ctttcacctt	agcgatatag	aagtggacct	gctgaaaaac	ggagagagga	tagaaaaggt	540

eolf-seql (10).txt

cgaacacagc	gacctctcct	tttccaagga	ctggagcttt	tatcttctgt	attatactga	600
atttacaccc	acggaaaaag	atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	660
gccccaaaata	gtaaaatggg	atcgcgacat	gggtgggtggc	ggttctggtg	gtggcggtag	720
tggcggcgga	ggaagcgggtg	gtggcgggttc	cggatctcac	tccttgaagt	atttccacac	780
ttccgtgtcc	cggccccggcc	gcggggagcc	ccgcttcac	tctgtgggct	acgtggacga	840
caccagttc	gtgcgcttcg	acaacgacgc	cgcgagtcgc	aggatggtgc	cgcgggcgcc	900
gtggatggag	caggaggggt	cagagtattg	ggaccgggag	acacggagcg	ccagggaacac	960
cgcacagatt	ttccgagtga	acctgcggac	gctgcgcggc	tactacaatc	agagcgaggc	1020
cgggtctcac	acctgcagtg	ggatgcatgg	ctgcgagctg	gggcccgcga	ggcgcttcct	1080
ccgcgggtat	gaacagttcg	cctacgacgg	caaggattat	ctcaccctga	atgaggacct	1140
gcgctcctgg	accgcgggtg	acacggcggc	tcagatctcc	gagcaaaagt	caaagtatgc	1200
ctctgaggcg	gagcaccaga	gagcctacct	ggaagacaca	tgcgtggagt	ggctccacaa	1260
atacctggag	aaggggaagg	agacgtgct	tcacctggag	cccccaaaga	cacacgtgac	1320
tcaccacccc	atctctgacc	atgaggccac	cctgaggtgc	tgggctctgg	gcttctaccc	1380
tgcggagatc	acactgacct	ggcagcagga	tggggagggc	catacccagg	acacggagct	1440
cgtggagacc	aggcctgcag	gggatggaac	cttcagaag	tgggcagctg	tgggtggtgcc	1500
ttctggagag	gagcagagat	acacgtgcca	tgtgcagcat	gaggggctac	ccgagcccgt	1560
caccctgaga	tggaaagccgg	cttcccagcc	caccatcccc	atcgtgggca	tcattgctgg	1620
cctggttctc	cttggatctg	tggctctctgg	agctgtgggt	gctgctgtga	tatggaggaa	1680
gaagagctca	ggtggaaaag	gagggagcta	ctataaggct	gagtggagcg	acagtgcccc	1740
ggggctctgag	tctcacagct	tgtaaactgtg	ccttctagtt	gccagccatc	tggtgtttgc	1800
ccctcccccg	tgcttctctt	gacctggaa	ggtgccactc	ccactgtcct	ttcctaataa	1860
aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	1920
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcgggtg	1980
ggctctatgt	ctctttctgg	cctggaggct	atccagcgtg	agtctctcct	accctcccgc	2040
tctggtcctt	cctctcccgc	tctgcaccct	ctgtggccct	cgctgtgctc	tctcgctccg	2100
tgacttccct	tctccaagtt	ctccttggtg	gcccgcctg	gggctagtcc	agggtctggat	2160
ctcggggaag	cggcggggtg	gcctgggagt	ggggaagggg	gtgcgcaccc	gggacgcgcg	2220
ctacttgccc	ctttcggcgg	ggagcagggg	agacctttgg	cctacggcga	cgggagggtc	2280
gggacaaaag						2289

<210> 72

<211> 2531

<212> DNA

<213> artificial sequence

<220>

<223> UL18Trimer matrix\_Actine peptide inserted at the B2m locus

<400> 72

cacttagcat	ctctggggcc	agtctgcaaa	gcgagggggc	agccttaatg	tgcttccagc	60
ctgaagtcct	agaatgagcg	cccgggtgtcc	caagctgggg	cgcgcacccc	agatcggagg	120
gcgccgatgt	acagacagca	aactcaccca	gtctagtga	tgctttctta	aacatcacga	180
gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	ctctaacctg	gactgcgtc	240
gctggcttgg	agacaggtga	cggctccctgc	gggccttgtc	ctgattggct	gggcacgcgt	300
ttaatataag	tggaggcgtc	gcgctggcgg	gcattcctga	agctgacagc	attcgggccg	360

eolf-seql (10).txt

```

agatgtctcg ctccgtggcc ttagctgtgc tcgcgctact ctctcttagc ggcctcgaag 420
ctgccctgcc ccacgccatt ttgcggctcg gtgggtggcgg atccggtggt ggcgggttctg 480
gtgggtggcgg ctccatccag cgtacgcca aaattcaagt ctacagccga catcctgcag 540
agaacggcaa atctaatttc ctgaactgct atgtatcagg ctttcaccct agcgatatag 600
aagtggacct gctgaaaaac ggagagagga tagaaaagg cgaacacagc gacctctcct 660
tttccaagga ctggagcttt tatcttctgt attatactga atttacaccc acggaaaaag 720
atgagtatgc gtgccgagta aaccacgtca cgctgtcaca gcccataata gtaaaatggg 780
atcgcgacat ggggtgggtggc ggttctgggt gtggcggtag tggcggcgga ggaagcgggtg 840
gtggcggttc cggatctatg cacgtgctga gatacggata taccggcatc ttcgacgata 900
catcccatat gactctgacc gtggtcggga tttttgacgg acagcacttc tttacatacc 960
atgtgaacag ctccgataag gcttctagtc gagcaaatgg caccatctca tggatggcca 1020
acgtgagcgc agcctacccc acatatctgg acggagaacg cgctaaaggc gatctgatct 1080
tcaatcagac cgagcagaac ctgctggagc tggaaattgc tctgggggtac aggtctcaga 1140
gtgtcctgac atggactcac gaatgtaata ccacagagaa cgggagcttc gtggcaggat 1200
atgagggctt tgggtgggac ggagaaacac tgatggagct gaaggataat ctgactctgt 1260
ggaccggccc taactacgaa atcagctggc tgaagcagaa caagacttac atcgacggaa 1320
agatcaaaaa catcagcgag ggcgatacta ccatccagcg caattacctg aagggaact 1380
gcacccagtg gagcgtgac tactctgggt tccagacacc tgtcactcac ccagtggta 1440
aagggggagt gcgaaaccag aatgacaacc gggccgaggc cttctgtaca tcctacggct 1500
tctttccgg ggagatcaat attactttta tccattacgg caacaaggcc cccgacgatt 1560
ctgagcctca gtgcaatccc ctgctgccta ctttcgatgg cacatttcac caggggtgct 1620
acgtcgtat cttctgcaat cagaactata cttgccgggt gacccatggg aactggactg 1680
tggaaatccc aatttcagtc accagccccg acgattcaag ctccggagag gtgccagatc 1740
accccaccgc aaataagaga tacaacacca tgacaatctc tagtgtgctg ctggccctgc 1800
tgctgtgctg actgctgttc gcttttctgc attacttcac aactctgaag cagtatctgc 1860
ggaacctggc atttgcctgg cggtacagaa aagtgagatc aagctgactg tgccttctag 1920
ttgccagcca tctgttgttt gcccctcccc cgtgccttc ttgacctgg aaggtgccac 1980
tcccactgtc ctttcctaata aaaatgagga aattgcatcg cattgtctga gtaggtgtca 2040
ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg aagacaatag 2100
caggcatgct ggggatgcgg tgggctctat gtctctttct ggcctggagg ctatccagcg 2160
tgagtctctc ctaccctccc gctctggtcc ttcctctccc gctctgcacc ctctgtggcc 2220
ctcgtgtgct tctctcgctc cgtgacttcc cttctccaag ttctccttgg tggcccgccg 2280
tggggctagt ccagggtggt atctcgggga agcggcgggg tggcctggga gtggggaagg 2340
gggtgcgcac ccgggacgcg cgctacttgc ccttttcggc ggggagcagg ggagacctt 2400
ggcctacggc gacgggaggg tcgggacaaa gtttagggcg tcgataagcg tcagagcgcc 2460
gaggttgggg gaggttttct cttccgctct ttcgcggggc ctctggctcc cccagcgag 2520
ctggagtggg g 2531

```

<210> 73

<211> 2331

<212> DNA

<213> artificial sequence

<220>

<223> UL18Trimer matrix\_Actine peptide

eolf-seql (10).txt

<400> 73

```

cgcgcacccc agatcggagg ggcgccgatgt acagacagca aactcaccca gtctagtgca    60
tgcttcttta aacatcacga gactctaaga aaaggaaact gaaaacggga aagtccctct    120
ctctaacctg gcactgcgtc gctggcttgg agacaggtag cgggtccctgc gggccttgct    180
ctgattggct gggcacgcgt ttaataataag tggaggcgct gcgctggcgg gcattcctga    240
agctgacagc attcgggccg agatgtctcg ctccgtggcc ttagctgtgc tcgcgctact    300
ctctcttagc ggccctgaag ctgccctgcc ccacgccatt ttgcggctcg gtggtggcgg    360
atccggtggg ggcggttctg gtggtggcgg ctccatccag cgtacgcca aaattcaagt    420
ctacagccga catcctgcag agaacggcaa atctaatttc ctgaactgct atgtatcagg    480
ctttcaccct agcgatatag aagtggacct gctgaaaaac ggagagagga tagaaaaggt    540
cgaacacagc gacctctcct tttccaagga ctggagcttt tatcttctgt attatactga    600
atttacaccc acggaaaaag atgagtatgc gtgccgagta aaccacgtca cgctgtcaca    660
gccccaaata gtaaaatggg atcgcgacat ggggtggtagc ggttcttggtg gtggcggtag    720
tggcggcgga ggaagcgggt gtggcggttc cggatctatg cacgtgctga gatacgata    780
taccggcatc ttcgacgata catcccatat gactctgacc gtggtcggga tttttgacgg    840
acagcacttc ttacataacc atgtgaacag ctccgataag gcttctagtc gagcaaattg    900
caccatctca tggatggcca acgtgagcgc agcctacccc acatatctgg acggagaacg    960
cgctaaaggc gatctgatct tcaatcagac cgagcagaac ctgctggagc tggaaattgc   1020
tctggggtag aggtctcaga gtgtcctgac atggactcac gaatgtaata ccacagagaa   1080
cgggagcttc gtggcaggat atgagggttc tgggtgggac ggagaaacac tgatggagct   1140
gaaggataat ctgactctgt ggaccggccc taactacgaa atcagctggc tgaagcagaa   1200
caagacttac atcgacggaa agatcaaaaa catcagcgag ggcgatacta ccatccagcg   1260
caattacctg aagggcaact gcaccagtg gagcgtgatc tactctgggt tccagacacc   1320
tgtcactcac ccagtgggtc aagggggagt gcgaaaccag aatgacaacc gggccgaggc   1380
cttctgtaca tcctacggct tctttcccgg ggagatcaat attactttta tccattacgg   1440
caacaaggcc cccgacgatt ctgagcctca gtgcaatccc ctgctgccta ctttcgatgg   1500
cacatttcac caggggtgct acgtcgctat cttctgcaat cagaactata cttgccgggt   1560
gacccatggg aactggactg tggaatccc aatttcagtc accagccccg acgattcaag   1620
ctccggagag gtgccagatc accccaccgc aaataagaga tacaacacca tgacaatctc   1680
tagtgtgctg ctggccctgc tgctgtgctc actgctgttc gcttttctgc attacttcac   1740
aactctgaag cagtatctgc ggaacctggc atttgcctgg cggtagagaa aagttagatc   1800
aagctgactg tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc   1860
ttgaccctgg aaggtgccac tcccactgtc ctttcctaataaaatgagga aattgcatcg   1920
cattgtctga gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg   1980
gaggattggg aagacaatag caggcatgct ggggatgcgg tgggctctat gtctctttct   2040
ggcctggagg ctatccagcg tgagtctctc ctacctccc gctctggtcc ttctctctcc   2100
gctctgcacc ctctgtggcc ctgctgtgct tctctcgctc cgtgacttcc cttctccaag   2160
ttctccttgg tggcccgccg tggggctagt ccagggtggt atctcgggga agcggcgggg   2220
tggcctggga gtggggaagg ggggtgcgcac ccgggacgcg cgctacttgc ccctttcggc   2280
ggggagcagg ggagaccttt ggcctacggc gacgggaggg tcgggacaaa g          2331

```

<210> 74

<211> 2531

<212> DNA

<213> artificial sequence

eolf-seql (10).txt

<220>

<223> UL18Trimer matrix \_HLACw peptide inserted at the B2m locus

<400> 74

cacttagcat	ctctggggcc	agtctgcaaa	gcgagggggc	agccttaatg	tgccctccagc	60
ctgaagtcct	agaatgagcg	cccgggtgtcc	caagctgggg	cgcgcacccc	agatcggagg	120
gcgccgatgt	acagacagca	aactcaccca	gtctagtgc	tgcccttctta	aacatcacga	180
gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	ctctaacctg	gactgcgtc	240
gctggcttgg	agacaggtga	cggtcctctgc	gggccttgtc	ctgattggct	gggcacgcgt	300
ttaatataag	tggaggcgtc	gcgctggcgg	gcattcctga	agctgacagc	attcggggccg	360
agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	ctctcttagc	ggcctcgaag	420
ctgttatggc	tccgcggact	ttaatttttag	gtgggtggcg	atccgggtgg	ggcggttctg	480
gtgggtggcg	ctccatccag	cgtacgcca	aaattcaagt	ctacagccga	catcctgcag	540
agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	ctttcacct	agcgatatag	600
aagtggacct	gctgaaaaac	ggagagagga	tagaaaaggt	cgaacacagc	gacctctct	660
tttccaagga	ctggagcttt	tatcttctgt	attatactga	atttacaccc	acggaaaaag	720
atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	gccccaaaata	gtaaaatggg	780
atcgcgacat	gggtgggtggc	ggttctggtg	gtggcggtag	tggcggcgga	ggaagcggtg	840
gtggcggttc	cggatctatg	cacgtgctga	gatacggata	taccggcatc	ttcgacgata	900
catcccatat	gactctgacc	gtggctggga	tttttgacgg	acagcacttc	tttacatacc	960
atgtgaacag	ctccgataag	gcttctagtc	gagcaaattg	caccatctca	tggatggcca	1020
acgtgagcgc	agcctacccc	acatatctgg	acggagaacg	cgctaaaggc	gatctgatct	1080
tcaatcagac	cgagcagaac	ctgctggagc	tggaaattgc	tctgggggtac	aggtctcaga	1140
gtgtcctgac	atggactcac	gaatgtaata	ccacagagaa	cgggagcttc	gtggcaggat	1200
atgagggctt	tgggtggggac	ggagaaacac	tgatggagct	gaaggataat	ctgactctgt	1260
ggaccggccc	taactacgaa	atcagctggc	tgaagcagaa	caagacttac	atcgacggaa	1320
agatcaaaaa	catcagcgag	ggcgatacta	ccatccagcg	caattacctg	aagggaact	1380
gcaccagtg	gagcgtgatc	tactctgggt	tccagacacc	tgtcactcac	ccagtgggtca	1440
aagggggagt	gcgaaaccag	aatgacaacc	gggccgaggc	cttctgtaca	tcctacggct	1500
tctttcccgg	ggagatcaat	attactttta	tccattacgg	caacaaggcc	cccgacgatt	1560
ctgagcctca	gtgcaatccc	ctgctgccta	ccttcgatgg	cacatttcac	caggggtgct	1620
acgtcgctat	cttctgcaat	cagaactata	cttgccgggt	gacccatggg	aactggactg	1680
tggaaatccc	aatttcagtc	accagccccg	acgattcaag	ctccggagag	gtgccagatc	1740
accccaccgc	aaataagaga	tacaacacca	tgacaatctc	tagtgtgctg	ctggccctgc	1800
tgctgtgcgc	actgctgttc	gcttttctgc	attacttcac	aactctgaag	cagtatctgc	1860
ggaacctggc	atttgcctgg	cggtagagaa	aagttagatc	aagctgactg	tgcccttctag	1920
ttgccagcca	tctgttgttt	gccccctccc	cgtgccttcc	ttgacctgg	aaggtgccac	1980
tcccactgtc	ctttccta	aaaatgagga	aattgcatcg	cattgtctga	gtaggtgtca	2040
ttctattctg	gggggtgggg	tggggcagga	cagcaagggg	gaggattggg	aagacaatag	2100
caggcatgct	ggggatgcgg	tgggctctat	gtctctttct	ggcctggagg	ctatccagcg	2160
tgagtctctc	ctaccctccc	gctctgggtcc	ttcctctccc	gctctgcacc	ctctgtggcc	2220
ctcgtgtgct	tctctcgctc	cgtgacttcc	cttctccaag	ttctccttgg	tggcccgccg	2280
tggggctagt	ccagggtggg	atctcgggga	agcggcgggg	tggcctggga	gtgggggaagg	2340
gggtgcgcac	ccgggacgcg	cgctacttgc	ccctttcggc	ggggagcagg	ggagaccttt	2400
ggcctacggc	gacgggaggg	tcgggacaaa	gttttagggcg	tcgataagcg	tcagagcgcc	2460
gaggttgggg	gagggtttct	cttccgctct	ttcgcggggc	ctctggctcc	cccagcgag	2520
ctggagtggg	g					2531

eolf-seql (10).txt

<210> 75

<211> 2331

<212> DNA

<213> artificial sequence

<220>

<223> UL18Trimer matrix \_HLACw peptide

<400> 75

cgcgaccccc	agatcggagg	gcgccgatgt	acagacagca	aactcaccca	gtctagtgca	60
tgcttcttta	aacatcacga	gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	120
ctctaacctg	gcactgcgtc	gctggcttgg	agacaggtga	cggtccctgc	gggccttgct	180
ctgattggct	gggcacgcgt	ttaatataag	tggaggcgct	gcgctggcgg	gcattcctga	240
agctgacagc	attcggggcg	agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	300
ctctcttagc	ggcctcgaag	ctgttatggc	tccgcggact	ttaatttttag	gtggtggcgg	360
atccgggtgg	ggcggttctg	gtggtggcgg	ctccatccag	cgtacgcca	aaattcaagt	420
ctacagccga	catcctgcag	agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	480
ctttcacctt	agcgatatag	aagtggacct	gctgaaaaac	ggagagagga	tagaaaaggt	540
cgaacacagc	gacctctcct	tttccaagga	ctggagcttt	tatcttctgt	attatactga	600
atttacaccc	acggaaaaag	atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	660
gccccaaaata	gtaaaatggg	atcgcgacat	gggtggtggc	ggttctggtg	gtggcggtag	720
tggcggcgga	ggaagcgggt	gtggcggttc	cggatctatg	cacgtgctga	gatacggata	780
taccggcatc	ttcgacgata	catcccatat	gactctgacc	gtggtcggga	tttttgacgg	840
acagcacttc	tttacatacc	atgtgaacag	ctccgataag	gcttctagtc	gagcaaatgg	900
caccatctca	tggatggcca	acgtgagcgc	agcctacccc	acatatctgg	acggagaacg	960
cgctaaaggc	gatctgatct	tcaatcagac	cgagcagaac	ctgctggagc	tggaaattgc	1020
tctggggtag	aggtctcaga	gtgtcctgac	atggactcac	gaatgtaata	ccacagagaa	1080
cgggagcttc	gtggcaggat	atgagggttt	tgggtgggac	ggagaaaacac	tgatggagct	1140
gaaggataat	ctgactctgt	ggaccggccc	taactacgaa	atcagctggc	tgaagcagaa	1200
caagacttac	atcgacggaa	agatcaaaaa	catcagcgag	ggcgatacta	ccatccagcg	1260
caattacctg	aagggcaact	gcacccagtg	gagcgtgac	tactctgggt	tccagacacc	1320
tgtcactcac	ccagtggcca	aagggggagt	gcgaaaccag	aatgacaacc	gggccgaggc	1380
cttctgtaca	tcctacggct	tctttcccgg	ggagatcaat	attactttta	tccattacgg	1440
caacaaggcc	cccgaacgatt	ctgagcctca	gtgcaatccc	ctgctgccta	ccttcgatgg	1500
cacatttcac	caggggtgct	acgtcgctat	cttctgcaat	cagaactata	cttgccgggt	1560
gacccatggg	aactggactg	tggaaatccc	aatttcagtc	accagccccg	acgattcaag	1620
ctccggagag	gtgccagatc	accccaccgc	aaataagaga	tacaacacca	tgacaatctc	1680
tagtggtgct	ctggccctgc	tgctgtgcgc	actgctgttc	gcttttctgc	attacttcac	1740
aactctgaag	cagtatctgc	ggaacctggc	atttgcttgg	cggtacagaa	aagtgagatc	1800
aagctgactg	tgcttcttag	ttgccagcca	tctgttgttt	gcccctcccc	cgtgccttcc	1860
ttgacctggg	aaggtgccac	tcccactgtc	ctttccta	aaaatgagga	aattgcatcg	1920
cattgtctga	gtaggtgtca	ttctattctg	gggggtgggg	tggggcagga	cagcaagggg	1980
gaggattggg	aagacaatag	caggcatgct	ggggatgcgg	tgggctctat	gtctctttct	2040
ggcctggagg	ctatccagcg	tgagtctctc	ctaccctccc	gctctggtcc	ttcctctccc	2100
gctctgcacc	ctctgtggcc	ctcgctgtgc	tctctcgctc	cgtgacttcc	cttctccaag	2160
ttctccttgg	tggcccgccg	tggggctagt	ccagggtcgg	atctcgggga	agcggcgggg	2220

eolf-seql (10).txt

tggcctggga	gtggggaagg	gggtg'gcac	ccgggacgcg	cgctacttgc	ccctttcggc	2280
ggggagcagg	ggagacctt	ggcctacggc	gacgggaggg	tcgggacaaa	g	2331

<210> 76

<211> 2531

<212> DNA

<213> artificial sequence

<220>

<223> UL18Trimer matrix \_HLA peptide inserted at the B2m locus

<400> 76

cacttagcat	ctctggggcc	agtctgcaaa	gcgagggggc	agccttaatg	tgcctccagc	60
ctgaagtcct	agaatgagcg	cccgggtgtcc	caagctgggg	cgcgaccccc	agatcggagg	120
gcgccgatgt	acagacagca	aactcaccca	gtctagtgc	tgccttctta	aacatcacga	180
gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	ctctaacctg	gactgcgtc	240
gctggcttgg	agacaggtga	cggctccctgc	gggccttgtc	ctgattggct	gggcacgcgt	300
ttaatatag	tggaggcgtc	gcgctggcgg	gcattcctga	agctgacagc	attcgggccg	360
agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	ctctcttagc	ggcctcgaag	420
ctgttatggc	tccgcggact	ttattcttag	gtggtggcgg	atccggtggt	ggcggttctg	480
gtggtggcgg	ctccatccag	cgtacgcca	aaattcaagt	ctacagccga	catcctgcag	540
agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	ctttcacct	agcgatatag	600
aagtggacct	gctgaaaaac	ggagagagga	tagaaaagg	cgaacacagc	gacctctcct	660
tttccaagga	ctggagcttt	tatcttctgt	attatactga	atttacaccc	acggaaaaag	720
atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	gccccaaata	gtaaaatggg	780
atcgcgacat	gggtgggtggc	ggttctggtg	gtggcggtag	tggcggcgga	ggaagcgggtg	840
gtggcggttc	cggatctatg	cacgtgctga	gatacggata	taccggcatc	ttcgacgata	900
catcccatat	gactctgacc	gtggtcggga	tttttgacgg	acagcacttc	tttacataacc	960
atgtgaacag	ctccgataag	gcttctagtc	gagcaaatgg	caccatctca	tggatggcca	1020
acgtgagcgc	agcctacccc	acatatctgg	acggagaacg	cgctaaaggc	gatctgatct	1080
tcaatcagac	cgagcagaac	ctgctggagc	tggaaattgc	tctgggggtac	aggtctcaga	1140
gtgtcctgac	atggactcac	gaatgtaata	ccacagagaa	cgggagcttc	gtggcaggat	1200
atgagggctt	tgggtgggac	ggagaaacac	tgatggagct	gaaggataat	ctgactctgt	1260
ggaccggccc	taactacgaa	atcagctggc	tgaagcagaa	caagacttac	atcgacggaa	1320
agatcaaaaa	catcagcgag	ggcgatacta	ccatccagcg	caattacctg	aagggaact	1380
gcacccagtg	gagcgtgatc	tactctgggt	tccagacacc	tgtcactcac	ccagtgggtca	1440
aagggggagt	gcgaaaccag	aatgacaacc	gggccgaggc	cttctgtaca	tcctacggct	1500
tctttcccgg	ggagatcaat	attactttta	tccattacgg	caacaaggcc	cccgcgatt	1560
ctgagcctca	gtgcaatccc	ctgctgccta	ccttcgatgg	cacatttcac	caggggtgct	1620
acgtcgctat	cttctgcaat	cagaactata	cttgccgggt	gacccatggg	aactggactg	1680
tggaaatccc	aatttcagtc	accagccccg	acgattcaag	ctccggagag	gtgccagatc	1740
acccaccgc	aaataagaga	tacaacacca	tgacaatctc	tagtgtgtctg	ctggccctgc	1800
tgctgtgcgc	actgctgttc	gcttttctgc	attacttcac	aactctgaag	cagtatctgc	1860
ggaacctggc	atttgcttgg	cggtagagaa	aagtgcagtc	aagctgactg	tgccttctag	1920
ttgccagcca	tctgtgtgtt	gcccctcccc	cgtgccttcc	ttgaccctgg	aaggtgccac	1980
tcccactgtc	ctttccta	aaaatgagga	aattgcacgc	cattgtctga	gtaggtgtca	2040

## eolf-seql (10).txt

ttctattctg	gggggtgggg	tggggcagga	cagcaagggg	gaggattggg	aagacaatag	2100
caggcatgct	ggggatgcgg	tgggctctat	gtctctttct	ggcctggagg	ctatccagcg	2160
tgagtctctc	ctaccctccc	gctctgggtcc	ttcctctccc	gctctgcacc	ctctgtggcc	2220
ctcgtgtgct	tctctcgctc	cgtgacttcc	cttctccaag	ttctccttgg	tggcccgcgc	2280
tggggcctagt	ccagggctgg	atctcgggga	agcggcgggg	tggcctggga	gtggggaagg	2340
gggtgcgcac	ccgggacgcg	cgctacttgc	ccctttcggc	ggggagcagg	ggagaccttt	2400
ggcctacggc	gacgggaggg	tcgggacaaa	gtttagggcg	tcgataagcg	tcagagcgcc	2460
gaggttgggg	gagggtttct	cttccgctct	ttcgcggggc	ctctggctcc	cccagcgag	2520
ctggagtggg	g					2531

&lt;210&gt; 77

&lt;211&gt; 2331

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; UL18Trimer matrix \_HLA peptide

&lt;400&gt; 77

cgcgaccccc	agatcggagg	gcgccgatgt	acagacagca	aactcaccca	gtctagtgca	60
tgcttcttta	aacatcacga	gactctaaga	aaaggaaact	gaaaacggga	aagtccctct	120
ctctaacctg	gcactgcgtc	gctggcttgg	agacaggtga	cggctccctgc	gggccttgtc	180
ctgattggct	gggcacgcgt	ttaatataag	tggaggcgct	gcgctggcgg	gcattcctga	240
agctgacagc	attcggggcg	agatgtctcg	ctccgtggcc	ttagctgtgc	tcgcgctact	300
ctctcttagc	ggcctcgaag	ctgttatggc	tccgcggact	ttattcttag	gtggtggcgg	360
atccggtggg	ggcggttctg	gtggtggcgg	ctccatccag	cgtacgcca	aaattcaagt	420
ctacagccga	catcctgcag	agaacggcaa	atctaatttc	ctgaactgct	atgtatcagg	480
ctttcaccct	agcgatatag	aagtggacct	gctgaaaaac	ggagagagga	tagaaaagg	540
cgaacacagc	gacctctcct	tttccaagga	ctggagcttt	tatcttctgt	attatactga	600
atttacaccc	acggaaaaag	atgagtatgc	gtgccgagta	aaccacgtca	cgctgtcaca	660
gccccaaaata	gtaaaaatggg	atcgcgacat	gggtggtggc	ggttctggtg	gtggcggtag	720
tggcggcgga	ggaagcgggt	gtggcggttc	cggatctatg	cacgtgctga	gatacggata	780
taccggcatc	ttcgacgata	catcccatat	gactctgacc	gtggtcggga	tttttgacgg	840
acagcacttc	tttacatacc	atgtgaacag	ctccgataag	gcttctagtc	gagcaaatgg	900
caccatctca	tggatggcca	acgtgagcgc	agcctacccc	acatatctgg	acggagaacg	960
cgctaaaaggc	gatctgatct	tcaatcagac	cgagcagaac	ctgctggagc	tggaaattgc	1020
tctgggggtac	aggtctcaga	gtgtcctgac	atggactcac	gaatgtaata	ccacagagaa	1080
cgggagcttc	gtggcaggat	atgagggctt	tgggtgggac	ggagaaacac	tgatggagct	1140
gaaggataat	ctgactctgt	ggaccggccc	taactacgaa	atcagctggc	tgaagcagaa	1200
caagacttac	atcgacggaa	agatcaaaaa	catcagcgag	ggcgatacta	ccatccagcg	1260
caattacctg	aagggcaact	gcacccagtg	gagcgtgatc	tactctgggt	tccagacacc	1320
tgtcactcac	ccagtgggtca	aagggggagt	gcgaaaccag	aatgacaacc	gggccgaggc	1380
cttctgtaca	tcctacggct	tctttcccgg	ggagatcaat	attactttta	tccattacgg	1440
caacaaggcc	cccgcgatt	ctgagcctca	gtgcaatccc	ctgctgccta	ccttcgatgg	1500
cacatttcac	caggggtgct	acgtcgctat	cttctgcaat	cagaactata	cttgccgggt	1560
gacccatggg	aactggactg	tggaaatccc	aatttcagtc	accagccccg	acgattcaag	1620

eolf-seql (10).txt

ctccggagag	gtgccagatc	acccaccgc	aaataagaga	tacaacacca	tgacaatctc	1680
tagtgtgctg	ctggccctgc	tgctgtgctg	actgctgttc	gcttttctgc	attacttcac	1740
aactctgaag	cagtatctgc	ggaacctggc	atgtgcctgg	cgttacagaa	aagtgagatc	1800
aagctgactg	tgcttcttag	ttgccagcca	tctgttgttt	gcccctcccc	cgtgccttcc	1860
ttgaccctgg	aaggtgccac	tcccactgtc	ctttcctaata	aaaatgagga	aattgcatcg	1920
cattgtctga	gtaggtgtca	ttctattctg	gggggtgggg	tggggcagga	cagcaagggg	1980
gaggattggg	aagacaatag	caggcatgct	ggggatgcgg	tgggctctat	gtctctttct	2040
ggcctggagg	ctatccagcg	tgagtctctc	ctaccctccc	gctctgggtcc	ttcctctccc	2100
gctctgcacc	ctctgtggcc	ctcgctgtgc	tctctcgctc	cgtgacttcc	cttctccaag	2160
ttctccttgg	tggcccgccg	tggggctagt	ccagggctgg	atctcgggga	agcggcgggg	2220
tggcctggga	gtgggggaagg	gggtgcgcac	ccgggacgcg	cgctacttgc	ccctttcggc	2280
ggggagcagg	ggagaccttt	ggcctacggc	gacgggaggg	tcgggacaaa	g	2331

<210> 78

<211> 47

<212> DNA

<213> artificial sequence

<220>

<223> TALEN target B2m1

<400> 78

tccgtggcct	tagtgtgct	cgcgctactc	tctctttctg	gcctgga	47
------------	-----------	------------	------------	---------	----

<210> 79

<211> 47

<212> DNA

<213> artificial sequence

<220>

<223> TALEN target B2m2

<400> 79

ttagctgtgc	tcgcgctact	ctctctttct	ggcctggagg	ctatcca	47
------------	------------	------------	------------	---------	----

<210> 80

<211> 936

<212> PRT

<213> artificial sequence

<220>

&lt;223&gt; pCLS31134 right TALEN B2m1

&lt;400&gt; 80

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
 1 5 10 15

Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
 20 25 30

Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
 35 40 45

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
 50 55 60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
 65 70 75 80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
 85 90 95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
 100 105 110

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
 115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val  
 130 135 140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
 145 150 155 160

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys  
 165 170 175

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala

## eolf-seql (10).txt

180

185

190

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly  
 195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
 210 215 220

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
 225 230 235 240

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
 245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
 260 265 270

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
 275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
 290 295 300

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
 305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
 325 330 335

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val  
 340 345 350

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
 355 360 365

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu

eolf-seql (10).txt

370

375

380

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
485 490 495

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
500 505 510

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
530 535 540

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
545 550 555 560

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala

## eolf-seql (10).txt

565

570

575

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
 580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
 595 600 605

Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val  
 610 615 620

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
 625 630 635 640

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu  
 645 650 655

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
 660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
 675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ala Leu Ala  
 690 695 700

Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala Cys Leu Gly Gly Arg  
 705 710 715 720

Pro Ala Leu Asp Ala Val Lys Lys Gly Leu Gly Asp Pro Ile Ser Arg  
 725 730 735

Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys Lys Ser Glu Leu Arg  
 740 745 750

His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile Glu Leu Ile Glu Ile

## eolf-seql (10).txt

755

760

765

Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu Met Lys Val Met Glu  
 770 775 780

Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys His Leu Gly Gly Ser  
 785 790 795 800

Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly Ser Pro Ile Asp Tyr  
 805 810 815

Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly Gly Tyr Asn Leu Pro  
 820 825 830

Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val Glu Glu Asn Gln Thr  
 835 840 845

Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp Lys Val Tyr Pro Ser  
 850 855 860

Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser Gly His Phe Lys Gly  
 865 870 875 880

Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His Ile Thr Asn Cys Asn  
 885 890 895

Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile Gly Gly Glu Met Ile  
 900 905 910

Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg Arg Lys Phe Asn Asn  
 915 920 925

Gly Glu Ile Asn Phe Ala Ala Asp  
 930 935

&lt;210&gt; 81

eolf-seql (10).txt

<211> 936

<212> PRT

<213> artificial sequence

<220>

<223> pCLS31135 left TALEN B2m1

<400> 81

Met	Gly	Asp	Pro	Lys	Lys	Lys	Arg	Lys	Val	Ile	Asp	Tyr	Pro	Tyr	Asp
1				5					10					15	

Val	Pro	Asp	Tyr	Ala	Ile	Asp	Ile	Ala	Asp	Leu	Arg	Thr	Leu	Gly	Tyr
			20					25					30		

Ser	Gln	Gln	Gln	Gln	Glu	Lys	Ile	Lys	Pro	Lys	Val	Arg	Ser	Thr	Val
			35				40					45			

Ala	Gln	His	His	Glu	Ala	Leu	Val	Gly	His	Gly	Phe	Thr	His	Ala	His
						55					60				

Ile	Val	Ala	Leu	Ser	Gln	His	Pro	Ala	Ala	Leu	Gly	Thr	Val	Ala	Val
65					70					75				80	

Lys	Tyr	Gln	Asp	Met	Ile	Ala	Ala	Leu	Pro	Glu	Ala	Thr	His	Glu	Ala
				85					90					95	

Ile	Val	Gly	Val	Gly	Lys	Gln	Trp	Ser	Gly	Ala	Arg	Ala	Leu	Glu	Ala
			100					105					110		

Leu	Leu	Thr	Val	Ala	Gly	Glu	Leu	Arg	Gly	Pro	Pro	Leu	Gln	Leu	Asp
			115					120				125			

Thr	Gly	Gln	Leu	Leu	Lys	Ile	Ala	Lys	Arg	Gly	Gly	Val	Thr	Ala	Val
	130					135					140				

Glu	Ala	Val	His	Ala	Trp	Arg	Asn	Ala	Leu	Thr	Gly	Ala	Pro	Leu	Asn
145					150					155					160

eolf-seql (10).txt

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys  
165 170 175

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
225 230 235 240

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
260 265 270

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
290 295 300

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
325 330 335

Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val  
340 345 350

eolf-seql (10).txt

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
355 360 365

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
370 375 380

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys  
485 490 495

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
500 505 510

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
530 535 540

eolf-seql (10).txt

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu  
545 550 555 560

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
565 570 575

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val  
595 600 605

Val Ala Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val  
610 615 620

Gln Ala Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
625 630 635 640

Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu  
645 650 655

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ala Leu Ala  
690 695 700

Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala Cys Leu Gly Gly Arg  
705 710 715 720

Pro Ala Leu Asp Ala Val Lys Lys Gly Leu Gly Asp Pro Ile Ser Arg  
725 730 735

eolf-seql (10).txt

Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys Lys Ser Glu Leu Arg  
740 745 750

His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile Glu Leu Ile Glu Ile  
755 760 765

Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu Met Lys Val Met Glu  
770 775 780

Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys His Leu Gly Gly Ser  
785 790 795 800

Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly Ser Pro Ile Asp Tyr  
805 810 815

Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly Gly Tyr Asn Leu Pro  
820 825 830

Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val Glu Glu Asn Gln Thr  
835 840 845

Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp Lys Val Tyr Pro Ser  
850 855 860

Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser Gly His Phe Lys Gly  
865 870 875 880

Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His Ile Thr Asn Cys Asn  
885 890 895

Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile Gly Gly Glu Met Ile  
900 905 910

Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg Arg Lys Phe Asn Asn  
915 920 925

eolf-seql (10).txt

Gly Glu Ile Asn Phe Ala Ala Asp  
930 935

<210> 82

<211> 936

<212> PRT

<213> artificial sequence

<220>

<223> pCLS31136 right TALEN B2m2

<400> 82

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
1 5 10 15

Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
20 25 30

Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
35 40 45

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
50 55 60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
65 70 75 80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
85 90 95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
100 105 110

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val

eolf-seql (10).txt

130

135

140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
145 150 155 160

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys  
165 170 175

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn Ile Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn  
225 230 235 240

Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
260 265 270

Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
290 295 300

Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val

## eolf-seql (10).txt

325

330

335

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val  
                   340                                  345                                  350

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln  
                   355                                  360                                  365

Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu  
                   370                                  375                                  380

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
   385                                  390                                  395                                  400

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala  
                   405                                  410                                  415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
                   420                                  425                                  430

Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys  
                   435                                  440                                  445

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
                   450                                  455                                  460

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly  
   465                                  470                                  475                                  480

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
                   485                                  490                                  495

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His  
                   500                                  505                                  510

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val

## eolf-seql (10).txt

515

520

525

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
 530 535 540

Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
 545 550 555 560

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
 565 570 575

Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
 580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
 595 600 605

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val  
 610 615 620

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
 625 630 635 640

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
 645 650 655

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
 660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
 675 680 685

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ala Leu Ala  
 690 695 700

Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala Cys Leu Gly Gly Arg

705                      710                      715                      720

Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys Lys Ser Glu Leu Arg  
740 745 750

His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile Glu Leu Ile Glu Ile  
755 760 765

Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu Met Lys Val Met Glu  
770 775 780

Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys His Leu Gly Gly Ser  
785 790 795 800

Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly Ser Pro Ile Asp Tyr  
805 810 815

Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly Gly Tyr Asn Leu Pro  
820 825 830

Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val Glu Glu Asn Gln Thr  
835 840 845

Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp Lys Val Tyr Pro Ser  
850 855 860

Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser Gly His Phe Lys Gly  
865 870 875 880

Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His Ile Thr Asn Cys Asn  
885 890 895

Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile Gly Gly Glu Met Ile

900

905

910

Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg Arg Lys Phe Asn Asn  
           915                          920                          925

Gly Glu Ile Asn Phe Ala Ala Asp  
      930                          935

<210> 83

<211> 936

<212> PRT

<213> artificial sequence

<220>

<223> pCLS31137 left TALEN B2m2

<400> 83

Met Gly Asp Pro Lys Lys Lys Arg Lys Val Ile Asp Tyr Pro Tyr Asp  
   1                  5                          10                          15

Val Pro Asp Tyr Ala Ile Asp Ile Ala Asp Leu Arg Thr Leu Gly Tyr  
           20                          25                          30

Ser Gln Gln Gln Gln Glu Lys Ile Lys Pro Lys Val Arg Ser Thr Val  
      35                          40                          45

Ala Gln His His Glu Ala Leu Val Gly His Gly Phe Thr His Ala His  
      50                          55                          60

Ile Val Ala Leu Ser Gln His Pro Ala Ala Leu Gly Thr Val Ala Val  
   65                          70                          75                          80

Lys Tyr Gln Asp Met Ile Ala Ala Leu Pro Glu Ala Thr His Glu Ala  
           85                          90                          95

Ile Val Gly Val Gly Lys Gln Trp Ser Gly Ala Arg Ala Leu Glu Ala  
      100                          105                          110

eolf-seql (10).txt

Leu Leu Thr Val Ala Gly Glu Leu Arg Gly Pro Pro Leu Gln Leu Asp  
115 120 125

Thr Gly Gln Leu Leu Lys Ile Ala Lys Arg Gly Gly Val Thr Ala Val  
130 135 140

Glu Ala Val His Ala Trp Arg Asn Ala Leu Thr Gly Ala Pro Leu Asn  
145 150 155 160

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly Gly Lys  
165 170 175

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
180 185 190

His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Asn Gly  
195 200 205

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
210 215 220

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser Asn  
225 230 235 240

Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu Pro Val  
245 250 255

Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala Ile Ala  
260 265 270

Ser Asn Gly Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu  
275 280 285

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala  
290 295 300

eolf-seql (10).txt

Ile Ala Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala  
305 310 315 320

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
325 330 335

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val  
340 345 350

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
355 360 365

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
370 375 380

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
385 390 395 400

Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala  
405 410 415

Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly  
420 425 430

Leu Thr Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Lys  
435 440 445

Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala  
450 455 460

His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His Asp Gly  
465 470 475 480

Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val Leu Cys  
485 490 495

eolf-seql (10).txt

Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala Ser His  
500 505 510

Asp Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg Leu Leu Pro Val  
515 520 525

Leu Cys Gln Ala His Gly Leu Thr Pro Glu Gln Val Val Ala Ile Ala  
530 535 540

Ser Asn Ile Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Ala Leu Leu  
545 550 555 560

Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val Val Ala  
565 570 575

Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val Gln Arg  
580 585 590

Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Gln Gln Val  
595 600 605

Val Ala Ile Ala Ser Asn Asn Gly Gly Lys Gln Ala Leu Glu Thr Val  
610 615 620

Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr Pro Glu  
625 630 635 640

Gln Val Val Ala Ile Ala Ser His Asp Gly Gly Lys Gln Ala Leu Glu  
645 650 655

Thr Val Gln Arg Leu Leu Pro Val Leu Cys Gln Ala His Gly Leu Thr  
660 665 670

Pro Gln Gln Val Val Ala Ile Ala Ser Asn Gly Gly Gly Arg Pro Ala  
675 680 685

eolf-seql (10).txt

Leu Glu Ser Ile Val Ala Gln Leu Ser Arg Pro Asp Pro Ala Leu Ala  
690 695 700

Ala Leu Thr Asn Asp His Leu Val Ala Leu Ala Cys Leu Gly Gly Arg  
705 710 715 720

Pro Ala Leu Asp Ala Val Lys Lys Gly Leu Gly Asp Pro Ile Ser Arg  
725 730 735

Ser Gln Leu Val Lys Ser Glu Leu Glu Glu Lys Lys Ser Glu Leu Arg  
740 745 750

His Lys Leu Lys Tyr Val Pro His Glu Tyr Ile Glu Leu Ile Glu Ile  
755 760 765

Ala Arg Asn Ser Thr Gln Asp Arg Ile Leu Glu Met Lys Val Met Glu  
770 775 780

Phe Phe Met Lys Val Tyr Gly Tyr Arg Gly Lys His Leu Gly Gly Ser  
785 790 795 800

Arg Lys Pro Asp Gly Ala Ile Tyr Thr Val Gly Ser Pro Ile Asp Tyr  
805 810 815

Gly Val Ile Val Asp Thr Lys Ala Tyr Ser Gly Gly Tyr Asn Leu Pro  
820 825 830

Ile Gly Gln Ala Asp Glu Met Gln Arg Tyr Val Glu Glu Asn Gln Thr  
835 840 845

Arg Asn Lys His Ile Asn Pro Asn Glu Trp Trp Lys Val Tyr Pro Ser  
850 855 860

Ser Val Thr Glu Phe Lys Phe Leu Phe Val Ser Gly His Phe Lys Gly  
865 870 875 880

eolf-seql (10).txt

Asn Tyr Lys Ala Gln Leu Thr Arg Leu Asn His Ile Thr Asn Cys Asn  
885 890 895

Gly Ala Val Leu Ser Val Glu Glu Leu Leu Ile Gly Gly Glu Met Ile  
900 905 910

Lys Ala Gly Thr Leu Thr Leu Glu Glu Val Arg Arg Lys Phe Asn Asn  
915 920 925

Gly Glu Ile Asn Phe Ala Ala Asp  
930 935

<210> 84

<211> 338

<212> PRT

<213> artificial sequence

<220>

<223> HLAG1

<400> 84

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser  
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln

## eolf-seql (10).txt

85

90

95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
 100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly  
 115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly  
 130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala  
 145 150 155 160

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val  
 165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu  
 180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro  
 195 200 205

Pro Lys Thr His Val Thr His His Pro Val Phe Asp Tyr Glu Ala Thr  
 210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr  
 225 230 235 240

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu  
 245 250 255

Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val  
 260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu

eolf-seql (10).txt

275

280

285

Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Lys Gln Ser Ser Leu Pro  
290 295 300

Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Val Val Leu Ala Ala  
305 310 315 320

Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp Arg Lys Lys Ser  
325 330 335

Ser Asp

<210> 85

<211> 246

<212> PRT

<213> artificial sequence

<220>

<223> HLAG2

<400> 85

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser  
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
65 70 75 80

eolf-seql (10).txt

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln  
85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
100 105 110

Glu Ala Lys Pro Pro Lys Thr His Val Thr His His Pro Val Phe Asp  
115 120 125

Tyr Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu  
130 135 140

Ile Ile Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val  
145 150 155 160

Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp  
165 170 175

Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His  
180 185 190

Val Gln His Glu Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Lys Gln  
195 200 205

Ser Ser Leu Pro Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Val  
210 215 220

Val Leu Ala Ala Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp  
225 230 235 240

Arg Lys Lys Ser Ser Asp  
245

<210> 86

<211> 154

eolf-seql (10).txt

<212> PRT

<213> artificial sequence

<220>

<223> HLAG3

<400> 86

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser  
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln  
85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
100 105 110

Glu Ala Lys Gln Ser Ser Leu Pro Thr Ile Pro Ile Met Gly Ile Val  
115 120 125

Ala Gly Leu Val Val Leu Ala Ala Val Val Thr Gly Ala Ala Val Ala  
130 135 140

Ala Val Leu Trp Arg Lys Lys Ser Ser Asp  
145 150

<210> 87

eolf-seql (10).txt

<211> 246

<212> PRT

<213> artificial sequence

<220>

<223> HLAG4

<400> 87

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser  
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln  
85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly  
115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly  
130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala  
145 150 155 160

eolf-seql (10).txt

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val  
165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu  
180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Lys Gln  
195 200 205

Ser Ser Leu Pro Thr Ile Pro Ile Met Gly Ile Val Ala Gly Leu Val  
210 215 220

Val Leu Ala Ala Val Val Thr Gly Ala Ala Val Ala Ala Val Leu Trp  
225 230 235 240

Arg Lys Lys Ser Ser Asp  
245

<210> 88

<211> 319

<212> PRT

<213> artificial sequence

<220>

<223> HLAG5

<400> 88

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser

## eolf-seql (10).txt

50

55

60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
 65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln  
 85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
 100 105 110

Glu Ala Ser Ser His Thr Leu Gln Trp Met Ile Gly Cys Asp Leu Gly  
 115 120 125

Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln Tyr Ala Tyr Asp Gly  
 130 135 140

Lys Asp Tyr Leu Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala  
 145 150 155 160

Asp Thr Ala Ala Gln Ile Ser Lys Arg Lys Cys Glu Ala Ala Asn Val  
 165 170 175

Ala Glu Gln Arg Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu  
 180 185 190

His Arg Tyr Leu Glu Asn Gly Lys Glu Met Leu Gln Arg Ala Asp Pro  
 195 200 205

Pro Lys Thr His Val Thr His His Pro Val Phe Asp Tyr Glu Ala Thr  
 210 215 220

Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ile Leu Thr  
 225 230 235 240

Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val Glu Leu Val Glu

eolf-seql (10).txt

245

250

255

Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val  
260 265 270

Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His Val Gln His Glu  
275 280 285

Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Ser Lys Glu Gly Asp Gly  
290 295 300

Gly Ile Met Ser Val Arg Glu Ser Arg Ser Leu Ser Glu Asp Leu  
305 310 315

<210> 89

<211> 227

<212> PRT

<213> artificial sequence

<220>

<223> HLAG6

<400> 89

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser  
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
65 70 75 80

eolf-seql (10).txt

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln  
85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
100 105 110

Glu Ala Lys Pro Pro Lys Thr His Val Thr His His Pro Val Phe Asp  
115 120 125

Tyr Glu Ala Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu  
130 135 140

Ile Ile Leu Thr Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Val  
145 150 155 160

Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp  
165 170 175

Ala Ala Val Val Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys His  
180 185 190

Val Gln His Glu Gly Leu Pro Glu Pro Leu Met Leu Arg Trp Ser Lys  
195 200 205

Glu Gly Asp Gly Gly Ile Met Ser Val Arg Glu Ser Arg Ser Leu Ser  
210 215 220

Glu Asp Leu  
225

<210> 90

<211> 116

<212> PRT

<213> artificial sequence

<220>

eolf-seql (10).txt

<223> HLAG7

<400> 90

Met Val Val Met Ala Pro Arg Thr Leu Phe Leu Leu Leu Ser Gly Ala  
1 5 10 15

Leu Thr Leu Thr Glu Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe  
20 25 30

Ser Ala Ala Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala  
35 40 45

Met Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ser  
50 55 60

Ala Cys Pro Arg Met Glu Pro Arg Ala Pro Trp Val Glu Gln Glu Gly  
65 70 75 80

Pro Glu Tyr Trp Glu Glu Glu Thr Arg Asn Thr Lys Ala His Ala Gln  
85 90 95

Thr Asp Arg Met Asn Leu Gln Thr Leu Arg Gly Tyr Tyr Asn Gln Ser  
100 105 110

Glu Ala Ser Glu  
115